JP6377570B2 - Pharmaceutical composition containing 2-substituted cephem compound - Google Patents

Description

  The present invention relates to a pharmaceutical composition comprising a 2-substituted cephem compound having a broad antibacterial spectrum represented by the formula (I), and particularly exhibiting a strong antibacterial activity against β-lactamase producing gram-negative bacteria.

  Various β-lactam drugs have been developed so far, and β-lactam drugs have become clinically extremely important antibacterial drugs. However, the number of bacterial species that have acquired resistance to β-lactam drugs by producing β-lactamase that degrades β-lactam drugs is increasing.

  According to Ambler's molecular taxonomy, β-lactamases are roughly divided into four classes. Specifically, class A (TEM type, SHV type, CTX-M type, KPC type, etc.), class B (IMP type, VIM type, L-1 type, etc.), class C (AmpC type, etc.), class D, etc. (Such as OXA type). Of these, class A, C and D types are broadly divided into serine-β-lactamases, while class B types are broadly divided into metallo-β-lactamases. Both are known to have different mechanisms for the hydrolysis of β-lactam drugs.

  In recent years, the production of class A and class D serine-β-lactamases with an extended substrate range and class B type metallo-β-lactamases with an extended substrate range has led to many βs including cephem and carbapenem. -Clinical problems have arisen due to the presence of gram-negative bacteria that have acquired high resistance to lactams. In particular, metallo-β-lactamase is known to contribute to the acquisition of multidrug resistance in Gram-negative bacteria. Cephem compounds that exhibit moderate activity against metallo-β-lactamase-producing gram-negative bacteria are known (for example, Patent Document 1 and Non-Patent Document 1). However, there is a need for the development of cefem compounds with more potent antibacterial activity, particularly more effective against various β-lactamase producing gram negative bacteria.

One known antibacterial agent having high anti-gram-negative bacterial activity is a cephem compound having a catechol group in the molecule (for example, Non-Patent Documents 2 to 4). The action is that the catechol group forms a chelate with Fe ³⁺ , whereby the compound is efficiently taken up into the microbial cell via the Fe ³⁺ transport system (tonB-dependent iron transport system) on the cell membrane. is there. For this reason, research has been conducted on compounds having a catechol group or a similar structure to the 3-position side chain or 7-position side chain portion of the cephem skeleton.

  Non-Patent Document 5 and Patent Documents 2 to 7 each describe a catechol-type derivative having a catechol group at the 3-position side chain portion of the cephem skeleton. Patent Documents 8 to 11 describe pseudo-catechol type derivatives having a hydroxypyridone group at the 3-position side chain portion of the cephem skeleton. Patent Documents 12 and 13 disclose cephem compounds having a quaternary ammonium group, but do not describe catechol type derivatives.

  Furthermore, the above document describing cephem compounds having a catechol group in the structure also describes the class B type metallo-β-lactamase, which is specific to a wide range of gram-negative bacteria including the class B type. There is no description of antibacterial activity.

  In addition, Patent Documents 14 and 15 and Non-Patent Documents 6 to 8 each describe a cephem compound having a substituent at the 2-position of the cephem skeleton. However, these compounds do not have a quaternary ammonium group and a catechol group at the 3-position of the cephem skeleton.

  Non-Patent Documents 9 and 10 describe oxa-cephem compounds having a substituent at the 2-position of the oxa-cephem skeleton. However, these compounds do not have a catechol group at the 3-position of the oxa-cephem skeleton.

  The present applicant has filed a patent application for a cephem compound having a catechol-type substituent (for example, Patent Documents 16 to 19). However, these applications do not disclose a compound having a substituent at the 2-position of the cephem skeleton.

International Publication No. 2007/119511 Pamphlet JP-A-4-364189 JP-A-3-173893 JP-A-2-15090 JP-A-2-28187 Japanese Patent Laid-Open No. 2-117678 JP-A-2-28185 JP-A-2-15090 JP-A-2-28187 JP-A-6-510523 JP-A-5-213971 International Publication No. 2007/096740 Pamphlet International Publication No. 2003/078440 Pamphlet European Patent Publication No. 35357 U.S. Pat. No. 3,487,079 International Publication No. 2010/050468 Pamphlet International Publication No. 2011-125966 Pamphlet International Publication No. 2011/125967 Pamphlet International Publication No. 2011/136268 Pamphlet

Applied Microbiology and Biotechnology (1994), 40 (6), 892-7 The Journal of Antibiotics, vol. 61, pp. 36-39 (2008) The Journal of Antibiotics, vol. 43, pp. 1617-1620 (1990) The Journal of Antibiotics, vol. 42, pp. 795-806 (1989) Applied Microbiology and Biotechnology (1994), 40 (6), 892-7 Chemical & Pharmaceutical Bulletin, vol. 31, 1482-1493 (1983) Journal of Medicinal Chemistry, vol. 14, 420-425 (1971) International Journal of Peptide & Protein Research, vol. 10, 51-59 (1977) The Journal of Antibiotics, vol. 41, pp. 1154-1157 (1988) The Journal of Antibiotics, vol. 43, pp. 357-371 (1989)

  The present invention provides 2-substitution having a quaternary ammonium group in the side chain at position 3, preferably with a catechol group, which exhibits a strong antibacterial spectrum against various bacteria including gram negative and / or gram positive bacteria. A cephem compound is provided. Preferably, the compound comprises a multi-drug resistant bacterium, in particular a crumb B-type metallo-β-lactamase (MBL) producing gram negative bacterium, and a spectrum extended β-lactamase (ESBL) producing bacterium. Effective against gram-negative bacteria. Furthermore, the present invention preferably provides cephem compounds having antibacterial activity against resistant strains against 2-unsubstituted cephem compounds.

A cephem compound having the following structural features and solving the above-mentioned problems is provided.
1) A substituent at the 2-position, preferably an alkyl group.
2) A quaternary ammonium group in the 3rd position side chain.
3) The terminal or internal catechol group of the quaternary ammonium group of the 3-position side chain as a preferred embodiment.

［式中、
Ｒ^１は、置換されていてもよい炭素環式基または置換されていてもよい複素環式基であり；
Ｒ^２ＡおよびＲ^２Ｂについては、
ａ）Ｒ^２Ａが水素、置換されていてもよいアミノ、−ＳＯ_３Ｈ、置換されていてもよいアミノスルホニル、カルボキシル、置換されていてもよい（低級アルキル）オキシカルボニル、置換されていてもよいカルバモイル、ヒドロキシル、もしくは置換カルボニルオキシであり；かつ、Ｒ^２Ｂが水素である（ただし、Ｒ^２ＡとＲ^２Ｂは同時に水素であることはない）か、または
ｂ）Ｒ^２ＡおよびＲ^２Ｂが一緒になって、置換されていてもよいメチリデンもしくは置換されていてもよいヒドロキシイミノを形成し；
Ｒ^３は、水素、−ＯＣＨ_３または−ＮＨ−ＣＨ（＝Ｏ）であり；
Ｒ^５ＡおよびＲ^５Ｂについては、
ａ）Ｒ^５ＡおよびＲ^５Ｂがそれぞれ独立に、水素、または低級アルキルであり、かつ、Ｒ^５ＡとＲ^５Ｂは同時に水素であることはないか、
ｂ）Ｒ^５ＡおよびＲ^５Ｂが隣接原子と一緒になって、置換されていてもよい炭素環または置換されていてもよい複素環式基を形成していてもよいか、または
ｃ）Ｒ^５ＡおよびＲ^５Ｂが一緒になって、置換されていてもよいメチリデンを形成していてもよく；
Ｌは、−ＣＨ_２−、−ＣＨ＝ＣＨ−、−ＣＨ_２−ＣＨ＝ＣＨ−、−ＣＨ＝ＣＨ−ＣＨ_２−、−Ｓ−、−ＣＨ_２−Ｓ−、−ＣＨ＝ＣＨ−Ｓ−または−ＣＨ＝ＣＨ−ＣＨ_２−Ｓ−であり；
Ｅは、少なくとも１個の第四級アンモニウムイオンを有する置換されていてもよい二価の基であり；
Ｒ^１０は、水素、または式（Ｉ−Ｂ）：

で示される基であり、ここで、
環Ａは、ベンゼン環、単環式複素環または縮合複素環であり；
ｎは、０〜２の整数であり；
各Ｒ^４は独立に、水素、ハロゲン、オキソ、−ＯＨ、−ＣＮ、−ＮＯ_２、−Ｏ−Ｃ（＝Ｏ）−Ｒ^９、−Ｃ（＝Ｏ）−Ｒ^９、−Ｃ（＝Ｏ）−ＯＨ、−Ｃ（＝Ｏ）−ＯＲ^９、−ＯＲ^９，、−ＮＲ^９Ｒ^９、−ＳＯ_２Ｒ^９、−ＳＲ^９、−ＮＲ^９−Ｃ（＝Ｏ）−Ｒ^９、置換されていてもよい低級アルキル、置換されていてもよいシクロアルキル、置換されていてもよいアリール、または置換されていてもよいヘテロアリールであり；ただし、環Ａ上の２個のヒドロキシル基は、各々隣接して位置する炭素原子とそれぞれ結合しており；
各Ｒ^９は独立に、低級アルキルまたはハロ（低級）アルキルであり；
Ｇは、単結合、置換されていてもよい低級アルキレン、置換されていてもよい低級アルケニレンまたは置換されていてもよい低級アルキニレンであり；
Ｂは、存在しないか、単結合、または少なくとも１〜３個の窒素原子を含有する５員もしくは６員の複素環式基であり；
Ｄは、存在しないか、単結合、−Ｃ（＝Ｏ）−、−Ｏ−Ｃ（＝Ｏ）−、−Ｃ（＝Ｏ）−Ｏ−、−ＮＲ^６−、−ＮＲ^６−Ｃ（＝Ｏ）−、−Ｃ（＝Ｏ）−ＮＲ^６−、−Ｃ（＝Ｏ）−Ｃ（＝Ｏ）−、−ＮＲ^６−Ｃ（＝Ｏ）−ＮＲ^６−、−Ｃ（＝Ｏ）−Ｃ（＝Ｏ）−ＮＲ^６−、−Ｃ（＝Ｏ）−ＮＲ^６−Ｃ（＝Ｏ）−、−ＮＲ^６−Ｃ（＝Ｏ）−Ｃ（＝Ｏ）−、−ＮＲ^６−ＮＲ^６−Ｃ（＝Ｏ）−、−Ｃ（＝Ｏ）−ＮＲ^６−ＮＲ^６−、−Ｎ＝Ｎ−Ｃ（＝Ｏ）−、−Ｃ（＝Ｏ）−Ｎ＝Ｎ−、−Ｃ＝Ｎ−ＮＲ^６−Ｃ（＝Ｏ）−、−Ｃ＝Ｎ−Ｃ（＝Ｏ）−、−Ｎ＝Ｃ−Ｃ（＝Ｏ）−、−Ｃ＝Ｎ−Ｃ（＝Ｏ）−ＮＲ^６−、−ＮＲ^６−Ｃ（＝Ｏ）−Ｃ（＝Ｎ−ＯＲ^６）−、−Ｃ（＝Ｎ−ＯＲ^６）−Ｃ（＝Ｏ）−ＮＲ^６−、−ＮＲ^６−Ｃ（＝Ｎ−ＯＲ^６）−、−Ｃ（＝Ｎ−ＯＲ^６）−ＮＲ^６−、−Ｃ（＝Ｏ）−Ｃ（＝Ｎ−ＯＲ^６）−、−Ｃ（＝Ｎ−ＯＲ^６）−Ｃ（＝Ｏ）−、−Ｏ−、−Ｓ−、−Ｓ（＝Ｏ）−、−Ｓ（＝Ｏ）_２−ＮＲ^６−、−ＮＲ^６−Ｓ（＝Ｏ）_２−、−ＮＲ^６−ＣＨ_２−、−ＣＨ_２−ＮＲ^６−または−Ｓ（＝Ｏ）_２−であり；
各Ｒ^６は独立に、水素または置換されていてもよい低級アルキルであり；
ただし、Ｒ^１０が水素である場合、Ｅは置換されていてもよい二価の環式基であり、該環式基は、少なくとも１個の第四級アンモニウムイオンと、該環式基上の各々隣接して位置する炭素原子にそれぞれ結合している少なくとも２個のヒドロキシル基とを有する］
で示される化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 The present invention provides the following inventions.
1. Formula (I):

[Where:
R ¹ is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group;
For R ^2A and R ^2B
a) R ^2A is hydrogen, optionally substituted amino, —SO ₃ H, optionally substituted aminosulfonyl, carboxyl, optionally substituted (lower alkyl) oxycarbonyl, optionally substituted. Carbamoyl, hydroxyl, or substituted carbonyloxy; and R ^2B is hydrogen (provided R ^2A and R ^2B are not simultaneously hydrogen), or b) R ^2A and R ^2B are taken together Forming an optionally substituted methylidene or an optionally substituted hydroxyimino;
R ³ is hydrogen, —OCH ₃ or —NH—CH (═O);
For R ^5A and R ^5B ,
a) R ^5A and R ^5B are each independently hydrogen or lower alkyl, and R ^5A and R ^5B are not simultaneously hydrogen,
b) R ^5A and R ^5B may be taken together with adjacent atoms to form an optionally substituted carbocycle or an optionally substituted heterocyclic group, or c) R ^5A and R ^5B may be taken together to form an optionally substituted methylidene;
L _{is, -CH 2 -, - CH =} CH -, - CH 2 -CH = CH -, - CH = CH-CH 2 -, - S -, - CH 2 -S -, - CH = CH-S- Or —CH═CH—CH ₂ —S—;
E is an optionally substituted divalent group having at least one quaternary ammonium ion;
R ¹⁰ is hydrogen or the formula (IB):

A group represented by:
Ring A is a benzene ring, monocyclic heterocycle or fused heterocycle;
n is an integer from 0 to 2;
Each R ⁴ is independently hydrogen, halogen, oxo, —OH, —CN, —NO ₂ , —O—C (═O) —R ⁹ , —C (═O) —R ⁹ , —C (═O ) —OH, —C (═O) —OR ⁹ , —OR ⁹ , —NR ⁹ R ⁹ , —SO ₂ R ⁹ , —SR ⁹ , —NR ⁹ —C (═O) —R ⁹ , substituted Optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; provided that the two hydroxyl groups on ring A are each Each bonded to adjacent carbon atoms;
Each R ⁹ is independently lower alkyl or halo (lower) alkyl;
G is a single bond, an optionally substituted lower alkylene, an optionally substituted lower alkenylene or an optionally substituted lower alkynylene;
B is absent, a single bond, or a 5- or 6-membered heterocyclic group containing at least 1 to 3 nitrogen atoms;
D is absent, a single bond, -C (= O) -, - O-C (= O) -, - C (= O) -O -, - NR 6 -, - NR 6 -C (= ^{O) -, - C (=} O) -NR 6 -, - C (= O) -C (= O) -, - NR 6 -C (= O) -NR 6 -, - C (= O) - ^{C (= O) -NR 6 -} , - C (= O) -NR 6 -C (= O) -, - NR 6 -C (= O) -C (= O) -, - NR 6 -NR 6 -C (= O)-, -C (= O) -NR < ⁶ > -NR < ⁶ >-, -N = NC (= O)-, -C (= O) -N = N-, -C = N. —NR ⁶ —C (═O) —, —C═N—C (═O) —, —N═C—C (═O) —, —C═N—C (═O) —NR ⁶ —, ^{-NR 6 -C (= O) -C} (= N-OR 6) -, - C (= N-OR 6) -C (= O) -NR 6 -, - NR 6 -C (= ^{-OR 6) -, - C (} = N-OR 6) -NR 6 -, - C (= O) -C (= N-OR 6) -, - C (= N-OR 6) -C (= O) -, - O -, - S -, - S (= O) -, - S (= O) 2 -NR 6 -, - NR 6 -S (= O) 2 -, - NR 6 -CH 2 _-, - CH 2 -NR ⁶ - or -S (= _{O) 2} - and is;
Each R ⁶ is independently hydrogen or optionally substituted lower alkyl;
However, when R ¹⁰ is hydrogen, E is an optionally substituted divalent cyclic group, and the cyclic group includes at least one quaternary ammonium ion and the cyclic group. Each having at least two hydroxyl groups bonded to adjacent carbon atoms respectively]
Or an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmaceutically acceptable salt thereof.

［式中、
Ｇ、ＢおよびＤは上記１に定義される通りであり；
環Ａは、ともに縮合した少なくとも２つの環からなる縮合複素環系として定義され；
ここで、
Ｒ^４はそれぞれ独立に、環Ａとして定義される縮合複素環系の各環上で置換していてもよく、水素、ハロゲン、オキソ、−ＯＨ、−ＣＮ、−ＮＯ_２、−Ｏ−Ｃ（＝Ｏ）−Ｒ^９、−Ｃ（＝Ｏ）−Ｒ^９、−Ｃ（＝Ｏ）−ＯＨ、−Ｃ（＝Ｏ）−ＯＲ^９、−ＯＲ^９，、−ＮＲ^９Ｒ^９、−ＳＯ_２Ｒ^９、−ＳＲ^９、−ＮＲ^９−Ｃ（＝Ｏ）−Ｒ^９、置換されていてもよい低級アルキル、置換されていてもよいシクロアルキル、置換されていてもよいアリール、または置換されていてもよいヘテロアリールから選択され；
ただし、環Ａ上の２個のヒドロキシル基は各々隣接して位置する炭素原子とそれぞれ結合しており；かつ
ｎは０〜２の整数である］。 In one aspect of the invention, formula (IB) is defined as follows:

[Where:
G, B and D are as defined in 1 above;
Ring A is defined as a fused heterocyclic ring system consisting of at least two rings fused together;
here,
Each R ⁴ may be independently substituted on each ring of the fused heterocyclic ring system defined as ring A, and may be hydrogen, halogen, oxo, —OH, —CN, —NO ₂ , —O—C ( ^{= O) -R 9, -C (} = O) -R 9, -C (= O) -OH, -C (= O) -OR 9, -OR 9 ,, - NR 9 R 9, -SO 2 R ⁹ , —SR ⁹ , —NR ⁹ —C (═O) —R ⁹ , optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or substituted Selected from optionally heteroaryl;
Provided that the two hydroxyl groups on ring A are each bonded to adjacent carbon atoms; and n is an integer from 0 to 2.]

2. 2. The compound according to 1 above, wherein R ^5A is hydrogen and R ^5B is lower alkyl, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a compound thereof A pharmaceutically acceptable salt.

（式中、各記号は上記の１および本明細書に定義される通り）
で示される基である、上記１または２に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 3. R ¹⁰ is the formula (IB):

Wherein each symbol is as defined in 1 above and herein.
The compound according to 1 or 2, which is a group represented by the above, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the side chain at the 7-position, or a pharmaceutically acceptable salt thereof.

4). Ring A is a benzene ring or a monocyclic heterocycle, the compound according to the above 1, 2 or 3, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or Its pharmaceutically acceptable salt.

5. The compound according to the above 1, 2 or 3, wherein ring A is a condensed heterocyclic ring or an optionally substituted condensed heterocyclic ring, and each ring of the condensed heterocyclic ring is independently substituted with the same or different substituent , An ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmaceutically acceptable salt thereof.

In one embodiment, Ring A as defined herein is a fused heterocyclic ring system consisting of at least two rings fused together and may be further substituted with a substituent selected from R ⁴ ;
here,
R ⁴ is selected from the same or different substituents in each of at least two rings of the fused heterocyclic system defined as ring A, wherein each R ⁴ substituent on each ring of the fused heterocyclic system is independently May be substituted as follows;
here,
Each R ⁴ defined above may be independently substituted on each ring of the condensed heterocyclic ring, and may be hydrogen, halogen, oxo, —OH, —CN, —NO ₂ , —O—C (= O) —R ⁹ , —C (═O) —R ⁹ , —C (═O) —OH, —C (═O) —OR ⁹ , —OR ⁹ , —NR ⁹ R ⁹ , —SO ₂ R ⁹ , —SR ⁹ , —NR ⁹ —C (═O) —R ⁹ , optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or substituted Selected from good heteroaryl;
However, two hydroxyl groups on ring A are each bonded to adjacent carbon atoms; and n is an integer of 0-2.

6). R ¹⁰ is hydrogen; E has at least one quaternary ammonium ion and at least two hydroxyl groups each bonded to each adjacent carbon atom on the cyclic group. The compound according to the above 1 or 2, which is a divalent cyclic group which may be substituted, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the side chain at the 7-position, or Its pharmaceutically acceptable salt.

7). G is a single _{bond, -CH 2 -, - CH 2} -CH 2 -, - CH 2 -CH 2 -CH 2 -, - CH = CH -, - CH = CH-CH 2 -, - CH 2 -CH = CH—, —CH ₂ —CH (CH ₃ ) —, —CH ₂ —CH ( ⁱ Pr) — or —CH ₂ —CH (Ph) —, where ⁱ Pr is isopropyl and Ph 6. The compound according to any one of 1 to 5 above, wherein the ester is a carboxyl group, an amino-protected compound when amino is present on the ring of the side chain at the 7-position, or a pharmaceutically acceptable salt thereof salt.

（式中、左側の結合手はＧと結合し、右側の結合手はＤと結合している）
で示される基である、上記１、２、３、４、５または７に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 8). B is absent, single bond or formula:

(In the formula, the left bond is bonded to G, and the right bond is bonded to D)
The compound represented by the above 1, 2, 3, 4, 5 or 7, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the side chain at the 7-position, or a compound thereof A pharmaceutically acceptable salt.

9. Does not exist or D, a single bond, -C (= O) -, - O-C (= O) -, - C (= O) -O -, - NR 6 -, - O -, - C (= O) —C (═O) —, —NR ⁶ —C (═O) —NR ⁶ —, —C (═O) —C (═O) —NR ⁶ —, —C (═O) —NR ⁶ —C (═O) —, —NR ⁶ —C (═O) —C (═O) —, —NR ⁶ —C (═O) —, —C (═O) —NR ⁶ —, —NR ⁶ —NR ⁶ —C (═O) —, —C (═O) —NR ⁶ —NR ⁶ —, —N═N—C (═O) —, —C (═O) —N═N—, — C═N—NR ⁶ —C (═O) —, —C═N—C (═O) —, —N═C—C (═O) —, —C═N—C (═O) —NR ^{6 -, - NR 6 -C (} = O) -C (= N-OR 6) -, - C (= N-OR 6) -C (= O) -NR 6 -, - NR 6 - ^{(= N-OR 6) -} , - C (= O) -C (= N-OR 6) -, - C (= N-OR 6) -C (= O) - or -C (= N-OR ⁶ ) —NR ⁶ —, wherein R ⁶ is as defined in 1 above, the compound according to 1, 2, 3, 4, 5, 7 or 8 above, an ester at the carboxyl group, 7-position An amino-protected compound, or a pharmaceutically acceptable salt thereof, when amino is present on the ring of the side chain.

［式中、
Ｄは上記１に定義される通りであり；
環Ａは、ともに縮合した少なくとも２つの環からなる縮合複素環系として定義され；
ここで、
Ｒ^４はそれぞれ独立に、環Ａとして定義される縮合複素環系の各環上で置換していてもく、水素、ハロゲン、オキソ、−ＯＨ、−ＣＮ、−ＮＯ_２、−Ｏ−Ｃ（＝Ｏ）−Ｒ^９、−Ｃ（＝Ｏ）−Ｒ^９、−Ｃ（＝Ｏ）−ＯＨ、−Ｃ（＝Ｏ）−ＯＲ^９、−ＯＲ^９，、−ＮＲ^９Ｒ^９、−ＳＯ_２Ｒ^９、−ＳＲ^９、−ＮＲ^９−Ｃ（＝Ｏ）−Ｒ^９、置換されていてもよい低級アルキル、置換されていてもよいシクロアルキル、置換されていてもよいアリール、または置換されていてもよいヘテロアリールからそれぞれ独立に選択され；
ただし、環Ａ上の２個のヒドロキシル基は各々隣接して位置する炭素原子とそれぞれ結合しており；かつ
ｎは０〜２の整数である］
で示される基である。 In one embodiment, R ¹⁰ has the formula (I-C-1):

[Where:
D is as defined in 1 above;
Ring A is defined as a fused heterocyclic ring system consisting of at least two rings fused together;
here,
Each R ⁴ may be independently substituted on each ring of the fused heterocyclic ring system defined as ring A, hydrogen, halogen, oxo, —OH, —CN, —NO ₂ , —O—C ( ^{= O) -R 9, -C (} = O) -R 9, -C (= O) -OH, -C (= O) -OR 9, -OR 9 ,, - NR 9 R 9, -SO 2 R ⁹ , —SR ⁹ , —NR ⁹ —C (═O) —R ⁹ , optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or substituted Each independently selected from optionally heteroaryl;
Provided that two hydroxyl groups on ring A are each bonded to adjacent carbon atoms; and n is an integer of 0 to 2].
It is group shown by these.

が下式：

から選択される基であり、
ここで、各Ｒ^４ａ、Ｒ^４ｂおよびＲ^４ｃは独立に、水素、ハロゲン、−ＯＨ、−ＣＮ、−Ｃ（＝Ｏ）−Ｒ^９、−Ｃ（＝Ｏ）−ＯＨ、−Ｃ（＝Ｏ）−ＯＲ^９、−ＯＲ^９、置換されていてもよい低級アルキル、または置換されていてもよいシクロアルキルであり、かつ、Ｒ^６およびＲ^９は上記１に定義される通りであり、
波線は、結合がシス配置もしくはトランス配置、またはその混合であることを意味する、
上記１、２、３、４、７、８または９に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 10. The following groups in formula IB:

Is the following formula:

A group selected from
Here, each R ^4a , R ^4b and R ^4c is independently hydrogen, halogen, —OH, —CN, —C (═O) —R ⁹ , —C (═O) —OH, —C (═O ) —OR ⁹ , —OR ⁹ , optionally substituted lower alkyl, or optionally substituted cycloalkyl, and R ⁶ and R ⁹ are as defined in 1 above,
The wavy line means that the bond is in the cis or trans configuration, or a mixture
The compound according to the above 1, 2, 3, 4, 7, 8, or 9, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the side chain at the 7-position, or a pharmaceutically acceptable salt thereof salt.

が下式：

から選択される基であり、
ここで、Ｒ^６は、水素、メチル、エチル、ｔｅｒｔ−ブチル、カルボキシメチル、２−カルボキシプロパン−２−イルまたは１−カルボキシエチルであり、
波線は、結合がシス配置もしくはトランス配置、またはその混合であることを意味する、
上記１０に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 11. The following groups in formula IB:

Is the following formula:

A group selected from
Where R ⁶ is hydrogen, methyl, ethyl, tert-butyl, carboxymethyl, 2-carboxypropan-2-yl or 1-carboxyethyl;
The wavy line means that the bond is in the cis or trans configuration, or a mixture
11. The compound according to 10 above, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmaceutically acceptable salt thereof.

が下式：

から選択される基であり、
ここで、各Ｒ^４ａ、Ｒ^４ｂおよびＲ^４ｄは独立に、水素、ハロゲン、−ＯＨ、−ＣＮ、−Ｃ（＝Ｏ）−Ｒ^９、−Ｃ（＝Ｏ）−ＯＨ、−Ｃ（＝Ｏ）−ＯＲ^９、−ＯＲ^９、置換されていてもよい低級アルキル、または置換されていてもよいシクロアルキルであり、かつ、Ｒ^６およびＲ^９は上記１に定義される通りであり、
波線は、結合がシス配置もしくはトランス配置、またはその混合であることを意味する、
上記１、２、３、５、７、８または９に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 12 The following groups in formula IB:

Is the following formula:

A group selected from
Wherein each ^{R 4a,} independently ^{R 4b} and ^{R 4d,} hydrogen, ^{halogen, -OH, -CN, -C (=} O) -R 9, -C (= O) -OH, -C (= O ) —OR ⁹ , —OR ⁹ , optionally substituted lower alkyl, or optionally substituted cycloalkyl, and R ⁶ and R ⁹ are as defined in 1 above,
The wavy line means that the bond is in the cis or trans configuration, or a mixture
The compound according to the above 1, 2, 3, 5, 7, 8, or 9, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the side chain at position 7, or a pharmaceutically acceptable salt thereof salt.

が下式：

から選択される基である、上記１２に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 13. The following groups in formula IB:

Is the following formula:

13. The compound according to the above 12, which is a group selected from: an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmaceutically acceptable salt thereof.

［式中、
破線は環内における結合であり；
カチオン性窒素原子からの結合手はＬと結合し、他方の結合手はＲ^１０と結合し；
ただし、カチオン性窒素原子がＲ^１０と結合している場合には、破線は存在せず、かつ、
カチオン性窒素原子がＲ^１０と結合していない場合には、破線はカチオン性窒素原子と隣接原子との間の単結合またはカチオン性窒素原子と前記隣接原子以外の環員原子との間のアルキレン基を示す］
で示される、少なくとも１個の第四級アンモニウムイオンを有する、置換されていてもよい、飽和または不飽和型の単環式または縮合環式基である、上記１〜１３のいずれか一項に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 14 E represents the formula (ID):

[Where:
The dashed line is the bond in the ring;
The bond from the cationic nitrogen atom is bonded to L and the other bond is bonded to R ¹⁰ ;
However, when a cationic nitrogen atom is bonded to R ¹⁰ , there is no broken line, and
When the cationic nitrogen atom is not bonded to R ¹⁰ , the broken line indicates a single bond between the cationic nitrogen atom and an adjacent atom or an alkylene between the cationic nitrogen atom and a ring member atom other than the adjacent atom. Show group]
Any one of the above-mentioned 1 to 13 which is an optionally substituted saturated or unsaturated monocyclic or condensed cyclic group having at least one quaternary ammonium ion represented by The described compound, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmaceutically acceptable salt thereof.

（式中、カチオン性窒素原子からの結合手はＬと結合し、他方の結合手はＲ^１０と結合し；Ｒ^ｘは置換されていてもよい低級アルキルである）
で示される、少なくとも１個の第四級アンモニウムイオンを有する、置換されていてもよい、飽和または不飽和型の単環式または縮合環式基である、上記１〜１３のいずれか一項に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 15. E represents the formula (IE):

(Wherein the bond from the cationic nitrogen atom is bonded to L, the other bond is bonded to R ¹⁰ ; R ^x is an optionally substituted lower alkyl)
Any one of the above-mentioned 1 to 13 which is an optionally substituted saturated or unsaturated monocyclic or condensed cyclic group having at least one quaternary ammonium ion represented by The described compound, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmaceutically acceptable salt thereof.

16. L is _{-S -, - CH 2 -S -} , - CH = CH-S- or -CH = _CH-CH 2 -S- and and and, E is also good pyridinium or substituted substituted The compound according to any one of 1 to 13, which is a condensed pyridinium group which may be present, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the side chain at the 7-position, or the A pharmaceutically acceptable salt.

（式中、カチオン性窒素原子からの結合手はＲ^１０と結合し、他方の結合手はＬと結合している）
から選択される基である、上記１６に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 17. E may be substituted on the ring:

(Wherein the bond from the cationic nitrogen atom is bonded to R ¹⁰ and the other bond is bonded to L)
17. The compound according to 16 above, which is a group selected from: an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmaceutically acceptable salt thereof.

［式中、
第四級窒素原子からの結合手はＬと結合し、他方の結合手はＲ^１０と結合し；
ｐは、１〜３の整数であり；
ｎは、１または２の整数であり；
Ｒｘは、置換されていてもよい低級アルキルである］
から選択される基である、上記１〜１５のいずれか一項に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 18. E may be substituted on the ring:

[Where:
The bond from the quaternary nitrogen atom is bonded to L and the other bond is bonded to R ¹⁰ ;
p is an integer from 1 to 3;
n is an integer of 1 or 2;
Rx is optionally substituted lower alkyl]
The compound according to any one of the above 1 to 15, which is a group selected from: an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmacological agent thereof Acceptable salt.

19. E is the formula (2), (3), (7), (10), (11), (26), (27), (41), (42), (59), (60) and (77) 14. The compound according to the above 13, selected from the group consisting of: an ester at a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmaceutically acceptable salt thereof.

（式中、第四級窒素原子からの結合手はＬと結合し、他方の結合手はＲ^１０と結合している）
から選択される基である、上記１〜１５のいずれか一項に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 20. E may be substituted on the ring:

(Wherein, the bond from the quaternary nitrogen atom is bonded to L, and the other bond is bonded to R ¹⁰ )
The compound according to any one of the above 1 to 15, which is a group selected from: an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmacological agent thereof Acceptable salt.

（式中、第四級窒素原子からの結合手はＬと結合している）
から選択される基である、上記２０に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 21, E-R ¹⁰ is the following formula:

(Wherein the bond from the quaternary nitrogen atom is bonded to L)
21. The compound according to the above 20, which is a group selected from: an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmaceutically acceptable salt thereof.

（式中、第四級窒素原子からの結合手はＬと結合している）
で示される、上記２１に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 22. E-R ¹⁰ is the formula:

(Wherein the bond from the quaternary nitrogen atom is bonded to L)
22. The compound according to 21 above, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmaceutically acceptable salt thereof.

（式中、第四級窒素原子からの結合手はＲ^１０と結合し、他方の結合手はセフェムの３位と結合している）
で示される、上記１６に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 23. -LE is the formula:

(Wherein, the bond from the quaternary nitrogen atom is bonded to R ¹⁰ and the other bond is bonded to the 3rd position of Cephem)
17. The compound according to 16 above, an ester at a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmaceutically acceptable salt thereof.

24. 24. The compound according to any one of 1 to 23 above, wherein R ³ is hydrogen or —OCH ₃ , an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or Its pharmaceutically acceptable salt.

25. The compound according to any one of 1 to 24 above, wherein R ¹ is optionally substituted phenyl, an ester in a carboxyl group, and an amino-protected compound in the case where amino is present on the ring of the 7-position side chain Or a pharmaceutically acceptable salt thereof.

（式中、Ｘは、Ｎ、Ｃ（−Ｈ）またはＣ（−Ｃｌ）である）
で示される、上記１〜２４のいずれか一項に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 26. R ¹ is the formula:

(Wherein X is N, C (—H) or C (—Cl))
The compound according to any one of the above 1 to 24, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the side chain at the 7-position, or a pharmaceutically acceptable salt thereof .

27. 27. The compound according to 26 above, wherein X is N, an ester at a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmaceutically acceptable salt thereof.

28. 27. The compound according to the above 26, wherein X is C (—H) or C (—Cl), an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmaceutical Top acceptable salt.

29. R ^2A is hydrogen, optionally substituted amino, —SO ₃ H, optionally substituted aminosulfonyl, carboxyl, optionally substituted carbamoyl, hydroxyl, or substituted carbonyloxy, and R ^2B 29. The compound according to any one of the above 1 to 28, wherein the compound is hydrogen, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the side chain at the 7-position, or a pharmaceutically acceptable salt thereof salt.

以下に示される置換アミノスルホニル：

（式中、環Ｂは、置換されていてもよい複素環式基を表す）；
以下に示される置換カルバモイル：

（式中、環Ｂは、置換されていてもよい複素環式基を表す）；または
以下に示される置換カルボニルオキシ：

（式中、環Ｂは、置換されていてもよい複素環式基を表す）
である、上記１〜２９のいずれか一項に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 30. R ^2A is
The substituted amino shown below:

Substituted aminosulfonyl as shown below:

(Wherein ring B represents an optionally substituted heterocyclic group);
Substituted carbamoyl shown below:

(Wherein ring B represents an optionally substituted heterocyclic group); or substituted carbonyloxy as shown below:

(In the formula, ring B represents an optionally substituted heterocyclic group)
The compound according to any one of the above 1 to 29, an ester at a carboxyl group, an amino-protected compound when amino is present on the ring of the side chain at the 7-position, or a pharmaceutically acceptable salt thereof.

または
以下に示される置換ヒドロキシイミノ：

（式中、Ｒ^９は置換されていてもよい低級アルキルである）
を形成している、上記１〜２９のいずれか一項に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 31. R ^2A and R ^2B together
Substituted methylidene shown below:

Or the substituted hydroxyimino shown below:

(Wherein R ⁹ is an optionally substituted lower alkyl)
The compound according to any one of the above 1 to 29, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the side chain at the 7-position, or a pharmaceutically acceptable salt thereof Salt.

を形成し、式中、
Ｒ^７およびＲ^８はそれぞれ独立に、水素、ハロゲン、ヒドロキシル、カルボキシル、置換されていてもよい低級アルキル、置換されていてもよい炭素環式基、もしくは置換されていてもよい複素環式基であるか、または
Ｒ^７およびＲ^８は、隣接原子と一緒になって、置換されていてもよい炭素環式基もしくは置換されていてもよい複素環式基を形成していてもよく；
Ｑは、単結合、置換されていてもよい炭素環式基または置換されていてもよい複素環式基であり；かつ
ｍは、０〜３の整数である、
上記１〜２９のいずれか一項に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 32. R ^2A and R ^{2B taken} together are substituted hydroxyiminos shown below:

Form the formula,
R ⁷ and R ⁸ are each independently hydrogen, halogen, hydroxyl, carboxyl, optionally substituted lower alkyl, optionally substituted carbocyclic group, or optionally substituted heterocyclic group. Or R ⁷ and R ⁸ may be taken together with adjacent atoms to form an optionally substituted carbocyclic group or an optionally substituted heterocyclic group;
Q is a single bond, an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; and m is an integer of 0-3.
30. The compound according to any one of 1 to 29 above, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmaceutically acceptable salt thereof.

（各記号は上記で定義される通りである）
で示される、上記１〜２４のいずれか一項に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 33. Formula (IG-1):

(Each symbol is as defined above)
The compound according to any one of the above 1 to 24, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the side chain at the 7-position, or a pharmaceutically acceptable salt thereof .

（各記号は上記で定義される通りである）
で示される基である、上記３３に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 34. R ^5A is hydrogen and R ^5B is lower alkyl; R ¹⁰ is of formula (IB):

(Each symbol is as defined above)
34. The compound according to the above-mentioned 33, which is a group represented by the formula:

から選択される基であり、
ここで、Ｒｘは低級アルキルであり、ｐは１〜３の整数であり；
Ｇは単結合または低級アルキレンであり；
Ｂは存在しないか、または単結合であり；
Ｄは存在しないか、単結合、−Ｃ（＝Ｏ）−、−Ｃ（＝Ｏ）−Ｃ（＝Ｏ）−、−ＮＲ^６−Ｃ（＝Ｏ）−Ｃ（＝Ｏ）−、−ＮＲ^６−Ｃ（＝Ｏ）−または−ＮＨ−Ｃ（＝Ｏ）−Ｃ（＝Ｎ−ＯＲ^６ａ）であり；
Ｒ^６は水素または低級アルキルであり；
Ｒ^６ａは水素、メチル、カルボキシメチル、または２−カルボキシプロパン−２−イルであり；

は下式：

（式中、各Ｒ^４ａ、Ｒ^４ｂおよびＲ^４ｃは独立に、水素、ハロゲンまたは低級アルキルであり；Ｒ^４ｄは、水素、低級アルキルまたは低級シクロアルキルである）
から選択される基である、上記３４に記載の化合物、カルボキシル基におけるエステル、７位の側鎖の環上にアミノが存在する場合のアミノ保護化合物、またはその薬学上許容される塩。 35. X is C (—H), C (—Cl) or N;
Each R ⁷ and R ⁸ is independently hydrogen or lower alkyl;
R ³ is hydrogen;
m is 0 or 1;
Q is a single bond;
L is —CH ₂ —; E represents the following formula:

A group selected from
Where Rx is lower alkyl and p is an integer from 1 to 3;
G is a single bond or lower alkylene;
B is absent or is a single bond;
D is not present, or is a single bond, —C (═O) —, —C (═O) —C (═O) —, —NR ⁶ —C (═O) —C (═O) —, —NR ⁶ -C (= O)-or -NH-C (= O) -C (= N-OR ^6a );
R ⁶ is hydrogen or lower alkyl;
R ^6a is hydrogen, methyl, carboxymethyl, or 2-carboxypropan-2-yl;

Is the following formula:

Wherein each R ^4a , R ^4b and R ^4c is independently hydrogen, halogen or lower alkyl; R ^4d is hydrogen, lower alkyl or lower cycloalkyl.
35. The compound according to the above 34, which is a group selected from: an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmaceutically acceptable salt thereof.

36. The compound according to any one of the above 1 to 35, an ester in a carboxyl group, an amino-protected compound when amino is present on the ring of the 7-position side chain, or a pharmaceutically acceptable salt thereof. Pharmaceutical composition.

37. 37. The pharmaceutical composition according to the above 36, which has antibacterial activity.

The compound of the present invention has at least one of the following characteristics and is extremely useful as a medicine.
1) This compound exhibits a strong antibacterial spectrum against various bacteria including Gram negative bacteria and / or Gram positive bacteria.
2) This compound exhibits a strong antibacterial activity against β-lactamase producing gram-negative bacteria.
3) This compound exhibits a strong antibacterial activity against multidrug-resistant bacteria, particularly class B type metallo-β-lactamase-producing gram-negative bacteria.
4) This compound exhibits potent antibacterial activity against substrate-specific extended β-lactamase (ESBL) -producing bacteria.
5) This compound does not show cross-resistance with known cephem and / or carbapenem drugs. And 6) The compound shows no side effects such as toxicity and fever after administration to the body.
7) This compound is storage-stable and / or highly water-soluble.
8) The compound of the present invention has excellent characteristics regarding pharmacokinetics such as high blood concentration, high bioavailability, long duration of effect, and / or high tissue migration.
9) The compounds of the present invention may also include, but are not limited to, Yersinia pestis, Bacillus anthracis, Francisella tularensi, Burkholderia mallei, urchin may include or exhibit an antimicrobial activity against a biological threat organism, including biological threat organisms such as pseudomallei, Brucella suis, Brucella melitensis, or Brucella abortus obtain.

  The terms used in this specification should be understood to be used in the meaning commonly used in the art unless otherwise specified. Accordingly, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Specific definitions of terms specifically used in the present specification are described below. Each term used herein has a meaning alone or in combination with another word as described below.

  “Halogen” includes fluoro, chloro, bromo and iodo. Preferably the halogen is fluoro, chloro or bromo, more preferably chloro.

  “Lower alkyl” includes straight-chain or branched alkyl having 1 to 8 carbons, preferably 1 to 6 carbons, more preferably 1 to 4 carbons, such as methyl, ethyl, n- Examples include propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl and the like.

  “Lower alkylene” includes linear alkylene having 1 to 8 carbons, preferably 1 to 6 carbons, more preferably 1 to 4 carbons, most preferably 1 or 2 carbons, for example , Methylene, ethylene, n-propylene, n-butylene, n-pentylene, n-hexylene and the like.

  “Lower alkenylene” includes linear alkenylene having 2 to 8 carbons, preferably 2 to 6 carbons, more preferably 2 to 4 carbons, and at least one double bond at any position. For example, vinylene, allylene, propenylene, butenylene, plenylene, butanedienylene, pentenylene, pentadienylene, hexenylene, hexadienylene and the like can be mentioned.

  “Lower alkynylene” includes linear alkynylene having 2 to 8 carbons, preferably 2 to 6 carbons, more preferably 2 to 4 carbons, and at least one triple bond at any position, For example, ethynylene, propynylene, butynylene, pentynylene, hexynylene and the like can be mentioned.

  “Halo (lower) alkyl” means a group in which at least one position of the “lower alkyl” is substituted with the above “halogen”, and examples thereof include monofluoromethyl, difluoromethyl, trifluoromethyl, monochloromethyl, Examples include dichloromethyl, trichloromethyl, monobromomethyl, monofluoroethyl, monochloroethyl, chlorodifluoromethyl and the like. Preferable is trifluoromethyl or trichloromethyl.

  “Aralkyl” includes the above lower alkyl substituted with 1 to 3 groups selected from the following “aryl”, preferably the alkyl has 1 to 4 carbon atoms, more preferably 1 or 2 carbon atoms. Examples thereof include benzyl, phenethyl, phenylpropyl, trityl and the like.

  “Heteroaralkyl” includes the above lower alkyl substituted with 1 to 3 groups selected from the following “heteroaryl”, preferably the alkyl has 1 to 4 carbon atoms, more preferably 1 Or two, for example, furylmethyl, thienylmethyl, pyrrolylmethyl, pyridylmethyl, thienylethyl, furylethyl, imidazolylmethyl, benzothienylmethyl, thiazolylmethyl and the like.

  “Acyl” includes formyl, optionally substituted lower alkylcarbonyl (eg, acetyl, propionyl, butynyl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, octanoyl, methoxyethylcarbonyl, 2,2,2-trifluoro Ethylcarbonyl), optionally substituted alkenyloxycarbonyl (eg, Alloc, cinnamyloxycarbonyl), alkoxycarbonylacetyl (eg, ethoxycarbonylmethylcarbonyl), (lower) alkoxy (lower) alkylcarbonyl (eg, methoxyethyl) Carbonyl), (lower) alkylcarbamoyl (lower) alkylcarbonyl (eg methylcarbamoylethylcarbonyl), optionally substituted arylcarbonyl (eg Benzoyl, toluoyl), optionally substituted cycloalkyloxycarbonyl (eg cyclohexyloxycarbonyl), optionally substituted aralkyloxycarbonyl (eg benzyloxycarbonyl, p-nitrobenzyloxycarbonyl), substituted Optionally including heteroaralkylcarbonyl (eg thienylmethylcarbonyl) and the like.

  Substituents for “optionally substituted amino” or “optionally substituted carbamoyl” include optionally substituted lower alkyl (eg, methyl, ethyl, isopropyl, benzyl, carbamoylalkyl (eg, carbamoyl Methyl), mono- or di (lower) alkylcarbamoyl (lower) alkyl (eg dimethylcarbamoylethyl), hydroxy (lower) alkyl, heterocyclyl (lower) alkyl (eg morpholinoethyl, tetrahydropyranylethyl), alkoxycarbonyl (Lower) alkyl (eg ethoxycarbonylmethyl, ethoxycarbonylethyl), mono or di (lower) alkylamino (lower) alkyl (eg dimethylaminoethyl)); (lower) alkoxy (lower) alkyl (eg Methoxyethyl, ethoxymethyl, ethoxyethyl, isopropoxyethyl, etc.); acyl (eg, formyl, optionally substituted lower alkylcarbonyl (eg, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, octanoyl) , Methoxyethylcarbonyl, 2,2,2-trifluoroethylcarbonyl, alkoxycarbonylacetyl (eg ethoxycarbonylmethylcarbonyl), (lower) alkoxy (lower) alkylcarbonyl (eg methoxyethylcarbonyl), (lower) alkylcarbamoyl (Lower) alkylcarbonyl (eg methylcarbamoylethylcarbonyl), optionally substituted arylcarbonyl (eg benzoyl, toluoyl) Optionally substituted aralkyl (eg benzyl, 4-fluorobenzyl); hydroxy; optionally substituted lower alkylsulfonyl (eg methanesulfonyl, ethanesulfonyl, isopropylsulfonyl, 2,2,2-trifluoro); Ethanesulfonyl, benzylsulfonyl, methoxyethylsulfonyl); arylsulfonyl optionally having lower alkyl or halogen as a substituent (eg, benzenesulfonyl, toluenesulfonyl, 4-fluorobenzenesulfonyl), cycloalkyl (eg, cyclopropyl) ); Aryl optionally having lower alkyl as a substituent (eg, phenyl, tolyl); lower alkylaminosulfonyl (eg, methylaminosulfonyl, dimethylaminosulfonyl); Lower alkoxycarbonyl (eg, ethoxycarbonyl); cycloalkylcarbonyl (eg, cyclopropylcarbonyl, cyclohexylcarbonyl); optionally substituted sulfamoyl (eg, sulfamoyl, methylsulfayl); Lower alkylcarbonylamino (eg methylcarbonylamino); heterocyclic groups (eg morpholino, tetrahydropyranyl); optionally substituted amino (eg mono- or dialkylamino (eg , Dimethylamino), formylamino) and the like.

  The substituted amino or substituted carbamoyl can be mono- or di-substituted.

  The “lower alkenyl” means a straight or branched alkenyl having 2 to 8 carbons and having one or more double bonds on the “lower alkyl”. Examples include vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, 3-methyl-2-butenyl and the like. Alkenyl having 2 to 6 carbons, more preferably 2 to 4 carbons is preferred.

  For "optionally substituted amino" or "optionally substituted carbamoyl", the two substituents of the amino group, together with the adjacent nitrogen atom, can be combined with a sulfur atom and / or A nitrogen-containing heterocyclic ring that may contain an oxygen atom (preferably, the heterocyclic ring is a 5- to 7-membered ring, preferably a saturated type) may be formed. The heterocycle may be substituted with oxo or hydroxy. When the sulfur atom forms a heterocyclic ring, the sulfur atom may be substituted with oxo. Examples thereof include 5- or 6-membered rings such as piperazinyl, piperidino, morpholino, pyrrolidino, 2-oxopiperidino, 2-oxopyrrolidino, 4-hydroxymorpholino.

  The substituent of “optionally substituted lower alkyl” includes at least one group selected from substituent group α. There may be a plurality of substitutions, and these substituents may be the same or different.

  The substituent of “optionally substituted lower alkylene”, “optionally substituted lower alkenylene” and “optionally substituted lower alkynylene” is at least one group selected from substituent group α Is included. There may be a plurality of substitutions, and these substituents may be the same or different.

  The substituent of “optionally substituted cycloalkyl” includes at least one group selected from substituent group α. There may be a plurality of substitutions, and these substituents may be the same or different.

  The substituent of “optionally substituted aryl” includes at least one group selected from substituent group α. There may be a plurality of substitutions, and these substituents may be the same or different.

  The substituent of “optionally substituted heteroaryl” includes at least one group selected from substituent group α. There may be a plurality of substitutions, and these substituents may be the same or different.

  The substituent of “optionally substituted aminosulfonyl” includes at least one group selected from substituted lower alkyl and substituent group α.

  The substituent of “optionally substituted lower alkyloxycarbonyl” includes at least one group selected from substituent group α.

  The substituent of “substituted carbonyloxy” means “—O—C (═O) -substituent”, and the substituent is optionally substituted lower alkyl, optionally substituted lower alkenyl, substituted Selected from lower alkynyl which may be substituted, carbocyclic group which may be substituted, heterocyclic group which may be substituted, amino which may be substituted with heterocyclic group, and substituent group α Containing at least one group.

  Examples of the substituent of “optionally substituted carboxyl” include optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, and optionally substituted carbocycle. Formula groups and optionally substituted heterocyclic groups are included.

  Examples of the “optionally substituted acyl group” include an optionally substituted lower alkyl, an optionally substituted lower alkenyl, an optionally substituted lower alkynyl, and an optionally substituted carbocyclic group. Or, a carbonyl substituted with an optionally substituted heterocyclic group is included.

  The substituent of “optionally substituted saturated or unsaturated monocyclic or fused cyclic quaternary ammonium group” is selected from optionally substituted lower alkyl and substituent group α. Included are one group or any two substituents that may be taken together to form a carbocyclic or heterocyclic group. Lower alkylene as a substituent in a heterocyclic ring containing a quaternary ammonium group may form a crosslinked structure between the quaternary ammonium group in the heterocyclic ring and any carbon atom.

  “Substituent group α” includes halogen, hydroxy, lower alkoxy, lower alkylene, hydroxy (lower) alkoxy, (lower) alkoxy (lower) alkoxy, carboxy, amino, acylamino, lower (alkyl) amino, imino, hydroxyimino, Lower (alkoxy) imino, lower (alkyl) thio, carbamoyl, lower (alkyl) carbamoyl, hydroxy (lower) alkylcarbamoyl, sulfamoyl, lower (alkyl) sulfamoyl, lower (alkyl) sulfinyl, cyano, nitro, carbocyclic group, And a heterocyclic group.

  “Lower alkoxy”, “hydroxy (lower) alkoxy”, “(lower) alkoxy (lower) alkoxy”, “lower (alkyl) amino”, “lower (alkoxy) imino”, “lower (alkyl) thio”, “lower” (Alkyl) carbamoyl ”,“ hydroxy (lower) alkylcarbamoyl ”, and“ lower (alkyl) sulfamoyl ”,“ lower (alkyl) sulfinyl ”,“ lower (alkyl) oxycarbonyl ”,“ lower (alkyl) sulfonyl ” The alkyl moiety is as defined above for “lower alkyl”.

  The lower alkenyl part of “lower (alkenyl) oxy” is as defined above for “lower alkenyl”.

  The aryl moiety of “aryloxy” is as defined below for “aryl”.

  Preferred embodiments of the “optionally substituted lower alkyl” substituent include fluoro, chloro, bromo, hydroxy, carboxy, methoxy, ethoxy, hydroxymethoxy, hydroxyethoxy, methoxymethoxy, methoxyethoxy, amino, acetylamino , Methylamino, dimethylamino, imino, hydroxyimino, methoxyimino, methylthio, carbamoyl, methylcarbamoyl, hydroxymethylcarbamoyl, sulfamoyl, methylsulfamoyl, lower alkylsulfamoyl, cyano, nitro, phenyl, cyclopropyl, cyclobutyl, Examples include cyclohexyl, pyridyl, morpholinyl and the like.

  Preferred embodiments of “optionally substituted lower alkyl” include methyl, ethyl, isopropyl, tert-butyl, halo (lower) alkyl (eg, monochloromethyl, dichloromethyl, trichloromethyl, monofluoromethyl, difluoromethyl) , Trifluoromethyl), carboxymethyl, carboxyethyl, carbamoylmethyl, carbamoylethyl, hydroxymethyl, hydroxyethyl, methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl, methylthiomethyl, ethylthiomethyl, benzyl, phenethyl, 4-hydroxy Examples include benzyl, 4-methoxybenzyl, 4-carboxybenzyl and the like.

  Preferred embodiments of the “optionally substituted cycloalkyl” substituent include fluoro, chloro, bromo, hydroxy, carboxy, methoxy, ethoxy, hydroxymethoxy, hydroxyethoxy, methoxymethoxy, methoxyethoxy, amino, acetylamino , Methylamino, dimethylamino, imino, hydroxyimino, methoxyimino, methylthio, carbamoyl, methylcarbamoyl, hydroxymethylcarbamoyl, sulfamoyl, methylsulfamoyl, lower alkylsulfamoyl, cyano, nitro, phenyl, cyclopropyl, cyclobutyl, Examples include cyclohexyl, pyridyl, morpholinyl and the like.

  “Carbocyclic groups” include cycloalkyl, cycloalkenyl, aryl and non-aromatic fused carbocyclic groups.

  “Cycloalkyl” has 3 to 10 carbons, preferably 3 to 8 carbons, more preferably 3 to 6 carbons, eg, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclo Examples include octyl, cyclononyl, cyclodecyl and the like.

  “Cycloalkenyl” is cycloalkyl containing at least one double bond at any position, and includes, for example, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptynyl, cyclooctynyl, cyclohexadienyl, and the like. .

  “Aryl” includes phenyl, naphthyl, anthryl, phenanthryl, and the like, with phenyl being preferred.

  “Aromatic carbocycle” means a ring derived from aryl as described below.

  “Aromatic heterocycle” means a monocyclic or bicyclic or more aromatic ring having one or more heteroatoms independently or independently selected from O, S or N.

  The bicyclic or higher aromatic heterocyclic group includes those in which a monocyclic or bicyclic or higher aromatic heterocyclic ring is condensed with the above “aromatic carbocycle”.

  “Non-aromatic carbocyclic group” includes the above “cycloalkyl” and “cycloalkenyl”, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopropenyl , Cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptynyl, cyclooctynyl, cyclohexadienyl, and the like.

  As the “non-aromatic fused carbocyclic group”, one or more cyclic groups selected from the above “cycloalkyl” and “cycloalkenyl” are condensed with the above “cycloalkyl”, “cycloalkenyl” or “aryl”. Groups such as indanyl, indenyl, tetrahydronaphthyl, fluorenyl and the like.

  “Heterocyclic group” includes a heterocyclic group having at least one heteroatom arbitrarily selected from O, S, and N in the ring, for example, a 5-membered or 6-membered monocyclic group Non-aromatic heterocyclic groups such as pyrrolidyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydrothienyl and the like; 5- or 6-membered monocyclic heteroaryl such as pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, Pyrazinyl, triazolyl, triazinyl, tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, thiadiazolyl, furyl, thienyl, etc .; 9-membered or 10-membered bicyclic fused heterocyclic group such as indolyl, isoindolyl, indazolyl, indolizinyl Indolinyl, isoindolinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzopyranyl, benzimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzisothiazolyl, Benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, pyrazolopyridine, triazolopyridyl, imidazothiazolyl, pyrazinopyridazinyl, quinazolinyl, quinolyl, isoquinolyl, Naphthyridinyl, dihydrobenzofuryl, tetrahydroquinolyl, tetrahydroisoquinolyl, dihydrobenzoxazine, tetrahydrobenzoyl Zothienyl and the like; tricyclic fused heterocyclic groups such as carbazolyl, acridinyl, xanthenyl, phenothiazinyl, phenoxathinyl, phenoxazinyl, dibenzofuryl, imidazoquinolyl and the like; non-aromatic heterocyclic groups such as dioxanyl, thiylyl, Oxiranyl, oxathiolanyl, azetidinyl, thianyl, thiazolidine, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, thiomorpholino, dihydropyridyltetrapyridyl, dihydrobenzhydropyridyl hydropyridyl Tetrahydrothiazolyl, tetrahydroisothiazolyl, dihydrooxazinyl, hexahydro Examples thereof include azepinyl and tetrahydrodiazepinyl. Preferably, the heterocyclic group is a 5 or 6 membered monocyclic heterocyclic group, or a 9 or 10 membered bicyclic fused heterocyclic group, more preferably a 5 or 6 membered heteroaryl, or 9 It is a membered or 10-membered bicyclic fused heterocyclic group.

  “Heteroaryl” means an aromatic heterocyclic group as described above. 5-membered or 6-membered monocyclic heteroaryl or 9-membered or 10-membered bicyclic heteroaryl are preferred.

  “Heterocycle” means a ring derived from a heterocyclic group as described above. 5-membered or 6-membered monocyclic heterocycle or 9-membered or 10-membered bicyclic heterocycle is preferred.

  The “fused heterocycle” means a ring fused with at least one heterocycle, and includes those in which a monocycle or two or more heterocycles are fused with the above “carbocycle”. A 9-membered or 10-membered bicyclic heterocycle having at least one nitrogen atom is preferred.

  The “monocyclic heterocycle” is preferably a 5- to 7-membered heterocycle having at least one nitrogen atom, more preferably a 6-membered heterocycle.

  The “non-aromatic heterocyclic group” means a group that does not exhibit the aromaticity of the “heterocyclic group”.

  “Optionally substituted carbocyclic group”, “optionally substituted heterocyclic group”, “optionally substituted non-aromatic carbocyclic group”, and “optionally substituted” The substituent of the “non-aromatic heterocyclic group” includes optionally substituted lower alkyl and at least one group selected from the substituent group α.

  “Optionally substituted carbocyclic group”, “optionally substituted heterocyclic group”, “optionally substituted non-aromatic carbocyclic group” and “optionally substituted non-cyclic group” Preferred embodiments of the substituent of “aromatic heterocyclic group” include methyl, ethyl, isopropyl, tert-butyl, fluorine atom, chlorine atom, bromine atom, hydroxy, carboxy, methoxy, ethoxy, hydroxymethoxy, hydroxyethoxy, Methoxymethoxy, methoxyethoxy, amino, acetylamino, methylamino, dimethylamino, imino, hydroxyimino, methoxyimino, methylthio, carbamoyl, methylcarbamoyl, hydroxymethylcarbamoyl, sulfamoyl, methylsulfamoyl, lower alkylsulfamoyl, cyano , Nitro, phenyl, chic Propyl, cyclobutyl, cyclohexyl, pyridyl, morpholinyl and the like.

  5-membered or 6-membered aromatic heterocyclic groups having 1 to 3 nitrogen atoms include pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl , Thiadiazolyl, furyl, thienyl and the like.

Examples of the “optionally substituted carbocyclic group” or “optionally substituted heterocyclic group” for R ¹ include phenyl, aminothiazole, aminothiadiazole, thiophene, furan, benzothiazole, pyridine, Examples include pyrimidine, pyridazine, aminopyridine and the like, each of which may be substituted with hydroxyl and / or halogen. Preferable examples include the following.

Examples of R ^2A include hydrogen, optionally substituted amino, —COOH, —SO ₃ H, optionally substituted aminosulfonyl, carboxyl, optionally substituted carbamoyl, hydroxyl, substituted carbonyloxy and the like. Is mentioned.

の好ましい例では、Ｒ^２Ｂは水素であり、かつ、Ｒ^２Ａは下記の基である：
１）以下に示される置換アミノ基：

２）以下に示される置換アミノスルホニル基：

（式中、環Ｂは、置換されていてもよい複素環式基を表す）；
３）以下に示される置換カルバモイル基：

（式中、環Ｂは、置換されていてもよい複素環式基を表す）；または
４）以下に示される置換カルボニルオキシ：

（式中、環Ｂは、置換されていてもよい）。

In a preferred example of R ^2B is hydrogen and R ^2A is the following group:
1) Substituted amino group shown below:

2) The substituted aminosulfonyl group shown below:

(Wherein ring B represents an optionally substituted heterocyclic group);
3) Substituted carbamoyl group shown below:

(Wherein ring B represents an optionally substituted heterocyclic group); or 4) a substituted carbonyloxy shown below:

(Wherein ring B may be substituted).

（式中、Ｒ^９は、置換されていてもよい低級アルキル、好ましくは、

）を形成していてもよい。 Alternatively, R ^2A and R ^2B are taken together to form a substituted methylidene group as shown below:

Wherein R ⁹ is optionally substituted lower alkyl, preferably

) May be formed.

（式中、Ｒ^９は上記で定義される通り）
を形成していてもよい。以下に示される基が好ましい。

（式中、各記号は上記で定義される通り） R ^2A and R ^2B together can be substituted hydroxyimino as shown below:

(Wherein R ⁹ is as defined above)
May be formed. The groups shown below are preferred.

(Where each symbol is as defined above)

Examples of “R ⁷ and R ⁸ ” are hydrogen, fluoro, chloro, hydroxy, carboxy, methyl, ethyl, isopropyl, tert-butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, carboxymethyl, carboxyethyl, carbamoyl Methyl, carbamoylethyl, hydroxymethyl, hydroxyethyl, methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl, methylthiomethyl, ethylthiomethyl, benzyl, 4-hydroxybenzyl, 4-methoxybenzyl, 4-carboxybenzyl, 3,4 -Dihydroxybenzyl, phenyl, 4-hydroxyphenyl, 3,4-dihydroxyphenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolyl, imidazoli , Pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, thiadiazolyl, furyl, thienyl and the like.

Preferred combinations of (R ⁷ , R ⁸ ) include (hydrogen, hydrogen), (methyl, hydrogen), (hydrogen, methyl), (methyl, methyl), (ethyl, hydrogen), (hydrogen, ethyl), ( Ethyl, ethyl), (phenyl, hydrogen), (hydrogen, phenyl), (dihydroxyphenyl, hydrogen), (hydrogen, dihydroxyphenyl), (carboxymethyl, hydrogen), (hydrogen, carboxymethyl), (carboxyethyl, hydrogen ), (Hydrogen, carboxyethyl), (hydroxyethyl, hydrogen), (hydrogen, hydroxylethyl), (carbamoylmethyl, hydrogen), (hydrogen, carbamoylmethyl), (trifluoromethyl, hydrogen), (carboxy, hydrogen) , (Carbamoylethyl, hydrogen), (benzyl, hydrogen), (dihydroxybenzyl, hydrogen) and the like. More preferred combinations of (R ⁷ , R ⁸ ) include (methyl, methyl), (hydrogen, carboxymethyl), and (carboxyethyl, hydrogen).

Preferable examples of the substituted hydroxyimino include the groups shown below.

More preferable examples of the substituted hydroxyimino include the groups shown below.

（各記号は定義されている通り）
において、「Ｒ^７およびＲ^８は隣接原子と一緒になって、置換されていてもよい炭素環式基または置換されていてもよい複素環式基を形成していてもよい」場合、Ｒ^７およびＲ^８は、シクロアルカン、シクロアルケン、または置換基群αから選択される基で置換されていてもよい非芳香族複素環を形成していてもよい。例えば、式：

の基は、以下に示されるものを含む：

（式中、各環は、置換基群αから選択される基で置換されていてもよい）。 formula:

(Each symbol is as defined)
In which R ⁷ and R ⁸ together with adjacent atoms may form an optionally substituted carbocyclic group or an optionally substituted heterocyclic group, R ⁷ And R ⁸ may form a non-aromatic heterocyclic ring that may be substituted with a group selected from cycloalkane, cycloalkene, or substituent group α. For example, the formula:

The groups of include those shown below:

(In the formula, each ring may be substituted with a group selected from the substituent group α).

  Examples of “Q” include a single bond, phenyl, pyridyl and the like. A single bond is particularly preferred.

  “M” is preferably 0 or 1, with 0 being particularly preferred.

が含まれる。 As a preferable example of the above embodiment,

Is included.

“R ³ ” is preferably hydrogen or —OCH ₃ , more preferably hydrogen.

Lower alkyl of R ^5A and R ^5B includes linear or branched alkyl having 1 to 6 carbons, preferably 1 to 4 carbons, such as methyl, ethyl, n-propyl, isopropyl, Examples thereof include n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl and the like.

Examples of the combination of (R ^5A , R ^5B ) include (hydrogen, methyl), (hydrogen, ethyl), (hydrogen, isopropyl), (hydrogen, tert-butyl), (methyl, methyl), and the like. Preferably, (R ^5A , R ^5B ) is (hydrogen, methyl) or (methyl, methyl).

The carbocycle of “R ^5A and R ^5B may be combined with adjacent atoms to form an optionally substituted carbocycle” has 3 to 8 carbons, preferably 3 to 6 carbons. Cycloalkanes and cycloalkenes having the following carbons: Preferred embodiments include cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, and more preferably cyclopropane. Carbon ring substituents include halogen, hydroxyl, lower alkyl, lower alkoxy, and the like. Preferred embodiments include fluoro, chloro, hydroxyl, methyl, ethyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropoxy and the like.

The heterocyclic ring of “R ^5A and R ^5B may be combined with an adjacent atom to form an optionally substituted heterocyclic ring” includes aromatic or non-aromatic, monocyclic or condensed ring Formula rings are included. Preferred embodiments include non-aromatic 3-6 membered monocyclic rings. Heterocyclic substituents include halogen, hydroxyl, lower alkyl, lower alkoxy and the like. Preferred embodiments include fluoro, chloro, hydroxyl, methyl, ethyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropoxy and the like.

（式中、Ｒ^１３およびＲ^１４はそれぞれ独立に、水素、ハロゲン、または置換されていてもよい低級アルキルであり、好ましいＲ^１３およびＲ^１４は水素である）
で示される。 An optionally substituted methylidene of “R ^5A and R ^5B together may form an optionally substituted methylidene” has the formula:

(Wherein R ¹³ and R ¹⁴ are each independently hydrogen, halogen, or optionally substituted lower alkyl, and preferred R ¹³ and R ¹⁴ are hydrogen)
Indicated by

_{"L", -CH 2 -, - CH =} CH -, - CH 2 -CH = CH -, - CH = CH-CH 2 -, - S -, - CH 2 -S -, - CH = CH- S— or —CH═CH—CH ₂ —S—, preferably —CH ₂ —, —CH ₂ —CH═CH—, —S— or —CH ₂ —S—.

  E is an optionally substituted saturated or unsaturated monocyclic or fused cyclic group having at least one quaternary ammonium ion, preferably the above formulas (1) to (77) Which may be substituted on the ring. The substituent on the ring includes one or more groups selected from optionally substituted lower alkyl or substituent group α. Preferred embodiments of such substituents include methyl, ethyl, isopropyl, tert-butyl, fluorine atom, chlorine atom, bromine atom, hydroxyl, carboxyl, methoxy, ethoxy, hydroxymethoxy, hydroxyethoxy, methoxymethoxy, methoxyethoxy , Methylene, ethylene, propylene, butylene, amino, acetylamino, methylamino, dimethylamino, imino, hydroxyimino, methoxyimino, methylthio, carbamoyl, methylcarbamoyl, hydroxymethylcarbamoyl, sulfamoyl, methylsulfamoyl, (lower) alkyl Sulfamoyl, cyano, nitro, phenyl, cyclopropyl, cyclobutyl, cyclohexyl, pyridyl, morpholinyl and the like are included. More preferred embodiments include rings that are unsubstituted or mono- or disubstituted with hydroxyl groups. Such rings that are mono- or disubstituted with a hydroxyl group may be further substituted with another substituent. Here, when the substituent is lower alkylene such as ethylene, propylene, or butylene, the lower alkylene is between the quaternary ammonium group in E and any carbon atom, or between any two carbon atoms. A cross-linked structure may be formed.

［式中、
破線は環内における結合であり；
カチオン性窒素原子からの結合手はＬと結合し、他方の結合手はＲ^１０と結合し；
ただし、カチオン性窒素原子がＲ^１０と結合している場合には、破線は存在せず、かつ、
カチオン性窒素原子がＲ^１０と結合していない場合には、破線はカチオン性窒素原子と隣接原子との間の単結合またはカチオン性窒素原子と前記隣接原子以外の環員原子との間のアルキレン基を示す］
または式（Ｉ−Ｅ）：

（式中、カチオン性窒素原子からの結合手はＬと結合し、他方の結合手はＲ^１０と結合し；Ｒｘは置換されていてもよい低級アルキルである）
である。 A preferred embodiment of E is of formula (ID):

[Where:
The dashed line is the bond in the ring;
The bond from the cationic nitrogen atom is bonded to L and the other bond is bonded to R ¹⁰ ;
However, when a cationic nitrogen atom is bonded to R ¹⁰ , there is no broken line, and
When the cationic nitrogen atom is not bonded to R ¹⁰ , the broken line indicates a single bond between the cationic nitrogen atom and an adjacent atom or an alkylene between the cationic nitrogen atom and a ring member atom other than the adjacent atom. Show group]
Or formula (IE):

(In the formula, a bond from a cationic nitrogen atom is bonded to L, and the other bond is bonded to R ¹⁰ ; Rx is an optionally substituted lower alkyl)
It is.

（式中、カチオン性窒素原子からの結合手はＲ^１０と結合し、他方の結合手はＬと結合している）
で示される単環式または縮合複素環式基であり、より好ましいＥは、置換されていてもよいピリジニウム基または置換されていてもよい縮合ピリジニウム基である。 L is _{-S -, - CH 2 -S -} , - CH = CH-S- or -CH = _CH-CH 2 -S- case is, preferred embodiments of E has the formula (I-D '):

(Wherein the bond from the cationic nitrogen atom is bonded to R ¹⁰ and the other bond is bonded to L)
And more preferable E is an optionally substituted pyridinium group or an optionally substituted fused pyridinium group.

（式中、第四級窒素原子からの結合手はＬと結合し、他方の結合手はＲ^１０と結合し；ｐは１〜３の整数であり；ｎは１または２であり；各Ｒｘは独立に置換されていてもよい低級アルキル基である）。 Preferred examples of E include the following formula which may be substituted on the ring:

(Wherein, the bond from the quaternary nitrogen atom is bonded to L, and the other bond is bonded to R ¹⁰ ; p is an integer of 1 to 3; n is 1 or 2; Are independently substituted lower alkyl groups).

  Among the above formulas, the formulas (1) to (7), (10) to (12), (14), (25) to (29), (31), (41) to (44), (47) , (50), (52), (53), (59), (60), (64), (73) and (77) are more preferred.

  In particular, the formulas (2), (3), (5), (6), (7), (10), (11), (26), (27), (41), (42), (59) , (60) and (77) are preferred.

In the present invention, E is an optionally substituted saturated or unsaturated monocyclic or fused cyclic group having at least one quaternary ammonium ion, and includes the following embodiments:
1) when E is an aromatic heterocyclic group in which two hydroxyl groups are each bonded to each of two adjacent carbon atoms on the aromatic ring;
2) If E is one or more hydroxyl groups not bonded to the ring, or if one or hydroxyl groups are bonded, then two hydroxyl groups are each two adjacent carbons on the ring If it is a heterocyclic group not bonded to each of the atoms; and 3) if E is an acyclic group.

1) or 2) is preferred.

（式中、第四級窒素原子との一方の結合手はＬと結合し、他方の結合手はＲ^１０と結合している）
が挙げられる。 As a preferable example of the above 1),

(In the formula, one bond to the quaternary nitrogen atom is bonded to L, and the other bond is bonded to R ¹⁰ )
Is mentioned.

（式中、第四級窒素原子との一方の結合はＬと結合し、Ｒ^１２は上記で定義される通りである）
が挙げられる。 As a preferable example of E-R ¹⁰ ,

(Wherein one bond to the quaternary nitrogen atom is bonded to L and R ¹² is as defined above).
Is mentioned.

（式中、第四級窒素原子からの結合手はＬと結合している）
が挙げられる。 As a more preferable example of E-R ¹⁰ ,

(Wherein the bond from the quaternary nitrogen atom is bonded to L)
Is mentioned.

である。 R ⁶ is hydrogen or optionally substituted lower alkyl, preferably hydrogen, straight or branched alkyl having 1 to 4 carbons, or 1 to 4 substituted with carboxy, halogen, hydroxyl or carbonyl. Linear or branched alkyl having 4 carbons, more preferably hydrogen, methyl, ethyl, tert-butyl,

It is.

In the present invention, “B” or “D” in the above formula is as defined throughout the present specification, that is, as follows.
B is absent, a single bond or a 5- or 6-membered heterocyclic group containing at least 1 to 3 nitrogen atoms.
D is absent, a single bond, -C (= O) -, - O-C (= O) -, - C (= O) -O -, - NR 6 -, - NR 6 -C (= ^{O) -, - C (=} O) -NR 6 -, - C (= O) -C (= O) -, - NR 6 -C (= O) -NR 6 -, - C (= O) - ^{C (= O) -NR 6 -} , - C (= O) -NR 6 -C (= O) -, - NR 6 -C (= O) -C (= O) -, - NR 6 -NR 6 -C (= O)-, -C (= O) -NR < ⁶ > -NR < ⁶ >-, -N = NC (= O)-, -C (= O) -N = N-, -C = N. —NR ⁶ —C (═O) —, —C═N—C (═O) —, —N═C—C (═O) —, —C═N—C (═O) —NR ⁶ —, ^{-NR 6 -C (= O) -C} (= N-OR 6) -, - C (= N-OR 6) -C (= O) -NR 6 -, - NR 6 -C (= ^{-OR 6) -, - C (} = N-OR 6) -NR 6 -, - C (= O) -C (= N-OR 6) -, - C (= N-OR 6) -C (= O) -, - O -, - S -, - S (= O) -, - S (= O) 2 -NR 6 -, - NR 6 -S (= O) 2 -, - NR 6 -CH 2 _-, - CH 2 -NR ⁶ - or -S (= _{O) 2} - a.

  In view of the above definitions and the description throughout this specification, “B” and “D” in the above formulas may not be present individually or independently, or both “B” and “D” When referring to a single bond, “B” and “D” may be together or together (ie, “BD” interconnected), so that the corresponding as defined by the present invention. It may represent a single bond that binds to adjacent or adjacent functional groups.

で示される基としてのＲ^１０の好ましい実施形態を以下に記載する。 formula:

Preferred embodiments of R ¹⁰ as the group represented by are described below.

  G is preferably a single bond or an optionally substituted lower alkylene, more preferably a single bond, methylene or ethylene.

（式中、左側の結合手はＧと結合し、右側の結合手はＤと結合している）
で示される基である。 B is absent or preferably a single bond or the formula:

(In the formula, the left bond is bonded to G, and the right bond is bonded to D)
It is group shown by these.

  B is absent or more preferably a single bond.

D is absent or preferably a single bond, —C (═O) —, —O—C (═O) —, —C (═O) —O—, —NR ⁶ —, —O—, ^{-C (= O) -C (=} O) -, - NR 6 -C (= O) -NR 6 -, - C (= O) -C (= O) -NR 6 -, - C (= O ) —NR ⁶ —C (═O) —, —NR ⁶ —C (═O) —C (═O) —, —NR ⁶ —C (═O) —, —C (═O) —NR ⁶ — , —NR ⁶ —NR ⁶ —C (═O) —, —C (═O) —NR ⁶ —NR ⁶ —, —N═N—C (═O) —, —C (═O) —N = N-, -C = N-NR < ⁶ > -C (= O)-, -C = N-C (= O)-, -N = C-C (= O)-, -C = N-C (= ^{O) -NR 6 -, - NR} 6 -C (= O) -C (= N-OR 6) -, - C (= N-OR 6) -C (= O) -NR 6 - ^{-NR 6 -C (= N-OR} 6) -, - C (= O) -C (= N-OR 6) -, - C (= N-OR 6) -C (= O) - or -C (═N—OR ⁶ ) —NR ⁶ — (wherein R ⁶ is hydrogen, methyl, carboxymethyl or 2-carboxypropan-2-yl), more preferably a single bond, —C ( = O)-, -C (= O) -C (= O)-, -NH-C (= O) -C (= O)-, -NH-C (= O)-, -NH-C ( ^{= O) -C (= N-} oR 6) -, - C (= O) -C (= N-oR 6) -, - NH -, - O-, or -C = N-NH-C ( = O)-and R ⁶ is hydrogen, methyl, ethyl, tert-butyl, carboxymethyl, 2-carboxypropan-2-yl or 1-carboxyethyl.

［式中、
ｋは０〜３の整数であり、Ｒ^６は上記で定義される通りであり、
波線は、結合がシス配置もしくはトランス配置、またはその混合であることを意味する］
が挙げられる。 As a preferable combination of “—GBD”, the following formula:

[Where:
k is an integer from 0 to 3, R ⁶ is as defined above,
The wavy line means that the bond is a cis configuration or a trans configuration, or a mixture thereof]
Is mentioned.

［式中、
Ｍｅはメチル基を表し、
ｈは０〜３の整数であり、
Ｒ^６は、水素、メチル、エチル、ｔｅｒｔ−ブチル、カルボキシメチル、２−カルボキシプロパン−２−イルまたは１−カルボキシエチルであり、
波線は、結合がシス配置もしくはトランス配置、またはその混合であることを意味する］
が挙げられる。 Preferable examples of “-E-GBD-” include the formulas shown below:

[Where:
Me represents a methyl group,
h is an integer of 0 to 3,
R ⁶ is hydrogen, methyl, ethyl, tert-butyl, carboxymethyl, 2-carboxypropan-2-yl or 1-carboxyethyl;
The wavy line means that the bond is a cis configuration or a trans configuration, or a mixture thereof]
Is mentioned.

については、
環Ａは、ともに縮合した少なくとも２つの環からなる縮合複素環系として定義され；
ここで、
Ｒ^４は、環Ａとして定義される縮合複素環系の少なくとも２つの環のそれぞれにおいて、その縮合複素環系の各環上の各Ｒ^４置換基が同一または異なる置換基から独立に選択されるように置換していてもよく；
ここで、
上記で定義される各Ｒ^４は、縮合複素環の各環上で独立に置換していてもく、水素、ハロゲン、オキソ、−ＯＨ、−ＣＮ、−ＮＯ_２、−Ｏ−Ｃ（＝Ｏ）−Ｒ^９、−Ｃ（＝Ｏ）−Ｒ^９、−Ｃ（＝Ｏ）−ＯＨ、−Ｃ（＝Ｏ）−ＯＲ^９、−ＯＲ^９，、−ＮＲ^９Ｒ^９、−ＳＯ_２Ｒ^９、−ＳＲ^９、−ＮＲ^９−Ｃ（＝Ｏ）−Ｒ^９、置換されていてもよい低級アルキル、置換されていてもよいシクロアルキル、置換されていてもよいアリール、または置換されていてもよいヘテロアリールから選択され；
ただし、環Ａ上の２個のヒドロキシル基は各々隣接して位置する炭素原子とそれぞれ結合しており；かつ
ｎは０〜２の整数である。 In one embodiment of the present invention, the formula (IB):

about,
Ring A is defined as a fused heterocyclic ring system consisting of at least two rings fused together;
here,
R ^4, at each of the at least two rings fused heterocyclic ring system which is defined as a ring A, each of R ⁴ substituents on each ring in the fused heterocyclic ring system is independently selected from the same or different substituents May be substituted as follows;
here,
Each R ⁴ defined above may be independently substituted on each ring of the condensed heterocyclic ring, and may be hydrogen, halogen, oxo, —OH, —CN, —NO ₂ , —O—C (═O ) —R ⁹ , —C (═O) —R ⁹ , —C (═O) —OH, —C (═O) —OR ⁹ , —OR ⁹ , —NR ⁹ R ⁹ , —SO ₂ R ⁹ , —SR ⁹ , —NR ⁹ —C (═O) —R ⁹ , optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted Selected from good heteroaryl;
However, two hydroxyl groups on ring A are each bonded to adjacent carbon atoms; and n is an integer of 0-2.

の基の好ましい実施形態としては、
環Ａが、それぞれ本明細書の全体にわたって定義されるようなベンゼン環、単環式複素環または縮合複素環であり；
各Ｒ^４が独立に、水素、ハロゲン、オキソ、−ＯＨ、−ＣＮ、−ＮＯ２、−Ｏ−Ｃ（＝Ｏ）−Ｒ^９、−Ｃ（＝Ｏ）−Ｒ^９、−Ｃ（＝Ｏ）−ＯＨ、−Ｃ（＝Ｏ）−ＯＲ^９、−ＯＲ^９、−ＮＲ^９Ｒ^９、−ＳＯ_２Ｒ^９、−ＳＲ^９、−ＮＲ^９−Ｃ（＝Ｏ）−Ｒ^９、低級アルキル、ハロ（低級）アルキル、シクロアルキル、アリール、またはヘテロアリールであり；各Ｒ^９は独立に、低級アルキルまたはハロ（低級）アルキルであり；ｎは０〜２の整数であり；ただし、環Ａ上の２個のヒドロキシル基は、各々隣接して位置する炭素原子とそれぞれ結合している。 formula:

As a preferred embodiment of the group of
Ring A is a benzene ring, monocyclic heterocycle or fused heterocycle, each as defined throughout the specification;
Each R ⁴ is independently hydrogen, halogen, oxo, —OH, —CN, —NO 2, —O—C (═O) —R ⁹ , —C (═O) —R ⁹ , —C (═O). —OH, —C (═O) —OR ⁹ , —OR ⁹ , —NR ⁹ R ⁹ , —SO ₂ R ⁹ , —SR ⁹ , —NR ⁹ —C (═O) —R ⁹ , lower alkyl, halo (Lower) alkyl, cycloalkyl, aryl, or heteroaryl; each R ⁹ is independently lower alkyl or halo (lower) alkyl; n is an integer from 0 to 2; provided that on ring A The two hydroxyl groups are each bonded to adjacent carbon atoms.

  Preferred examples of ring A include benzene, 5- to 7-membered monocyclic heterocycle and 8- to 12-membered fused heterocycle, as defined throughout this specification.

  Preferable examples of the 5- to 7-membered monocyclic heterocycle of ring A include a ring having 1 to 3 nitrogen atoms, more preferably 1 nitrogen atom.

  Preferable examples of the 8- to 12-membered condensed heterocyclic ring of ring A include a ring having 1 to 4 nitrogen atoms, more preferably 1 or 2 nitrogen atoms.

  More preferred examples of ring A include benzene, a 5-6 membered monocyclic heterocycle having 1 nitrogen atom, and a 9-10 membered condensed heterocycle having 1 or 2 nitrogen atoms.

の基の好ましい例としては、以下に示される式：

［式中、
各Ｒ^４ａ、Ｒ^４ｂ、Ｒ^４ｃおよびＲ^４ｄは独立に、水素、ハロゲン、−ＯＨ、−ＣＮ、−Ｃ（＝Ｏ）−Ｒ^９、−Ｃ（＝Ｏ）−ＯＨ、−Ｃ（＝Ｏ）−ＯＲ^９、−ＯＲ^９、置換されていてもよい低級アルキル、または置換されていてもよいシクロアルキルであり；
Ｒ^９は独立に、低級アルキルまたはハロ（低級）アルキルであり；
Ｒ^６は、水素、または置換されていてもよい低級アルキルである］
が挙げられる。 formula:

Preferable examples of the group of the formula:

[Where:
Each R ^4a , R ^4b , R ^4c and R ^4d is independently hydrogen, halogen, —OH, —CN, —C (═O) —R ⁹ , —C (═O) —OH, —C (═O ) -OR 9, ^{-OR 9,} be optionally substituted lower alkyl or optionally substituted cycloalkyl;
R ⁹ is independently lower alkyl or halo (lower) alkyl;
R ⁶ is hydrogen or optionally substituted lower alkyl.]
Is mentioned.

の基のより好ましい例としては、以下に示される式：

（式中、Ｍｅはメチル基を表す）
が挙げられる。 formula:

More preferred examples of the group of the formula:

(In the formula, Me represents a methyl group)
Is mentioned.

の基の好ましい例としては、以下に示される式：

［式中、
各Ｒ^４ａ、Ｒ^４ｂ、Ｒ^４ｃおよびＲ^４ｄは独立に、水素、ハロゲン、−ＯＨ、−ＣＮ、−Ｃ（＝Ｏ）−Ｒ^９、−Ｃ（＝Ｏ）−ＯＨ、−Ｃ（＝Ｏ）−ＯＲ^９、−ＯＲ^９、置換されていてもよい低級アルキル、または置換されていてもよいシクロアルキルであり；
Ｒ^９は独立に、低級アルキルまたはハロ（低級）アルキルであり；
Ｒ^６は、水素、または置換されていてもよい低級アルキルであり；
波線は、結合がシス配置もしくはトランス配置、またはその混合であることを意味する］
が挙げられる。 Formula (1-C-1):

Preferable examples of the group of the formula:

[Where:
Each R ^4a , R ^4b , R ^4c and R ^4d is independently hydrogen, halogen, —OH, —CN, —C (═O) —R ⁹ , —C (═O) —OH, —C (═O ) -OR 9, ^{-OR 9,} be optionally substituted lower alkyl or optionally substituted cycloalkyl;
R ⁹ is independently lower alkyl or halo (lower) alkyl;
R ⁶ is hydrogen or optionally substituted lower alkyl;
The wavy line means that the bond is a cis configuration or a trans configuration, or a mixture thereof]
Is mentioned.

Examples of R ^4a , R ^4b , R ^4c and R ^4d include hydrogen, chloro, fluoro, bromo, cyano, hydroxy, carboxy, acetyl, methoxy, ethoxy, trifluoromethyl and the like. Preferably, each R ^4a , R ^4b , R ^4c and R ^4d is independently hydrogen, hydroxy, carboxy, methoxy, fluoro, trifluoromethyl, or chloro.

の基のより好ましい例としては、以下に示される式：

［式中、Ｒ^６は、水素、メチル、エチル、ｔｅｒｔ−ブチル、カルボキシメチル、２−カルボキシプロパン−２−イルまたは１−カルボキシエチルであり、
波線は、結合がシス配置もしくはトランス配置、またはその混合であることを意味する］
が挙げられる。 Formula (1-C-1):

More preferred examples of the group of the formula:

[Wherein R ⁶ is hydrogen, methyl, ethyl, tert-butyl, carboxymethyl, 2-carboxypropan-2-yl or 1-carboxyethyl;
The wavy line means that the bond is a cis configuration or a trans configuration, or a mixture thereof]
Is mentioned.

The nomenclature of the substitution positions on the cephem skeleton of formula (I) is as follows. In the present specification, the 3-position side chain, the 4-position side chain, and the 7-position side chain mean groups bonded to the 3-position, 4-position, and 7-position of the cephem skeleton, respectively.

（式中、各記号は上記で定義される通り）
に示されるＲ^１、Ｒ^２ＡまたはＲ^２Ｂの末端において、置換されていてもよいアミノ、置換されていてもよいアミノスルホニル、カルボキシル、置換されていてもよい（低級）アルキルオキシカルボニル、置換されていてもよいカルバモイル、置換カルボニルオキシなどにおける任意のカルボキシ基がエステル化されている化合物が含まれる。例えば、カルボキシ（−ＣＯＯＨ）の場合、このようなエステルは構造式−ＣＯＯＲ^ａで示され、ここで、Ｒ^ａはカルボキシル保護基などのエステル残基である。このようなエステルには、体内で容易に代謝されてカルボキシ状態となるものが含まれる。 The ester of formula (I) preferably comprises an ester in the 7-position side chain. As an ester in the carboxy group on the 7-position side chain, the formula:

(Where each symbol is as defined above)
In the terminal of R ¹ , R ^2A or R ^2B shown in the above, optionally substituted amino, optionally substituted aminosulfonyl, carboxyl, optionally substituted (lower) alkyloxycarbonyl, Compounds in which any carboxy group in carbamoyl, substituted carbonyloxy and the like may be esterified are included. For example, in the case of carboxy (—COOH), such esters are represented by the structural formula —COOR ^a , where R ^a is an ester residue such as ^a carboxyl protecting group. Such esters include those that are easily metabolized in the body to the carboxy state.

  The above protecting groups such as carboxyl are described in Protective Groups in Organic Synthesis, T .; W. By Greene, John Wiley & Sons Inc. Any group may be used as long as it can be protected and / or deprotected by the method described in (1991). Examples include lower alkyl (eg, methyl, ethyl, t-butyl), (lower) alkylcarbonyloxymethyl (eg, pivaloyl), optionally substituted aralkyl (eg, benzyl, benzhydryl, phenethyl, p- Methoxybenzyl, p-nitrobenzyl), silyl group (t-butyldimethylsilyl, diphenyl (t-butyl) silyl) and the like.

  The amino-protected compound in the amino group on the 7-position side chain of formula (I) means a structure in which the amino group on the ring (eg, thiazole, thiadiazole) is protected.

An amino protecting group is represented by the formula —NHR ^c , where R ^c represents an amino protecting group. Such amino protecting groups include those that are readily metabolized in the body to form amino. The amino protecting groups described above are described in Protective Groups in Organic Synthesis, T .; W. By Greene, John Wiley & Sons Inc. Any group may be used as long as it can be protected and / or deprotected by the method described in (1991). Examples thereof include (lower) alkoxycarbonyl (eg, t-butoxycarbonyl, benzyloxycarbonyl, p-nitrobenzyloxycarbonyl), optionally substituted aralkanoyl (eg, benzoyl, p-nitrobenzoyl), acyl ( Examples thereof include formyl and chloroacetyl.

  The compound (I) of the present invention is not limited to a specific isomer, and all isomers that can exist (for example, keto-enol isomer, imine-enamine isomer, diastereoisomer, geometric isomer, optical isomerism) , Rotamers, etc.), racemates and mixtures thereof.

には、

が含まれる。 For example, the following structure in formula (I):

In

Is included.

（式中、各記号は上記で定義される通り）
には、下記の共鳴構造：

（式中、Ｒ^４は上記で定義される通り）
が含まれる。 For example, the following structure in formula (I):

(Where each symbol is as defined above)
The following resonance structure:

(Wherein R ⁴ is as defined above)
Is included.

（式中、各記号は上記で定義される通り）
が含まれる。 The group “E” in formula (I) includes, for example, the following resonance structure:

(Where each symbol is as defined above)
Is included.

（式中、Ｒ^６は上記で定義される通り）
には、

およびそれらの混合物が含まれる。 For example, the following structure in formula (I):

(Wherein R ⁶ is as defined above)
In

And mixtures thereof.

At least one hydrogen atom, carbon atom and / or other atom can be replaced with an isotope of said hydrogen atom, carbon atom and / or other atom. Examples of such isotopes include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine and chlorine isotopes, such as ² H, ³ H, ¹¹ C, ¹³ C, ¹⁴ C, ¹⁵ N , ¹⁸ O, ¹⁷ O, ³¹ P, ³² P, ³⁵ S, ¹⁸ F, ¹²³ I and ³⁶ Cl. Compounds of formula (I) include compounds having an atom substituted with such an isotope. Such compounds substituted with isotopes are also useful as pharmaceuticals, and the compounds of formula (I) include all such radiolabeled compounds. The present invention also includes radiolabeling methods for the production of such radiolabeled compounds and is therefore useful in metabolic pharmacokinetic studies, binding assays and / or diagnostic tools.

Radiolabeled compounds of formula (I) can be made according to techniques well known in the art. For example, to make a tritium labeled compound of formula (I), tritium can be introduced into a specific compound of formula (I) by catalytic dehalogenation using tritium. This method comprises reacting a compound of formula (I) with a suitably halogen-substituted precursor and tritium gas in the presence of a suitable catalyst, for example Pd / C, in the presence or absence of a base. Comprising. Another method for the preparation of tritium labeled compounds is described in the literature Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A), Chapter 6 (1987), and the like. ¹⁴ C-labeled compounds can be made using starting materials containing ¹⁴ C.

  The salt of the compound of the formula (I) includes a salt formed by a 7-position side chain carboxy group and / or a 7-position side chain amino group with an inorganic acid or an organic acid, and a 3-position side chain quaternary amine moiety. Are included with the counter anion.

  Pharmaceutically acceptable salts of the compounds of formula (I) include, for example, alkali metals (eg, lithium, sodium, potassium, etc.), alkaline earth metals (eg, calcium, barium, etc.), magnesium, transition metals (eg, , Zinc, iron, etc.), ammonia, organic bases (eg trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, diethanolamine, ethylenediamine, pyridine, picoline, quinoline, etc.) and salts formed with amino acids Or inorganic acids (eg, hydrochloric acid, sulfuric acid, nitric acid, carbonic acid, hydrobromic acid, phosphoric acid, hydroiodic acid, etc.) and organic acids (eg, formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid, Lactic acid, tartaric acid, sh Acid, maleic acid, fumaric acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, ascorbic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, etc.) In particular, mention may be made of salts formed with hydrochloric acid, sulfuric acid, phosphoric acid, tartaric acid, methanesulfonic acid. These salts can be formed according to conventional methods.

  A compound of formula (I) or a pharmaceutically acceptable salt thereof may form solvates (eg, hydrates, etc.) and / or crystalline polymorphs, and the present invention also provides such solvates. And polymorphs. In such a “solvate”, any number of solvent molecules (eg, water molecules) may be coordinated with the compound of formula (I). The compound of formula (I) or a pharmaceutically acceptable salt thereof may absorb moisture and adhere to adsorbed water or form a hydrate when left in the air. A crystalline polymorph of the compound of formula (I) or a pharmaceutically acceptable salt thereof can also be formed by recrystallization.

  The compounds of formula (I) or pharmaceutically acceptable salts thereof may form prodrugs and the present invention also includes such prodrugs. Prodrugs are derivatives of the compounds of the invention which have groups that are chemically or metabolically degradable so that they can be converted to pharmaceutically active compounds by solvolysis or in vivo under physiological conditions. . A prodrug is a compound that can be converted to a compound of formula (I) by enzymatic oxidation, reduction, hydrolysis under physiological conditions in vivo, or a compound that can be converted to a compound of formula (I) by hydrolysis with gastric acid, etc. including. Methods for selecting and producing suitable prodrug derivatives are described, for example, in Design of Prodrugs, Elsevier, Amsterdam 1985.

  Prodrugs can themselves be active compounds.

When the compound of formula (I) or a pharmaceutically acceptable salt thereof has a hydroxyl group, an acyloxy derivative or a sulfonyloxy derivative can be prepared as a prodrug. For example, such a compound having a hydroxyl is reacted with a suitable acyl halide, acid anhydride, or a suitable sulfonyl chloride, anhydrous sulfonyl, mixed anhydride, or the like, or, for example, CH ₃ COO—, C ₂ H ₅ COO _{-, t-BuCOO-, C 15} H 31 COO-, PhCOO -, (m-NaOOCPh) COO-, NaOOCCH 2 CH 2 COO-, CH 3 CH (NH 2) COO-, CH 2 N (CH 3) 2 _{COO-, CH 3 SO 3 -,} CH 3 CH 2 SO 3 -, CF 3 SO 3 -, CH 2 FSO 3 -, CF 3 CH 2 SO 3 -, p-CH 3 -O-PhSO 3 -, PhSO 3 _{-, p-CH 3 PhSO 3} - may be reacted with a coupling agent having such a group.

［式中、
Ｙは脱離基であり；Ｐ^２は保護基であり；
Ｒ^５Ａ、Ｒ^５ＢおよびＬは上記で定義される通りである］
の化合物またはその薬学上許容される塩が中間体として好ましい。 For the synthesis of compounds of formula (I), formula (IH):

[Where:
Y is a leaving group; P ² is a protecting group;
R ^5A , R ^5B and L are as defined above]
Or a pharmaceutically acceptable salt thereof is preferred as an intermediate.

Compounds of formula (IH) wherein P ² is a benzhydryl group, p-methoxybenzyl group, trityl group, 2,6-dimethoxybenzyl group, methoxymethyl group, benzyloxymethyl group or 2- (trimethylsilyl) ethoxymethyl group Or its salt is preferable as an intermediate.

A compound of formula (IH) or a salt thereof in which R ^5A is methyl and R ^5B is hydrogen is preferred as an intermediate.

［式中、
Ｙは脱離基であり；Ｐ^２は保護基であり；
Ｒ^５ＡおよびＬは上記で定義される通りである］
の化合物またはその塩、またはその薬学上許容される塩が中間体として好ましい。 For the synthesis of compounds of formula (I), compounds of formula (I-I):

[Where:
Y is a leaving group; P ² is a protecting group;
R ^5A and L are as defined above]
Or a pharmaceutically acceptable salt thereof is preferred as an intermediate.

（式中、Ｙは脱離基であり；Ｐ^２は保護基であり；Ｒ^５Ａ、Ｒ^５ＢおよびＬは上記で定義される通りである）
の化合物またはその薬学上許容される塩が中間体として好ましい。７−アミノは、カウンターアニオン（Ｚ⁻）を用いて塩（−ＮＨ_３ ^＋Ｚ⁻）とすることで形成することができる。 For the synthesis of compounds of formula (I), the formula:

Wherein Y is a leaving group; P ² is a protecting group; R ^5A , R ^5B and L are as defined above.
Or a pharmaceutically acceptable salt thereof is preferred as an intermediate. 7-amino can be formed by using a counter anion (Z ⁻ ) to form a salt (—NH ₃ ⁺ Z ⁻ ).

  Examples of the leaving group include halogen (Cl, Br, I, F), acetoxy, methanesulfonyloxy, p-toluenesulfonyloxy, trifluoromethanesulfonyloxy and the like.

（式中、Ｙは脱離基であり；Ｐ２は保護基であり；Ｒ^５Ａ、Ｒ^５ＢおよびＬは上記で定義される通りである）
の化合物の好ましい例は、式：

（式中、Ｙは脱離基であり；Ｐ^２は保護基であり；Ｌは上記で定義される通りである）
の化合物である。 formula:

Where Y is a leaving group; P2 is a protecting group; R ^5A , R ^5B and L are as defined above.
Preferred examples of the compound of formula:

Where Y is a leaving group; P ² is a protecting group; L is as defined above.
It is a compound of this.

As described in the general synthesis and examples below, the intermediate compounds described above can be reacted with side chain moieties at the 3rd, 4th and 7th positions of the cephem skeleton to yield compounds of formula (I). Examples of protecting groups “P ² ” are those described in the general synthesis below, preferably benzhydryl, p-methoxybenzyl, trityl, 2,6-dimethoxybenzyl, methoxymethyl, benzyloxymethyl or 2- (Trimethylsilyl) ethoxymethyl and the like.

式中、Ｐ^１およびＰ^２は保護基であり；Ｙは脱離基（例えば、ハロゲン（Ｃｌ、Ｂｒ、Ｉ、Ｆ）、メタンスルホニルオキシ、ｐ−トルエンスルホキシ）であり；Ｒ^５は水素または低級アルキルであり；他の記号は上記で定義される通りである。 (General synthesis method)
Scheme 1 represents a general scheme for the preparation of compounds of the present invention.

Where P ¹ and P ² are protecting groups; Y is a leaving group (eg halogen (Cl, Br, I, F), methanesulfonyloxy, p-toluenesulfoxy); R ⁵ is hydrogen Or lower alkyl; other symbols are as defined above.

1) Formation of 2-methylcephem: Synthesis step 1 of compound (X)
The 4-carboxyl group of compound (II) is protected with a carboxyl protecting group by a conventional method to give compound (III). Carboxyl protecting groups are exemplified by diphenylmethyl, p-methoxybenzyl, and the like.

  Examples of the reaction solvent include ethers (eg, dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether), esters (eg, ethyl formate, ethyl acetate, isopropyl acetate), and halogenated hydrocarbons (eg, dichloromethane). , Chloroform, carbon tetrachloride), hydrocarbon (eg, n-hexane, benzene, toluene), amide (eg, formamide, N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone), ketone ( For example, acetone, methyl ethyl ketone), nitrile (for example, MeCN, propionitrile), dimethyl sulfoxide, water, and a mixed solvent thereof can be mentioned.

  The reaction temperature is usually in the range of about -100 ° C to 100 ° C, preferably about -80 ° C to 80 ° C, more preferably about -60 ° C to 60 ° C. The reaction time may vary depending on the reagent, solvent or reaction temperature used, but is usually 0.5 to 24 hours.

Process 2
Compound (IV) can be obtained by subjecting compound (III) to an oxidation reaction using an oxidizing agent (for example, m-chloroperbenzoic acid or acetic acid peroxide) well known to those skilled in the art.

  Examples of the reaction solvent include ethers (for example, anisole, dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether), esters (for example, ethyl formate, ethyl acetate, n-butyl acetate, isopropyl acetate), halogen Hydrocarbons (eg, dichloromethane, chloroform, carbon tetrachloride), hydrocarbons (eg, n-hexane, benzene, toluene), amides (eg, formamide, N, N-dimethylformamide, N, N-dimethylacetamide, N -Methylpyrrolidone), ketones (eg acetone, methyl ethyl ketone), nitriles (eg MeCN, propionitrile), nitro (eg nitromethane, nitroethane, nitrobenzene), dimethyl sulfoxide, water, And a mixture of two or more solvents selected from these solvents. The reaction temperature is usually in the range of about -100 ° C to 100 ° C, preferably about -80 ° C to 50 ° C, more preferably about -60 ° C to -30 ° C. The reaction time may vary depending on the reagent, solvent or reaction temperature used, but is usually 0.5 to 24 hours.

Process 3
Compound (IV) is reacted with an aldehyde (ie, R ⁵ CHO) and a primary or secondary amine to give compound (V).

  Examples of aldehydes include formaldehyde and lower alkyl aldehydes (for example, acetaldehyde and propionaldehyde). The aldehyde is generally used in an amount of about 1 to 100 mol, preferably 1 to 30 mol, per mol of compound (IV).

  Examples of the primary or secondary amine include methylamine, dimethylamine, ethylamine and diethylamine. The primary or secondary amine, including its salt, is generally used in an amount of about 1 to 100 mol, preferably 1 to 30 mol, per mol of compound (IV).

  Examples of the reaction solvent include ethers (eg, dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether), esters (eg, ethyl formate, ethyl acetate, isopropyl acetate), and halogenated hydrocarbons (eg, dichloromethane). , Chloroform, carbon tetrachloride), hydrocarbon (eg, n-hexane, benzene, toluene), amide (eg, formamide, N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone), ketone ( For example, acetone, methyl ethyl ketone), nitrile (for example, MeCN, propionitrile), dimethyl sulfoxide, water, and a mixed solvent thereof can be mentioned.

  The reaction temperature is usually in the range of about -100 ° C to 100 ° C, preferably about -80 ° C to 80 ° C, more preferably about 0 ° C to 80 ° C. The reaction time may vary depending on the reagent, solvent or reaction temperature used, but is usually 0.5 to 24 hours.

Process 4
Compound (V) is obtained by reacting compound (V) with a reducing agent (eg, zinc, copper, a mixture thereof) and an acid (eg, hydrochloric acid, acetic acid, formic acid).

  Zinc is generally used in an amount of about 1 to 100 mol, preferably 1 to 30 mol, per mol of compound (V). The acid (eg hydrochloric acid, acetic acid, formic acid) is generally used in an amount of about 1-100 mol, preferably 1-30 mol, per mol of compound (V).

  Examples of the reaction solvent include ethers (eg, dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether), esters (eg, ethyl formate, ethyl acetate, isopropyl acetate), and halogenated hydrocarbons (eg, dichloromethane). , Chloroform, carbon tetrachloride), hydrocarbon (eg, n-hexane, benzene, toluene), amide (eg, formamide, N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone), ketone ( For example, acetone, methyl ethyl ketone), nitrile (for example, MeCN, propionitrile), acid (for example, hydrochloric acid, acetic acid, formic acid), dimethyl sulfoxide, water, and a mixed solvent thereof can be mentioned.

  The reaction temperature is usually in the range of about -100 ° C to 100 ° C, preferably about -80 ° C to 80 ° C, more preferably about -20 ° C to 60 ° C. The reaction time may vary depending on the reagent, solvent or reaction temperature used, but is usually 0.5 to 24 hours.

Process 5
Compound (VII) is obtained by reacting compound (VI) with a hydrohalic acid such as hydrochloric acid.

  The hydrohalic acid is generally used in an amount of about 1-100 mol, preferably 1-30 mol, per mol of compound (VI).

  Examples of the reaction solvent include ethers (eg, dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether), esters (eg, ethyl formate, ethyl acetate, isopropyl acetate), and halogenated hydrocarbons (eg, dichloromethane). , Chloroform, carbon tetrachloride), hydrocarbon (eg, n-hexane, benzene, toluene), amide (eg, formamide, N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone), ketone ( For example, acetone, methyl ethyl ketone), nitrile (for example, MeCN, propionitrile), dimethyl sulfoxide, water, and a mixed solvent thereof can be mentioned.

  The reaction temperature is usually in the range of about -100 ° C to 100 ° C, preferably about -80 ° C to 80 ° C, more preferably about -20 ° C to 60 ° C. The reaction time may vary depending on the reagent, solvent or reaction temperature used, but is usually 0.5 to 24 hours.

Step 6
Compound (VII) is reacted with a peracid (for example, meta-chloroperoxybenzoic acid, peroxyacetic acid) to obtain a crude sulfoxide compound. The crude sulfoxide compound is further reacted with a base (eg, triethylamine, sodium acetate, sodium bicarbonate, sodium bicarbonate) to give a single stereoisomeric sulfoxide compound (VIII).

  The peracid is generally used in an amount of about 1 to 100 mol, preferably 1 to 30 mol, per mol of compound (VII). Examples of the reaction solvent include alcohols (eg, methanol, ethanol), halogenated hydrocarbons (eg, dichloromethane, chloroform, carbon tetrachloride), hydrocarbons (eg, n-hexane, benzene, toluene), amides (eg, Formamide, N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone). The reaction temperature is usually in the range of about -100 ° C to 100 ° C, preferably about -80 ° C to 50 ° C, more preferably about -20 ° C to 0 ° C. The reaction time may vary depending on the reagent, solvent or reaction temperature used, but is usually 0.5 to 24 hours.

Step 7
Compound (VIII) is reacted with a reducing agent (for example, phosphorus trichloride, phosphorus tribromide) to obtain compound (IX).

  The reducing agent (eg phosphorus trichloride, phosphorus tribromide) is generally used in an amount of about 1-100 mol, preferably 1-30 mol, per mol of compound (VIII).

  Examples of the reaction solvent include halogenated hydrocarbons (eg, dichloromethane, chloroform, carbon tetrachloride), hydrocarbons (eg, n-hexane, benzene, toluene), amides (eg, formamide, N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone). The reaction temperature is usually in the range of about -100 ° C to 100 ° C, preferably about -80 ° C to 50 ° C, more preferably about -60 ° C to 0 ° C. The reaction time may vary depending on the reagent, solvent or reaction temperature used, but is usually 0.5 to 24 hours.

Process 8
Compound (X) can be obtained by subjecting compound (IX) to a hydrolysis reaction to convert the amide on the 7-position side chain to an amino group and then reacting the compound with a hydrohalic acid such as hydrochloric acid. Examples of the reaction solvent include ethers (for example, anisole, dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether), esters (for example, ethyl formate, ethyl acetate, n-butyl acetate, isopropyl acetate), halogen Hydrocarbons (eg, dichloromethane, chloroform, carbon tetrachloride), hydrocarbons (eg, n-hexane, benzene, toluene), amides (eg, formamide, N, N-dimethylformamide, N, N-dimethylacetamide, N -Methylpyrrolidone), ketones (eg acetone, methyl ethyl ketone), nitriles (eg MeCN, propionitrile), nitro (eg nitromethane, nitroethane, nitrobenzene), dimethyl sulfoxide, water, And a mixture of two or more solvents selected from these. The reaction temperature is usually in the range of about −100 ° C. to 100 ° C., preferably about −50 ° C. to 50 ° C., more preferably about −40 ° C. to 30 ° C. The reaction time may vary depending on the reagent, solvent or reaction temperature used, but is usually 0.5 to 24 hours.

2) Formation of position 7 side chain: Synthesis step 9 of compound (XII)
Compound (X) is subjected to a condensation reaction with compound (XI) to give compound (XII). Examples of the reaction solvent include water, ether (for example, dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether), ester (for example, ethyl formate, ethyl acetate, isopropyl acetate), halogenated hydrocarbon (for example, , Dichloromethane, chloroform, carbon tetrachloride), hydrocarbons (eg, n-hexane, benzene, toluene), amides (eg, formamide, N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone), Examples include ketones (eg, acetone, methyl ethyl ketone), nitriles (eg, MeCN, propionitrile), dimethyl sulfoxide, water, and mixed solvents thereof.

  The reaction temperature is usually in the range of about -100 ° C to 100 ° C, preferably about -80 ° C to 80 ° C, more preferably about -60 ° C to 50 ° C. The reaction time may vary depending on the reagent, solvent or reaction temperature used, but is usually 0.5 to 24 hours.

3) Formation of 3-position side chain: Synthesis step 10 of compound (I)
Compound (I ′) can be obtained by subjecting compound (XII) to a substitution reaction with compound (XIII) and then subjecting it to a deprotection reaction. Examples of the reaction solvent used in the reaction between the compound (XII) and the compound (XIII) include ethers (for example, dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether), esters (for example, ethyl formate). , Ethyl acetate, isopropyl acetate), halogenated hydrocarbons (eg, dichloromethane, chloroform, carbon tetrachloride), hydrocarbons (eg, n-hexane, benzene, toluene), amides (eg, formamide, N, N-dimethylformamide) , N, N-dimethylacetamide, N-methylpyrrolidone), ketones (eg acetone, methyl ethyl ketone), nitriles (eg MeCN, propionitrile), dimethyl sulfoxide, water, and mixed solvents thereof It is. The reaction temperature is usually in the range of about -100 ° C to 100 ° C, preferably about -80 ° C to 80 ° C, more preferably about -20 ° C to 30 ° C. The reaction time may vary depending on the reagent, solvent or reaction temperature used, but is usually 0.5 to 24 hours.

  Protecting groups such as amino protecting group and hydroxy protecting group used in the above reaction include, for example, Protective Groups in Organic Synthesis, T. et al. W. By Greene, John Wiley & Sons Inc. (1991) and the like. Methods for introducing and removing protecting groups are the same as those used in synthetic organic chemistry (for example, those described in Protective Groups in Organic Synthesis, TW Greene, John Wiley & Sons Inc. (1991)). Or can be obtained by a modification thereof. Furthermore, the functional group contained in each substituent may be converted by a known method (for example, those described in Comprehensive Organic Transformations, written by R. C. Larock (1989), etc.) in addition to the above production method. Can do. Some of the compounds of the present invention can be used with synthetic intermediates to give novel derivatives. The intermediates and target compounds produced by each of the above production methods can be obtained by a purification method commonly used in synthetic organic chemistry, such as neutralization, filtration, extraction, washing, drying, concentration, recrystallization, and various chromatography. Can be separated and purified. Furthermore, the intermediate can be subjected to the next reaction without any purification.

  Examples of amino protecting groups include phthalimide, lower alkoxycarbonyl (such as butoxycarbonyl (Boc)), lower alkenyloxycarbonyl (such as allyloxycarbonyl (Alloc)), benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, substituted Aralkylanoyl (such as p-nitrobenzoyl), acyl (such as formyl, chloroacetyl), optionally substituted aralkyl (such as trityl), benzhydryl (BH) and the like may be mentioned.

  Examples of hydroxy protecting groups include lower alkoxycarbonyl, eg, C1-C4 alkoxycarbonyl (eg, t-butyloxycarbonyl), halogenated lower alkoxycarbonyl, eg, halogenated (C1-C3) alkoxycarbonyl (eg, 2 -Iodoethyloxycarbonyl, 2,2,2-trichloroethyloxycarbonyl), aryl- (lower) alkoxycarbonyl, for example, phenyl- (C1-C4) alkoxycarbonyl which may have a substituent on the benzene ring (Benzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl), p-methoxybenzyl (PMB), tri-lower alkylsilyl, such as tri- (C1-C ) Alkylsilyl (eg trimethylsilyl, t-butyldimethylsilyl), substituted methyl, eg C1-C4 alkoxymethyl (eg methoxymethyl), C1-C4 alkoxy- (C1-C4) alkoxymethyl (eg 2-methoxy) Ethoxymethyl), C1-C4 alkylthiomethyl (eg methylthiomethyl), tetrahydropyranyl and the like.

The above deprotection reaction is performed using tetrahydrofuran, dimethylformamide, diethyl ether, dichloromethane, toluene, benzene, xylene, cyclohexane, hexane, chloroform, ethyl acetate, butyl acetate, pentane, heptane, dioxane, acetone, acetonitrile, or a mixed solvent thereof. In a solvent such as Lewis acid (eg, AlCl ₃ , SnCl ₄ , TiCl ₄ ), protonic acid (eg, HCl, HBr, H ₂ SO ₄ , HCOOH) or the like.

  The resulting compound can be further chemically modified to synthesize an ester, or a compound in which the amino on the thiazole or thiadiazole ring at position 7 is protected, or a pharmaceutically acceptable salt, or a solvate thereof. .

式中、Ｐ^１およびＰ^２は保護基であり；Ｙは脱離基（例えば、ハロゲン（Ｃｌ、Ｂｒ、Ｉ、Ｆ）、メタンスルホニルオキシ、ｐ−トルエンスルホキシ）であり；Ｒ^５は低級アルキルであり；他の記号は上記で定義される通りである。

Where P ¹ and P ² are protecting groups; Y is a leaving group (eg, halogen (Cl, Br, I, F), methanesulfonyloxy, p-toluenesulfoxy); R ⁵ is lower Alkyl; the other symbols are as defined above.

(1) Synthesis step 1 of compound (XV)
Compound (V) is reacted with a reducing agent (for example, phosphorus trichloride, phosphorus tribromide), and then the reducing agent is reacted with a hydrohalic acid such as hydrochloric acid to obtain compound (XIV).

  Examples of the reaction solvent include ethers (eg, dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether), esters (eg, ethyl formate, ethyl acetate, isopropyl acetate), and halogenated hydrocarbons (eg, dichloromethane). , Chloroform, carbon tetrachloride), hydrocarbon (eg, n-hexane, benzene, toluene), amide (eg, formamide, N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone), ketone ( For example, acetone, methyl ethyl ketone), nitrile (for example, MeCN, propionitrile), dimethyl sulfoxide, water, and a mixed solvent thereof can be mentioned.

  The reaction temperature is usually in the range of about -100 ° C to 100 ° C, preferably about -80 ° C to 80 ° C, more preferably about -20 ° C to 60 ° C. The reaction time may vary depending on the reagent, solvent or reaction temperature used, but is usually 0.5 to 24 hours.

Process 2
Compound (XV) can be obtained by subjecting compound (XIV) to a hydrolysis reaction to convert the amide on the 7-position side chain to an amino group and then reacting the compound with a hydrohalic acid such as hydrochloric acid. Examples of the reaction solvent include ethers (for example, anisole, dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether), esters (for example, ethyl formate, ethyl acetate, n-butyl acetate, isopropyl acetate), halogen Hydrocarbons (eg, dichloromethane, chloroform, carbon tetrachloride), hydrocarbons (eg, n-hexane, benzene, toluene), amides (eg, formamide, N, N-dimethylformamide, N, N-dimethylacetamide, N -Methylpyrrolidone), ketones (eg acetone, methyl ethyl ketone), nitriles (eg MeCN, propionitrile), nitro (eg nitromethane, nitroethane, nitrobenzene), dimethyl sulfoxide, water, And a mixture of two or more solvents selected from these. The reaction temperature is usually in the range of about −100 ° C. to 100 ° C., preferably about −50 ° C. to 50 ° C., more preferably about −40 ° C. to 30 ° C. The reaction time may vary depending on the reagent, solvent or reaction temperature used, but is usually 0.5 to 24 hours.

2) Formation of position 7 side chain: Synthesis step 3 of compound (XVII)
Compound (XV) is subjected to a condensation reaction with compound (XI) to give compound (XVI). Examples of the reaction solvent include water, ether (for example, dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether), ester (for example, ethyl formate, ethyl acetate, isopropyl acetate), halogenated hydrocarbon (for example, , Dichloromethane, chloroform, carbon tetrachloride), hydrocarbons (eg, n-hexane, benzene, toluene), amides (eg, formamide, N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone), Examples include ketones (eg, acetone, methyl ethyl ketone), nitriles (eg, MeCN, propionitrile), dimethyl sulfoxide, water, and mixed solvents thereof.

  The reaction temperature is usually in the range of about -100 ° C to 100 ° C, preferably about -80 ° C to 80 ° C, more preferably about -60 ° C to 50 ° C. The reaction time may vary depending on the reagent, solvent or reaction temperature used, but is usually 0.5 to 24 hours.

Process 4
Compound (XVII) can be obtained by subjecting compound (XVI) to an oxidation reaction using an oxidizing agent well known to those skilled in the art (for example, m-chloroperbenzoic acid, acetic acid peroxide).

  Examples of the reaction solvent include ethers (for example, anisole, dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether), esters (for example, ethyl formate, ethyl acetate, n-butyl acetate, isopropyl acetate), halogen Hydrocarbons (eg, dichloromethane, chloroform, carbon tetrachloride), hydrocarbons (eg, n-hexane, benzene, toluene), amides (eg, formamide, N, N-dimethylformamide, N, N-dimethylacetamide, N -Methylpyrrolidone), ketones (eg acetone, methyl ethyl ketone), nitriles (eg MeCN, propionitrile), nitro (eg nitromethane, nitroethane, nitrobenzene), dimethyl sulfoxide, water, And a mixture of two or more solvents selected from these. The reaction temperature is usually in the range of about -100 ° C to 100 ° C, preferably about -80 ° C to 50 ° C, more preferably about -60 ° C to -30 ° C. The reaction time may vary depending on the reagent, solvent or reaction temperature used, but is usually 0.5 to 24 hours.

  The obtained compound (XVII) can be purified by column chromatography to obtain each 2-methyl stereoisomer.

3) Formation of 3-position side chain: Synthesis step 5 of compound (I ′)
Compound (I ′) is obtained by subjecting compound (XVII) to a substitution reaction with compound (XIII) by a method well known to those skilled in the art, and then subjecting it to a reducing agent well known to those skilled in the art (eg, phosphorus chloride, tribromide, etc.). Obtained by subjecting it to a deprotection reaction. Examples of the reaction solvent include ethers (for example, anisole, dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether), esters (for example, ethyl formate, ethyl acetate, n-butyl acetate, isopropyl acetate), halogen Hydrocarbons (eg, dichloromethane, chloroform, carbon tetrachloride), hydrocarbons (eg, n-hexane, benzene, toluene), amides (eg, formamide, N, N-dimethylformamide, N, N-dimethylacetamide, N -Methylpyrrolidone), ketones (eg acetone, methyl ethyl ketone), nitriles (eg MeCN, propionitrile), nitro (eg nitromethane, nitroethane, nitrobenzene), dimethyl sulfoxide, water, And a mixture of two or more solvents selected from these. The reaction temperature is usually in the range of about -100 ° C to 100 ° C, preferably about -80 ° C to 50 ° C, more preferably about -40 ° C to 0 ° C. The reaction time may vary depending on the reagent, solvent or reaction temperature used, but is usually 0.5 to 24 hours.

式中、Ｐ^２は保護基であり；Ｙは脱離基（例えば、ハロゲン（Ｃｌ、Ｂｒ、Ｉ、Ｆ）、メタンスルホニルオキシ、ｐ−トルエンスルホキシ）であり；他の記号は上記で定義される通りである。

Where P ² is a protecting group; Y is a leaving group (eg, halogen (Cl, Br, I, F), methanesulfonyloxy, p-toluenesulfoxy); other symbols as defined above. It is as it is done.

(1) Synthesis step 1 of compound (I)
Compound (XVIII) is obtained by reaction of compound (XI) and compound (IH) as in a similar procedure described in Scheme 9, Step 9.

Process 2
Compound (I) is obtained by reaction of compound (XVIII) and compound (XIII) as in a similar procedure described in step 10 of scheme 1.

  The compounds of the present invention have a broad spectrum of antibacterial activity, and various diseases caused by pathogenic bacteria in various mammals including humans such as respiratory tract infections, urinary tract infections, respiratory infections, sepsis, nephritis It can be used for prevention or treatment of cholecystitis, oral infection, endocarditis, pneumonia, osteomyelitis, otitis media, enteritis, empyema, wound infection, opportunistic infection, etc.

  The compounds of the invention are in particular gram-negative bacteria, preferably gram-negative bacteria of the family Enterobacteriaceae (E. coli, Klebsiella, Serratia, Enterobacter, Citrobacter ( Citrobacter, Morganella, Providencia, Proteus, etc., Gram-negative bacteria (Haemophilus, Moraxella, etc.) that colonize the respiratory system, and non-glucose gram-negative bacteria (such as Moraxella) Pseudomonas aeruginosa, Pseudomonas other than Pseudomonas aeruginosa, Stenotropomonas homomonas, Burkholderia, Acinetobacter, etc.). These compounds are stable against β-lactamases belonging to classes A, B, C and D produced by these gram-negative bacteria, and various β-lactam drug-resistant gram-negative bacteria such as ESBL-producing bacteria Has high antibacterial activity. These are particularly stable against metallo-β-lactamases belonging to class B including IMP type, VIM type, L-1 type and the like. Therefore, they are also effective against various β-lactam drug resistant gram-negative bacteria including cephem and carbapenem. The compounds of the present invention also have antibacterial activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP) and the like. Even more preferred compounds also have pharmacokinetic characteristics such as high blood levels, long-term effects, and / or significant tissue migration. More preferred compounds are safe with respect to side effects such as fever and nephrotoxicity. More preferred compounds have high water solubility and are therefore particularly preferred as injections.

  The compounds of the present invention can be administered either orally or parenterally. When the compound of the present invention is administered orally, it is a usual formulation, for example, solid preparations such as tablets, powders, granules, capsules; liquid preparations; oily suspensions; or liquid preparations such as syrups or elixirs. Can be used in any dosage form. When administered parenterally, the compounds of the invention can be used as aqueous or oily suspension injections or nasal drops. In the preparation, conventional excipients, binders, lubricants, aqueous solvents, oily solvents, emulsifiers, suspending agents, preservatives, stabilizers and the like can be arbitrarily used. The formulations of the present invention are prepared by combining (eg, mixing) a therapeutically effective amount of a compound of the present invention with a pharmaceutically acceptable carrier or diluent.

  The compounds of the present invention can be administered parenterally or orally as injections, capsules, tablets, and granules, preferably as injections. The dose of the compound is usually about 0.1 to 100 mg / day, preferably about 0.5 to 50 mg / day per kg of the patient or animal body weight, divided into 2 to 4 times a day, if desired. do it. The carrier when used as an injection is, for example, distilled water, brine or the like, and a base for adjusting pH may be used. When used as capsules, granules, or tablets, the carriers are known excipients (eg starch, lactose, sucrose, calcium carbonate, calcium phosphate etc.), binders (eg starch, gum arabic, carboxymethylcellulose) , Hydroxypropyl cellulose, crystalline cellulose, etc.), lubricants (eg, magnesium stearate, talc, etc.) and the like.

General Methods Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. Unless otherwise noted, all temperatures are expressed in ° C. (degrees Centigrade). Unless otherwise noted, all reactions are conducted at ambient temperature under an inert atmosphere.

All temperatures are given in degrees Celsius, all solvents are of the highest purity available, and all reactions are conducted under anhydrous conditions in an argon (Ar) or nitrogen (N ₂ ) atmosphere as required.

1H NMR (hereinafter also referred to as “NMR”) spectra were recorded on a Brucker AVANCE-400 spectrometer. CDCI ₃ is deuterated chloroform, d6-DMSO is hexadeuterated dimethyl sulfoxide, D ₂ O is deuterium oxide, and CD ₃ OD is deuterated methanol. Chemical shifts are expressed in parts per million (ppm, 8 units). The coupling constant is in hertz (Hz). The splitting pattern indicates the apparent multiplicity, s (single line), d (double line), t (triple line), q (quadruple line), quint (quintet line), m (multiple line), br (Broad).

  Mass spectra were measured with a Waters Open Architecture System, UPLC SQD MS analysis system. The compound is eluted with an acetonitrile and water gradient containing a low percentage acid modifier such as 0.02% TFA or 0.1% formic acid, eg, a reverse phase column such as Xbridge-C18, Sunfire-C18, The analysis is performed using Thermo Aquasil / Aquasil C18, Acquity HPLC C18, Acquity UPLC BEH C18, Shim-pack XR-ODS, and Thermo Hypersil Gold.

  Analytical HPLC uses an Agilent system (1100 series) with variable wavelength UV detection, uses a Luna C18 column, and contains acetonitrile / water containing 0.05% or 0.1% TFA modifier (added to each solvent). Perform by gradient elution.

  Unless otherwise noted, flash chromatography uses a disposable Redi-Sep flash column (normal or reversed phase stationary phase as indicated) and a UV wavelength detector at 254 nm at Teledine Isco Combiflash RF. I went. The styrene adsorption resin DIAION ™ HP20SS was used for the post-treatment and purification of the cephalosporin analog, but in the examples below, it is simply referred to as HP20SS.

  Hereinafter, the present invention will be described in more detail with reference to Examples, Reference Examples, Test Examples and Formulation Examples. However, the present invention is not limited to these.

The meaning of each abbreviation is as described below.
Ac: Acetyl Alloc: Allyloxycarbonyl BH or Bzh: Benzhydryl Boc: tert-butoxycarbonyl Bn: Benzyl Bt: Benzotriazole Cbz: Carbobenzoxy DMF: N, N-dimethylformamide EDC: 1-ethyl-3- (3- Dimethylaminopropyl) carbodiimide Et: ethyl HOBt: 1-hydroxybenzotriazole i-Pr: isopropyl mCPBA: m-chloroperoxybenzoic acid Me: methyl ODS: octadecylsilyl PMB: para-methoxybenzyl TBS: tert-butyldimethylsilyl t- Bu: tert-butyl TFA: trifluoroacetic acid Tr: trityl WSCD: N-ethyl-N ′-(3-dimethylaminopropyl) carbodiimide rt: room temperature FA: trifluoroacetic acid THF: Tetrahydrofuran DCM: Dichloromethane MeOH: Methanol EA or EtOAc: ethyl acetate Pd / C: Palladium on carbon NaBH _(OAc) 3: Sodium triacetoxyborohydride _Pd 2 _(dba) 3: tris (dibenzylideneacetone ) Dipalladium (0)
XPhos: dicyclohexyl [2 ′, 4 ′, 6′-tris (1-methylethyl) -2-biphenylyl] phosphane SEMCl: 2- (trimethylsilyl) ethoxymethyl chloride CDI: 1,1′-carbonyldiimidazole AlCl ₃ : chloride Aluminum LAH: Lithium aluminum hydride DIBAL-H: Isobutylaluminum hydride PyBOP: (Benzotriazol-1-yloxy) tripyrrolidinophosphonium hexafluorophosphate HATU: 2- (3H- [1,2,3] triazolo [4 5-b] pyridin-3-yl) -1,1,3,3-tetramethylisouronium hexafluorophosphate (V)
DIPEA or DIEA: diisopropylethylamine K ₂ CO ₃ : potassium carbonate TMS: tetramethylsilane CDCl ₃ : deuterated chloroform CD ₃ OD: tetradeuterated methanol DMSO-d ₆ : hexadeuterated dimethyl sulfoxide

Reference Example 1: Synthesis of Compound X-1

Step (1): Compound X-1a → Compound X-1b
Compound X-1a (26.47 g, 51.2 mmol) synthesized according to the synthesis of US Pat. 102 mmol) was added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether / dichloromethane to obtain compound X-1b (21.1 g, 75%).
¹ H-NMR (CDCl ₃ ) δ: 7.37-7.26 (11H, m), 7.03-6.99 (2H, m), 6.87 (1H, s), 6.36 (1H , D, J = 8.7 Hz), 5.63-5.59 (1H, m), 5.23-5.20 (2H, m), 4.31 (1H, d, J = 12.3. Hz), 4.09 (1H, d, J = 12.3 Hz), 3.86 (2H, s), 1.99 (3H, s).

Step (2): Compound X-1b → Compound X-1c
Compound X-1b (5.53 g, 10 mmol) was dissolved in dichloromethane (60 mL), and then a solution of m-chloroperoxybenzoic acid (3.45 g, 13 mmol) in dichloromethane (40 mL) at −40 ° C. was added dropwise thereto. did. The mixture was stirred at −40 ° C. for 1 hour. The reaction mixture was diluted with aqueous sodium thiosulfate, then separated, washed with saturated sodium bicarbonate solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with methanol to obtain Compound X-1c (3.79 g, 67%).
MS (M + 1) = 569

Step (3): Compound X-1c → Compound X-1d
Compound X-1c (3.79 g, 6.6 mmol) was dissolved in dimethylformamide (35 mL), and then phosphorus trichloride (1.7 mL, 20 mmol) was added thereto at −50 ° C. The mixture was stirred at −20 ° C. for 30 minutes. The reaction mixture was diluted with water and ethyl acetate, then separated, washed with water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with hexane / ethyl acetate. The objective compound-containing fraction was concentrated under reduced pressure to obtain Compound X-1d (1.98 g, 54%).
MS (M + 1) = 553

Step (4): Compound X-1d → Compound X-1e
Phosphorus pentachloride (1.47 g, 7.1 mmol) was suspended in dichloromethane (20 mL), which was then added to pyridine (0.63 ml, 7.8 mmol) and compound X-1d (1.95 g, 3.5 mmol) was added. The mixture was stirred at 0 ° C. for 1 hour. Next, methanol (10 mL) was added thereto at −40 ° C. The mixture was stirred at 0 ° C. for 30 minutes. The mixture was diluted with saturated sodium bicarbonate solution and dichloromethane, then separated and dried over magnesium sulfate. Magnesium sulfate was filtered off, ethyl acetate (20 ml) was added, and the mixture was concentrated under reduced pressure to obtain an ethyl acetate solution of compound X-1e. This solution was used in the next reaction without purification.

Step (5): Compound X-1e + Compound X-1f → Compound X-1g, Compound X-1h
Compound X-1f (1.82 g, 4.2 mmol) and triethylamine (0.68 mL, 4.9 mmol) were dissolved in dimethylacetamide (20 mL), and then methanesulfonyl chloride (0.36 mL, 4 mL) at −20 ° C. .6 mmol) was added. The mixture was stirred at −10 ° C. for 20 minutes. Pyridine (0.57 mL, 7.1 mmol) and the reaction mixture were added at 0 ° C. to a solution of compound X-1e in ethyl acetate (3.5 mol). The mixture was stirred at 0 ° C. for 20 minutes. The reaction mixture was diluted with water and ethyl acetate, then separated, washed with water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with hexane / ethyl acetate. The objective compound-containing fraction was concentrated under reduced pressure to obtain Compound X-1g (0.13 g, 4.4%) and Compound X-1h (1.17 g, 40%).
Compound X-1g
¹ H-NMR (CDCl ₃ ) δ: 8.18-8.16 (2H, m), 7.42-7.30 (11H, m), 6.93 (1H, s), 6.03 (1H , Dd, J = 9.0, 5.0 Hz), 5.23 (1H, d, J = 5.0 Hz), 4.83 (1H, d, J = 12.3 Hz), 4.21 (1H, d, J = 12.3 Hz), 4.01 (1H, q, J = 7.2 Hz), 1.64 (3H, s), 1.61 (3H, s), 1.57 (3H, d, J = 7.2 Hz), 1.53 (9H, s), 1.41 (9H, s).
Compound X-1h
¹ H-NMR (CDCl ₃ ) δ: 8.22-8.19 (2H, m), 7.46-7.30 (11H, m), 7.01 (1H, s), 6.13 (1H , Dd, J = 9.0, 5.1 Hz), 5.19 (1H, d, J = 5.1 Hz), 4.43 (1H, d, J = 11.5 Hz), 4.18. (1H, d, J = 11.5 Hz), 3.85 (1H, q, J = 7.3 Hz), 1.63 (3H, s), 1.60 (3H, s), 1.58 (3H, d, J = 7.3 Hz), 1.53 (9H, s), 1.39 (9H, s).

Step (6): Compound X-1g → Compound X-1
Compound X-1 g (77.6 g, 92 mmol) was dissolved in tetrahydrofuran (770 mL), and then sodium iodide (41.5 g, 277 mmol) was added thereto at 15 ° C. The resulting solution was stirred at 15 ° C. for 1 day. The reaction mixture was diluted with aqueous sodium bisulfite and ethyl acetate, then separated, washed with water and saturated salt solution, and dried over magnesium sulfate. After filtering off magnesium sulfate, the liquid was concentrated under reduced pressure to obtain compound X-1 (85.2 g, 99%). ¹ H-NMR (CDCl ₃ ) δ: 8.24 (1H, d, J = 8.8 Hz), 7.42-7.29 (12H, m), 6.94 (1H, s), 5. 94 (1H, dd, J = 8.8, 4.9 Hz), 5.27 (1H, d, J = 4.9 Hz), 4.97 (1H, d, J = 9.8 Hz), 4.07-4.00 (2H, m), 1.64 (3H, s), 1.61 (3H, s), 1.55-1.53 (12H, m), 1.41 (9H, s).

Reference Example 2: Synthesis of Compound X-2

Step (1): Compound X-1e + Compound X-2a → Compound X-2b
Using Compound X-1e (8.3 g, 15 mmol) and Compound X-2a (10.4 g, 18 mmol) in the same manner as in Steps 4 and 5 of Reference Example 1, the target compound was synthesized.
Yield: 10.4 g (70%)
¹ H-NMR (CDCl ₃ ) δ: 8.27 (1H, d, J = 8.1 Hz), 8.09 (1H, s), 7.43-7.29 (11H, m), 7. 23 (2H, d, J = 8.5 Hz), 6.94 (1H, s), 6.82 (2H, d, J = 8.5 Hz), 5.92 (1H, dd, J = 8 .1, 4.9 Hz), 5.36 (1H, dd, J = 8.4, 4.6 Hz), 5.23 (1H, d, J = 4.9 Hz), 5.14 (1H , D, J = 11.9 Hz), 5.05 (1H, d, J = 11.9 Hz), 4.85 (1H, d, J = 12.3 Hz), 4.23 (1H, d , J = 12.3 Hz), 4.00 (1H, q, J = 7.4 Hz), 3.76 (3H, s), 2.92 (1H, dd, J 16.4, 8.4 Hz), 2.83 (1H, dd, J = 16.4, 4.6 Hz), 1.57 (3H, d, J = 7.4 Hz), 1.54 ( 9H, s), 1.41 (9H, s).

Step (2): Compound X-2b → Compound X-2
The target compound was synthesized in the same manner as in Step 6 of Reference Example 1 using Compound X-2b (10.4 g, 11 mmol).
Yield: 10.7 g (95%)
¹ H-NMR (CDCl ₃ ) δ: 8.30 (1H, d, J = 7.9 Hz), 8.11 (1H, s), 7.44-7.29 (11H, m), 7. 23 (2H, d, J = 8.7 Hz), 6.95 (1H, s), 6.82 (2H, d, J = 8.7 Hz), 5.84 (1H, dd, J = 7 .9, 4.8 Hz), 5.37 (1H, dd, J = 8.3, 4.8 Hz), 5.27 (1H, d, J = 4.8 Hz), 5.14 (1H , D, J = 11.8 Hz), 5.05 (1H, d, J = 11.8 Hz), 4.99 (1H, d, J = 9.8 Hz), 4.06-4.01 (2H, m), 3.76 (3H, s), 2.92 (1H, dd, J = 16.4, 8.3 Hz), 2.84 (1H, dd, J 16.4, 4.8 Hz), 1.54-1.52 (12H, m), 1.41 (9H, s).

Reference Example 3: Synthesis of compounds X-3 and X-24

Step (1): Compound X-3a → Compound X-3b → Compound X-3c
To a precooled solution of compound X-3a (50 g, 97 mmol) (synthesized according to the synthesis of Tetrahedron Letter, 37, 1971-1974 (1996)) in dichloromethane (450 mL) at −10 ° C. was added peracetic acid (19.82 g, 102 mmol, 37% by weight) was added. The mixture was stirred at -10 to -5 ° C. To the resulting mixture was added a solution of sodium bisulfite (12.1 g, 116 mmol) in water (200 mL). After adding water (150 mL) to this mixture, the organic layer was separated. The organic layer was washed with water (250 mL), 10% aqueous sodium chloride solution (250 mL). The aqueous layer was extracted continuously with dichloromethane (150 mL). The combined organic layers were dried with magnesium sulfate and filtered. Dimethylformamide (200 mL) was added to the filtrate and the solution was concentrated. The residue was placed in a reaction bottle containing dimethylformamide (30 mL), and then formaldehyde (15.7 g, 194 mmol, 37 wt%) and dimethylamine hydrochloride (7.89 g, 97 mmol) were added to the solution. The mixture was stirred at 60 ° C. for 3 hours and then cooled in an ice bath. Water (250 mL) was added dropwise to the mixture over 8 minutes. The resulting mixture was stirred for 3.5 hours. The precipitated material was collected by filtration and washed with water (250 mL) and ethanol (250 mL). The solid was air dried for 3 days to give compound X-3c (48.5 g, 92%).
¹ H-NMR (DMSO-D ₆ ) δ: 8.61 (1H, d, J = 8.3 Hz), 7.39-7.35 (3H, m), 6.98-6.93 (4H , M), 6.40 (1H, s), 6.21 (1H, s), 5.95 (1H, dd, J = 8.3, 5.1 Hz), 5.31-5.26 ( 2H, m), 5.21 (1H, d, J = 11.9 Hz), 5.07 (1H, d, J = 5.1 Hz), 4.74 (1H, d, J = 12.5) Hz), 3.91 (1H, d, J = 15.4 Hz), 3.83 (1H, d, J = 15.4 Hz), 3.75 (3H, s), 1.96 (3H, s).

Step (2): Compound X-3c → Compound X-3d → Compound X-3e
In a pre-cooled suspension of compound X-3c (25.0 g, 45.9 mmol) in 1,4-dioxane (175 mL) and dichloromethane (50 mL) in an ice bath, zinc (15.01 g, 230 mmol) was added. Concentrated hydrochloric acid (19.1 mL, 230 mmol, 12 M) was added dropwise to the mixture over 45 minutes in an ice bath, and the mixture was washed with dichloromethane (10 mL). The mixture was stirred in an ice bath for 1 hour, filtered through celite, and washed with dichloromethane (300 mL). The filtrate was washed successively with water (500 mL) and water (125 mL). These aqueous layers were extracted sequentially with dichloromethane (75 mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated. The residue was dissolved in 1,4-dioxane (75 mL) to remove dichloromethane, and then cooled in an ice bath. To this mixture was added hydrochloric acid in 1,4-dioxane (23.0 mL, 4M) and then stirred in an ice bath for 2 hours. Isopropyl ether (122 mL) was added to the resulting mixture, and the mixture was stirred in an ice bath for 1.5 hours. The precipitated material was collected by filtration and washed with isopropyl ether. The solid was air dried overnight to give compound X-3e (15.3 g, 58%).
¹ H-NMR (DMSO-D ₆ ) δ: 9.27 (1H, d, J = 7.8 Hz), 7.38-7.34 (3H, m), 6.97-6.92 (4H M), 5.48 (1H, dd, J = 7.8, 3.8 Hz), 5.19 (1H, d, J = 3.8 Hz), 5.15-5.08 (3H, m), 4.64 (1H, d, J = 12.2 Hz), 4.31 (1H, d, J = 12.2 Hz), 3.77-3.74 (5H, m), 2. 04 (3H, s).

Step (3): Compound X-3e → Compound X-3f
In an ice bath, peracetic acid (18.4 g, 94 mmol, 39% by weight) was added dropwise over 10 minutes to a precooled suspension of compound X-3e (50.0 g, 94 mmol) in dichloromethane (500 mL). The mixture was stirred in an ice bath for 3 hours. A solution of sodium bisulfite (11.8 g, 113 mmol) in water (250 mL) was added. Additional water (250 mL) was added. The organic layer was washed with water (500 mL) and 10% aqueous sodium chloride solution (500 mL). The aqueous layer was extracted continuously with dichloromethane (50 mL). The combined organic layers were concentrated and the solvent was replaced with acetonitrile by adding acetonitrile twice (250 mL, 100 mL). To the remaining suspension (approximately 250 mL) was added acetonitrile (612 mL) and water (150 mL). After adding 10% aqueous sodium acetate solution (100 mL) to the mixture, the pH was 6.29. The mixture was stirred for 1.5 hours while monitoring the pH at room temperature. 2 mol / L hydrochloric acid (24.5 mL) was added and quenched. The insoluble material was collected by filtration and washed with water (200 mL) and acetonitrile (150 mL). This solid was air-dried for 3 days to obtain Compound X-3f (32.6 g, 66%).
¹ H-NMR (DMSO-D ₆ ) δ: 8.53 (1H, d, J = 8.3 Hz), 7.38-7.36 (3H, m), 6.97-6.93 (4H M), 5.88 (1H, dd, J = 8.3, 4.9 Hz), 5.30 (1H, d, J = 12.0 Hz), 5.21 (1H, d, J = 12.0 Hz), 5.10 (1 H, d, J = 4.9 Hz), 4.81 (1 H, d, J = 12.3 Hz), 4.42 (1 H, d, J = 12. 3 Hz), 3.90-3.79 (3H, m), 3.76 (3H, s), 1.61 (3H, d, J = 7.5 Hz).

Step (4): Compound X-3f → Compound X-3g
To a pre-cooled suspension of compound X-3f (30.0 g, 57.4 mmol) in dimethylformamide (240 mL), phosphorus trichloride (23.6 g, 172 mmol) was added over 10 minutes with stirring at −40 ° C. It was. The mixture was stirred at -35 ° C for 1 hour. To the resulting mixture was added dichloromethane (300 mL) and water (300 mL). The organic layer was separated and washed with water (300 mL) and 10% aqueous sodium chloride solution (300 mL). The aqueous layer was extracted continuously with dichloromethane (90 mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated to approximately 150 mL. After 2-propanol (180 mL) was added to the remaining suspension, the suspension was again concentrated to approximately 150 mL. To this residue was added 2-propanol (14 mL) and diisopropyl ether (120 mL). The mixture was stirred for 3 hours. Insoluble matter was collected by filtration and air-dried for 3 days to obtain Compound X-3g (20.8 g, 71%).
¹ H-NMR (DMSO-D ₆ ) δ: 9.21 (1H, d, J = 8.4 Hz), 7.38-7.34 (3H, m), 6.96-6.91 (4H M), 5.73 (1H, dd, J = 8.4, 5.0 Hz), 5.33 (1H, d, J = 5.0 Hz), 5.27 (1H, d, J = 11.9 Hz), 5.17 (1H, d, J = 11.9 Hz), 4.66 (1H, d, J = 12.0 Hz), 4.49 (1H, d, J = 12. 0 Hz), 4.08 (1H, q, J = 7.2 Hz), 3.75 (5H, s), 1.53 (3H, d, J = 7.2 Hz).

Step (5): Compound X-3g → Compound X-3h
To a precooled suspension of phosphorus pentachloride (8.21 g, 39.4 mmol) in dichloromethane (90 mL) in dichloromethane (90 mL) with stirring at −5 ° C., pyridine (3.43 g, 43.4 mmol) and compound X-3 g (10.0 g, 19.7 mmol) was added. The mixture was stirred at 10-15 ° C. for 1 hour. The resulting mixture was poured into pre-cooled methanol (25 mL) in an ice bath and water (50 mL) was added. The organic layer was separated and washed with water (100 mL). The aqueous layer was extracted continuously with dichloromethane (40 mL). The combined organic layers were dried with magnesium sulfate and filtered. To this filtrate was added p-toluenesulfonic acid monohydrate (3.75 g, 19.7 mmol) and ethyl acetate (60 mL). The mixture was concentrated to remove dichloromethane. Ethyl acetate (50 mL) was added to the remaining suspension. The mixture was stirred at 35 ° C. and then stirred in an ice bath for 2.5 hours. The insoluble material was collected by filtration and washed with ethyl acetate. This solid was dried by air drying to obtain Compound X-3h (7.30 g, 63%).
¹ H-NMR (DMSO-D ₆ ) δ: 9.02 (3H, br s), 7.48 (2H, d, J = 7.7 Hz), 7.36 (2H, d, J = 8. 3 Hz), 7.12 (2H, d, J = 7.7 Hz), 6.94 (2H, d, J = 8.3 Hz), 5.45 (1H, d, J = 5.0 Hz) ), 5.29-5.17 (3H, m), 4.68 (1H, d, J = 12.0 Hz), 4.51 (1H, d, J = 12.0 Hz), 4.21 (1H, q, J = 7.2 Hz), 3.75 (3H, s), 2.29 (3H, s), 1.57 (3H, d, J = 7.2 Hz).

Step (6): Compound X-3h + Compound X-1f → Compound X-3
Precooled suspension of compound X-1f (9.29 g, 21.6 mmol) and compound X-3h (12.0 g, 21.6 mmol) in ethyl acetate (120 mL) at -40 ° C in ethyl acetate (120 mL). To the solution was added phenyl dichlorophosphate (6.84 g, 4.82 mmol) and N-methylmorpholine (7.65 g, 76 mmol). The mixture was stirred at −40 ° C. for 1.5 hours. 0.5 mol / L hydrochloric acid (130 mL) was added and quenched. The organic layer was separated and washed with water (120 mL), 5% aqueous sodium bicarbonate (120 mL), and 10% aqueous sodium chloride (120 mL). These aqueous layers were continuously extracted with ethyl acetate (60 mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated to give the crude material (19.7 g). 6.58 g of the crude residue was purified by silica gel column chromatography eluting with n-hexane and ethyl acetate to give compound X-3 (5.77 g).
¹ H-NMR (DMSO-D ₆ ) δ: 11.84 (1H, s), 9.58 (1H, d, J = 8.3 Hz), 7.36 (2H, d, J = 8.2) Hz), 7.26 (1H, s), 6.94 (2H, d, J = 8.2 Hz), 5.87 (1H, dd, J = 8.1, 5.0 Hz), 5. 40 (1H, d, J = 4.9 Hz), 5.26 (1H, d, J = 11.8 Hz), 5.18 (1H, d, J = 11.8 Hz), 4.67 ( 1H, d, J = 12.2 Hz), 4.48 (1H, d, J = 12.0 Hz), 4.06 (1H, q, J = 7.2 Hz), 3.76 (3H, s), 1.52 (3H, d, J = 7.2 Hz), 1.46-1.44 (15H, m), 1.39 (9H, s).

Step (7): Compound X-3 → Compound X-24
Compound X-24 was synthesized in the same manner as in Step (6) of Reference Example 1 using Compound X-3 (25.6 g, 30.0 mmol).
Yield: 28.08 g (106%)
¹ H-NMR (CDCl ₃ ) δ: 8.14 (1H, d, J = 8.9 Hz), 7.35-7.33 (3H, m), 6.91 (2H, d, J = 8 .4 Hz), 5.91 (1H, dd, J = 8.9, 4.9 Hz), 5.27 (1H, d, J = 11.9 Hz), 5.21-5.18 (2H) , M), 5.05 (1H, d, J = 10.4 Hz), 4.09-4.07 (2H, m), 3.82 (3H, s), 1.62 (3H, s) , 1.60 (3H, s), 1.55 (3H, d, J = 7.3 Hz), 1.53 (9H, s), 1.41 (9H, s).

Reference Example 4: Synthesis of Compound X-4

Step (1): Compound X-3h + Compound X-2a → Compound X-4a
The target compound was synthesized using Compound X-3h (6.3 g, 11 mmol) and Compound X-2a (6.0 g, 11 mmol) in the same manner as in Step 6 of Reference Example 3.
Yield: 6.7 g (65%)
¹ H-NMR (DMSO-D ₆ ) δ: 11.87 (1H, s), 9.68 (1H, d, J = 8.2 Hz), 7.36 (2H, d, J = 8.0) Hz), 7.31-7.29 (3H, m), 6.94 (2H, d, J = 8.0 Hz), 6.87 (2H, d, J = 8.0 Hz), 5. 84 (1H, dd, J = 8.2, 4.8 Hz), 5.39 (1H, d, J = 4.8 Hz), 5.26 (1H, d, J = 12.0 Hz), 5.18 (1H, d, J = 12.0 Hz), 5.10 (2H, s), 4.96 (1H, t, J = 6.4 Hz), 4.68 (1H, d, J = 12.0 Hz), 4.49 (1H, d, J = 12.0 Hz), 4.07 (1H, q, J = 7.2 Hz), 3.75 (3H s), 3.73 (3H, s), 2.92-2.80 (2H, m), 1.51 (3H, d, J = 7.2 Hz), 1.47 (9H, s), 1.35 (9H, s).

Step (2): Compound X-4a → Compound X-4
The target compound X-4 was synthesized in the same manner as in Step 6 of Reference Example 1 using the compound X-4a (28.3 g, 30 mmol).
Yield: 32 g (103%)
¹ H-NMR (CDCl ₃ ) δ: 8.21 (1H, d, J = 8.0 Hz), 8.11 (1H, s), 7.37-7.35 (3H, m), 7. 23 (2H, d, J = 8.7 Hz), 6.92 (2H, d, J = 8.7 Hz), 6.83 (2H, d, J = 8.7 Hz), 5.81 ( 1H, dd, J = 8.0, 4.8 Hz), 5.36 (1H, dd, J = 8.2, 5.0 Hz), 5.30-5.04 (7H, m), 4 .09-4.03 (1H, m), 3.82 (3H, s), 3.79 (3H, s), 2.89 (1H, dd, J = 16.4, 8.2 Hz), 2.82 (1H, dd, J = 16.4, 5.0 Hz), 1.55-1.54 (12H, m), 1.40 (9H, s).

Reference Example 5: Synthesis of Compound X-5

Step (1): Compound X-5a → Compound X-5
Compound X-5a (2.1 g, 5 mmol) was suspended in toluene (20 mL), and then quinuclidin-4-ylmethanamine (0.74 g, 5.3 mmol) was added thereto at 0 ° C. The mixture was stirred at 50 ° C. for 1 hour. To this was added acetic acid (0.57 mL, 10 mmol). The resulting product was stirred under reflux for 3 days. The reaction mixture was diluted with ethyl acetate and aqueous sodium hydroxide solution, then separated, washed with water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether to obtain Compound X-5 (2.6 g, 95%).
1H-NMR (CDCl3) δ: 7.35 (4H, d, J = 8.7 Hz), 7.33 (2H, s), 6.90 (4H, d, J = 8.7 Hz), 5 .18 (4H, s), 3.82 (6H, s), 3.38 (2H, br s), 2.85-2.81 (6H, m), 1.42-1.38 (6H, m).

Reference Example 6: Synthesis of Compound X-6

Step (1): Compound X-5a → Compound X-6
Compound X-6 was synthesized in the same manner as in Reference Example 5 using Compound X-5a (2.1 g, 5 mmol).
Yield: 2.18 g (80%)
¹ H-NMR (CDCl ₃ ) δ: 7.36-7.32 (4H, m), 7.27 (2H, s), 6.91-6.87 (4H, m), 5.16 (4H , S), 4.59-4.49 (1H, m), 3.81 (6H, s), 3.24-3.20 (2H, m), 2.32-2.24 (2H, m ), 2.20 (3H, s), 2.15-2.11 (2H, m), 1.88-1.82 (2H, m), 1.72-1.67 (2H, m).

Reference Example 7: Synthesis of Compound X-7

Step (1): Compound X-7a → Compound X-7
Compound X-7a (0.48 mg, 4.2 mmol) and triethylamine (0.58 ml, 4.2 mmol) were dissolved in dimethylacetamide (12 mL), which was then dissolved in methanesulfonyl chloride (0.3 ml, 3 ml, −20 ° C.). .9 mmol) was added. The mixture was stirred at −20 ° C. for 30 minutes. Next, aminoethylpyrrolidine (0.48 g, 4.2 mmol) was added thereto at 0 ° C. The mixture was stirred at 0 ° C. for 1 hour. The reaction mixture was diluted with ethyl acetate, washed with aqueous sodium hydroxide, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with hexane / ethyl acetate (containing 3% triethylamine). The objective compound-containing fraction was concentrated under reduced pressure to obtain Compound X-7 (0.75 g, 45%).
¹ H-NMR (CDCl ₃ ) δ: 7.62 (1H, d, J = 8.7 Hz), 7.47-7.42 (1H, m), 7.34 (4H, dd, J = 8 .7, 2.3 Hz), 6.95-6.90 (3H, m), 6.85-6.81 (2H, m), 5.11 (2H, s), 4.96 (2H, s), 3.83 (3H, s), 3.80 (3H, s), 3.49 (2H, q, J = 5.9 Hz), 2.72-2.65 (2H, m), 2.58-2.50 (4H, m), 1.83-1.74 (4H, m).

Reference Example 8: Synthesis of Compound X-8

Step (1): Compound X-7a → Compound X-8
Compound X-7 was synthesized in the same manner as in Reference Example 7 using Compound X-7a (0.5 g, 3.9 mmol).
Yield: 0.62 g (39%)
¹ H-NMR (DMSO-D ₆ ) δ: 7.69-7.65 (1H, m), 7.47-7.45 (2H, m), 7.39 (1H, d, J = 8. 8 Hz), 7.31-7.26 (2H, m), 7.01-6.97 (2H, m), 6.87-6.83 (2H, m), 5.25 (2H, s ), 4.91 (2H, s), 3.78 (3H, s), 3.74 (3H, s), 3.08-2.89 (7H, m), 1.97-1.69 ( 6H, m).

Reference Example 9: Synthesis of Compound X-9

Step (1): Compound X-7a → Compound X-9
Compound X-9 was synthesized in the same manner as in Reference Example 7 using Compound X-7a (0.5 g, 3.9 mmol).
Yield: 0.64 g (43%)
¹ H-NMR (CDCl ₃ ) δ: 7.69 (1H, d, J = 8.9 Hz), 7.34 (4H, t, J = 8.2 Hz), 6.99 (1H, d, J = 8.9 Hz), 6.93 (2H, d, J = 8.7 Hz), 6.83 (2H, d, J = 8.7 Hz), 5.13 (2H, s), 4 .95 (2H, s), 4.72-4.55 (1H, m), 3.84 (3H, s), 3.80 (3H, s), 3.77-3.61 (1H, m ), 3.14-2.94 (3H, m), 2.32-2.03 (3H, m), 1.92-1.76 (3H, m), 1.50-1.34 (1H) , M).

Reference Example 10: Synthesis of Compound X-10

Step (1): Compound X-21 → Compound X-10
Compound X-21 (1.9 g, 5.0 mmol) and diisopropylethylamine (1.3 ml, 7.5 mmol) were dissolved in dichloromethane (25 mL), then to this at 0 ° C. with diphenyl chlorophosphate (1.2 ml, 6. 5 mmol) was added. The mixture was stirred at 0 ° C. for 1 hour. To this was then added aminoethylpyrrolidine (0.68 g, 6 mmol) at 0 ° C. The mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with ethyl acetate, washed with aqueous sodium hydroxide, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with hexane / ethyl acetate (containing 3% triethylamine). The objective compound-containing fraction was concentrated under reduced pressure to obtain Compound X-10 (0.56 g, 19%).
¹ H-NMR (DMSO-D ₆ ) δ: 8.85 (1H, t, J = 5.8 Hz), 7.58-7.32 (12H, m), 5.25 (2H, s), 5.22 (2H, s), 3.37-3.35 (2H, m), 2.56-2.54 (2H, m), 1.72-1.65 (3H, m).

  Each target compound was synthesized in the same manner as in Reference Example 10 using the compounds shown below.

収量：０．３７ｇ（１５％）
^１Ｈ−ＮＭＲ （ＤＭＳＯ−Ｄ_６） δ：７．４９−７．２１ （１５Ｈ， ｍ）， ５．２８ （２Ｈ， ｓ）， ５．２３ （２Ｈ， ｓ）， ２．９９−２．７２ （７Ｈ， ｍ）， ２．０２−１．５５ （６Ｈ， ｍ）． Reference Example 11: Synthesis of Compound X-11

Yield: 0.37 g (15%)
¹ H-NMR (DMSO-D ₆ ) δ: 7.49-7.21 (15H, m), 5.28 (2H, s), 5.23 (2H, s), 2.99-2.72 (7H, m), 2.02-1.55 (6H, m).

収量：０．５２ｇ（２０％）
^１Ｈ−ＮＭＲ （ＤＭＳＯ−Ｄ_６） δ：８．８２ （１Ｈ， ｔ， Ｊ ＝ ６．３ Ｈｚ）， ７．５７−７．２０ （１０Ｈ， ｍ）， ５．２４ （２Ｈ， ｓ）， ５．２３ （２Ｈ， ｓ）， ３．０２ （２Ｈ， ｄ， Ｊ ＝ ６．４ Ｈｚ）， ２．７４−２．７０ （６Ｈ， ｂｒ ｍ）， １．３３−１．２９ （６Ｈ， ｂｒ ｍ）． Reference Example 12: Synthesis of Compound X-12

Yield: 0.52 g (20%)
¹ H-NMR (DMSO-D ₆ ) δ: 8.82 (1H, t, J = 6.3 Hz), 7.57-7.20 (10H, m), 5.24 (2H, s), 5.23 (2H, s), 3.02 (2H, d, J = 6.4 Hz), 2.74-2.70 (6H, br m), 1.33-1.29 (6H, br m).

収量：０．８８ｇ（３６％）
^１Ｈ−ＮＭＲ （ＤＭＳＯ−Ｄ_６） δ：７．４９−７．３２ （１２Ｈ， ｍ）， ５．２８ （２Ｈ， ｓ）， ５．２４ （２Ｈ， ｓ）， ３．４１−２．８２ （８Ｈ， ｍ）， ２．１４−１．６３ （５Ｈ， ｍ）． Reference Example 13: Synthesis of Compound X-13

Yield: 0.88 g (36%)
¹ H-NMR (DMSO-D ₆ ) δ: 7.49-7.32 (12H, m), 5.28 (2H, s), 5.24 (2H, s), 3.41-2.82 (8H, m), 2.14-1.63 (5H, m).

収量：１．０ｇ（３９％）
^１Ｈ−ＮＭＲ （ＣＤＣｌ_３） δ：７．９７ （１Ｈ， ｂｒ ｓ）， ７．９３−７．９０ （１Ｈ， ｍ）， ７．５６−７．３０ （１０Ｈ， ｍ）， ５．２５ （２Ｈ， ｓ）， ５．１６ （２Ｈ， ｓ）， ４．１６−４．１１ （１Ｈ， ｍ）， ３．２４ （１Ｈ， ｂｒ ｓ）， ２．３４−２．１８ （６Ｈ， ｍ）， １．８４−１．７１ （５Ｈ， ｍ）． Reference Example 14: Synthesis of Compound X-14

Yield: 1.0 g (39%)
¹ H-NMR (CDCl ₃ ) δ: 7.97 (1H, br s), 7.93-7.90 (1H, m), 7.56-7.30 (10H, m), 5.25 ( 2H, s), 5.16 (2H, s), 4.16-4.11 (1H, m), 3.24 (1H, br s), 2.34-2.18 (6H, m), 1.84-1.71 (5H, m).

収量：０．８５ｇ（５０％）
［Ｍ＋Ｈ］ ＝ ５３７．２５ Reference Example 15: Synthesis of Compound X-15

Yield: 0.85 g (50%)
[M + H] = 537.25

収量：２．０ｇ（７１％）
^１Ｈ−ＮＭＲ （ＣＤＣｌ_３） δ：７．４１ （１Ｈ， ｓ）， ７．３６−７．２７ （５Ｈ， ｍ）， ６．９１ （２Ｈ， ｄ， Ｊ ＝ ８．４ Ｈｚ）， ６．８１ （２Ｈ， ｄ， Ｊ ＝ ８．４ Ｈｚ）， ６．２８ （１Ｈ， ｂｒ ｓ）， ５．０６ （２Ｈ， ｓ）， ５．０２ （２Ｈ， ｓ）， ３．８２ （３Ｈ， ｓ）， ３．７８ （３Ｈ， ｓ）， ３．１９ （２Ｈ， ｄ， Ｊ ＝ ６．３ Ｈｚ）， ２．９０−２．８６ （６Ｈ， ｍ）， １．４１−１．３８ （６Ｈ， ｍ）． Reference Example 16: Synthesis of Compound X-16

Yield: 2.0 g (71%)
¹ H-NMR (CDCl ₃ ) δ: 7.41 (1H, s), 7.36-7.27 (5H, m), 6.91 (2H, d, J = 8.4 Hz), 6. 81 (2H, d, J = 8.4 Hz), 6.28 (1H, br s), 5.06 (2H, s), 5.02 (2H, s), 3.82 (3H, s) , 3.78 (3H, s), 3.19 (2H, d, J = 6.3 Hz), 2.90-2.86 (6H, m), 1.41-1.38 (6H, m ).

収量：１．３ｇ（４９％）
^１Ｈ−ＮＭＲ （ＣＤＣｌ_３） δ：７．３４ （４Ｈ， ｄｄ， Ｊ ＝ ８．８， ２．６ Ｈｚ）， ７．１１ （１Ｈ， ｄ， Ｊ ＝ １．９ Ｈｚ）， ７．０２ （１Ｈ， ｄ， Ｊ ＝ １．９ Ｈｚ）， ６．９１ （２Ｈ， ｄ， Ｊ ＝ ８．５ Ｈｚ）， ６．８３ （２Ｈ， ｄ， Ｊ ＝ ８．５ Ｈｚ）， ５．０６ （２Ｈ， ｂｒ ｓ）， ５．００ （２Ｈ， ｂｒ ｓ）， ３．９８ （１Ｈ， ｓ）， ３．８３ （３Ｈ， ｄ， Ｊ ＝ １０．２ Ｈｚ）， ３．８０ （３Ｈ， ｓ）， ３．５４ （２Ｈ， ｓ）， ３．２５ （１Ｈ， ｓ）， ２．８２ （２Ｈ， ｓ）， ２．４２ （６Ｈ， ｄｄ， Ｊ ＝ ５３．５， ２０．３ Ｈｚ）． Reference Example 17: Synthesis of compound X-17

Yield: 1.3 g (49%)
¹ H-NMR (CDCl ₃ ) δ: 7.34 (4H, dd, J = 8.8, 2.6 Hz), 7.11 (1H, d, J = 1.9 Hz), 7.02 ( 1H, d, J = 1.9 Hz), 6.91 (2H, d, J = 8.5 Hz), 6.83 (2H, d, J = 8.5 Hz), 5.06 (2H, br s), 5.00 (2H, br s), 3.98 (1H, s), 3.83 (3H, d, J = 10.2 Hz), 3.80 (3H, s), 3. 54 (2H, s), 3.25 (1H, s), 2.82 (2H, s), 2.42 (6H, dd, J = 53.5, 20.3 Hz).

収量：０．３９ｇ（３２％）
［Ｍ＋Ｈ］ ＝ ５２１．３５ Reference Example 18: Synthesis of compound X-18

Yield: 0.39 g (32%)
[M + H] = 521.35

収量：１．３ｇ（５０％）
^１Ｈ−ＮＭＲ （ＣＤＣｌ_３） δ：７．３４ （２Ｈ， ｄｄ， Ｊ ＝ １１．５， ２．８ Ｈｚ）， ７．３１−７．２７ （２Ｈ， ｍ）， ７．２４ （１Ｈ， ｄ， Ｊ ＝ １．６ Ｈｚ）， ７．０１ （１Ｈ， ｄｄ， Ｊ ＝ １０．４， １．９ Ｈｚ）， ６．９２ （２Ｈ， ｄｔ， Ｊ ＝ ９．３， ２．４ Ｈｚ）， ６．８２ （２Ｈ， ｄｔ， Ｊ ＝ ９．２， ２．４ Ｈｚ）， ５．９５ （１Ｈ， ｔ， Ｊ ＝ ６．１ Ｈｚ）， ５．０８ （４Ｈ， ｓ）， ３．８２ （３Ｈ， ｓ）， ３．７９ （３Ｈ， ｓ）， ３．２０ （２Ｈ， ｄ， Ｊ ＝ ６．４ Ｈｚ）， ２．９１−２．８７ （６Ｈ， ｍ）， １．４２−１．３８ （６Ｈ， ｍ）． Reference Example 19: Synthesis of Compound X-19

Yield: 1.3 g (50%)
¹ H-NMR (CDCl ₃ ) δ: 7.34 (2H, dd, J = 11.5, 2.8 Hz), 7.31-7.27 (2H, m), 7.24 (1H, d , J = 1.6 Hz), 7.01 (1H, dd, J = 10.4, 1.9 Hz), 6.92 (2H, dt, J = 9.3, 2.4 Hz), 6 .82 (2H, dt, J = 9.2, 2.4 Hz), 5.95 (1H, t, J = 6.1 Hz), 5.08 (4H, s), 3.82 (3H, s), 3.79 (3H, s), 3.20 (2H, d, J = 6.4 Hz), 2.91-2.87 (6H, m), 1.42-1.38 (6H , M).

収量：１．１ｇ（４２％）
^１Ｈ−ＮＭＲ （ＣＤＣｌ_３） δ：７．３３ （４Ｈ， ｄｄ， Ｊ ＝ １３．７， ８．６ Ｈｚ）， ６．９１−６．７９ （６Ｈ， ｍ）， ５．０５ （４Ｈ， ｓ）， ４．００−３．８９ （１Ｈ， ｍ）， ３．８２ （３Ｈ， ｓ）， ３．７７ （３Ｈ， ｄｄ， Ｊ ＝ １８．３， ６．６ Ｈｚ）， ３．５９ （１Ｈ， ｔ， Ｊ ＝ ２０．３ Ｈｚ）， ３．２１ （１Ｈ， ｄ， Ｊ ＝ ２８．７ Ｈｚ）， ２．８５ （１Ｈ， ｓ）， ２．５７ （１Ｈ， ｄ， Ｊ ＝ ３９．９ Ｈｚ）， ２．３５ （３Ｈ， ｓ）， １．８１ （５Ｈ， ｓ）． Reference Example 20: Synthesis of Compound X-20

Yield: 1.1 g (42%)
¹ H-NMR (CDCl ₃ ) δ: 7.33 (4H, dd, J = 13.7, 8.6 Hz), 6.91-6.79 (6H, m), 5.05 (4H, s ), 4.00-3.89 (1H, m), 3.82 (3H, s), 3.77 (3H, dd, J = 18.3, 6.6 Hz), 3.59 (1H, t, J = 20.3 Hz), 3.21 (1H, d, J = 28.7 Hz), 2.85 (1H, s), 2.57 (1H, d, J = 39.9 Hz) , 2.35 (3H, s), 1.81 (5H, s).

Reference Example 21: Synthesis of compound X-21

Step (1): Compound X-21a → Compound X-21b
Compound X-21a (13.5 g, 38 mmol) was suspended in dichloromethane (100 mL), and then N, O-dimethylhydroxylamine hydrochloride (5.6 g, 57 mmol) and 1-ethyl-3- (3 -Dimethylaminopropyl) carbodiimide (11 g, 57 mmol) and triethylamine (7.94 ml, 57 mmol) were added sequentially. The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with dichloromethane and water. The resulting solution was then separated, washed with water and saturated salt solution and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether to obtain Compound X-21b (15.1 g, 100%).
¹ H-NMR (CDCl ₃ ) δ: 7.42-7.26 (12H, m), 7.16 (2H, d, J = 10.4 Hz), 5.17 (2H, s), 5. 13 (2H, s), 3.48 (3H, s), 3.32 (3H, s).

Step (2): Compound X-21b → Compound X-21c
Compound X-21b (15.1 g, 38 mmol) was suspended in tetrahydrofuran (320 mL), and then methylmagnesium bromide (0.99 mol / L in tetrahydrofuran, 77 ml 76 mmol) was added thereto at 0 ° C. The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with saturated ammonium chloride solution, then extracted with ethyl acetate and water, washed with saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether to obtain Compound X-21c (13 g, 97%).
¹ H-NMR (CDCl ₃ ) δ: 7.44-7.26 (12H, m), 5.21 (2H, s), 5.16 (2H, s), 2.52 (3H, s).

Step (2): Compound X-21c → Compound X-21
Compound X-21c (13 g, 37 mmol) was dissolved in pyridine (200 mL), and then selenium dioxide (10.3 g, 93 mmol) was added thereto. The mixture was stirred at 80 ° C. for 1 day. The reaction mixture was filtered and evaporated. The residue was diluted with aqueous hydrochloric acid and ethyl acetate, then separated, washed with water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether to obtain Compound X-21 (11.5 g, 82%).
¹ H-NMR (DMSO-D ₆ ) δ: 7.52-7.48 (3H, m), 7.44-7.32 (9H, m), 5.27 (2H, s), 5.23 (2H, s).

Reference Example 22: Synthesis of compound X-22

Step (1): Compound X-1g → Compound X-22
A solution of compound X-1 g (4.20 g, 5.0 mmol) in dichloromethane (20 ml) was cooled to −40 ° C. A solution of m-chloroperbenzoic acid (1.46 g, 5.5 mmol) in dichloromethane (20 ml) was added dropwise. After stirring at −40 ° C. for 30 minutes, 15% aqueous sodium thiosulfate solution was added thereto, and dichloromethane was evaporated under reduced pressure, followed by extraction with ethyl acetate. The organic layer was washed with 5% aqueous sodium hydrogen carbonate solution and then with saturated brine, and then dried over anhydrous magnesium sulfate. The inorganic material was filtered off and concentrated in vacuo. The resulting crude product was purified by silica gel column chromatography to give compound X-22 as a yellow form.
Yield: 2.59 g (60%)
¹ H-NMR (CDCl ₃ ) δ: 1.43 (9H, s), 1.59 (3H, s), 1.60 (3H, s), 1.61 (9H, s), 1.78 ( 3H, d, J = 7.53 Hz), 3.48 (1H, q, J = 7.53 Hz), 4.05 (1H, d, J = 12.67 Hz), 4.74 (1H, dd, J = 4.96, 1.38 Hz), 5.17 (1H, d, J = 12.67 Hz), 6.25 (1H, dd, J = 9.98, 4.96 Hz), 6.95 (1H, s), 7.28-7.44 (11H, m), 8.09 (1H, d, J = 9.98 Hz), 8.30 (1H, s).

Reference Example 23: Synthesis of Compound X-23

Step (1): Compound X-1h → Compound X-23
Compound X-23 was obtained as a white solid from Compound X-1h (4.20 g, 5.0 mmol) in the same manner as in Reference Example 22.
Yield: 2.26 g (53%)
¹ H-NMR (CDCl ₃ ) δ: 1.39 (3H, d, J = 7.47 Hz), 1.42 (9H, s), 1.53 (9H, s), 1.59 (3H, s), 1.60 (3H, s), 3.88 (1H, q, J = 7.47 Hz), 4.34 (1H, d, J = 12.05 Hz), 4.59 (1H, d, J = 5.03 Hz), 4.63 (1H, d, J = 12.05 Hz), 6.31 (1H, dd, J = 9.76, 5.03 Hz), 7.00 ( 1H, s), 7.25-7.48 (11H, m), 7.95 (1H, d, J = 9.76 Hz), 8.19 (1H, s).

Reference Example 25: Synthesis of compound X-25 Compound X-25: 5-chloro-1-cyclopropyl-6,7-bis ((4-methoxybenzyl) oxy) -N-((1R, 3r, 5S)- 8-Methyl-8-azabicyclo [3.2.1] octane-3-yl) -4-oxo-1,4-dihydroquinoline-3-carboxamide

5-Chloro-1-cyclopropyl-6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-1,4-dihydroquinoline-3-carboxylic acid (WO2013052568A1, 8 g in DCM (700 mL) , 14.93 mmol) and (1R, 5S) -8-methyl-8-azabicyclo [3.2.1] octane-3-amine dihydrochloride (3.34 g, 15.7 mmol) in DIPEA at room temperature. (9.12 mL, 52.2 mmol) and PyBOP (9.32 g, 17.9 mmol) were added. The reaction mixture was stirred overnight, then concentrated and the resulting residue was purified by automated silica gel chromatography (120 g column, 0-10% MeOH in DCM). The isolated product was purified again by automated silica gel chromatography (24 g column, 0-10% MeOH in DCM) to give compound X-25 (4.64 g, 47% yield) as a white solid.
LCMS: (M + H) ^<+> : 658.2. ¹ H NMR (DMSO-d ₆ ): 10.46 (d, J = 7.3 Hz, 1H), 8.57 (s, 1H), 7.67 (s, 1H), 7.50 (d, J = 8.6 Hz, 2H), 7.33 (d, J = 8.6 Hz, 2H), 7.02 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 5.35 (s, 2H), 4.91 (s, 2H), 4.04 (q, J = 6.8 Hz, 1H), 3.79 (s, 3H) , 3.75 (s, 3H), 3.62-3.69 (m, 1H), 3.02-3.16 (m, 2H), 2.21 (s, 3H), 1.90-2 .15 (m, 6H), 1.60 (d, J = 13.9 Hz, 2H), 1.25-1.35 (m, 2H), 0.99-1.07 (m, 2H).

Reference Example 26: Synthesis of Compound X-26 Compound X-26:
5-chloro-1-ethyl-6,7-bis ((4-methoxybenzyl) oxy) -N-((1R, 3r, 5S) -8-methyl-8-azabicyclo [3.2.1] octane- 3-yl) -4-oxo-1,4-dihydroquinoline-3-carboxamide

5-Chloro-1-ethyl-6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-1,4-dihydroquinoline-3-carboxylic acid (WO2013052568A1) in DCM (800 mL). 0 g, 19.1 mmol) and (1R, 5S) -8-methyl-8-azabicyclo [3.2.1] octane-3-amine dihydrochloride (4.07 g, 19.1 mmol) at room temperature. DIPEA (11.7 mL, 66.8 mmol) and PyBOP (11.92 g, 22.90 mmol) were added and the reaction mixture was stirred for 0.5 h. The mixture was concentrated and the resulting residue was purified by automated silica gel chromatography (120 g column, 0-10% MeOH in DCM). Fractions containing product were combined and washed sequentially with saturated aqueous NaHCO ₃ solution, brine, and water. The product was repurified by automated silica gel chromatography (24 g column, 0-10% MeOH in DCM) to give compound X-26 (5.95 g, 48% yield) as a white solid.
LCMS: (M + H) ^<+> : 646.2. ¹ H NMR (CDCl ₃ ) δ: 10.71 (d, J = 6.6 Hz, 1H), 8.64 (s, 1H), 7.41 (d, J = 8.6 Hz, 2H), 7.37 (d, J = 8.6 Hz, 2H), 6.96 (d, J = 9.1 Hz, 2H), 6.87 (d, J = 8.6 Hz, 1H), 6. 81 (s, 1H), 5.22 (s, 2H), 5.01 (s, 2H), 4.31 (q, J = 6.4 Hz, 1H), 4.17 (q, J = 7 .3 Hz, 2H), 3.85 (s, 3H), 3.83 (s, 3H), 3.40-3.55 (m, 2H), 2.58-2.73 (m, 2H) , 2.55 (s, 3H), 2.31-2.41 (m, 2H), 2.20-2.30 (m, 2H), 2.01 (d, J = 14.9 Hz, 2H , 1.41 (t, J = 7.2 Hz, 3H).

Example 1 Synthesis of Compound I-1

Step (1): Compound 1a → Compound 1b
Compound 1a (14.53 g, 74.8 mmol) was dissolved in dichloromethane (150 mL), and then boron tribromide (50 g, 200 mmol) was added dropwise thereto at 0 ° C. The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with ice water and evaporated. Next, the precipitated solid was collected by filtration and washed with water. In this way, compound 1b was obtained (11.2 g, 90%).
¹ H-NMR (DMSO-D ₆ ) δ: 10.18 (1H, s), 9.66 (1H, s), 7.06 (1H, s), 6.92 (1H, s), 5. 16 (2H, s).

Step (2): Compound 1b → Compound 1c
Compound 1b (13.20 g, 79 mmol) was dissolved in dimethylacetamide (130 mL) and then potassium carbonate (32.9 g, 238 mmol), p-methoxybenzyl chloride (26.0 ml, 191 mmol) and sodium iodide (11 .91 g, 79 mmol) was added sequentially. The mixture was stirred at 50 ° C. for 1 hour. The reaction mixture was poured into water. Next, the precipitated solid was collected by filtration and washed with water and diisopropyl ether. There was thus obtained compound 1c (37.32 g 116%).
¹ H-NMR (CDCl ₃ ) δ: 7.37-7.33 (5H, m), 6.92-6.88 (5H, m), 5.16 (2H, s), 5.16 (2H , S), 5.12 (2H, s), 3.82 (3H, s), 3.81 (3H, s).

Step (3): Compound 1c → Compound 1d
To a solution of the total amount of compound 1c obtained (37.32 g, 79 mmol) in tetrahydrofuran (30 mL) and methanol (30 mL) was added 2 mol / L aqueous sodium hydroxide solution (119 ml, 237 mmol). The resulting solution was stirred at 70 ° C. for 1 hour. Water and a 2 mol / L aqueous hydrochloric acid solution (120 mL) were added to the reaction mixture. Next, the precipitated solid was collected by filtration and washed with water to obtain Compound 1d (42.71 g, 127%).
¹ H-NMR (CDCl ₃ ) δ: 7.69 (1H, s), 7.36-7.34 (4H, m), 7.02 (1H, s), 6.91-6.87 (4H M), 5.15 (2H, s), 5.09 (2H, s), 4.73 (2H, s), 4.69 (1H, br s), 3.81 (3H, s), 3.80 (3H, s).

Step (4): Compound 1d → Compound 1e
The total amount (42.71 g, 79 mmol) of the obtained compound 1d was suspended in acetone (350 mL), and then Jones reagent (2.67 mol / L, 71.0 mL, 190 mmol) was added thereto at 0 ° C. The mixture was stirred at 0 ° C. for 1 hour. The reaction mixture was diluted with dichloromethane and water, and sodium bisulfite was added at 0 ° C. The resulting solution was then separated, washed with water and saturated salt solution and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether to obtain Compound 1e (26.94 g, 81%).
¹ H-NMR (CDCl ₃ ) δ: 7.38 (2H, s), 7.35 (4H, d, J = 8.1 Hz), 6.92 (4H, d, J = 8.1 Hz) , 5.21 (4H, s), 3.82 (6H, s).

Step (5): Compound 1e → Compound 1f
Compound 1e (1.88 g, 4.5 mmol) was suspended in toluene (20 mL), and then aminoethylpyrrolidine (0.60 mL, 4.7 mmol) was added thereto at 0 ° C. The mixture was stirred at room temperature for 30 minutes. To this was added acetic acid (0.28 mL, 4.9 mmol). The resulting mixture was stirred at reflux for 30 minutes. The reaction mixture was diluted with ethyl acetate and aqueous sodium hydroxide solution, then separated, washed with water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether to obtain Compound 1f (2.10 g, 91%).
¹ H-NMR (CDCl ₃ ) δ: 7.36-7.32 (6H, m), 6.92-6.89 (4H, m), 5.17 (4H, s), 3.81 (6H , S), 3.78-3.73 (2H, m), 2.72-2.68 (2H, m), 2.56 (4H, br s), 1.74 (4H, br s).

Step (6): Compound X-1 + Compound 1f → Compound 1g → Compound I-1
Compound 0f (517 mg, 1.0 mmol) was added to a solution of compound X-1 (932 mg, 1.00 mmol) in dimethylformamide (2 mL) at 0 ° C., and the resulting solution was stirred at 0 ° C. for 1 day. did. The reaction mixture was slowly added at 0 ° C. to 5% salt solution (30 ml) (containing 1.5 g sodium bisulfite). The precipitated solid was collected by filtration, washed with water and then suspended in water. The suspension was lyophilized to give 1 g of compound as an orange solid. The obtained compound 1g was used in the next step without purification.

The total amount of 1 g of the obtained compound was dissolved in dichloromethane (10 mL), and the solution was cooled to −40 ° C. To this was then added anisole (1.3 mL, 12 mmol) and a 2 mol / L aluminum chloride solution (6.00 mL, 12 mmol) in nitromethane sequentially. The resulting product was stirred at 0 ° C. for 30 minutes. The reaction mixture was dissolved in water, 2 mol / L hydrochloric acid aqueous solution, and acetonitrile. The resulting solution was then washed with diisopropyl ether. After adding HP20-SS resin to the aqueous phase, acetonitrile was distilled off under reduced pressure. The resulting mixture was purified by ODS column chromatography. After adding HP20-SS resin to the obtained target compound solution, acetonitrile was distilled off under reduced pressure. The resulting mixture was purified by HP20-SS column chromatography. A 0.2N sodium hydroxide aqueous solution was added to the obtained target compound solution until the pH reached 6.0 as a whole. Thereafter, a piece of dry ice was added thereto. The resulting solution was concentrated under reduced pressure and then lyophilized to obtain Compound I-1 as an orange powder.
Yield: 163.5 mg, (18%).
¹ H-NMR (D ₂ O) δ: 6.99 (3H, s), 5.80 (1H, d, J = 4.6 Hz), 5.47 (1H, d, J = 4.6 Hz) ), 5.07 (1H, d, J = 14.1 Hz), 4.30 (1H, d, J = 14.1 Hz), 4.11 (1H, d, J = 6.3 Hz), 4.00 (2H, br s), 3.69-3.52 (6H, m), 2.23 (4H, br s), 1.59 (3H, d, J = 5.8 Hz), 1 .53 (3H, s), 1.51 (3H, s).
Elemental analysis: C32H34N7O11S2Na (H2O) 4.8
Theoretical: C, 44.37; H, 5.07; N, 11.32; S, 7.40; Na, 2.65 (%)
Measurements: C, 44.29; H, 4.98; N, 11.52; S, 7.27; Na, 2.76 (%)

Example 2: Synthesis of compound I-2

Step (1): Compound 2a → Compound 2b
The target compound was synthesized in the same manner as in Step 1 of Example 1 using Compound 2a (2.33 g, 10.2 mmol).
Yield: 2.00 g (98%)
¹ H-NMR (DMSO-D ₆ ) δ: 10.55 (2H, br s), 7.09 (1H, s), 5.22 (2H, s).

Step (2): Compound 2b → Compound 2c
The target compound was synthesized in the same manner as in Step 2 of Example 1 using Compound 2b (2.00 g, 9.97 mmol).
Yield: 4.85 g (110%)
¹ H-NMR (CDCl ₃ ) δ: 7.39-7.37 (3H, m), 7.31 (2H, d, J = 8.7 Hz), 6.94 (2H, d, J = 8 .7 Hz), 6.83 (2H, d, J = 8.7 Hz), 5.18 (2H, s), 5.11 (2H, s), 5.09 (2H, s), 84 (3H, s), 3.80 (3H, s).

Step (3): Compound 2c → Compound 2d
The target compound was synthesized in the same manner as in Step 3 of Example 1 using the total amount of compound 2c (4.85 g, 9.97 mmol).
Yield: 4.46 g (98%)
¹ H-NMR (CDCl ₃ ) δ: 7.62 (1H, s), 7.36 (2H, d, J = 8.5 Hz), 7.33 (2H, d, J = 8.5 Hz) 6.92 (2H, d, J = 8.5 Hz), 6.83 (2H, d, J = 8.5 Hz), 5.09 (2H, s), 5.04 (2H, s) , 4.99 (2H, s), 3.83 (3H, s), 3.80 (3H, s).

Step (4): Compound 2d → Compound 2e
The target compound was synthesized in the same manner as in Step 4 of Example 1 using Compound 2d (4.46 g, 9.72 mmol).
Yield: 3.32 g, (75% containing compound 2c)
The obtained compound 2e was directly used in the next step without purification.

Step (5): Compound 2e → Compound 2f
The target compound was synthesized in the same manner as in Step 5 of Example 1 using Compound 2e (2.36 g, 5.19 mmol).
Yield: 0.98 g (34%)
¹ H-NMR (CDCl ₃ ) δ: 7.39-7.36 (3H, m), 7.30 (2H, d, J = 8.7 Hz), 6.94 (2H, d, J = 8 .7 Hz), 6.82 (2H, d, J = 8.7 Hz), 5.16 (2H, s), 5.03 (2H, s), 3.84 (3H, s), 80-3.77 (5H, m), 2.73 (2H, t, J = 6.8 Hz), 2.61-2.56 (4H, m), 1.77-1.74 (4H, m).

Step (6): Compound X-1 + Compound 2f → Compound 2g → Compound I-2
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound X-1 (932 mg, 1.00 mmol) and Compound 2f (551 mg, 1.00 mmol).
Yield: 124.3 mg, (13%)
¹ H-NMR (D ₂ O) δ: 7.31 (1H, dd, J = 7.78, 1.53 Hz), 7.07 (1H, dd, J = 7.78, 1.53 Hz) , 6.98 (1H, s), 6.83 (1H, t, J = 7.78 Hz), 5.89 (1H, d, J = 4.96 Hz), 5.38 (1H, d, J = 4.96 Hz), 4.31 (1H, t, J = 7.32 Hz), 4.11-3.94 (4H, m), 3.51 (1H, d, J = 17.23). Hz), 3.11 (3H, br s), 2.83-2.72 (2H, m), 2.61-2.41 (5H, m), 2.19 (1H, br s), 2 .13 (1H, br s), 1.52 (3H, s), 1.50 (3H, s).
Elemental analysis: C32H32.8ClN7O11S2Na1.2 (H2O) 6.7
Theoretical: C, 40.92; H, 4.96; Cl, 3.77; N, 10.44; S, 6.83; Na, 2.94 (%)
Measurements: C, 40.77; H, 4.91; Cl, 3.53; N, 10.72; S, 6.99; Na, 2.94 (%)

Example 3: Synthesis of compound I-3

Step (1): Compound 3a → Compound 3b
Compound 3a (60 g, 140 mmol) was suspended in dichloromethane (300 mL), which was then added N, O-dimethylhydroxylamine hydrochloride (16.5 g, 169 mmol) and 1-ethyl-3- (3-dimethylaminopropyl hydrochloride). ) Carbodiimide (32.2 g, 168 mmol) was added sequentially. The mixture was stirred at room temperature for 1 day. Next, N, O-dimethylhydroxylamine hydrochloride (4.10 g, 42 mmol) and 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (8.05 g, 42 mmol) were sequentially added thereto. The mixture was stirred at room temperature for 3 hours. Next, N, O-dimethylhydroxylamine hydrochloride (4.10 g, 42 mmol) and 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (8.05 g, 42 mmol) were sequentially added thereto. The mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with dichloromethane and water. The resulting solution was then separated, washed with water and saturated salt solution and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether to obtain Compound 3b (62.07 g, 94%).
¹ H-NMR (CDCl ₃ ) δ: 7.36-7.32 (4H, m), 7.02 (1H, d, J = 8.4 Hz), 6.93-6.89 (3H, m ), 6.81 (2H, d, J = 8.5 Hz), 5.06 (2H, s), 4.98 (2H, s), 3.83 (3H, s), 3.79 (3H , S), 3.45-3.31 (6H, br m).

Step (2): Compound 3b → Compound 3c
Compound 3b (18.88 g, 40 mmol) was suspended in tetrahydrofuran (380 mL), and then methylmagnesium bromide (0.99 mol / L in tetrahydrofuran, 81 ml 80 mmol) was added thereto at 0 ° C. The mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with saturated ammonium chloride solution, then extracted with ethyl acetate and water, washed with saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether to obtain Compound 3c (13.19 g, 77%).
¹ H-NMR (CDCl ₃ ) δ: 7.39-7.33 (5H, m), 6.93-6.91 (3H, m), 6.83 (2H, d, J = 8.5 Hz) ), 5.09 (2H, s), 4.96 (2H, s), 3.83 (3H, s), 3.80 (3H, s), 2.62 (3H, s).

Step (3): Compound 3c → Compound 3d
Compound 3c (13.19 g, 31 mmol) was dissolved in pyridine (130 mL), and then selenium dioxide (8.57 g, 77 mmol) was added thereto. The mixture was stirred at 80 ° C. for 1 day. The reaction mixture was filtered and evaporated. The residue was diluted with aqueous hydrochloric acid and ethyl acetate, then separated, washed with water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether to obtain Compound 3d (12.41 g, 88%).
¹ H-NMR (DMSO-D ₆ ) δ: 7.60 (1H, d, J = 8.8 Hz), 7.46 (2H, d, J = 8.5 Hz), 7.37 (1H, d, J = 8.8 Hz), 7.28 (2H, d, J = 8.5 Hz), 6.99 (2H, d, J = 8.5 Hz), 6.85 (2H, d, J = 8.5 Hz), 5.24 (2H, s), 4.92 (2H, s), 3.78 (3H, s), 3.74 (3H, s).

Step (4): Compound 3d → Compound 3e
Compound 3d (2.28 g, 5.0 mmol) was dissolved in dimethylacetamide (20 mL), and then 4-aminomethylquinuclidine (2.10 g, 15.0 mmol), hydroxybenzotriazole (0.74 g, 5 mmol) were dissolved therein. .50 mmol) and 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (1.05 g, 5.50 mmol) were added sequentially. The mixture was stirred at room temperature for 1 day and at 40 ° C. for 1 day. The reaction mixture was diluted with aqueous hydrochloric acid and stirred at room temperature for 30 minutes. The reaction mixture was diluted with ethyl acetate and aqueous sodium hydroxide solution, then separated, washed with water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The precipitated solid was then collected by filtration and washed with ethyl acetate to give compound 3e (0.50 g, 17%).
¹ H-NMR (DMSO-D ₆ ) δ: 8.80 (1H, t, J = 6.4 Hz), 7.50 (1H, d, J = 8.8 Hz), 7.46 (2H, d, J = 8.7 Hz), 7.33 (1H, d, J = 8.8 Hz), 7.28 (2H, d, J = 8.7 Hz), 6.99 (2H, d, J = 8.7 Hz), 6.85 (2H, d, J = 8.7 Hz), 5.22 (2H, s), 4.90 (2H, s), 3.78 (3H, s) 3.74 (3H, s), 3.01 (2H, d, J = 6.4 Hz), 2.81 (6H, t, J = 7.6 Hz), 1.37 (6H, t, J = 7.6 Hz).

Step (5): Compound X-1 + Compound 3e → Compound 3f → Compound I-3
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound X-1 (745 mg, 0.80 mmol) and Compound 3e (463 mg, 0.80 mmol).
Yield: 284.2 mg, (35%)
¹ H-NMR (D ₂ O) δ: 7.31 (1H, d, J = 8.7 Hz), 7.01 (1H, s), 6.88 (1H, d, J = 8.7 Hz) ), 5.84 (1H, d, J = 4.8 Hz), 5.45 (1H, d, J = 4.8 Hz), 4.65 (1H, d, J = 14.4 Hz), 4.11-4.05 (2H, m), 3.60-3.42 (6H, m), 3.36 (2H, s), 1.95 (6H, t, J = 7.8 Hz) , 1.57 (3H, d, J = 6.9 Hz), 1.52 (3H, s), 1.51 (3H, s).
Elemental analysis: C34H37ClN7O11S2Na (H2O) 6.4
Theoretical values: C, 42.65; H, 5.24; Cl, 3.70; N, 10.24; S, 6.70; Na, 2.40 (%)
Measurements: C, 42.61; H, 5.26; Cl, 3.83; N, 10.32; S, 6.71; Na, 2.43 (%)

Example 4: Synthesis of compound I-4

Step (1): Compound 1e + Compound 4a → Compound 4b
Compound 1e (1.88 g, 4.5 mmol) was dissolved in ethanol (10 mL), and then compound 4a (0.58 g, 4.5 mmol) was added thereto. The mixture was stirred at room temperature for 1 day. Next, the precipitated solid was collected by filtration and washed with ethanol and diisopropyl ether to obtain Compound 4b (2.00 g, 84%).
¹ H-NMR (CDCl ₃ ) δ: 7.80 (1H, s), 7.32 (2H, d, J = 8.5 Hz), 7.08 (2H, d, J = 8.5 Hz) 6.73 (2H, d, J = 8.5 Hz), 6.69 (2H, d, J = 8.5 Hz), 6.49 (1H, br s), 5.01 (2H, s ), 4.65 (2H, s), 4.35 (2H, br s), 3.78 (3H, s), 3.76 (3H, s), 3.27-3.01 (6H, br m), 1.90 (4H, br s).

Step (2): Compound X-1 + Compound 4b → Compound 4c → Compound I-4
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound X-1 (932 mg, 1.00 mmol) and Compound 4b (532 mg, 1.00 mmol).
Yield: 64.5 mg (6%)
¹ H-NMR (D ₂ O) δ: 7.31 (1H, s), 7.15 (1H, s), 6.98 (1H, s), 5.79 (1H, d, J = 4. 8 Hz), 5.45 (1H, d, J = 4.8 Hz), 5.03 (1H, d, J = 14.2 Hz), 4.45 (2H, d, J = 4.6 Hz). ), 4.25 (1H, d, J = 14.2 Hz), 4.01 (1H, q, J = 7.0 Hz), 3.81-3.43 (6H, m), 2.24 -2.06 (4H, m), 1.51-1.49 (9H, m).
Elemental analysis: C32H34.5N8O11S2Na1.5 (H2O) 10.3
Theoretical: C, 38.77; H, 5.60; N, 11.30; S, 6.47; Na, 3.48 (%)
Measurement: C, 38.76; H, 5.45; N, 11.42; S, 6.34; Na, 3.49 (%)

Example 5: Synthesis of compound I-5

Step (1): Compound 5a → Compound 5b
Compound 5a (8.50 g, 50 mmol) and hydroxylamine hydrochloride (5.21 g, 75 mmol) were dissolved in ethanol (50 mL) and water (25 ml), then sodium carbonate (10.6 g, 100 mmol) at 0 ° C. added. The mixture was stirred at reflux for 1 hour. The reaction mixture was diluted with ethyl ether and aqueous sodium hydroxide solution, separated and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The residue was distilled by vacuum distillation (4 mmHg, 116 ° C.) to give compound 5b (1.88 g, 29%).
¹ H-NMR (CDCl ₃ ) δ: 3.09 (2H, br s), 2.75 (2H, br s), 2.57 (4H, br s), 1.78 (4H, br s).

Step (2): Compound 5b + Compound 1e → Compound 5c
Compound 1e (2.10 g, 5.0 mmol) was dissolved in ethanol (10 mL), and then compound 5b (0.65 g, 5.0 mmol) was added thereto. The mixture was stirred at room temperature for 1 day, 50 ° C. for 2 hours, and 80 ° C. for 4 hours. Next, the precipitated solid was collected by filtration and washed with ethanol and diisopropyl ether to obtain Compound 5c (1.81 g, 68%).
¹ H-NMR (CDCl ₃ ) δ: 7.69 (1H, s), 7.61 (1H, s), 7.39-7.36 (4H, m), 6.92-6.89 (4H M), 5.23 (2H, s), 5.19 (2H, s), 4.19 (2H, t, J = 6.7 Hz), 3.81 (6H, s), 2.90. (2H, br s), 2.60 (4H, br s), 1.77 (4H, br s).

Step (3): Compound X-1 + Compound 5c → Compound 5d → Compound I-5
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound X-1 (932 mg, 1.00 mmol) and Compound 5c (533 mg, 1.00 mmol).
Yield: 158.9 mg, (14%)
¹ H-NMR (D ₂ O) δ: 7.47 (1H, s), 7.40 (1H, s), 7.02 (1H, s), 5.81 (1H, d, J = 4. 8 Hz), 5.48 (1H, d, J = 4.8 Hz), 5.04 (1H, d, J = 14.3 Hz), 4.63-4.58 (1H, m), 4 .32 (1H, d, J = 14.2 Hz), 4.08 (1H, q, J = 7.0 Hz), 3.89-3.49 (6H, m), 2.22 (4H, br s), 1.58 (3H, d, J = 7.2 Hz), 1.52 (3H, s), 1.50 (3H, s).
Elemental analysis: C32H33.8N7O12S2Na1.2 (H2O) 8.3
Theoretical: C, 40.47; H, 5.35; N, 10.32; S, 6.75; Na, 2.90 (%)
Measurements: C, 40.39; H, 5.30; N, 10.59; S, 6.64; Na, 3.02 (%)

Example 6: Synthesis of compound I-6

Step (1): Compound 6a → Compound 6b
Compound 6a (2.81 g, 9.11 mmol) was dissolved in dichloromethane (30 mL), and then boron tribromide (2.5 ml, 26.4 mmol) was added dropwise thereto at 0 ° C. The mixture was stirred at room temperature for 1 hour. Next, methanol (10 ml, 247 mmol) was added dropwise thereto at 0 ° C. The mixture was stirred at 0 ° C. for 10 minutes. The reaction mixture was evaporated. In this way, compound 6b was obtained (5.53 g, 168%). The obtained compound 6b was directly used in the next step without purification.

Step (2): Compound 6b → Compound 6c
The total amount of the obtained compound 6b (5.53 g, 9.11 mmol) and triethylamine (5.68 mL, 41.0 mmol) were dissolved in dichloromethane (30 mL), and then this was dissolved in di-t-butyl dicarbonate (30 mL) at 0 ° C. 6.35 ml, 27.3 mmol) and N, N-dimethyl-4-aminopyridine (0.06 g, 0.5 mmol) were added sequentially. The mixture was stirred at room temperature for 1 day. The reaction mixture was diluted with dichloromethane, washed with aqueous sodium hydroxide, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with hexane / ethyl acetate (containing 3% triethylamine). The target compound-containing fraction was concentrated under reduced pressure to obtain compound 6c (1.27 g, 29%).
¹ H-NMR (CDCl ₃ ) δ: 7.89 (1H, s), 7.47 (1H, s), 4.00 (2H, t, J = 6.0 Hz), 2.82 (2H, t, J = 6.0 Hz), 2.62 (4H, br s), 1.82 (4H, br s), 1.56 (18H, s).

Step (3): Compound X-1 + Compound 6c → Compound 6d → Compound I-6
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound X-1 (932 mg, 1.00 mmol) and Compound 6c (481 mg, 1.00 mmol).
Yield: 175.2 mg (18%)
¹ H-NMR (D ₂ O) δ: 7.33 (1H, s), 7.15 (1H, s), 7.02 (1H, s), 5.80 (1H, d, J = 4. 8 Hz), 5.46 (1H, d, J = 4.8 Hz), 4.47-4.25 (3H, m), 4.04 (1H, br s), 3.72-3.47. (6H, m), 2.22 (4H, br s), 1.56-1.50 (9H, m).
Elemental analysis: C31H34N7O10S3Na (H2O) 7.4
Theoretical values: C, 40.60; H, 5.36; N, 10.69; S, 10.49; Na, 2.51 (%)
Measurements: C, 40.65; H, 5.22; N, 10.88; S, 10.20; Na, 2.51 (%)

Example 7: Synthesis of Compound 1-7

Step (1): Compound 7a + Compound 7b → Compound 7c
Compound 7a (10.0 g, 41.6 mmol) was suspended in dichloromethane (100 mL), which was then added to 1-chloro-N, N, 2-trimethyl-1-propenylamine (6.1 mL, 45 mL) at 0 ° C. .8 mmol) was added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was added at 0 ° C. to a mixture of compound 7b (23.90 g, 125 mmol) and sodium bicarbonate (17.65 g, 167 mmol) in tetrahydrofuran (100 ml) and water (100 ml). The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with aqueous hydrochloric acid (adjusted to pH = 5) and ethyl acetate, then separated, washed with water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with hexane / ethyl acetate. The target compound-containing fraction was concentrated under reduced pressure to obtain Compound 7c (15.5 g, 101%).
¹ H-NMR (CDCl ₃ ) δ: 7.39 (1H, s), 6.51 (1H, s), 4.02-3.98 (4H, m), 3.89 (3H, s), 3.82 (3H, s), 0.89 (9H, s), 0.09 (6H, s).

Step (2): Compound 7c → Compound 7d
Compound 7c (14.5 g, 39.0 mmol) and triphenylphosphine (12.28 g, 46.8 mmol) were dissolved in tetrahydrofuran (150 mL), and then this was added at 0 ° C. to dimethyl azodicarboxylate (2.7 mol in toluene). / L, 17.35 ml, 46.8 mmol) was added dropwise. The mixture was stirred at room temperature for 2 hours. Next, a mixture of acetic acid and methanol (1: 1) was added dropwise thereto at 0 ° C. The mixture was stirred at 0 ° C. for 10 minutes. The reaction mixture was diluted with saturated sodium bicarbonate solution and toluene, then separated, washed with saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The residue was dissolved in toluene (150 mL) and hexane (100 ml) and stored at −20 ° C. overnight. The reaction mixture was filtered and washed with toluene / hexane (1/1).
The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with hexane / ethyl acetate. The target compound-containing fraction was concentrated under reduced pressure to obtain Compound 7d (6.37 g, 46%).
¹ H-NMR (CDCl ₃ ) δ: 7.17 (1H, s), 6.67 (1H, s), 4.11 (2H, t, J = 5.8 Hz), 3.95 (3H, s), 3.93-3.90 (5H, m), 0.83 (9H, s), -0.01 (6H, s).

Step (3): Compound 7d → Compound 7e
Triphenylphosphine (7.09 g, 27.0 mmol) was dissolved in dichloromethane (60 ml), and then bromine (1.30 ml, 25.3 mmol) was added dropwise thereto at 0 ° C. The mixture was stirred at room temperature for 20 minutes. To this was then added a solution of compound 7d (6.37 g, 18.0 mmol) in dichloromethane (20 ml) at 0 ° C. The resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with water and dichloromethane then separated, washed with saturated sodium bicarbonate solution and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with hexane / ethyl acetate. The target compound-containing fraction was concentrated under reduced pressure to obtain compound 7e (4.41 g, 81%).
¹ H-NMR (CDCl ₃ ) δ: 7.17 (1H, s), 6.69 (1H, s), 4.37 (2H, t, J = 6.8 Hz), 3.96 (3H, s), 3.91 (3H, s), 3.64 (2H, t, J = 6.8 Hz).

Step (4): Compound 7e → Compound 7f
The target compound was synthesized in the same manner as in Step 1 of Example 1 using Compound 7e (4.41 g, 14.6 mmol).
Yield: 3.80 g (95%)
¹ H-NMR (DMSO-D ₆ ) δ: 9.91 (2H, br s), 6.94 (1H, s), 6.73 (1H, s), 4.24 (2H, br s), 3.76 (2H, br s).

Step (5): Compound 7f → Compound 7g
The target compound was synthesized in the same manner as in Step 2 of Example 1 using Compound 7f (3.80 g, 13.87 mmol).
Yield: 7.25 g (102%)
¹ H-NMR (CDCl ₃ ) δ: 7.36-7.33 (4H, m), 7.23 (1H, s), 6.93-6.87 (4H, m), 6.71 (1H , S), 5.13 (2H, s), 5.06 (2H, s), 4.33 (2H, t, J = 6.8 Hz), 3.82 (3H, s), 3.81 (3H, s), 3.60 (2H, t, J = 6.8 Hz).

Step (6): Compound 7g → Compound 7h
Compound 7g (3.50 g, 6.80 mmol) was dissolved in dimethylacetamide (35 ml) and then pyrrolidine (1.13 ml, 13.61 mmol) and sodium iodide (1.02 g, 6.80 mmol) at 0 ° C. Was added. The mixture was stirred at room temperature for 1 day. The reaction mixture was diluted with ethyl acetate and aqueous sodium hydroxide solution, then separated, washed with water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to amino silica gel column chromatography, and the target compound was eluted with hexane / ethyl acetate. The target compound-containing fraction was concentrated under reduced pressure to obtain compound 7h (0.62 g, 18%).
¹ H-NMR (CDCl ₃ ) δ: 7.36-7.33 (4H, m), 7.22 (1H, s), 6.92-6.86 (4H, m), 6.70 (1H , S), 5.12 (2H, s), 5.06 (2H, s), 4.08 (2H, t, J = 6.7 Hz), 3.82 (3H, s), 3.81 (3H, s), 2.84 (2H, t, J = 6.7 Hz), 2.57 (4H, br s), 1.76 (4H, br s).

Step (7): Compound X-1 + Compound 7h → Compound 7i → Compound I-7
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound X-1 (932 mg, 1.00 mmol) and Compound 7h (505 mg, 1.00 mmol).
Yield: 292.8 mg, (33%)
¹ H-NMR (D ₂ O) δ: 7.13 (1H, s), 7.01 (1H, s), 6.83 (1H, s), 5.81 (1H, d, J = 4. 8 Hz), 5.46 (1H, d, J = 4.8 Hz), 5.05 (1H, d, J = 14.3 Hz), 4.62-4.45 (2H, m), 4 .29 (1H, d, J = 14.3 Hz), 4.06 (1H, q, J = 7.0 Hz), 3.91-3.71 (3H, m), 3.58 (2H, br s), 3.51-3.44 (1H, m), 2.22 (4H, br s), 1.56 (3H, d, J = 7.0 Hz), 1.52 (3H, s ), 1.50 (3H, s).
Elemental analysis: C31H34N7O11S2Na (H2O) 5.7
Theoretical: C, 42.77; H, 5.26; N, 11.26; S, 7.37; Na, 2.64 (%)
Measurements: C, 42.50; H, 5.22; N, 11.55; S, 7.40; Na, 2.70 (%)

Example 8: Synthesis of Compound I-8

Step (1): Compound 8a → Compound 8b
The target compound was synthesized in the same manner as in Step 1 of Example 3 using Compound 8a (21.4 g, 50 mmol).
Yield: 21.27 g, (90%)
¹ H-NMR (CDCl ₃ ) δ: 7.40 (1H, d, J = 1.9 Hz), 7.37-7.33 (4H, m), 7.29 (1H, d, J = 1) .9 Hz), 6.92 (2H, d, J = 8.7 Hz), 6.83 (2H, d, J = 8.5 Hz), 5.07 (2H, s), 5.03 ( 2H, s), 3.83 (3H, s), 3.80 (3H, s), 3.52 (3H, s), 3.34 (3H, s).

Step (2): Compound 8b → Compound 8c
The target compound was synthesized in the same manner as in Step 2 of Example 3 using Compound 8b (21.27 g, 45 mmol).
Yield: 17.17 g (89%)
¹ H-NMR (CDCl ₃ ) δ: 7.58 (1H, d, J = 2.0 Hz), 7.52 (1H, d, J = 2.0 Hz), 7.38 (2H, d, J = 8.7 Hz), 7.32 (2H, d, J = 8.7 Hz), 6.93 (2H, d, J = 8.7 Hz), 6.82 (2H, d, J = 8.7 Hz), 5.09 (2H, s), 5.07 (2H, s), 3.83 (3H, s), 3.80 (3H, s), 2.54 (3H, s) .

Step (3): Compound 8c → Compound 8d
The target compound was synthesized in the same manner as in Step 3 of Example 3 using Compound 8c (21.27 g, 45 mmol).
Yield: 17.58 g, (96%)
¹ H-NMR (DMSO-D ₆ ) δ: 7.64 (1H, s), 7.57 (1H, s), 7.46 (2H, d, J = 7.1 Hz), 7.28 ( 2H, d, J = 7.3 Hz), 6.99 (2H, d, J = 7.3 Hz), 6.86 (2H, d, J = 7.1 Hz), 5.21 (2H, s), 5.09 (2H, s), 3.78 (3H, s), 3.74 (3H, s).

Step (4): Compound 8d → Compound 8e
Compound 8d (2.28 g, 5.0 mmol) and diisopropylethylamine (1.3 ml, 7.5 mmol) were dissolved in dichloromethane (20 mL) and then diphenyl chlorophosphate (1.6 ml, 7.5 mmol) at 0 ° C. Was added. The mixture was stirred at 0 ° C. for 1 hour. Next, aminoethylpyrrolidine (0.7 ml, 5.5 mmol) was added thereto at 0 ° C. The mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with ethyl acetate, washed with aqueous sodium hydroxide, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with hexane / ethyl acetate (containing 3% triethylamine). The objective compound-containing fraction was concentrated under reduced pressure to obtain Compound 8e (0.58 g, 21%).
¹ H-NMR (CDCl ₃ ) δ: 8.11 (1H, s), 8.00 (1H, s), 7.50 (1H, br s), 7.38 (2H, d, J = 7. 7 Hz), 7.31 (2H, d, J = 7.7 Hz), 6.93 (2H, d, J = 7.7 Hz), 6.82 (2H, d, J = 7.7 Hz) ), 5.10 (4H, s), 3.83 (3H, s), 3.79 (3H, s), 3.47 (2H, t, J = 6.0 Hz), 2.68 (2H , T, J = 6.0 Hz), 2.55 (4H, br s), 1.79 (4H, br s).

Step (5): Compound X-1 + Compound 8e → Compound 8f → Compound I-8
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound X-1 (932 mg, 1.00 mmol) and Compound 8e (553 mg, 1.00 mmol).
Yield: 434.5 mg, (44%)
¹ H-NMR (D ₂ O) δ: 7.73 (1H, s), 7.39 (1H, s), 7.03 (1H, s), 5.80 (1H, d, J = 4. 6 Hz), 5.48 (1H, d, J = 4.6 Hz), 4.28 (1H, d, J = 13.8 Hz), 4.14-4.08 (1H, m), 3 99-3.92 (1H, m), 3.85-3.79 (1H, m), 3.74-3.69 (1H, m), 3.58 (5H, br s), 2. 24 (4H, br s), 1.58 (3H, d, J = 6.4 Hz), 1.52 (3H, s), 1.50 (3H, s).
Elemental analysis: C32H34.8ClN7O11S2Na1.2 (H2O) 5.5
Theoretical value: C, 41.79; H, 5.02; Cl, 3.85; N, 10.66; S, 6.97; Na, 3.00 (%)
Measurements: C, 41.69; H, 4.95; Cl, 3.83; N, 10.81; S, 7.10; Na, 2.96 (%)

Example 9: Synthesis of Compound I-9

Step (1): Compound X-4 + Compound 8e → Compound I-9
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound X-4 (1082 mg, 1.00 mmol) and Compound 8e (553 mg, 1.00 mmol).
Yield: 414.9 mg, (38%)
¹ H-NMR (D ₂ O) δ: 7.71 (1H, d, J = 2.1 Hz), 7.37 (1H, d, J = 2.1 Hz), 7.08 (1H, s ), 5.74 (1H, d, J = 4.6 Hz), 5.46 (1H, d, J = 4.6 Hz), 5.09 (1H, d, J = 14.2 Hz), 4.96 (1H, dd, J = 9.9, 3.6 Hz), 4.27 (1H, d, J = 14.2 Hz), 4.03 (1H, q, J = 7.0 Hz) ), 3.98-3.91 (1H, m), 3.85-3.45 (7H, m), 2.77-2.64 (2H, m), 2.24 (4H, br s) , 1.56 (3H, d, J = 7.0 Hz).
Elemental analysis: C32H31.4ClN7O13S2Na2.6 (H2O) 6.9
Theoretical value: C, 38.22; H, 4.53; Cl, 3.53; N, 9.75; S, 6.38; Na, 5.94 (%)
Measurements: C, 38.22; H, 4.53; Cl, 3.67; N, 9.84; S, 6.35; Na, 6.04 (%)

Example 10: Synthesis of Compound I-10

Step (1): Compound 8d → Compound 10a
The target compound was synthesized in the same manner as in Step 5 of Example 8 using Compound 8d (2.28 g, 5.00 mmol).
Yield: 0.81 g (29%)
¹ H-NMR (CDCl ₃ ) δ: 7.55 (1H, s), 7.52 (1H, s), 7.37 (2H, d, J = 7.8 Hz), 7.30 (2H, d, J = 7.8 Hz), 6.93 (2H, d, J = 7.8 Hz), 6.82 (2H, d, J = 7.8 Hz), 5.10 (4H, s) , 4.78-4.61 (1H, m), 3.84 (3H, s), 3.80 (3H, s), 3.58-3.43 (1H, m), 3.29-2 .96 (3H, m), 2.92-2.59 (1H, m), 2.28-2.12 (2H, m), 1.99-1.75 (4H, m), 1.51 -1.31 (1H, m).

Step (2): Compound X-1 + Compound 10a → Compound 10b → Compound I-10
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound X-1 (932 mg, 1.00 mmol) and Compound 10a (565 mg, 1.00 mmol).
Yield: 415.5 mg (42%)
¹ H-NMR (D ₂ O) δ: 7.58-7.56 (1H, m), 7.29 (1H, s), 7.02-7.01 (1H, m), 5.83- 5.81 (1H, m), 5.46-5.44 (1H, m), 5.17-5.07 (1H, m), 4.37-4.25 (2H, m), 4. 08-3.48 (8H, m), 2.50-2.00 (4H, m), 1.60-1.54 (3H, m), 1.53-1.52 (3H, m), 1.50-1.50 (3H, m).
Elemental analysis: C33H34.5ClN7O11S2Na1.5 (H2O) 6.4
Theoretical: C, 41.52; H, 4.99; Cl, 3.71; N, 10.27; S, 6.72; Na, 3.61 (%)
Measurements: C, 41.32; H, 5.00; Cl, 3.42; N, 10.56; S, 6.72; Na, 3.62 (%)

Example 11: Synthesis of Compound I-11

Step (1): Compound X-4 + Compound 10a → Compound 11b → Compound I-11
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound X-4 (1082 mg, 1.00 mmol) and Compound 10a (565 mg, 1.00 mmol).
Yield: 379.3 mg (35%)
¹ H-NMR (D ₂ O) δ: 7.58-7.56 (1H, m), 7.26 (1H, s), 7.07-7.06 (1H, m), 5.78- 5.76 (1H, m), 5.44-5.43 (1H, m), 5.22-5.10 (1H, m), 4.97-4.95 (1H, m), 4. 39-4.27 (2H, m), 4.00-3.48 (8H, m), 2.76-2.64 (2H, m), 2.50-2.01 (4H, m), 1.59-1.53 (3H, m).
Elemental analysis: C33H31.2ClN7O13S2Na2.8 (H2O) 8.2
Theoretical value: C, 37.91; H, 4.59; Cl, 3.39; N, 9.38; S, 6.13; Na, 6.16 (%)
Measurements: C, 37.92; H, 4.61; Cl, 3.41; N, 9.52; S, 6.02; Na, 6.21 (%)

Example 12: Synthesis of Compound I-12

Step (1): Compound 8d → Compound 12a
The target compound was synthesized in the same manner as in Step 4 of Example 8 using Compound 8d (2.28 g, 5.00 mmol).
Yield: 0.95 g (33%)
¹ H-NMR (CDCl ₃ ) δ: 8.15 (1H, s), 8.08 (1H, s), 7.56 (1H, d, J = 7.3 Hz), 7.38 (2H, d, J = 8.1 Hz), 7.31 (2H, d, J = 8.1 Hz), 6.93 (2H, d, J = 8.1 Hz), 6.82 (2H, d, J = 8.1 Hz), 5.10 (4H, s), 4.13 (1H, t, J = 6.7 Hz), 3.83 (3H, s), 3.79 (3H, s) 3.19 (2H, br s), 2.30-2.17 (7H, m), 1.81-1.79 (2H, m), 1.72-1.69 (2H, m).

Step (2): Compound X-1 + Compound 12a → Compound 12b → Compound I-12
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound X-1 (745 mg, 0.80 mmol) and Compound 12a (463 mg, 0.80 mmol).
Yield: 321 mg (39%)
¹ H-NMR (D ₂ O) δ: 7.65 (1H, d, J = 2.3 Hz), 7.34 (1H, d, J = 2.3 Hz), 7.03 (1H, s ), 5.82 (1H, d, J = 4.8 Hz), 5.47 (1H, d, J = 4.8 Hz), 4.31-4.27 (1H, m), 4.12 -4.05 (2H, m), 3.95 (1H, br s), 3.12-3.00 (3H, m), 2.86-2.74 (2H, m), 2.61 2.30 (4H, m), 2.19-2.15 (2H, m), 1.58 (3H, d, J = 7.0 Hz), 1.53 (3H, s), 1.51 (3H, s).
Elemental analysis: C34H36.8ClN7O11S2Na1.2 (H2O) 6.7
Theoretical: C, 42.21; H, 5.23; Cl, 3.66; N, 10.14; S, 6.63; Na, 2.85 (%)
Measurements: C, 42.22; H, 5.26; Cl, 3.54; N, 10.28; S, 6.74; Na, 2.92 (%)

Example 13: Synthesis of Compound I-13

Step (1): Compound X-4 + Compound 12a → Compound 13a → Compound I-13
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound X-4 (829 mg, 0.80 mmol) and Compound 12a (463 mg, 0.80 mmol).
Yield: 370.4 mg, (41%)
¹ H-NMR (D ₂ O) δ: 7.64 (1H, d, J = 2.4 Hz), 7.32 (1H, d, J = 2.4 Hz), 7.07 (1H, s ), 5.77 (1H, d, J = 4.6 Hz), 5.45 (1H, d, J = 4.6 Hz), 4.96 (1H, dd, J = 9.3, 4. 0 Hz), 4.31-4.27 (1H, m), 4.09-4.02 (2H, m), 3.95 (2H, br s), 3.11-3.02 (3H, m), 2.86-2.65 (4H, m), 2.61-2.12 (7H, m), 1.56 (3H, d, J = 7.0 Hz).
Elemental analysis: C34H33.5ClN7O13S2Na2.5 (H2O) 7.5
Theoretical: C, 39.25; H, 4.70; Cl, 3.41; N, 9.42; S, 6.16; Na, 5.52 (%)
Measurements: C, 39.51; H, 4.83; Cl, 3.68; N, 9.30; S, 5.78; Na, 5.46 (%)

Example 14: Synthesis of Compound I-14

Step (1): Compound 8d → Compound 14a
The target compound was synthesized in the same manner as in Step 4 of Example 8 using Compound 8d (2.28 g, 5.00 mmol).
Yield: 0.90 g (31%)
¹ H-NMR (DMSO-D ₆ ) δ: 8.81 (1H, t, J = 5.3 Hz), 7.64 (1H, s), 7.59 (1H, s), 7.45 ( 2H, d, J = 7.1 Hz), 7.28 (2H, d, J = 7.1 Hz), 6.99 (2H, d, J = 7.1 Hz), 6.86 (2H, d, J = 7.1 Hz), 5.18 (2H, s), 5.08 (2H, s), 3.78 (3H, s), 3.74 (3H, s), 3.02 ( 2H, d, J = 5.3 Hz), 2.72 (6H, br s), 1.31 (6H, br s).

Step (2): Compound X-1 + Compound 14a → Compound 14b → Compound I-14
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound X-1 (745 mg, 0.80 mmol) and Compound 14a (450 mg, 0.78 mmol).
Yield: 447 mg, (%)
¹ H-NMR (D ₂ O) δ: 7.66 (1H, d, J = 2.0 Hz), 7.37 (1H, d, J = 2.0 Hz), 7.00 (1H, s ), 5.84 (1H, d, J = 4.8 Hz), 5.44 (1H, d, J = 4.8 Hz), 4.64 (1H, d, J = 14.3 Hz), 4.08-4.05 (2H, m), 3.59-3.40 (6H, m), 3.36 (2H, s), 1.94 (6H, t, J = 7.6 Hz) , 1.56 (3H, d, J = 7.2 Hz), 1.52 (3H, s), 1.51 (3H, s).

Example 15: Synthesis of Compound I-15

Step (1): Compound X-4 + Compound 14a → Compound 15a → Compound I-15
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound X-4 (829 mg, 0.80 mmol) and Compound 14a (450 mg, 0.78 mmol).
Yield: 388mg
¹ H-NMR (D ₂ O) δ: 7.67 (1H, d, J = 2.3 Hz), 7.35 (1H, d, J = 2.3 Hz), 7.05 (1H, s ), 5.80 (1H, d, J = 4.8 Hz), 5.43 (1H, d, J = 4.8 Hz), 4.96 (1H, dd, J = 9.2, 4. 1 Hz), 4.68 (1H, d, J = 14.2 Hz), 4.08-3.99 (2H, m), 3.60-3.43 (6H, m), 3.37 ( 2H, s), 2.74-2.71 (2H, m), 1.95 (6H, t, J = 7.7 Hz), 1.55 (3H, d, J = 7.0 Hz).

Example 16: Synthesis of Compound I-16

Step (1): Compound 8d → Compound 16a
The target compound was synthesized in the same manner as in Step 4 of Example 8 using Compound 8d (2.28 g, 5.00 mmol).
Yield: 0.75 g (27%)
¹ H-NMR (DMSO-D ₆ ) δ: 7.54 (1H, s), 7.46-7.44 (3H, m), 7.29 (2H, d, J = 6.3 Hz), 7.00 (2H, d, J = 6.3 Hz), 6.87 (2H, d, J = 6.3 Hz), 5.22 (2H, s), 5.09 (2H, s), 4.54 (1H, s), 3.78-3.66 (8H, m), 3.01-2.78 (6H, m), 1.99-1.62 (4H, m).

Step (1): Compound X-1 + Compound 16a → Compound 16b → Compound I-16
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound X-1 (606 mg, 0.65 mmol) and Compound 16a (367 mg, 0.65 mmol).
Yield: 213.1 mg, (33%)
¹ H-NMR (D ₂ O) δ: 7.54 (1H, s), 7.23 (1H, s), 7.00 (1H, s), 5.87-5.84 (1H, m) 5.47-5.45 (1H, m), 4.38-4.08 (4H, m), 3.88 (2H, br s), 3.82-3.46 (6H, m), 2.42-2.23 (4H, m), 1.61-1.57 (3H, m), 1.53-1.52 (3H, m), 1.51-1.50 (3H, m ).
Elemental analysis: C33H34.4ClN7O11S2Na1.6 (H2O) 6.7
Theoretical: C, 41.20; H, 5.01; Cl, 3.68; N, 10.19; S, 6.67; Na, 3.82 (%)
Measurements: C, 40.92; H, 5.00; Cl, 3.48; N, 10.50; S, 6.87; Na, 3.77 (%)

Example 17: Synthesis of Compound I-17

Step (1): Compound X-4 + Compound 16a → Compound 17a → Compound I-17
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound X-4 (673 mg, 0.65 mmol) and Compound 16a (367 mg, 0.65 mmol).
Yield: 225.6 mg (31%)
¹ H-NMR (D ₂ O) δ: 7.54 (1H, s), 7.23 (1H, s), 7.04 (1H, s), 5.82-5.80 (1H, m) , 5.44-5.43 (1H, m), 4.98-4.94 (1H, m), 4.38-4.07 (3H, m), 3.89 (2H, br s), 3.81-3.44 (6H, m), 2.75-2.65 (2H, m), 2.46-2.24 (4H, m), 1.60-1.56 (3H, m ).
Elemental analysis: C33H31ClN7O13S2Na3 (H2O) 7.9
Theoretical: C, 37.95; H, 4.52; Cl, 3.39; N, 9.39; S, 6.14; Na, 6.60 (%)
Measurements: C, 37.93; H, 4.43; Cl, 3.34; N, 9.56; S, 6.18; Na, 6.59 (%)

Example 18: Synthesis of Compound I-18

Step (1): Compound 18a → Compound 18b
Compound 18a (59.1 g, 100 mmol) synthesized according to the synthesis of US Pat. No. 4,463,172 A1 was dissolved in dichloromethane (600 ml), and then this was added to N-methyl-N-nitroso-p-toluenesulfonamide (36,4 g, 170 mmol). Diazomethane (170 mmol) bubbles prepared from) were passed through at 0 ° C. The mixture was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether. There was thus obtained compound 18b (64.98 g, 103%). The obtained compound 18b was directly used in the next step without purification.
MS (m + 1) = 633

Step (2): Compound 18b → Compound 18c
The total amount (64.98 g, 100 mmol) of the obtained compound 18b was suspended in toluene (650 mL), and then stirred at 90 ° C. for 2 hours. The mixture was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with chloroform / ethyl acetate. The objective compound-containing fraction was concentrated under reduced pressure to obtain Compound 18c (23.5 g, 39%).
¹ H-NMR (CDCl ₃ ) δ: 7.41-7.29 (12H, m), 7.01-6.96 (3H, m), 6.85 (1H, d, J = 10.0 Hz) ), 6.13 (1H, dd, J = 10.0, 4.8 Hz), 4.87 (1H, d, J = 12.8 Hz), 4.64 (1H, d, J = 4. 8 Hz), 4.38 (1H, d, J = 12.8 Hz), 3.84 (2H, s), 1.91-1.75 (5H, m), 1.46-1.41 ( 1H, m), 0.92-0.86 (1H, m).

Step (3): Compound 18c → Compound 18d
Compound 18c (23.5 g, 39 mmol) was dissolved in dimethylacetamide (230 ml), and then potassium iodide (38.7 g, 233 mmol) and acetyl chloride (11.10 ml, 156 mmol) were sequentially added thereto at 0 ° C. The mixture was stirred at 0 ° C. for 4 hours. The reaction mixture was diluted with ethyl acetate and aqueous sodium thiosulfate and then separated, washed with saturated sodium bicarbonate solution and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with hexane / ethyl acetate. The fraction containing the target compound was concentrated under reduced pressure to obtain compound 18d (15.6 g, 68%).
¹ H-NMR (CDCl ₃ ) δ: 7.38-7.26 (11H, m), 7.03-6.95 (3H, m), 6.25-6.19 (1H, m), 5 .93-5.89 (1H, m), 5.21-5.16 (1H, m), 4.44-4.35 (2H, m), 3.86-3.82 (2H, m) 1.95-1.91 (3H, m), 1.45-1.30 (3H, m),

Step (4): Compound 18d → Compound 18e
Compound 18d (15.6 g, 26.5 mmol) and anisole (5.79 mL, 53.0 mmol) were dissolved in dichloromethane (70 mL), and then trifluoroacetic acid (70 mL) was added thereto at 0 ° C. The mixture was stirred at 0 ° C. for 30 minutes. The reaction mixture was concentrated under reduced pressure. The precipitated solid was then collected by filtration and washed with diisopropyl ether to give compound 18e (10.5 g, 94%).
¹ H-NMR (DMSO-D ₆ ) δ: 13.66 (1H, s), 9.17 (1H, d, J = 8.2 Hz), 7.38-7.35 (1H, m), 6.96-6.90 (2H, m), 5.81-5.78 (1H, m), 5.29-5.26 (1H, m), 4.48 (2H, s), 74 (2H, s), 2.00 (3H, s), 1.54-1.41 (2H, m), 1.35-1.30 (1H, m), 0.95-0.90 ( 1H, m).

Step (5): Compound 18e → Compound 18f
Compound 18e (8.9 g, 21.1 mmol) and sodium bicarbonate (2.3 g, 27.4 mmol) were dissolved in boronic acid-ammonia buffer (150 mL, pH = 8), and then this was dissolved in CAH immobilized enzyme at room temperature. (8.90 ml, 21.07 mmol) was added (pH was adjusted to approximately 8 with 7% aqueous NH3). The mixture was stirred at room temperature for 5 hours (pH adjusted to approximately 8 with 7% aqueous NH3). After the reaction mixture was diluted with acetone (300 ml), the pH was adjusted to approximately 3 with 2N HCl at 0 ° C. The reaction mixture was filtered and washed with acetone. To this filtrate was added diphenyldiazomethane (9.00 g, 46.3 mmol) in acetone (10 ml) at 0 ° C. The resulting mixture was stirred at 0 ° C. for 2 hours. The reaction mixture was concentrated under reduced pressure. The precipitated solid was then collected by filtration and washed with water and diisopropyl ether to give compound 18f (10.19 g, 89%).
¹ H-NMR (CDCl ₃ ) δ: 7.42-7.28 (11H, m), 7.01 (1H, dd, J = 5.1, 3.6 Hz), 6.96 (1H, d , J = 3.3 Hz), 6.91 (1H, s), 6.22 (1H, d, J = 8.9 Hz), 5.94 (1H, dd, J = 9.0, 4. 8 Hz), 5.12 (1H, d, J = 4.8 Hz), 3.99 (1H, dd, J = 12.8, 3.9 Hz), 3.84 (2H, s), 3 27-3.21 (1H, m), 2.61 (1H, dd, J = 11.2, 3.9 Hz), 1.77-1.71 (1H, m), 1.39-1 .31 (2H, m), 1.05-1.01 (1H, m).

Step (6): Compound 18f → Compound 18g
Compound 18f (10.2 g, 18.6 mmol) was suspended in dichloromethane (100 mL), which was then added at 0 ° C. to 2,6-lutidine (8.7 ml, 74.6 mmol) and triphosgene (2.8 g, 9 .3 mmol) was added sequentially. The mixture was stirred at room temperature for 2 hours. The mixture was diluted with aqueous hydrochloric acid and ethyl acetate, then separated, washed with saturated sodium bicarbonate and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with chloroform / ethyl acetate. The fraction containing the target compound was concentrated under reduced pressure to obtain 18 g (5.63 g, 53%) of compound.
¹ H-NMR (CDCl ₃ ) δ: 7.42-7.26 (11H, m), 7.02-6.95 (3H, m), 6.23 (1H, d, J = 8.8 Hz) ), 5.90 (1H, dd, J = 8.8, 4.9 Hz), 5.18 (1H, d, J = 4.9 Hz), 4.15 (1H, d, J = 11. 8 Hz), 3.83 (2H, s), 3.77 (1H, d, J = 11.8 Hz), 1.75-1.69 (1H, m), 1.45-1.38 ( 2H, m), 1.04-0.98 (1H, m).

Step (7): Compound 18g → Compound 18h
Phosphorus pentachloride (2.08 g, 10 mmol) was suspended in dichloromethane (30 mL), and then pyridine (0.89 ml, 11 mmol) and compound 18 g (2.83 g, 5.0 mmol) were sequentially added thereto at 0 ° C. It was. The mixture was stirred at 0 ° C. for 1 hour. To this was then added methanol (6.1 mL, 150 mmol) at −40 ° C. The mixture was stirred at room temperature for 30 minutes. The mixture was diluted with water and dichloromethane then separated, washed with saturated sodium bicarbonate solution and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure to give compound 18h (2.98 g, 135%). The obtained compound 18h was directly used in the next step without purification.
MS (m + 1) = 633

Step (8): Compound X-1f + Compound 18h → Compound 18i
Compound 18h and Compound X-1f were dissolved in dichloromethane (25 mL), and then phenylphosphorodichloridate (1.121 ml, 7.50 mmol) and NMM (1.924 ml, 17.50 mmol) were sequentially added at −40 ° C. added. The mixture was stirred at −40 to −20 ° C. for 1 hour. The mixture was diluted with 0.2 mol / L hydrochloric acid aqueous solution and ethyl acetate, separated, washed with saturated sodium bicarbonate and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with hexane / ethyl acetate. The target compound-containing fraction was concentrated under reduced pressure to give compound 18i (2.28 g, 54%).
¹ H-NMR (CDCl ₃ ) δ: 8.23 (1H, d, J = 8.7 Hz), 7.45-7.30 (13H, m), 7.00 (1H, s), 6. 08 (1H, dd, J = 8.7, 5.0 Hz), 5.29 (1H, d, J = 5.0 Hz), 4.14 (1H, d, J = 11.8 Hz), 3.81 (1H, d, J = 11.8 Hz), 1.77-1.71 (1H, m), 1.53-1.37 (26H, m), 1.07-0.99 ( 1H, m).

Step (9): Compound 18i + Compound 18j → Compound I-18
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound 18i (852 mg, 1.00 mmol), Compound 18j (551 mg, 1.05 mmol), and sodium iodide (300 mg, 2.00 mmol).
Yield: 320.3 mg, (34%)
¹ H-NMR (D ₂ O) δ: 6.93-6.91 (2H, m), 6.84 (1H, d, J = 8.3 Hz), 5.66-5.63 (2H, m), 4.30 (1H, br s), 3.90-3.63 (9H, m), 2.28-2.16 (4H, m), 1.60-1.40 (9H, m ), 1.22-1.17 (1H, m).
Elemental analysis: C32H35ClN7O10S2Na (H2O) 5
Theoretical: C, 43.17; H, 5.09; Cl, 3.98; N, 11.01; S, 7.20; Na, 2.58 (%)
Measurements: C, 43.12; H, 5.08; Cl, 4.24; N, 11.03; S, 7.08; Na, 2.47 (%)

Example 19: Synthesis of Compound I-19

Step (1): Compound 18i + Compound 19a → Compound 19b → Compound I-19
The target compound was synthesized in the same manner as in Step 6 of Example 1 using Compound 18i (852 mg, 1.00 mmol), Compound 19a (542 mg, 1.05 mmol) and sodium iodide (300 mg, 2.00 mmol).
Yield: 202.9 mg, (21%)
¹ H-NMR (D ₂ O) δ: 7.12 (1H, d, J = 7.5 Hz), 7.01 (1H, d, J = 7.5 Hz), 6.94 (1H, s ), 5.74-5.66 (2H, m), 4.36 (1H, br s), 4.09 (2H, br s), 3.94-3.58 (7H, m), 2. 25-2.17 (4H, m), 1.63-1.43 (9H, m), 1.31-1.14 (1H, m).
Elemental analysis: C33H34N7O11S2Na (H2O) 5.6
Theoretical: C, 44.40; H, 5.10; N, 10.98; S, 7.18; Na, 2.58 (%)
Measurement: C, 44.40; H, 5.01; N, 11.02; S, 7.08; Na, 2.55 (%)

Example 20: Synthesis of Compound I-20

Step (1): Compound 20a + Compound 20b → Compound 20c
A solution of compound 20a (1.00 g, 2.19 mmol) in dichloromethane (10 mL) was cooled with ice, and DIEA (573 μL, 3.28 mmol) and diphenyl chlorophosphate (681 μL, 3.28 mmol) were added thereto. The liquid was stirred at 0 ° C. for 30 minutes.

A solution of compound 20b (513 g, 2.41 mmol) in dichloromethane (10 mL) was cooled with ice, and to this was added triethylamine (698 μL, 5.03 mmol) and a mixed anhydride solution of compound 20a prepared above. After stirring at room temperature for 1 hour, aqueous sodium hydroxide solution was added to the reaction mixture, and then extracted twice with ethyl acetate. The combined organic layers were washed with water then saturated brine and then dried over anhydrous magnesium sulfate. The inorganic substance was removed by filtration and then concentrated, and then dried under reduced pressure to obtain Compound 20c as a yellow powder oil.
Yield: 1.00 g (79%)
¹ H-NMR (CDCl ₃ ) δ: 1.75 (3H, d, J = 14.56 Hz), 1.86 (2H, dd, J = 15.31, 6.65 Hz), 2.18- 2.21 (2H, m), 2.28-2.30 (2H, m), 2.33 (3H, s), 3.23 (2H, s), 3.80 (3H, s), 3 .83 (3H, s), 4.96 (2H, s), 5.11 (2H, s), 6.83 (2H, d, J = 8.53 Hz), 6.91-6.96 ( 3H, m), 7.33-7.36 (4H, m), 7.65 (1H, d, J = 8.78 Hz).

Step (2): Compound X-1 + Compound 20c → Compound 20d → Compound I-20
A solution of compound 20c (579 mg, 1.0 mmol) in dimethylformamide (2.0 mL) was cooled with ice. Next, the reaction vessel was degassed under reduced pressure, and Compound X-1 (932 mg, 1.0 mmol) was added thereto. After stirring at 0 ° C. for 7 hours, the reaction mixture was slowly added to ice-cooled 5% sodium chloride and aqueous sodium bisulfite. The precipitated solid was collected by filtration, washed with water and suspended in water. The suspension was lyophilized to give compound 20d as a brown solid. The obtained compound 20d was directly used in the next step without purification.

The total amount of the obtained compound 20d was dissolved in dichloromethane (12 mL), and this solution was cooled to −40 ° C. To this was then added anisole (1.09 mL, 10 mmol) and a 2 mol / L aluminum chloride solution (5.0 mL, 10 mmol) in nitromethane sequentially. The liquid was stirred at 0 ° C. for 30 minutes. Diisopropyl ether and a small amount of water were added to the reaction solution, and the resulting product was stirred to form a precipitate. The supernatant was removed by decantation. A diluted hydrochloric acid aqueous solution and acetonitrile were added to the insoluble matter adhering to the reaction vessel. The obtained product was stirred to completely dissolve insoluble matters. Next, diisopropyl ether was added thereto, and the aqueous phase was separated and recovered. The organic phase was extracted again with water and all the aqueous phases obtained were combined. To this was added HP20-SS resin. Next, acetonitrile was distilled off therefrom under reduced pressure. The resulting mixture was purified by ODS column chromatography. The target compound-containing fraction was concentrated under reduced pressure and then lyophilized to obtain Compound I-20 as a yellow powder.
Yield: 385 mg (43%)
¹ H-NMR (D ₂ O) δ: 1.51 (3H, s), 1.53 (3H, s), 1.58 (3H, d, J = 7.15 Hz), 2.17 (2H , D, J = 16.81 Hz), 2.37-2.61 (5H, m), 2.71-2.85 (2H, m), 3.10 (3H, s), 3.95 ( 1H, s), 4.04-4.11 (3H, m), 4.24 (1H, t, J = 7.53 Hz), 5.46 (1H, d, J = 4.89 Hz), 5.83 (1H, d, J = 4.89 Hz), 6.90 (1H, d, J = 8.66 Hz), 7.02 (1H, s), 7.37 (1H, d, J = 8.66 Hz).
MS (m + 1) = 820.28

Example 21: Synthesis of compound I-21

Step (1): Compound X-2 + Compound 20c → Compound I-21
Using a method similar to that in Example 20, compound I-21 was obtained as a yellow powder from compound X-2 (1.082 g, 1.0 mmol) and compound 20c (579 mg, 1.0 mmol).
Yield: 385 mg, (43%)
¹ H-NMR (D ₂ O) δ: 1.56 (3H, d, J = 7.15 Hz), 2.18 (2H, d, J = 16.81 Hz), 2.27-2.83 (9H, m), 3.11 (3H, s), 3.95 (1H, s), 3.99-4.09 (3H, m), 4.24 (1H, t, J = 7.47) Hz), 4.97 (1H, dd, J = 9.22, 4.08 Hz), 5.44 (1H, d, J = 4.77 Hz), 5.77 (1H, d, J = 4 .77 Hz), 6.87 (1H, d, J = 8.66 Hz), 7.07 (1H, s), 7.37 (1H, d, J = 8.66 Hz).
MS (m + 1) = 850.27

Example 22: Synthesis of compound I-22

Step (1): Compound X-2 + Compound 22a → Compound I-22
Using a method similar to that in Example 20, compound I-22 was obtained as a yellow powder from compound X-2 (866 mg, 0.80 mmol) and compound 22a (442 mg, 0.80 mmol).
Yield: 85 mg (12%)
¹ H-NMR (D ₂ O) δ: 1.56 (3H, d, J = 7.03 Hz), 2.24 (4H, s), 2.65-2.77 (2H, m), 3 .53-4.04 (9H, m), 4.26 (1H, d, J = 14.18 Hz), 4.96 (1H, dd, J = 9.60, 3.58 Hz), 5. 07 (1H, d, J = 14.18 Hz), 5.45 (1H, d, J = 4.64 Hz), 5.74 (1H, d, J = 4.64 Hz), 6.87 ( 1H, d, J = 8.66 Hz), 7.07 (1H, s), 7.34 (1H, d, J = 8.66 Hz).
MS (m + 1) = 824.31

Example 23: Synthesis of Compound I-23

Step (1): Compound X-2 + Compound 23a → Compound I-23
Using a method similar to that in Example 20, compound I-23 was obtained as a yellow powder from compound X-2 (1.082 g, 1.0 mmol) and compound 23a (565 mg, 1.0 mmol).
Yield: 369 mg (42%)
¹ H-NMR (D ₂ O) δ: 1.57 (3H, dd, J = 10.73, 7.09 Hz), 2.06-2.48 (4H, m), 2.70-2. 74 (3H, m), 3.57-4.03 (8H, m), 4.29-4.35 (2H, m), 4.95-4.98 (1H, m), 5.12- 5.21 (1H, m), 5.44 (1H, d, J = 4.64 Hz), 5.77 (1H, dd, J = 4.64, 2.13 Hz), 6.83 (1H , D, J = 8.78 Hz), 7.06 (1H, d, J = 2.26 Hz), 7.48 (1H, d, J = 8.78 Hz).
MS (m + 1) = 836.19

Example 24: Synthesis of compound I-24

Step (1): Compound X-2 + Compound 24a → Compound I-24
Using a method similar to that in Example 20, compound I-24 was obtained as a yellow powder from compound X-2 (1.082 g, 1.0 mmol) and compound 24a (579 mg, 1.0 mmol).
Yield: 442 mg, (49%)
¹ H-NMR (D ₂ O) δ: 1.55 (3H, d, J = 7.15 Hz), 1.94 (6H, t, J = 7.72 Hz), 2.72 (2H, t , J = 5.77 Hz), 3.35 (2H, s), 3.50 (6H, dt, J = 29.32, 7.75 Hz), 3.98-4.08 (2H, m) 4.68 (1H, d, J = 14.18 Hz), 4.96 (1H, dd, J = 9.10, 4.33 Hz), 5.42 (1H, d, J = 4.89) Hz), 5.80 (1H, d, J = 4.89 Hz), 6.90 (1H, d, J = 8.53 Hz), 7.05 (1H, s), 7.31 (1H, d, J = 8.53 Hz).
MS (m + 1) = 850.20

Example 25: Synthesis of Compound I-25

Step (1): Compound X-4 + Compound 25a → Compound I-25
Using a method similar to that in Example 20, compound I-25 was obtained as a yellow powder from compound X-4 (1.036 g, 1.0 mmol) and compound 25a (565 mg, 1.0 mmol).
Yield: 550 mg (63%)
¹ H-NMR (D ₂ O) δ: 1.58 (3H, dd, J = 9.35, 7.22 Hz), 2.29-2.42 (4H, m), 2.70-2. 74 (2H, m), 3.54-3.95 (7H, m), 4.02-4.10 (1H, m), 4.22-4.38 (2H, m), 4.87 ( 2H, d, J = 13.93 Hz), 4.95-4.98 (1H, m), 5.43 (1H, d, J = 4.77 Hz), 5.81 (1H, t, J = 4.83 Hz), 6.83 (1H, dd, J = 8.78, 6.84 Hz), 7.04 (1H, s), 7.48 (1H, d, J = 8.78 Hz). ).
MS (m + 1) = 836.19

Example 26: Synthesis of compound I-26

Step (1): Compound 26a → Compound 26b → Compound 26d
A solution of compound 26a (1.29 g, 10 mmol) in ethanol (10 mL) was cooled with ice, and a Boc ₂ O solution (2.44 mL, 10.5 mmol) in ethanol (10 mL) was added dropwise thereto. After stirring at room temperature overnight, the reaction mixture was concentrated and then dried under reduced pressure to give compound 26b as a colorless oil. The obtained compound 26b was used in the next reaction without purification.

The total amount of the obtained compound 26b was dissolved in toluene (40 mL), and this solution was cooled with ice. To this was added compound 26c (4.20 g, 10 mmol). After stirring at room temperature for 1 hour and then under reflux for 6 hours, an aqueous sodium hydroxide solution was added to the reaction mixture, followed by extraction with ethyl acetate. The inorganic material was removed by filtration and then concentrated under reduced pressure. The resulting crude product was purified by silica gel column chromatography (ethyl acetate / 3% triethylamine in hexane) to give compound 26d as a white solid.
Yield: 3.60 g (57%)
¹ H-NMR (CDCl ₃ ) δ: 1.51 (4H, s), 1.56 (9H, s), 2.42-2.46 (4H, m), 2.71 (2H, q, J = 7.24 Hz), 3.71-3.79 (2H, m), 3.82 (6H, s), 5.18 (4H, s), 6.89-6.92 (4H, m) , 7.33-7.37 (6H, m).

Step (2): Compound X-1 + Compound 26d → Compound I-26
Using a method similar to that in Example 20, compound I-26 was obtained as a white powder from compound X-1 (932 mg, 1.0 mmol) and compound 26d (632 mg, 1.0 mmol).
Yield: 449 mg (57%)
¹ H-NMR (D ₂ O) δ: 1.50 (3H, s), 1.51 (3H, s), 1.53 (3H, d, J = 7.07 Hz), 2.22 (4H , S), 3.45-3.53 (6H, m), 3.64-3.77 (2H, m), 3.97 (1H, q, J = 7.07 Hz), 4.26 ( 1H, d, J = 14.31 Hz), 4.92 (1H, d, J = 14.31 Hz), 5.39 (1H, d, J = 4.77 Hz), 5.77 (1H, d, J = 4.77 Hz), 6.98 (1H, s), 7.20 (2H, s).
MS (m + 1) = 773.33

Example 27: Synthesis of compound I-27

Step (1): Compound 27a → Compound 27b
A solution of compound 27a (911 mg, 7.0 mmol) in toluene (30 mL) was cooled with ice and to this was added compound 26c (2.94 g, 7.0 mmol). After stirring at room temperature for 30 minutes, acetic acid (440 μL, 7.7 mmol) was added thereto. After stirring for 1 hour under reflux, an aqueous sodium hydroxide solution was added to the reaction mixture, followed by extraction with ethyl acetate. The inorganic material was removed by filtration and then concentrated under reduced pressure. Diisopropyl ether was added thereto to precipitate a solid. The solid was collected by filtration to give compound 27b as a white solid.
Yield: 2.60 g (70%)
¹ H-NMR (CDCl ₃ ) δ: 1.71-1.74 (4H, m), 2.58 (4H, s), 2.89 (2H, t, J = 5.71 Hz), 81 (6H, s), 4.29 (2H, t, J = 5.71 Hz), 5.17 (4H, s), 6.90 (4H, d, J = 8.66 Hz), 7. 32 (2H, s), 7.34 (4H, d, J = 8.66 Hz).

Step (2): Compound 1a + Compound 9a → Compound (I-9)
Using a method similar to that in Example 1, compound I-9 was obtained as a white powder from compound 1a (932 mg, 1.0 mmol) and compound 9a (632 mg, 1.0 mmol).
Yield: 453 mg (57%)
¹ H-NMR (D ₂ O) δ: 1.51 (3H, s), 1.53 (3H, s), 1.61 (3H, d, J = 7.03 Hz), 2.27 (4H , S), 3.52-3.62 (2H, m), 3.71-3.78 (2H, m), 3.84-3.95 (2H, m), 4.10 (1H, q , J = 7.03 Hz), 4.38 (1H, d, J = 14.43 Hz), 4.56-4.69 (2H, m), 5.00 (1H, d, J = 14. 43 Hz), 5.47 (1H, d, J = 4.77 Hz), 5.82 (1H, d, J = 4.77 Hz), 7.01 (1H, s), 7.12 (2H) , S).
MS (m + 1) = 774.34

Example 28: Synthesis of compound I-28

Step (1): Compound 28a → Compound 28b → Compound 28c
A solution of compound 28a (24.4 g, 93 mmol) in dichloromethane (120 mL) was cooled with ice to which N, O-dimethylhydroxylamine hydrochloride (16.4 g, 168 mmol) and 1-ethyl-3- (3 -Dimethylaminopropyl) carbodiimide (32.2 g, 168 mmol) was added. After stirring at room temperature for 4.5 hours, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated brine and then dried over anhydrous magnesium sulfate. The inorganic material was filtered off, concentrated, and then dried under reduced pressure to give compound 28b as an orange oil. The obtained compound 28b was used in the next reaction without purification.

The total amount of the obtained compound 28b was dissolved in tetrahydrofuran (500 mL), and this solution was cooled to 0 ° C. To this was added a 1 mol / L methylmagnesium bromide solution (186 mL, 186 mmol) in tetrahydrofuran. After stirring at room temperature for 5 hours, an aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with water and then with saturated brine and then dried over anhydrous magnesium sulfate. The inorganic material was removed by filtration and then concentrated under reduced pressure. Diisopropyl ether was added thereto to precipitate a solid. The solid was collected by filtration to give compound 28c.
Yield: 23.5 g (97%)
¹ H-NMR (CDCl ₃ ) δ: 2.68 (3H, s), 3.90 (3H, s), 3.92 (3H, s), 7.05 (1H, s), 7.15 ( 1H, s).

Step (2): Compound 28c → Compound 28d
A solution of copper bromide (7.97 g, 35.7 mmol) in ethyl acetate (20 mL) was heated to reflux and to this was added a solution of compound 28c (5.0 g, 19.3 mmol) in chloroform (20 mL). . After stirring under reflux for 2.5 hours, the insoluble material was removed by filtration, and then concentrated under reduced pressure. The resulting crude product was purified by silica gel column chromatography (ethyl acetate / hexane) to give compound 28d as a yellow oil.
Yield: 4.61 g (71%)
¹ H-NMR (CDCl ₃ ) δ: 3.90 (3H, s), 3.93 (3H, s), 4.59 (2H, s), 7.06 (1H, s), 7.13 ( 1H, s).

Step (3): Compound 28d → Compound 28e → Compound 28f
To a solution of compound 28d (4.61 g, 13.6 mmol) in methanol (180 mL) and water (30 mL) was added hydroxylamine hydrochloride (7.58 g, 109 mmol). After stirring overnight at room temperature, an aqueous hydrochloric acid solution was added to the reaction mixture, and then extracted with ethyl acetate. The organic layer was washed with water then saturated brine and then dried over anhydrous magnesium sulfate. The inorganic material was filtered off and concentrated, and then dried under reduced pressure to give compound 28e as a yellow oil. The obtained compound 28e was used in the next reaction without purification.

The total amount of the obtained compound 28e was dissolved in tetrahydrofuran (50 mL), and pyrrolidine (3.38 mL, 40.9 mmol) was added thereto. After stirring at room temperature for 1 hour, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with water and then with saturated brine and then dried over anhydrous magnesium sulfate. The inorganic substance was removed by filtration and concentrated, and then dried under reduced pressure to obtain compound 28f as a yellow powder.
Yield: 4.63 g (99%)
¹ H-NMR (CDCl ₃ ) δ: 1.77-1.80 (4H, m), 2.64 (4H, br s), 3.49 (2H, s), 3.86 (3H, s) 3.88 (3H, s), 6.68 (1H, s), 7.06 (1H, s).

Step (4): Compound 28f → Compound 28g
To a solution of compound 28f (4.29 g, 12.5 mmol) in 1,4-dioxane (300 mL) was added sodium tert-butoxide (1.80 g, 18.8 mmol). The reaction vessel was then degassed under reduced pressure, to which palladium acetate (421 mg, 1.88 mmol) and 1,3-bis (diphenylphosphino) propane (1.19 mg, 2.88 mmol) were added. After stirring at 80 ° C. for 4.5 hours, water was added to the reaction mixture, and then extracted twice with ethyl acetate. The combined organic layers were washed with saturated brine and then dried over anhydrous sodium sulfate. The inorganic material was removed by filtration and then concentrated under reduced pressure. The resulting crude product was purified by silica gel column chromatography (ethyl acetate / hexane) to obtain 28 g of a compound as a yellow oil.
Yield: 1.82 g (56%)
¹ H-NMR (CDCl ₃ ) δ: 1.79-1.83 (4H, m), 2.60-2.63 (4H, m), 3.94 (3H, s), 3.97 (3H , S), 3.98 (2H, s), 7.02 (1H, s), 7.18 (1H, s).

Step (5): Compound 28g → Compound 28h → Compound 28i
A solution of 28 g (1.82 g, 6.94 mmol) of compound in dichloromethane (20 mL) was cooled with ice and boron tribromide (1.97 mL, 20.8 mmol) was added dropwise thereto. After stirring at room temperature for 1.5 hours, methanol was added to the reaction mixture at 0 ° C., and the mixture was concentrated and dried under reduced pressure to give compound 28h as a brown solid. The obtained compound 28h was used in the next reaction without purification.

The total amount of compound 28h obtained was suspended in dichloromethane (20 mL) and the suspension was cooled with ice, to which triethylamine (1.44 mL, 10.4 mmol), DMAP (42 mg, 0.35 mmol), and Boc ₂ O (4.83 mL, 20.8 mmol) was added. After stirring at room temperature overnight, water was added to the reaction mixture and then extracted with ethyl acetate. The organic layer was washed with water and then with saturated brine and then dried over anhydrous sodium sulfate. The inorganic material was removed by filtration and then concentrated under reduced pressure. The resulting crude product was purified by silica gel column chromatography (ethyl acetate / 3% triethylamine in hexane) to give compound 28i as a yellow solid.
Yield: 602 mg (20%)
¹ H-NMR (CDCl ₃ ) δ: 1.57 (18H, s), 1.78-1.81 (4H, m), 2.58-2.61 (4H, m), 4.00 (2H) , S), 7.51 (1H, s), 7.78 (1H, s).

Step (6): Compound X-1 + Compound 28i → Compound I-28
Using a method similar to that in Example 20, compound I-28 was obtained as a white powder from compound X-1 (932 mg, 1.0 mmol) and compound 28i (434 mg, 1.0 mmol).
Yield: 344 mg, (47%)
¹ H-NMR (D ₂ O) δ: 1.42 (3H, d, J = 7.03 Hz), 1.48 (3H, s), 1.50 (3H, s), 2.28 (4H , S), 3.52-3.65 (3H, m), 3.81-3.84 (1H, m), 4.01 (1H, q, J = 7.15 Hz), 4.40 ( 1H, d, J = 14.05 Hz), 4.90 (2H, dd, J = 32.12, 14.68 Hz), 5.07 (1H, d, J = 14.05 Hz), 5. 40 (1H, d, J = 4.77 Hz), 5.79 (1H, d, J = 4.77 Hz), 6.97 (1H, s), 7.18 (1H, s), 7. 22 (1H, s).
MS (m + 1) = 716.06

Example 29: Synthesis of compound I-29

Step (1): Compound 29a → Compound 29b
To a solution of compound 29a (12.6 g, 76 mmol) in DMF (120 mL) was added potassium carbonate (23.0 g, 166 mmol), 4-methoxybenzyl chloride (22.7 mL, 166 mmol) and sodium iodide (5.67 g, 38 mmol) was added and the mixture was stirred at 70 ° C. for 1.5 h. The solvent was removed by evaporation and the residue was diluted with water and ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate, filtered and concentrated. The precipitated material was filtered off using diisopropyl ether and dried under high vacuum to give compound 29b (22.7 g, 74%) as a yellowish solid.
¹ H-NMR (CDCl ₃ ) δ: 3.79 (3H, s), 3.82 (3H, s), 5.05 (2H, s), 5.17 (2H, s), 5.26 ( 2H, s), 6.82 (2H, d, J = 8.5 Hz), 6.89 (2H, d, J = 8.5 Hz), 7.00 (1H, d, J = 8.2) Hz), 7.22 (1H, d, J = 8.2 Hz), 7.30 (2H, d, J = 8.2 Hz), 7.42 (2H, d, J = 8.4 Hz) .

Step (2): Compound 29b → Compound 29c
To a solution of compound 29b (22.4 g, 55 mmol) in methanol (55 mL) and tetrahydrofuran (55 mL) was added 2 mol / L sodium hydroxide (83 mL, 166 mmol) and the mixture was stirred at 70 ° C. for 1.5 h. did. The resulting mixture was cooled to room temperature and diluted with diethyl ether. The aqueous layer was separated and the pH was adjusted to 3.0 by adding 2 mol / L hydrochloric acid. This mixture was extracted with dichloromethane. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated and dried under high vacuum to give compound 29c (20.5 g, 88%) as a pale pink solid.
¹ H-NMR (CDCl ₃ ) δ: 3.80 (3H, s), 3.84 (3H, s), 4.67 (2H, s), 5.11 (2H, s), 5.12 ( 2H, s), 6.82 (2H, d, J = 8.7 Hz), 6.95 (2H, d, J = 8.7 Hz), 7.19-7.24 (4H, m), 7.39 (2H, d, J = 8.7 Hz).

Step (3): Compound 29c → Compound 29d → Compound 29e
To a solution of compound 29c (45.7 g, 108 mmol) in tetrahydrofuran (350 mL) was added a solution of diphenyldiazomethane (23.0 g, 118 mmol) in tetrahydrofuran (100 mL) at room temperature over 20 minutes. After the mixture was stirred at room temperature overnight, the solvent was removed by evaporation. The residue was dried under high vacuum to give a crude material containing compound 29d as the main product, which was used in the next step without further purification.

To a solution of compound 29d produced above in dichloromethane (640 mL) was added Dess-Martin periodinane (50.4 g, 119 mmol) with stirring at 0 ° C., and the mixture was stirred at 0 ° C. for 2 hours. The mixture was diluted with water and the organic solvent was removed by evaporation. The resulting aqueous mixture was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate, filtered and concentrated. The residue was triturated with diisopropyl ether and the solid was collected by filtration and dried under high vacuum to give compound 29e (51.1 g, 80%) as a colorless solid.
¹ H-NMR (CDCl ₃ ) δ: 3.79 (3H, s), 3.84 (3H, s), 4.86 (2H, s), 5.14 (2H, s), 6.68 ( 2H, d, J = 8.66 Hz), 6.93 (2H, d, J = 8.78 Hz), 6.97 (2H, d, J = 8.66 Hz), 7.14 (1H, d, J = 8.41 Hz), 7.19 (1H, s), 7.25-7.27 (5H, m), 7.36-7.38 (7H, m), 7.61 (1H) , D, J = 8.41 Hz), 9.74 (1H, s).

Step (4): Compound 29e → Compound 29f
To a solution of compound 29e (51.1 g, 87 mmol) in 1,4-dioxane (600 mL) and water (200 mL) was added amidosulfuric acid (16.9 g, 174 mmol) and sodium chlorite (19.6 g, 174 mmol). added. The mixture was stirred at 0 ° C. for 30 minutes, and then an aqueous sodium bisulfite solution (36.2 g, 348 mmol) was added. This mixture was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate, filtered and concentrated. The precipitated solid by adding diisopropyl ether was collected by filtration and dried under high vacuum to give compound 29f (51.4 g, 98%) as a colorless solid.
¹ H-NMR (DMSO-D ₆ ) δ: 3.73 (3H, s), 3.77 (3H, s), 4.71 (2H, s), 5.20 (2H, s), 6. 69 (2H, d, J = 8.59 Hz), 6.85 (2H, d, J = 8.59 Hz), 6.97-6.99 (3H, m), 7.26-7.28 (6H, m), 7.36-7.38 (5H, m), 7.45 (2H, d, J = 8.59 Hz), 7.75 (1H, d, J = 8.84 Hz) .

Step (5): Compound 29f → Compound 29g
To a solution of compound 29f (9.07 g, 15 mmol) in DMF (90 mL) with stirring at 0 ° C., 1-hydroxybenzotriazole (2.23 g, 16.5 mmol), 1- (2-aminoethyl) pyrrolidine. (2.26 mL, 18 mmol) and EDC hydrochloride (3.74 g, 19.5 mmol) were added and the mixture was stirred at room temperature for 3.5 hours. The organic solvent was removed by evaporation and the residue was diluted with water. This mixture was extracted with ethyl acetate. The organic layer was washed with 1 mol / L sodium hydroxide, water and brine, then dried over magnesium sulfate, filtered and concentrated. The precipitate was collected by filtration and dried under high vacuum to give compound 29g (6.73 g, 87%) as a colorless solid.
¹ H-NMR (CDCl ₃ ) δ: 1.74-1.77 (4H, m), 2.57-2.60 (4H, m), 2.73 (2H, t, J = 6.96 Hz) ), 3.78-3.81 (5H, m), 3.83 (3H, s), 5.09 (2H, s), 5.28 (2H, s), 6.82 (2H, d, J = 8.66 Hz), 6.92 (2H, d, J = 8.66 Hz), 7.12 (1H, d, J = 8.03 Hz), 7.31 (2H, d, J = 8.66 Hz), 7.38 (2H, d, J = 8.66 Hz), 7.47 (1H, d, J = 8.03 Hz).

Step (6): Compound 29g → Compound 29h
To a solution of compound 29 g (1.55 g, 3.0 mmol) in acetic acid (60 mL) was added zinc powder (3.92 g, 60 mmol). After stirring at 80 ° C. for 3 hours, insoluble materials were removed by filtration, water was added to the filtrate, and then the mixture was extracted with ethyl acetate. The organic layer was washed with aqueous sodium hydroxide then saturated brine and then dried over anhydrous magnesium sulfate. The inorganic material was removed by filtration and then concentrated under reduced pressure. The resulting crude product was purified by silica gel column chromatography (ethyl acetate / 3% triethylamine in hexane) to give compound 29h as a colorless oil.
Yield: 870 mg (58%)
¹ H-NMR (CDCl ₃ ) δ: 1.74-1.78 (4H, m), 2.52-2.55 (4H, m), 2.64 (2H, t, J = 6.90 Hz) ), 3.64 (2H, t, J = 6.90 Hz), 3.79 (3H, s), 3.83 (3H, s), 4.09 (2H, s), 5.04 (2H , S), 5.14 (2H, s), 6.81 (2H, d, J = 6.65 Hz), 6.93 (2H, d, J = 8.66 Hz), 7.09 (1H , D, J = 8.28 Hz), 7.20 (2H, d, J = 8.66 Hz), 7.40 (2H, d, J = 8.53 Hz), 7.50 (1H, d , J = 8.28 Hz).

Step (7): Compound X-1 + Compound 29h → Compound I-29
Using a method similar to that in Example 20, compound I-29 was obtained as a white powder from compound X-1 (745 mg, 0.80 mmol) and compound 29h (402 mg, 0.80 mmol).
Yield: 244 mg (40%)
¹ H-NMR (D ₂ O) δ: 1.50 (3H, s), 1.52 (3H, s), 1.57 (3H, d, J = 6.06 Hz), 2.22 (4H , S), 3.51-3.73 (6H, m), 4.05-4.10 (3H, m), 4.29 (1H, d, J = 14.15 Hz), 4.49 ( 2H, s), 5.04 (1H, d, J = 14.15 Hz), 5.47 (1H, d, J = 2.53 Hz), 5.80 (1H, d, J = 2.53) Hz), 7.00-7.04 (2H, m), 7.22 (1H, d, J = 8.08 Hz).
MS (m + 1) = 744.21

Example 30: Synthesis of Compound I-30

Step (1): Compound 30a → Compound 30b
Using a method similar to that in Example 29, compound 30b was obtained as a white solid from compound 30a (1.03 g, 2.0 mmol).
Yield: 585 mg (58%)
¹ H-NMR (CDCl ₃ ) δ: 1.76 (4H, s), 2.56 (4H, s), 2.72 (2H, t, J = 6.32 Hz), 3.70 (2H, t, J = 6.32 Hz), 3.81 (6H, s), 4.34 (2H, s), 5.12 (4H, s), 6.89 (4H, d, J = 8.59) Hz), 6.93 (1H, s), 7.33-7.38 (5H, m).

Step (2): Compound X-1 + Compound 30b → Compound I-30
Using a method similar to that in Example 20, compound I-30 was obtained as a white powder from compound X-1 (745 mg, 0.80 mmol) and compound 30b (402 mg, 0.80 mmol).
Yield: 236 mg, (39%)
¹ H-NMR (D ₂ O) δ: 1.50 (3H, s), 1.52 (3H, s), 1.56 (3H, d, J = 6.57 Hz), 2.23 (4H , S), 3.49-3.73 (6H, m), 4.02-4.10 (3H, m), 4.28 (1H, d, J = 14.15 Hz), 4.42 ( 2H, s), 5.02 (1H, d, J = 14.15 Hz), 5.46 (1H, d, J = 3.28 Hz), 5.80 (1H, d, J = 3.28). Hz), 7.01 (1H, s), 7.03 (1H, s), 7.17 (1H, s).
MS (m + 1) = 744.21

Example 31: Synthesis of compound I-31

Step (1): Compound 31a → Compound 31b
To a solution of compound 31a (6.31 g, 32.5 mmol) in acetonitrile (60 mL) was added NCS (4.77 g, 35.7 mmol). After stirring at 60 ° C. for 1 hour, the insoluble material was collected by filtration to obtain Compound 31b.
Yield: 6.15 g (83%)
¹ H-NMR (CDCl ₃ ) δ: 3.91 (3H, s), 4.09 (3H, s), 5.15 (2H, s), 7.16 (1H, s).

Step (2): Compound 31b → Compound 31c
A solution of compound 31b (6.83 g, 30 mmol) in dichloromethane (60 mL) was cooled with ice, and boron tribromide (9.43 mL, 100 mmol) was added dropwise thereto. After stirring at room temperature for 2 hours, the reaction mixture was poured onto ice and concentrated in dichloromethane. The solid was collected by filtration to give compound 31c.
Yield: 5.57 g (93%)
¹ H-NMR (DMSO-D ₆ ) δ: 5.15 (2H, s), 7.10 (1H, s).

Step (3): Compound 31c → Compound 31d
Using a method similar to that in Example 29, compound 31d was obtained as a white solid from compound 31c (5.57 g, 27.8 mmol).
Yield: 8.45 g (69%)
¹ H-NMR (CDCl ₃ ) δ: 3.79 (3H, s), 3.83 (3H, s), 5.03 (2H, s), 5.12 (2H, s), 5.24 ( 2H, s), 6.81 (2H, d, J = 8.54 Hz), 6.91 (2H, d, J = 8.54 Hz), 7.17 (1H, s), 7.30 ( 2H, d, J = 8.39 Hz), 7.37 (2H, d, J = 8.54 Hz).

Step (4): Compound 31d → Compound 31e
Using a method similar to that in Example 29, compound 31e was obtained as a white solid from compound 31d (8.45 g, 19.2 mmol).
Yield: 8.08 g, (92%)
¹ H-NMR (DMSO-D ₆ ) δ: 3.74 (3H, s), 3.77 (3H, s), 4.49 (2H, s), 4.85 (2H, s), 5. 15 (2H, s), 6.85 (2H, d, J = 8.54 Hz), 6.97 (2H, d, J = 8.54 Hz), 7.23 (2H, d, J = 8 .54 Hz), 7.30 (1H, s), 7.42 (2H, d, J = 8.54 Hz).

Step (5): Compound 31e → Compound 31f
A solution of compound 31e (8.23 g, 17.9 mmol) in dichloromethane (80 mL) was cooled with ice and to this was added Dess-Martin periodinane (8.37 g, 19.7 mmol). After stirring at room temperature for 30 minutes, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with water and then with saturated brine and then dried over anhydrous sodium sulfate. The inorganic material was removed by filtration and then concentrated under reduced pressure. Diisopropyl ether was added thereto to precipitate a solid. The solid was collected by filtration to give compound 31f.
Yield: 6.38 g (78%)
¹ H-NMR (DMSO-D ₆ ) δ: 3.73 (3H, s), 3.77 (3H, s), 5.06 (2H, s), 5.15 (2H, s), 6. 85 (2H, d, J = 8.54 Hz), 6.97 (2H, d, J = 8.54 Hz), 7.30 (2H, d, J = 8.54 Hz), 7.38 ( 2H, d, J = 8.39 Hz), 7.58 (1H, s).

Step (6): Compound 31f → Compound 31g → Compound 31h
To a solution of compound 31f (6.38 g, 14.0 mmol) in tetrahydrofuran (30 mL) was added dropwise diphenyldiazomethane solution (2.98 g, 15.4 mmol) in tetrahydrofuran (30 mL). After stirring at room temperature overnight, the reaction mixture was concentrated under reduced pressure. Diisopropyl ether was added thereto to precipitate a solid. The solid was collected by filtration, thereby obtaining 31 g of a compound.

In the same manner as in Example 29, compound 31h was obtained as a white solid from compound 31g.
Yield: 8.72 g (98%)
¹ H-NMR (DMSO-D ₆ ) δ: 3.71 (3H, s), 3.77 (3H, s), 4.72 (2H, s), 5.19 (2H, s), 6. 67 (2H, d, J = 8.73 Hz), 6.79 (2H, d, J = 8.73 Hz), 6.91 (1H, s), 6.98 (2H, d, J = 8 .73 Hz), 7.26-7.47 (13H, m).

Step (7): Compound 31h → Compound 31i
Using a method similar to that in Example 29, compound 31i was obtained as a white solid from compound 31h (4.16 g, 6.51 mmol).
Yield: 2.36 g (66%)
¹ H-NMR (CDCl ₃ ) δ: 1.76 (4H, s), 2.58 (4H, s), 2.73 (2H, t, J = 6.82 Hz), 3.78-3. 81 (5H, m), 3.84 (3H, s), 5.06 (2H, s), 5.22 (2H, s), 6.81 (2H, d, J = 8.59 Hz), 6.93 (2H, d, J = 8.59 Hz), 7.03 (1H, s), 7.30-7.35 (4H, m).

Step (8): Compound 31i → Compound 31j
Using a method similar to that in Example 29, compound 31j was obtained as a colorless oil from compound 31i (1.10 g, 2.0 mmol).
Yield: 381 mg, (36%)
¹ H-NMR (CDCl ₃ ) δ: 1.76 (4H, s), 2.53 (4H, s), 2.63 (2H, t, J = 6.19 Hz), 3.60 (2H, t, J = 6.69 Hz), 3.79 (3H, s), 3.84 (3H, s), 4.00 (2H, s), 5.01 (2H, s), 5.11 ( 2H, s), 6.81 (2H, d, J = 8.34 Hz), 6.94 (2H, d, J = 8.08 Hz), 7.02 (1H, s), 7.17 ( 2H, d, J = 7.33 Hz), 7.39 (2H, d, J = 7.83 Hz).

Step (9): Compound X-1 + Compound 31j → Compound I-31
Using a method similar to that in Example 20, compound I-31 was obtained as a white powder from compound X-1 (745 mg, 0.80 mmol) and compound 31j (430 mg, 0.80 mmol).
Yield: 155 mg (24%)
¹ H-NMR (D ₂ O) δ: 1.50 (3H, s), 1.52 (3H, s), 1.58 (3H, d, J = 7.03 Hz), 2.23 (4H , S), 3.49-3.64 (5H, m), 3.74-3.78 (1H, m), 4.00-4.11 (3H, m), 4.27 (1H, d) , J = 14.18 Hz), 4.39 (2H, s), 5.05 (1H, d, J = 14.18 Hz), 5.48 (1H, d, J = 4.77 Hz), 5.80 (1H, d, J = 4.77 Hz), 6.87 (1H, s), 7.01 (1H, s).
MS (m + 1) = 778.23

Example 32: Synthesis of Compound 1-32

Step (1): Compound 29f → Compound 32a
Using a method similar to that in Example 29, compound 32a was obtained as a white solid from compound 29f (3.02 g, 5.0 mmol) and 1- (2-aminoethyl) piperidine (775 μL, 5.5 mmol).
Yield: 2.51 g (95%)
¹ H-NMR (CDCl ₃ ) δ: 1.38-1.43 (2H, m), 1.51-1.56 (4H, m), 2.46 (4H, s), 2.57 (2H , T, J = 6.96 Hz), 3.76-3.79 (5H, m), 3.83 (3H, s), 5.09 (2H, s), 5.28 (2H, s) 6.82 (2H, d, J = 8.53 Hz), 6.92 (2H, d, J = 8.53 Hz), 7.11 (1H, d, J = 8.16 Hz), 7 .30-7.39 (4H, m), 7.47 (1H, d, J = 8.16 Hz).

Step (2): Compound X-2 + Compound 32a → Compound I-32
Using a method similar to that in Example 20, compound I-32 was obtained as a yellow powder from compound X-2 (1.082 g, 1.0 mmol) and compound 32a (624 mg, 1.0 mmol).
Yield: 176 mg (21%)
¹ H-NMR (D ₂ O) δ: 1.59 (3H, d, J = 7.03 Hz), 1.80-1.99 (6H, m), 2.69-2.73 (2H, m), 3.29-3.39 (3H, m), 3.60-3.81 (3H, m), 4.05-4.09 (3H, m), 4.29 (1H, d, J = 13.93 Hz), 4.96 (1H, dd, J = 9.66, 3.76 Hz), 5.11 (1H, d, J = 13.93 Hz), 5.49 (1H, d, J = 4.64 Hz), 5.78 (1H, d, J = 4.64 Hz), 7.02 (1H, d, J = 7.78 Hz), 7.09 (1H, s) , 7.19 (1H, d, J = 7.78 Hz).
MS (m + 1) = 801.88

Example 33: Synthesis of Compound 1-33

Step (1): Compound X-2 + Compound 33a → Compound I-33
Using a method similar to that in Example 20, compound I-33 was obtained as a white powder from compound X-2 (1.082 g, 1.0 mmol) and compound 33a (539 mg, 1.0 mmol).
Yield: 181 mg, (21%)
¹ H-NMR (D ₂ O) δ: 1.57 (3H, d, J = 7.03 Hz), 1.82-2.01 (5H, m), 2.68-1.72 (2H, m), 3.29-3.35 (3H, m), 3.61-3.96 (5H, m), 4.03 (1H, q, J = 7.03 Hz), 4.23 (1H , D, J = 13.93 Hz), 4.96 (1H, dd, J = 9.47, 3.83 Hz), 5.05 (1H, d, J = 13.93 Hz), 5.46. (1H, d, J = 4.64 Hz), 5.77 (1H, d, J = 4.64 Hz), 6.91 (1H, d, J = 8.41 Hz), 7.00 (1H , D, J = 8.41 Hz), 7.06 (1H, s).
MS (m + 1) = 809.98

Example 34: Synthesis of Compound 1-34

Step (1): Compound X-2 + Compound 29g → Compound I-34
Using a method similar to that in Example 20, compound I-34 was obtained as a yellow powder from compound X-2 (1.082 g, 1.0 mmol) and compound 29 g (517 mg, 1.0 mmol).
Yield: 414 mg (50%)
¹ H-NMR (D ₂ O) δ: 1.59 (3H, d, J = 7.03 Hz), 2.23 (4H, s), 2.70-2.74 (2H, m), 3 .53-3.71 (6H, m), 4.04-4.09 (3H, m), 4.32 (1H, d, J = 14.18 Hz), 4.96 (1H, dd, J = 9.79, 3.64 Hz), 5.12 (1H, d, J = 14.18 Hz), 5.47 (1H, d, J = 4.64 Hz), 5.76 (1H, d , J = 4.64 Hz), 7.02 (1H, d, J = 7.78 Hz), 7.08 (1H, s), 7.17 (1H, d, J = 7.78 Hz).
MS (m + 1) = 788.02

Example 35: Synthesis of compound 1-35

Step (1): Compound X-2 + Compound 35a → Compound I-35
Using a method similar to that in Example 20, compound I-35 was obtained as a white powder from compound X-2 (1.082 g, 1.0 mmol) and compound 35a (525 mg, 1.0 mmol).
Yield: 441 mg, (53%)
¹ H-NMR (D ₂ O) δ: 1.56 (3H, d, J = 7.15 Hz), 2.24 (4H, s), 2.69-2.72 (2H, m), 3 .47-3.96 (9H, m), 4.01 (1H, q, J = 7.07 Hz), 4.27 (1H, d, J = 14.18 Hz), 4.96 (1H, dd, J = 9.66, 3.76 Hz), 5.07 (1H, d, J = 14.18 Hz), 5.44 (1H, d, J = 4.64 Hz), 5.75 ( 1H, d, J = 4.64 Hz), 6.90 (1H, d, J = 8.41 Hz), 6.99 (1H, d, J = 8.41 Hz), 7.06 (1H, s).
MS (m + 1) = 795.97

Example 36: Synthesis of compound 1-36

Step (1): Compound 29f → Compound 36a
Using a method similar to that in Example 29, compound 36a was obtained as a white solid from compound 29f (3.63 g, 6.0 mmol) and N, N-diethylethylenediamine (1.01 mL, 7.2 mmol).
Yield: 1.98 g (64%)
¹ H-NMR (CDCl ₃ ) δ: 7.47 (1H, d, J = 8.03 Hz), 7.38 (2H, d, J = 8.53 Hz), 7.31 (2H, d, J = 8.53 Hz), 7.11 (1H, d, J = 8.03 Hz), 6.92 (2H, d, J = 8.50 Hz), 6.82 (2H, d, J = 8.53 Hz), 5.28 (2H, s), 5.08 (2H, s), 3.83 (3H, s), 3.79 (3H, s), 3.73 (2H, t, J = 7.10 Hz), 2.69 (2H, t, J = 7.09 Hz), 2.58 (4H, q, J = 7.11 Hz), 1.01 (6H, t, J = 7.09 Hz).

Step (2): Compound X-1 + Compound 36a → Compound I-36
Using a method similar to that in Example 20, compound I-36 was obtained as a yellow powder from compound X-1 (559 mg, 0.60 mmol) and compound 36a (311 mg, 0.60 mmol).
Yield: 110 mg, (24%)
¹ H-NMR (D ₂ O) δ: 1.45 (6H, q, J = 7.40 Hz), 1.50 (3H, s), 1.52 (3H, s), 1.59 (3H , D, J = 6.90 Hz), 3.45-3.52 (6H, m), 3.95-4.11 (3H, m), 4.20 (1H, d, J = 14.31). Hz), 5.03 (1H, d, J = 14.31 Hz), 5.48 (1H, d, J = 4.64 Hz), 5.77 (1H, d, J = 4.64 Hz) 7.00 (1H, d, J = 7.78 Hz), 7.04 (1H, s), 7.15 (1H, d, J = 7.78 Hz).
MS (m + 1) = 760.08

Example 37: Synthesis of compound 1-37

Step (1): Compound 37a → Compound 37b
To a suspension of compound 37a (4.29 g, 10 mmol) in dichloromethane (40 ml), N, N-diethylethylenediamine (1.69 ml, 12 mmol), HOBt (1.62 g, 12 mmol) with stirring in an ice bath. ) And EDC (2.30 g, 12 mmol) were added and the mixture was stirred at room temperature overnight. The resulting mixture was diluted with ethyl acetate and washed with dilute aqueous sodium hydroxide, water and brine. The organic layer was dried over magnesium sulfate, filtered and concentrated. The precipitated material was collected by filtration to give compound 37b (4.55 g, 86%).
¹ H-NMR (CDCl ₃ ) δ: 7.47 (1H, d, J = 8.7 Hz), 7.35-7.34 (4H, m), 7.03 (1H, br s), 6 .94-6.92 (3H, m), 6.83 (2H, d, J = 8.4 Hz), 5.08 (2H, s), 4.95 (2H, s), 3.83 ( 3H, s), 3.80 (3H, s), 3.50 (2H, q, J = 5.8 Hz), 2.64 (2H, t, J = 5.8 Hz), 2.55 ( 4H, q, J = 7.1 Hz), 1.01 (6H, t, J = 7.1 Hz).

Step (2): Compound X-1 + Compound 37b → Compound I-37
Using a method similar to that in Example 20, compound I-37 was obtained as a white powder from compound X-1 (932 mg, 1.0 mmol) and compound 37b (527 mg, 1.0 mmol).
Yield: 320 mg, (41%)
¹ H-NMR (D ₂ O) δ: 1.43 (6H, dd, J = 10.73, 6.84 Hz), 1.49 (3H, s), 1.52 (3H, s), 1 .57 (3H, d, J = 7.03 Hz), 3.48 (6H, q, J = 7.07 Hz), 3.74-3.95 (2H, m), 3.99 (1H, q, J = 6.86 Hz), 4.17 (1H, d, J = 14.31 Hz), 5.00 (1H, d, J = 14.31 Hz), 5.45 (1H, d, J = 4.64 Hz), 5.76 (1H, d, J = 4.64 Hz), 6.90 (1H, d, J = 8.41 Hz), 6.98 (1H, d, J = 8.41 Hz), 7.03 (1H, s).
MS (m + 1) = 768.22

Example 38: Synthesis of compound 1-38

Step (1): Compound 29f → Compound 38a
Using a method similar to Example 29, compound 38a was obtained as a colorless oil from compound 29f (3.02 g, 5.0 mmol), 20b (1.17 g, 5.5 mmol), and DIEA (1.92 mL, 11 mmol). Got as.
Yield: 100 mg, (4%)
¹ H-NMR (CDCl ₃ ) δ: 1.74 (2H, dd, J = 13.93, 6.27 Hz), 1.87-1.93 (2H, m), 2.13-2.16 (2H, m), 2.21 (3H, s), 2.66-2.34 (2H, m), 3.24 (2H, s), 3.79 (3H, s), 3.83 ( 3H, s), 4.55-4.65 (1H, m), 5.08 (2H, s), 5.25 (2H, s), 6.81 (2H, d, J = 8.53 Hz) ), 6.91 (2H, d, J = 8.53 Hz), 7.09 (1H, d, J = 8.16 Hz), 7.30 (2H, d, J = 8.66 Hz), 7.37 (2H, d, J = 8.66 Hz), 7.42 (1H, d, J = 8.16 Hz).

Step (2): Compound X-1 + Compound 38a → Compound I-38
Using a method similar to that in Example 20, compound I-38 was obtained as a yellow powder from compound X-1 (466 mg, 0.50 mmol) and compound 38a (271 mg, 0.50 mmol).
Yield: 126 mg (31%)
¹ H-NMR (D ₂ O) δ: 1.51 (3H, s), 1.53 (3H, s), 1.59 (3H, d, J = 7.15 Hz), 2.21 (2H , T, J = 19.39 Hz), 2.51-2.66 (4H, m), 2.83-2.99 (2H, m), 3.12 (3H, s), 4.00 ( 1H, s), 4.07-4.15 (3H, m), 4.75 (2H, d, J = 14.68 Hz), 5.47 (1H, d, J = 4.89 Hz), 5.84 (1H, d, J = 4.89 Hz), 7.02 (1H, s), 7.04 (1H, d, J = 7.78 Hz), 7.17 (1H, d, J = 7.78 Hz).
MS (m + 1) = 786.06

Example 39 Synthesis of Compound I-39

Step (1): Compound 29f → Compound 39b
Using a method similar to that in Example 29, compound 39b was obtained as a white solid from compound 29f (3.02 g, 5.0 mmol) and compound 39a (771 mg, 5.5 mmol).
¹ H-NMR (CDCl ₃ ) δ: 1.41 (6H, t, J = 7.65 Hz), 2.85 (6H, t, J = 7.65 Hz), 3.79 (3H, s) 3.83 (3H, s), 5.11 (2H, s), 5.28 (2H, s), 6.81 (2H, d, J = 8.66 Hz), 6.92 (2H, d, J = 8.66 Hz), 7.14 (1H, d, J = 8.03 Hz), 7.33 (2H, d, J = 8.66 Hz), 7.37 (2H, d, J = 8.66 Hz), 7.48 (1H, d, J = 8.03 Hz).

Step (2): Compound 39b + Compound X-2 → Compound 39c
To a solution of compound X-2 (932 mg, 1.0 mmol) in dimethylformamide (2 mL) at 0 ° C. was added compound 39b (543 mg, 1.0 mmol) and the resulting solution was stirred at 0 ° C. for 1 hour. The reaction mixture was slowly added to a 5% salt solution (30 ml) (containing 1.5 g sodium bisulfite) at 0 ° C. The precipitated solid was collected by filtration, washed with water and then suspended in water. This suspension was lyophilized to give compound 39c as an orange solid. The obtained compound 39c was directly used in the next step without purification.

Step (3): Compound 39c → Compound I-39
The total amount of the obtained compound 39c was dissolved in dichloromethane (10 mL), and this solution was cooled to −40 ° C. To this was then added anisole (1.1 mL, 10 mmol) and 2M aluminum chloride solution in nitromethane (5.00 mL, 10 mmol) sequentially. The resulting product was stirred at 0 ° C. for 30 minutes. The reaction mixture was dissolved in water, 2 mol / L hydrochloric acid aqueous solution, and acetonitrile. The resulting solution was then washed with diisopropyl ether. After adding HP20-SS resin to the aqueous phase, acetonitrile was distilled off under reduced pressure. The resulting mixture was purified by ODS column chromatography. After adding HP20-SS resin to the obtained target compound solution, acetonitrile was distilled off under reduced pressure. The resulting mixture was purified by HP20-SS column chromatography. A 0.2N sodium hydroxide aqueous solution was added to the obtained target compound solution until the pH reached 6.0 as a whole. Thereafter, a piece of dry ice was added thereto. The resulting solution was concentrated under reduced pressure and then lyophilized to obtain Compound I-39 as an orange powder.
Yield: 168 mg (20%).
¹ H-NMR (D ₂ O) δ: 1.50 (3H, s), 1.52 (3H, s), 1.55 (3H, d, J = 7.15 Hz), 1.93 (6H , T, J = 7.72 Hz), 3.41-3.53 (8H, m), 4.03-4.10 (2H, m), 4.61 (1H, d, J = 14.43). Hz), 5.43 (1H, d, J = 4.89 Hz), 5.84 (1H, d, J = 4.89 Hz), 6.99 (1H, s), 7.04 (1H, d, J = 7.91 Hz), 7.17 (1H, d, J = 7.91 Hz).
MS (m + 1) = 784.06

Example 40: Synthesis of Compound I-40

Step (1): Compound X-1 + Compound 40a → Compound I-40
Using a method similar to that in Example 20, compound I-40 was obtained as a white powder from compound X-1 (932 mg, 1.0 mmol) and compound 40a (543 mg, 1.0 mmol).
Yield: 523 mg, (64%)
¹ H-NMR (D ₂ O) δ: 1.51 (3H, s), 1.53 (3H, s), 1.56 (3H, d, J = 7.15 Hz), 1.96 (6H , T, J = 7.59 Hz), 3.35 (2H, s), 3.45-3.57 (6H, m), 4.05-4.09 (2H, m), 4.64 ( 1H, d, J = 14.31 Hz), 5.45 (1H, d, J = 4.89 Hz), 5.85 (1H, d, J = 4.89 Hz), 6.90 (1H, d, J = 8.41 Hz), 6.95 (1H, d, J = 8.41 Hz), 7.00 (1H, s).
MS (m + 1) = 792.01

Example 41: Synthesis of compound 1-41

Step (1): Compound X-1 + Compound 41a → Compound I-41
Using a method similar to that in Example 20, compound I-41 was obtained as a white powder from compound X-1 (932 mg, 1.0 mmol) and compound 41a (537 mg, 1.0 mmol).
Yield: 443 mg, (55%)
¹ H-NMR (D ₂ O) δ: 1.50 (3H, d, J = 1.63 Hz), 1.52 (3H, d, J = 1.88 Hz), 1.57 (3H, dd , J = 17.69, 6.90 Hz), 2.02-2.46 (4H, m), 3.46-4.08 (9H, m), 4.25-4.53 (2H, m ), 5.11 (1H, dd, J = 19.89, 15.00 Hz), 5.45 (1H, d, J = 4.64 Hz), 5.83 (1H, d, J = 4. 64 Hz), 6.83-6.88 (1H, m), 6.95-6.98 (1H, m), 7.01 (1H, s).
MS (m + 1) = 778.04

Example 42: Synthesis of compound I-42

Step (1): Compound X-1 + Compound 32a → Compound I-42
Using a method similar to that in Example 20, compound I-42 was obtained as a yellow powder from compound X-1 (932 mg, 1.0 mmol) and compound 32a (624 mg, 1.0 mmol).
Yield: 192 mg, (24%)
¹ H-NMR (D ₂ O) δ: 1.51 (3H, s), 1.53 (3H, s), 1.61 (3H, d, J = 7.03 Hz), 1.81-2 .00 (6H, m), 3.28-3.39 (3H, m), 3.59-3.80 (3H, m), 4.02-4.07 (2H, m), 4.16 (1H, q, J = 7.03 Hz), 4.29 (1H, d, J = 14.05 Hz), 5.07 (1H, d, J = 14.05 Hz), 5.50 (1H , D, J = 4.77 Hz), 5.83 (1H, d, J = 4.77 Hz), 7.02-7.04 (2H, m), 7.17 (1H, d, J = 7.78 Hz).
MS (m + 1) = 772.07

Example 43: Synthesis of Compound 1-43

Step (1): Compound X-1 + Compound 33a → Compound I-43
Using a method similar to that in Example 20, compound I-43 was obtained as a white powder from compound X-1 (932 mg, 1.0 mmol) and compound 33a (539 mg, 1.0 mmol).
Yield: 272 mg, (29%)
¹ H-NMR (D ₂ O) δ: 1.50 (3H, s), 1.52 (3H, s), 1.59 (3H, d, J = 7.03 Hz), 1.82-2 .01 (6H, m), 3.28-3.36 (3H, m), 3.62 (1H, d, J = 11.92 Hz), 3.69-3.82 (3H, m), 3.89-3.96 (1H, m), 4.11 (1H, q, J = 7.03 Hz), 4.23 (1H, d, J = 14.18 Hz), 5.00 (1H , D, J = 14.18 Hz), 5.48 (1H, d, J = 4.77 Hz), 5.83 (1H, d, J = 4.77 Hz), 6.87 (1H, d , J = 8.28 Hz), 6.95 (1H, d, J = 8.28 Hz), 7.02 (1H, s).

Example 44: Synthesis of compound 1-44

Step (1): Compound X-1h + Compound 44b → Compound 44c → Compound I-44
A solution of compound 44b (404 mg, 0.80 mmol) in dimethylacetamide (2.0 mL) was cooled with ice and to this was added compound X-1h (672 mg, 0.80 mmol). Next, the reaction vessel was degassed under reduced pressure, and sodium iodide (240 mg, 1.6 mmol) was added thereto. After stirring at 15 ° C. for 7 hours, the reaction mixture was slowly added to ice-cooled 5% sodium chloride and sodium bisulfite vinegar solution. The precipitated solid was collected by filtration, washed with water and suspended in water. The suspension was lyophilized to give compound 44c as a brown solid. The obtained compound 44c was directly used in the next step without purification.

Using a method similar to that in Example 20, compound I-44 was obtained as a white powder from compound 44c.
Yield: 359 mg (58%)
¹ H-NMR (D ₂ O) δ: 1.44 (3H, s), 1.45 (3H, s), 1.61 (3H, d, J = 6.78 Hz), 3.49 (1H , Q, J = 6.78 Hz), 5.12 (1H, d, J = 14.68 Hz), 5.43-5.46 (2H, m), 5.92 (1H, d, J = 4.39 Hz), 6.87 (1H, d, J = 8.41 Hz), 6.90 (1H, s), 7.12 (1H, d, J = 8.41 Hz), 8.09 (2H, d, J = 6.53 Hz), 8.76 (2H, d, J = 6.53 Hz).
MS (m + 1) = 745.97

Example 45: Synthesis of compound 1-45

Step (1): Compound X-1h + Compound 45a → Compound I-45
Using a method similar to that in Example 44, compound I-45 was obtained as a white powder from compound X-1h (672 mg, 0.80 mmol) and compound 45a (300 mg, 1.0 mmol).
Yield: 332 mg, (61%)
¹ H-NMR (D ₂ O) δ: 1.39 (3H, d, J = 7.15 Hz), 1.47 (6H, s), 2.69 (3H, s), 3.46 (1H , Q, J = 6.94 Hz), 5.22 (1H, d, J = 15.31 Hz), 5.33 (1H, d, J = 15.31 Hz), 5.47 (1H, d , J = 4.89 Hz), 5.91 (1H, d, J = 4.89 Hz), 6.88 (1H, s), 6.90 (1H, s), 7.29 (1H, s) ), 7.54 (1H, s), 8.83 (1H, s).
MS (m + 1) = 657.01

Example 46: Synthesis of Compound 1-46

Step (1): Compound X-1h + Compound 46a → Compound I-46
Using a method similar to that in Example 44, Compound I-46 was obtained as a white powder from Compound X-1h (672 mg, 0.80 mmol) and Compound 46a (289 mg, 1.0 mmol).
Yield: 356 mg (67%)
¹ H-NMR (D ₂ O) δ: 1.43 (3H, s), 1.45 (3H, s), 1.57 (3H, d, J = 7.15 Hz), 3.40 (1H , Q, J = 7.15 Hz), 5.12 (1H, d, J = 14.68 Hz), 5.43-5.47 (2H, m), 5.88 (1H, d, J = 4.77 Hz), 6.79 (1H, s), 7.06 (1H, s), 7.36 (1H, s), 7.72 (1H, d, J = 6.90 Hz), 8 .11 (1H, d, J = 6.90 Hz), 9.01 (1H, s).
MS (m + 1) = 643.01

Example 47: Synthesis of Compound 1-47

Step (1): Compound X-1g + Compound 44b → Compound I-47
Using a method similar to that in Example 44, Compound I-47 was obtained as a white powder from Compound X-1g (672 mg, 0.80 mmol) and Compound 44b (404 mg, 0.80 mmol).
Yield: 367 mg, (60%)
¹ H-NMR (D ₂ O) δ: 1.27 (3H, d, J = 7.16 Hz), 1.45 (3H, s), 1.48 (3H, s), 3.95 (1H , Q, J = 7.16 Hz), 5.28 (1H, d, J = 15.16 Hz), 5.35-5.39 (2H, m), 5.74 (1H, d, J = 4.80 Hz), 6.88 (1H, s), 6.91 (1H, d, J = 8.34 Hz), 7.15 (1H, d, J = 8.34 Hz), 8.19. (2H, d, J = 7.33 Hz), 8.76 (2H, d, J = 7.33 Hz).
MS (m + 1) = 745.93

Example 48: Synthesis of compound 1-48

Step (1): Compound X-1g + Compound 48a → Compound I-48
Using a method similar to that in Example 44, Compound I-48 was obtained as a white powder from Compound X-1g (672 mg, 0.80 mmol) and Compound 48a (395 mg, 0.80 mmol).
Yield: 320 mg, (53%)
¹ H-NMR (D ₂ O) δ: 1.50 (3H, s), 1.52 (3H, s), 1.56 (3H, d, J = 7.15 Hz), 4.11 (1H , Q, J = 7.15 Hz), 4.17 (1H, d, J = 13.80 Hz), 4.75 (1H, d, J = 13.80 Hz), 5.30 (1H, d , J = 4.64 Hz), 5.73 (1H, d, J = 4.64 Hz), 7.00-7.02 (2H, m), 7.08 (1H, d, J = 8. 78 Hz), 7.91 (2H, d, J = 6.90 Hz), 8.52 (2H, d, J = 6.90 Hz).
MS (m + 1) = 734.92

Example 49: Synthesis of Compound I-49

Step (1): Compound X-1g + Compound 45a → Compound I-49
Using a method similar to that in Example 44, Compound I-49 was obtained as a white powder from Compound X-1g (672 mg, 0.80 mmol) and Compound 45a (300 mg, 1.0 mmol).
Yield: 244 mg, (45%)
¹ H-NMR (D ₂ O) δ: 1.25 (3H, d, J = 7.15 Hz), 1.50 (3H, s), 1.51 (3H, s), 2.71 (3H , S), 3.95 (1H, q, J = 7.15 Hz), 5.22 (1H, d, J = 15.69 Hz), 5.44 (1H, d, J = 15.69 Hz) ), 5.51 (1H, d, J = 4.77 Hz), 5.80 (1H, d, J = 4.77 Hz), 6.97-6.98 (2H, m), 7.34 (1H, s), 7.58 (1H, s), 8.83 (1H, s).
MS (m + 1) = 657.01

Example 50: Synthesis of Compound I-50

Step (1): Compound X-1g + Compound 46a → Compound I-50
Using a method similar to that in Example 44, Compound I-50 was obtained as a white powder from Compound X-1g (672 mg, 0.80 mmol) and Compound 46a (289 mg, 1.0 mmol).
Yield: 294 mg, (55%)
¹ H-NMR (D ₂ O) δ: 1.35 (3H, d, J = 7.33 Hz), 1.49 (3H, s), 1.51 (3H, s), 3.89 (1H , Q, J = 7.33 Hz), 5.30 (1H, d, J = 14.91 Hz), 5.43 (1H, d, J = 4.80 Hz), 5.46 (1H, d , J = 14.91 Hz), 5.82 (1H, d, J = 4.80 Hz), 6.98 (1H, s), 7.10 (1H, s), 7.41 (1H, s ), 7.76 (1H, d, J = 6.82 Hz), 8.00 (1H, d, J = 6.82 Hz), 8.91 (1H, s).
MS (m + 1) = 643.01

Example 51: Synthesis of Compound I-51

Step (1): Compound X-1 + Compound 29g → Compound I-51
Using a method similar to that in Example 20, compound I-51 was obtained as a yellow powder from compound X-1 (932 mg, 1.0 mmol) and compound 29 g (517 mg, 1.0 mmol).
Yield: 222 mg (29%)
¹ H-NMR (D ₂ O) δ: 1.50 (3H, s), 1.53 (3H, s), 1.60 (3H, d, J = 7.03 Hz), 2.23 (4H , S), 3.52-3.71 (6H, m), 3.99-4.16 (3H, m), 4.32 (1H, d, J = 14.18 Hz), 5.07 ( 1H, d, J = 14.18 Hz), 5.48 (1H, d, J = 4.77 Hz), 5.81 (1H, d, J = 4.77 Hz), 7.00-7. 02 (2H, m), 7.15 (1H, d, J = 7.78 Hz).
MS (m + 1) = 758.25

Example 52: Synthesis of Compound I-52

Step (1): Compound X-22 + Compound 35a → Compound 52b → Compound I-52
A solution of compound X-22 (420 mg, 0.80 mmol) in dimethylacetamide (2.0 mL) was cooled with ice and to this was added compound 35a (685 mg, 0.80 mmol). The reaction vessel was then degassed under reduced pressure. To this was added sodium iodide (240 mg, 1.6 mmol) and the solution was stirred at 15 ° C. for 6 hours. To this was added dimethylformamide (5.0 mL) and the solution was cooled to -40 ° C. To this was added phosphorus tribromide (151 μL, 1.6 mmol). The solution was stirred at 0 ° C. for 30 minutes. The reaction mixture was slowly added to a 5% salt solution cooled with ice. The precipitated solid was collected by filtration, washed with water and suspended in water. This suspension was lyophilized to give compound 52b as a brown solid. The obtained compound 52b was directly used in the next step without purification.

Using a method similar to that in Example 20, compound I-52 was obtained as a white powder from compound 52b.
Yield: 269 mg, (43%)
¹ H-NMR (D ₂ O) δ: 1.50 (3H, s), 1.52 (3H, s), 1.58 (3H, d, J = 7.02 Hz), 2.23 (4H , S), 3.55-3.59 (2H, m), 3.73-3.88 (5H, m), 4.04-4.10 (1H, m), 4.22-4.29 (2H, m), 5.02 (1H, d, J = 13.88 Hz), 5.45 (1H, d, J = 5.03 Hz), 5.73 (1H, d, J = 5. 03 Hz), 6.88-6.90 (2H, m), 7.00 (1H, s).
MS (m + 1) = 766.62

Example 53: Synthesis of Compound I-53

Step (1): Compound X-23 + Compound 35a → Compound I-53
Using a method similar to that in Example 52, Compound I-53 was obtained as a white powder from Compound X-23 (514 mg, 0.60 mmol) and Compound 35a (315 mg, 0.60 mmol).
Yield: 198 mg (42%)
¹ H-NMR (D ₂ O) δ: 1.48 (6H, s), 1.64 (3H, d, J = 6.86 Hz), 2.23 (4H, s), 3.55-3 .59 (2H, m), 3.73-3.88 (6H, m), 4.22-4.29 (2H, m), 4.50 (1H, d, J = 14.03 Hz), 5.47 (1H, d, J = 5.03 Hz), 5.79 (1H, d, J = 5.03 Hz), 6.82 (1H, d, J = 8.39 Hz), 6. 89 (1H, s), 6.98 (1H, d, J = 8.39 Hz).
MS (m + 1) = 766.36

Example 54: Synthesis of Compound I-54

Step (1): Compound X-22 + Compound 54a → Compound I-54
Using a method similar to that in Example 51, Compound I-54 was obtained as a white powder from Compound X-22 (685 mg, 0.80 mmol) and Compound 54a (441 mg, 0.80 mmol).
Yield: 164 mg (25%)
¹ H-NMR (D ₂ O) δ: 1.50 (3H, s), 1.52 (3H, s), 1.62 (3H, d, J = 7.02 Hz), 2.17 (2H , Dd, J = 16.11, 6.86 Hz), 2.36-2.79 (7H, m), 3.14 (3H, s), 3.80 (1H, q, J = 6.66). Hz), 4.01 (1H, s), 4.10-4.23 (3H, m), 5.43 (1H, d, J = 4.88 Hz), 5.91 (1H, d, J = 4.88 Hz), 6.89 (1H, d, J = 8.39 Hz), 6.94 (1H, d, J = 8.39 Hz), 6.98 (1H, s).
MS (m + 1) = 792.62

Example 55: Synthesis of Compound I-55

Step (1): Compound X-23 + Compound 54a → Compound I-55
Using a method similar to that in Example 51, Compound I-55 was obtained as a white powder from Compound X-23 (514 mg, 0.60 mmol) and Compound 54a (331 mg, 0.60 mmol).
Yield: 30 mg, (6%)
¹ H-NMR (D ₂ O) δ: 1.50 (3H, s), 1.52 (3H, s), 1.62 (3H, d, J = 7.02 Hz), 2.17 (2H , Dd, J = 16.11, 6.86 Hz), 2.36-2.79 (7H, m), 3.14 (3H, s), 3.80 (1H, q, J = 6.66). Hz), 4.01 (1H, s), 4.10-4.23 (3H, m), 5.43 (1H, d, J = 4.88 Hz), 5.91 (1H, d, J = 4.88 Hz), 6.89 (1H, d, J = 8.39 Hz), 6.94 (1H, d, J = 8.39 Hz), 6.98 (1H, s).
MS (m + 1) = 792.44

Example 56: Synthesis of Compound I-56

Step (1): Compound 56a → Compound 56c
To a solution of compound 56a (10.19 g, 24.0 mmol) in dichloromethane (100 mL) was added compound 56b (9.62 g, 48.0 mmol), and the mixture was stirred at room temperature overnight. The solvent was removed by evaporation and water and ethyl acetate were added to the residue. The organic layer was separated and washed with water and brine, then dried over MgSO ₄ , filtered and concentrated. The residue was purified by column chromatography on silica gel eluting with n-hexane / ethyl acetate to give compound 56c (4.45 g, 39%) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 1.55 (9H, s), 2.54 (1H, t, J = 6.65 Hz), 3.80 (3H, s), 3.83 (3H, s), 4.52 (2H, d, J = 6.65 Hz), 5.00 (2H, s), 5.05 (2H, s), 6.81 (2H, d, J = 8.66) Hz), 6.90 (2H, d, J = 8.66 Hz), 7.00 (1H, d, J = 8.28 Hz), 7.08 (1H, d, J = 8.28 Hz) 7.29 (2H, d, J = 8.53 Hz), 7.35 (2H, d, J = 8.53 Hz).

Step (2): Compound 56c → Compound 56d
To a solution of compound 56c (4.45 g, 9.26 mmol) in dichloromethane (45 mL) at 0 ° C. was added Dess-Martin periodinane (4.32 g, 10.19 mmol), and the mixture was stirred at room temperature. Stir overnight. Water was added to the resulting mixture. The organic solvent was removed by evaporation and the aqueous residue was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate, filtered and concentrated. The residue was purified by column chromatography on silica gel eluting with n-hexane / ethyl acetate to give compound 56d (2.91 g, 66%) as a colorless solid.
¹ H-NMR (CDCl ₃ ) δ: 1.56 (9H, s), 3.80 (3H, s), 3.84 (3H, s), 4.97 (2H, s), 5.14 ( 2H, s), 6.80 (2H, d, J = 8.08 Hz), 6.93 (2H, d, J = 8.34 Hz), 7.10 (1H, d, J = 8.34) Hz), 7.26-7.28 (2H, m), 7.37 (2H, d, J = 8.34 Hz), 7.60 (1H, d, J = 8.34 Hz), 9. 88 (1H, s).

Step (3): Compound 56d → Compound 56e
To a solution of compound 56d (2.91 g, 6.08 mmol) in 1,4-oxane (30 mL) and water (10 mL) with stirring in an ice bath, amidosulfuric acid (1.18 g, 12.16 mmol) and Sodium chlorite (1.38 g, 12.16 mmol) was added and the mixture was then stirred at 0 ° C. for 30 minutes. Sodium bisulfate (2.53 g, 24.32 mmol) was added to the resulting mixture. This mixture was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate, filtered and concentrated. The residue was triturated with diisopropyl ether and the solid was collected by filtration and dried under high vacuum to give compound 56e (2.79 g, 93%) as a colorless solid.
¹ H-NMR (DMSO-D ₆ ) δ: 1.45 (9H, s), 3.74 (3H, s), 3.78 (3H, s), 4.84 (2H, s), 5. 19 (2H, s), 6.83 (2H, d, J = 8.66 Hz), 6.98 (2H, d, J = 8.78 Hz), 7.20 (2H, d, J = 8 .66 Hz), 7.31 (1H, d, J = 8.78 Hz), 7.46 (2H, d, J = 8.66 Hz), 7.69 (1H, d, J = 8.66) Hz).

Step (4): Compound 56e → Compound 56f
To a solution of compound 56e (989 mg, 2.0 mmol) in dimethylformamide (3 mL) at 0 ° C., 1-hydroxybenzotriazole (324 mg, 2.4 mmol), 1- (2-aminoethyl) pyrrolidine (0.30 mL). 2.4 mmol) and EDC hydrochloride (460 mg, 2.4 mmol) were added. The mixture was stirred at room temperature for 4.5 hours. Ice water was added to the resulting mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with 1 mol / L sodium hydroxide solution, water and brine, then dried over magnesium sulfate, filtered and evaporated at 25 ° C. The residue was dried under high vacuum to give compound 56f (1.16 g, 98%) as a yellowish oil.
¹ H-NMR (CDCl ₃ ) δ: 1.53 (9H, s), 1.79 (4H, br s), 2.58 (4H, br s), 2.70 (2H, t, J = 5 .81 Hz), 3.52 (2H, q, J = 5.56 Hz), 3.79 (3H, s), 3.83 (3H, s), 4.97 (2H, s), 5. 07 (2H, s), 6.80 (2H, d, J = 8.34 Hz), 6.91 (2H, d, J = 8.34 Hz), 6.96 (1H, d, J = 8 .59 Hz), 7.29 (2H, d, J = 8.34 Hz), 7.33-7.36 (3H, m).

Step (5): Compound X-22 + Compound 56f → Compound I-56
Using a method similar to that in Example 52, Compound I-56 was obtained as a white powder from Compound X-22 (475 mg, 0.59 mmol) and Compound 56f (346 mg, 0.59 mmol).
Yield: 51 mg (11%)
¹ H-NMR (D ₂ O) δ: 1.50 (3H, s), 1.52 (3H, s), 1.59 (3H, d, J = 7.03 Hz), 2.24 (4H , S), 3.35-3.87 (8H, m), 4.11 (1H, q, J = 7.03 Hz), 4.28 (1H, d, J = 14.31 Hz), 5 .00 (1H, d, J = 14.31 Hz), 5.48 (1H, d, J = 4.77 Hz), 5.82 (1H, d, J = 4.77 Hz), 6.74. (1H, d, J = 8.16 Hz), 6.96 (1H, d, J = 8.16 Hz), 7.03 (1H, s).
MS (m + 1) = 776.03

Example 57: Synthesis of Compound I-57

Step (1): Compound X-23 + Compound 56f → Compound I-57
Using a method similar to that in Example 52, Compound I-57 was obtained as a white powder from Compound X-23 (685 mg, 0.80 mmol) and Compound 56f (473 mg, 0.80 mmol).
Yield: 52 mg (8%)
¹ H-NMR (D ₂ O) δ: 1.50 (6H, s), 1.65 (3H, d, J = 6.82 Hz), 2.22 (4H, s), 3.58-3 .87 (9H, m), 4.31 (1H, d, J = 14.40 Hz), 4.46 (1H, d, J = 14.40 Hz), 5.48 (1H, d, J = 4.80 Hz), 5.83 (1H, d, J = 4.80 Hz), 6.68 (1H, d, J = 8.08 Hz), 6.93 (1H, d, J = 8. 08 Hz), 6.96 (1H, s).
MS (m + 1) = 776.06

Example 58: Synthesis of Compound I-58

Step (1): Compound X-23 + Compound 29g → Compound I-58
Using a method similar to that in Example 52, compound I-58 was obtained as a yellow powder from compound X-23 (685 mg, 0.80 mmol) and compound 29 g (413 mg, 0.80 mmol).
Yield: 46 mg (7%)
¹ H-NMR (D ₂ O) δ: 1.46 (3H, s), 1.47 (3H, s), 1.68 (3H, d, J = 6.78 Hz), 2.21 (4H , S), 3.49-3.55 (1H, m), 3.74-3.93 (6H, m), 4.02-4.05 (2H, m), 4.27 (1H, d) , J = 14.43 Hz), 4.55 (1H, d, J = 13.93 Hz), 5.52 (1H, d, J = 4.77 Hz), 5.87 (1H, d, J = 4.77 Hz), 6.91 (1H, s), 6.96 (1H, s), 7.04 (1H, d, J = 7.53 Hz).
MS (m + 1) = 758.03

  The compounds shown below were obtained from Compound X-1g and the corresponding amines as in Example 39.

収量：４２３ｇ（５２％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：６．９３−６．９１ （１Ｈ， ｍ）， ６．９３−６．９１ （１Ｈ， ｍ）， ６．８１−６．７７ （１Ｈ， ｍ）， ５．８６−５．８３ （１Ｈ， ｍ）， ５．４７−５．４４ （１Ｈ， ｍ）， ４．１３−３．９８ （４Ｈ， ｍ）， ３．６９−３．６３ （２Ｈ， ｍ）， ３．４９−２．９５ （７Ｈ， ｍ）， １．５９−１．５６ （３Ｈ， ｍ）， １．５２ （３Ｈ， ｓ）， １．５０ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ７７８．２３ Example 59: Synthesis of Compound I-59

Yield: 423 g (52%)
¹ H-NMR (D ₂ O) δ: 6.93-6.91 (1H, m), 6.93-6.91 (1H, m), 6.81-6.77 (1H, m), 5.86-5.83 (1H, m), 5.47-5.44 (1H, m), 4.13-3.98 (4H, m), 3.69-3.63 (2H, m ), 3.49-2.95 (7H, m), 1.59-1.56 (3H, m), 1.52 (3H, s), 1.50 (3H, s).
[M + H] = 778.23

収量：５１６ｇ（６２％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．３９ （１Ｈ， ｓ）， ７．１９ （１Ｈ， ｓ）， ７．０１ （１Ｈ， ｓ）， ５．８４ （１Ｈ， ｄ， Ｊ ＝ ５．０ Ｈｚ）， ５．４５ （１Ｈ， ｄ， Ｊ ＝ ５．０ Ｈｚ）， ４．６３ （１Ｈ， ｄ， Ｊ ＝ １４．９ Ｈｚ）， ４．０９−４．０４ （２Ｈ， ｍ）， ３．５５−３．４３ （６Ｈ， ｍ）， ３．３５ （２Ｈ， ｂｒ ｓ）， １．９３ （６Ｈ， ｔ， Ｊ ＝ ７．８ Ｈｚ）， １．５６ （３Ｈ， ｄ， Ｊ ＝ ７．３ Ｈｚ）， １．５２ （３Ｈ， ｓ）， １．５０ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ７９２．２７ Example 60: Synthesis of Compound 1-60

Yield: 516 g (62%)
¹ H-NMR (D ₂ O) δ: 7.39 (1H, s), 7.19 (1H, s), 7.01 (1H, s), 5.84 (1H, d, J = 5. 0 Hz), 5.45 (1H, d, J = 5.0 Hz), 4.63 (1H, d, J = 14.9 Hz), 4.09-4.04 (2H, m), 3 .55-3.43 (6H, m), 3.35 (2H, br s), 1.93 (6H, t, J = 7.8 Hz), 1.56 (3H, d, J = 7. 3 Hz), 1.52 (3H, s), 1.50 (3H, s).
[M + H] = 792.27

収量：３４６ｍｇ （４２％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．３９ （１Ｈ， ｓ）， ７．２３ （１Ｈ， ｓ）， ７．０１ （１Ｈ， ｓ）， ５．８０ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．４５ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．０３ （１Ｈ， ｄ， Ｊ ＝ １４．３ Ｈｚ）， ４．２５ （１Ｈ， ｄ， Ｊ ＝ １４．３ Ｈｚ）， ４．０９−４．０４ （１Ｈ， ｍ）， ３．９２−３．８５ （１Ｈ， ｍ）， ３．７９−３．７０ （２Ｈ， ｍ）， ３．６０−３．４４ （５Ｈ， ｍ）， ２．２９−２．１５ （４Ｈ， ｍ）， １．５７ （３Ｈ， ｄ， Ｊ ＝ ７．０ Ｈｚ）， １．５２ （３Ｈ， ｓ）， １．５０ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ７６６．２４ Example 61 Synthesis of Compound I-61

Yield: 346 mg (42%)
¹ H-NMR (D ₂ O) δ: 7.39 (1H, s), 7.23 (1H, s), 7.01 (1H, s), 5.80 (1H, d, J = 4. 8 Hz), 5.45 (1H, d, J = 4.8 Hz), 5.03 (1H, d, J = 14.3 Hz), 4.25 (1H, d, J = 14.3 Hz). ), 4.09-4.04 (1H, m), 3.92-3.85 (1H, m), 3.79-3.70 (2H, m), 3.60-3.44 (5H M), 2.29-2.15 (4H, m), 1.57 (3H, d, J = 7.0 Hz), 1.52 (3H, s), 1.50 (3H, s) .
[M + H] = 766.24

収量：３９６ｍｇ（４８％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．０２−７．００ （１Ｈ， ｍ）， ６．９２ （１Ｈ， ｄ， Ｊ ＝ ８．３ Ｈｚ）， ６．８１−６．７７ （１Ｈ， ｍ）， ５．８６−５．８３ （１Ｈ， ｍ）， ５．４７−５．４４ （１Ｈ， ｍ）， ４．１３−３．９８ （５Ｈ， ｍ）， ３．６９−２．９５ （１１Ｈ， ｍ）， １．５８ （３Ｈ， ｔ， Ｊ ＝ ６．６ Ｈｚ）， １．５２ （３Ｈ， ｓ）， １．５０ （３Ｈ， ｓ）． ［Ｍ＋Ｈ］ ＝ ７７８．２０ Example 62: Synthesis of Compound I-62

Yield: 396 mg (48%)
¹ H-NMR (D ₂ O) δ: 7.02-7.00 (1H, m), 6.92 (1H, d, J = 8.3 Hz), 6.81-6.77 (1H, m), 5.86-5.83 (1H, m), 5.47-5.44 (1H, m), 4.13-3.98 (5H, m), 3.69-2.95 ( 11H, m), 1.58 (3H, t, J = 6.6 Hz), 1.52 (3H, s), 1.50 (3H, s). [M + H] = 778.20

収量：４０５ｍｇ（５０％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．１４ （１Ｈ， ｂｒ ｓ）， ７．０２−６．９８ （２Ｈ， ｂｒ ｍ）， ５．８５−５．８１ （１Ｈ， ｍ）， ５．４５ （１Ｈ， ｄ， Ｊ ＝ ４．９ Ｈｚ）， ４．１４−３．６７ （８Ｈ， ｍ）， ３．４２−２．９５ （８Ｈ， ｍ）， １．５８−１．５５ （３Ｈ， ｍ）， １．５２ （３Ｈ， ｂｒ ｓ）， １．５０ （３Ｈ， ｂｒ ｓ）．
［Ｍ＋Ｈ］ ＝ ７７８．２０ Example 63: Synthesis of Compound I-63

Yield: 405 mg (50%)
¹ H-NMR (D ₂ O) δ: 7.14 (1H, br s), 7.02-6.98 (2H, br m), 5.85-5.81 (1H, m), 5. 45 (1H, d, J = 4.9 Hz), 4.14-3.67 (8H, m), 3.42-2.95 (8H, m), 1.58-1.55 (3H, m), 1.52 (3H, br s), 1.50 (3H, br s).
[M + H] = 778.20

収量：２７９ｍｇ（３５％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．１１ （１Ｈ， ｓ）， ７．０２ （１Ｈ， ｓ）， ６．９４ （１Ｈ， ｓ）， ５．８３ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．４６ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．１２ （１Ｈ， ｄ， Ｊ ＝ １４．３ Ｈｚ）， ４．２８ （１Ｈ， ｄ， Ｊ ＝ １４．３ Ｈｚ）， ４．０７−３．５５ （８Ｈ， ｍ）， ２．２１−２．００ （４Ｈ， ｂｒ ｍ）， １．５８ （３Ｈ， ｄ， Ｊ ＝ ６．８ Ｈｚ）， １．５３ （３Ｈ， ｓ）， １．５１ （３Ｈ， ｓ）． ［Ｍ＋Ｈ］ ＝ ７７８．２０ Example 64: Synthesis of compound I-64

Yield: 279 mg (35%)
¹ H-NMR (D ₂ O) δ: 7.11 (1H, s), 7.02 (1H, s), 6.94 (1H, s), 5.83 (1H, d, J = 4. 8 Hz), 5.46 (1H, d, J = 4.8 Hz), 5.12 (1H, d, J = 14.3 Hz), 4.28 (1H, d, J = 14.3 Hz). ), 4.07-3.55 (8H, m), 2.21-2.00 (4H, br m), 1.58 (3H, d, J = 6.8 Hz), 1.53 (3H , S), 1.51 (3H, s). [M + H] = 778.20

収量：４０６ｍｇ（５０％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．０８−７．０４ （１Ｈ， ｍ）， ６．９９ （１Ｈ， ｂｒ ｓ）， ６．９３ （１Ｈ， ｂｒ ｓ）， ５．８９−５．８４ （１Ｈ， ｂｒ ｍ）， ５．４７−５．４４ （１Ｈ， ｂｒ ｍ）， ４．３１−３．４７ （１１Ｈ， ｍ）， ２．３７−２．２３ （４Ｈ， ｂｒ ｍ）， １．５７ （３Ｈ， ｄ， Ｊ ＝ ６．５ Ｈｚ）， １．５２ （３Ｈ， ｂｒ ｓ）， １．５０ （３Ｈ， ｂｒ ｓ）．
［Ｍ＋Ｈ］ ＝ ７７８．２３ Example 65 Synthesis of Compound I-65

Yield: 406 mg (50%)
¹ H-NMR (D ₂ O) δ: 7.08-7.04 (1H, m), 6.99 (1H, br s), 6.93 (1H, br s), 5.89-5. 84 (1H, br m), 5.47-5.44 (1H, br m), 4.31-3.47 (11H, m), 2.37-2.23 (4H, br m), 1 .57 (3H, d, J = 6.5 Hz), 1.52 (3H, br s), 1.50 (3H, br s).
[M + H] = 778.23

収量：２７２ｍｇ（３３％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．３２ （１Ｈ， ｄ， Ｊ ＝ ２．０ Ｈｚ）， ７．１７ （１Ｈ， ｓ）， ７．０２ （１Ｈ， ｓ）， ５．８２ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．４６ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ４．２１−３．９４ （５Ｈ， ｍ）， ３．１１ （３Ｈ， ｂｒ ｓ）， ２．８１−２．３２ （７Ｈ， ｍ）， ２．１９ （２Ｈ， ｄ， Ｊ ＝ １７．２ Ｈｚ）， １．５８ （３Ｈ， ｄ， Ｊ ＝ ７．０ Ｈｚ）， １．５３ （３Ｈ， ｓ）， １．５１ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ７９２．２４ Example 66: Synthesis of Compound I-66

Yield: 272 mg (33%)
¹ H-NMR (D ₂ O) δ: 7.32 (1H, d, J = 2.0 Hz), 7.17 (1H, s), 7.02 (1H, s), 5.82 (1H , D, J = 4.8 Hz), 5.46 (1H, d, J = 4.8 Hz), 4.21-3.94 (5H, m), 3.11 (3H, br s), 2.81-2.32 (7H, m), 2.19 (2H, d, J = 17.2 Hz), 1.58 (3H, d, J = 7.0 Hz), 1.53 (3H , S), 1.51 (3H, s).
[M + H] = 792.24

収量：３２１ｍｇ（４０％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．００ （１Ｈ， ｓ）， ６．８９−６．８１ （２Ｈ， ｍ）， ５．８５ （１Ｈ， ｄ， Ｊ ＝ ４．６ Ｈｚ）， ５．４５ （１Ｈ， ｄ， Ｊ ＝ ４．６ Ｈｚ）， ４．３７−４．２７ （１Ｈ， ｍ）， ４．１１−４．０３ （３Ｈ， ｍ）， ３．８５−３．６２ （７Ｈ， ｍ）， ２．３５ （４Ｈ， ｂｒ ｓ）， １．５８ （３Ｈ， ｄ， Ｊ ＝ ６．０ Ｈｚ）， １．５２ （３Ｈ， ｓ）， １．５０ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ７６２．３２ Example 67: Synthesis of Compound I-67

Yield: 321 mg (40%)
¹ H-NMR (D ₂ O) δ: 7.00 (1H, s), 6.89-6.81 (2H, m), 5.85 (1H, d, J = 4.6 Hz), 5 .45 (1H, d, J = 4.6 Hz), 4.37-4.27 (1H, m), 4.11-4.03 (3H, m), 3.85-3.62 (7H M), 2.35 (4H, br s), 1.58 (3H, d, J = 6.0 Hz), 1.52 (3H, s), 1.50 (3H, s).
[M + H] = 762.32.

収量：３１９ｍｇ（４０％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．０１ （１Ｈ， ｓ）， ６．９２−６．８９ （１Ｈ， ｂｒ ｍ）， ６．８４ （１Ｈ， ｓ）， ５．８３ （１Ｈ， ｄ， Ｊ ＝ ４．９ Ｈｚ）， ５．４６ （１Ｈ， ｄ， Ｊ ＝ ４．９ Ｈｚ）， ５．１２ （１Ｈ， ｄ， Ｊ ＝ １４．４ Ｈｚ）， ４．３０−３．５２ （１０Ｈ， ｍ）， ２．２１−２．０２ （４Ｈ， ｂｒ ｍ）， １．５８ （３Ｈ， ｄ， Ｊ ＝ ７．０ Ｈｚ）， １．５３ （３Ｈ， ｓ）， １．５０ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ７６２．３２ Example 68 Synthesis of Compound I-68

Yield: 319 mg (40%)
¹ H-NMR (D ₂ O) δ: 7.01 (1H, s), 6.92-6.89 (1H, br m), 6.84 (1H, s), 5.83 (1H, d , J = 4.9 Hz), 5.46 (1H, d, J = 4.9 Hz), 5.12 (1H, d, J = 14.4 Hz), 4.30-3.52 (10H M), 2.21-2.02 (4H, br m), 1.58 (3H, d, J = 7.0 Hz), 1.53 (3H, s), 1.50 (3H, s ).
[M + H] = 762.32.

収量：３６９ｍｇ（４７％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．０１ （１Ｈ， ｄ， Ｊ ＝ ６．１ Ｈｚ）， ６．９５−６．９２ （１Ｈ， ｍ）， ６．８８ （１Ｈ， ｂｒ ｓ）， ５．８５−５．８１ （１Ｈ， ｍ）， ５．４５ （１Ｈ， ｄ， Ｊ ＝ ４．９ Ｈｚ）， ４．１４−２．９４ （１６Ｈ， ｍ）， １．５７ （３Ｈ， ｄ， Ｊ ＝ ７．０ Ｈｚ）， １．５２ （３Ｈ， ｓ）， １．５０ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ７６２．５０ Example 69: Synthesis of Compound I-69

Yield: 369 mg (47%)
¹ H-NMR (D ₂ O) δ: 7.01 (1H, d, J = 6.1 Hz), 6.95-6.92 (1H, m), 6.88 (1H, br s), 5.85-5.81 (1H, m), 5.45 (1H, d, J = 4.9 Hz), 4.14-2.94 (16H, m), 1.57 (3H, d, J = 7.0 Hz), 1.52 (3H, s), 1.50 (3H, s).
[M + H] = 762.50

収量：３００ｍｇ（３７％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．１９−７．１５ （２Ｈ， ｍ）， ７．０１ （１Ｈ， ｓ）， ５．８１ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．４６ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．０３ （１Ｈ， ｄ， Ｊ ＝ １４．３ Ｈｚ）， ４．２５ （１Ｈ， ｄ， Ｊ ＝ １４．３ Ｈｚ）， ４．０７ （１Ｈ， ｑ， Ｊ ＝ ７．１ Ｈｚ）， ３．９２−３．８６ （１Ｈ， ｍ）， ３．８１−３．７１ （２Ｈ， ｍ）， ３．６２−３．４４ （５Ｈ， ｍ）， ２．２７−２．１７ （４Ｈ， ｍ）， １．５７ （３Ｈ， ｄ， Ｊ ＝ ７．２ Ｈｚ）， １．５２ （３Ｈ， ｓ）， １．５０ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ７５０．４７ Example 70: Synthesis of Compound I-70

Yield: 300 mg (37%)
¹ H-NMR (D ₂ O) δ: 7.19-7.15 (2H, m), 7.01 (1H, s), 5.81 (1H, d, J = 4.8 Hz), 5 .46 (1H, d, J = 4.8 Hz), 5.03 (1H, d, J = 14.3 Hz), 4.25 (1H, d, J = 14.3 Hz), 4.07 (1H, q, J = 7.1 Hz), 3.92-3.86 (1H, m), 3.81-3.71 (2H, m), 3.62-3.44 (5H, m ), 2.27-2.17 (4H, m), 1.57 (3H, d, J = 7.2 Hz), 1.52 (3H, s), 1.50 (3H, s).
[M + H] = 750.47

収量：１４３ｍｇ（１７％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．１４−７．０９ （２Ｈ， ｍ）， ７．０２ （１Ｈ， ｓ）， ５．８３ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．４７ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ４．２０ （１Ｈ， ｔ， Ｊ ＝ ７．２ Ｈｚ）， ４．１３−４．０５ （３Ｈ， ｍ）， ３．９５ （１Ｈ， ｂｒ ｓ）， ３．１１ （３Ｈ， ｓ）， ２．８１−２．４１ （７Ｈ， ｍ）， ２．１９ （２Ｈ， ｄ， Ｊ ＝ １６．９ Ｈｚ）， １．５８ （３Ｈ， ｄ， Ｊ ＝ ７．０ Ｈｚ）， １．５３ （３Ｈ， ｓ）， １．５１ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ７７６．２５ Example 71: Synthesis of Compound I-71

Yield: 143 mg (17%)
¹ H-NMR (D ₂ O) δ: 7.14-7.09 (2H, m), 7.02 (1H, s), 5.83 (1H, d, J = 4.8 Hz), 5 .47 (1H, d, J = 4.8 Hz), 4.20 (1H, t, J = 7.2 Hz), 4.13-4.05 (3H, m), 3.95 (1H, br s), 3.11 (3H, s), 2.81-2.41 (7H, m), 2.19 (2H, d, J = 16.9 Hz), 1.58 (3H, d, J = 7.0 Hz), 1.53 (3H, s), 1.51 (3H, s).
[M + H] = 776.25

収量：４８６ｍｇ（６０％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．１８−７．１３ （２Ｈ， ｍ）， ７．００ （１Ｈ， ｓ）， ５．８４ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．４４ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ４．６４ （１Ｈ， ｄ， Ｊ ＝ １４．６ Ｈｚ）， ４．０７ （２Ｈ， ｄｄ， Ｊ ＝ １４．６， ８．２ Ｈｚ）， ３．５７−３．４０ （６Ｈ， ｍ）， ３．３５ （２Ｈ， ｓ）， １．９３ （６Ｈ， ｔ， Ｊ ＝ ７．７ Ｈｚ）， １．５６ （３Ｈ， ｄ， Ｊ ＝ ７．２ Ｈｚ）， １．５２ （３Ｈ， ｓ）， １．５０ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ７７６．２２ Example 72: Synthesis of Compound I-72

Yield: 486 mg (60%)
¹ H-NMR (D ₂ O) δ: 7.18-7.13 (2H, m), 7.00 (1H, s), 5.84 (1H, d, J = 4.8 Hz), 5 .44 (1H, d, J = 4.8 Hz), 4.64 (1H, d, J = 14.6 Hz), 4.07 (2H, dd, J = 14.6, 8.2 Hz) , 3.57-3.40 (6H, m), 3.35 (2H, s), 1.93 (6H, t, J = 7.7 Hz), 1.56 (3H, d, J = 7) .2 Hz), 1.52 (3H, s), 1.50 (3H, s).
[M + H] = 776.22

収量：３７９ｍｇ（４５％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．１６ （２Ｈ， ｂｒ ｓ）， ６．９９ （１Ｈ， ｓ）， ５．８３ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．４２ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ４．６２ （１Ｈ， ｄ， Ｊ ＝ １４．４ Ｈｚ）， ４．０８−４．０２ （２Ｈ， ｍ）， ３．５２−３．４０ （８Ｈ， ｍ）， １．９２ （６Ｈ， ｔ， Ｊ ＝ ７．７ Ｈｚ）， １．５４ （３Ｈ， ｄ， Ｊ ＝ ７．２ Ｈｚ）， １．５２ （３Ｈ， ｓ）， １．５０ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ７８４．３２ Example 73: Synthesis of Compound I-73

Yield: 379 mg (45%)
¹ H-NMR (D ₂ O) δ: 7.16 (2H, br s), 6.99 (1H, s), 5.83 (1H, d, J = 4.8 Hz), 5.42 ( 1H, d, J = 4.8 Hz), 4.62 (1H, d, J = 14.4 Hz), 4.08-4.02 (2H, m), 3.52-3.40 (8H M), 1.92 (6H, t, J = 7.7 Hz), 1.54 (3H, d, J = 7.2 Hz), 1.52 (3H, s), 1.50 (3H , S).
[M + H] = 784.32

収量：２０３ｍｇ（２３％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．３３ （１Ｈ， ｄ， Ｊ ＝ ８．７ Ｈｚ）， ７．０２ （１Ｈ， ｄ， Ｊ ＝ ２．４ Ｈｚ）， ６．８９ （１Ｈ， ｄ， Ｊ ＝ ８．７ Ｈｚ）， ５．８０ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．４７ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．０３ （１Ｈ， ｄ， Ｊ ＝ １４．３ Ｈｚ）， ４．２６ （１Ｈ， ｄ， Ｊ ＝ １４．３ Ｈｚ）， ４．０７ （１Ｈ， ｑ， Ｊ ＝ ７．１ Ｈｚ）， ３．９７−３．９０ （１Ｈ， ｍ）， ３．８４−３．７７ （１Ｈ， ｍ）， ３．７０−３．４８ （６Ｈ， ｍ）， ２．２７−２．１８ （４Ｈ， ｂｒ ｍ）， １．５７ （３Ｈ， ｄ， Ｊ ＝ ７．０ Ｈｚ）， １．５２ （３Ｈ， ｓ）， １．５０ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ７９４．３６ Example 74: Synthesis of Compound I-74

Yield: 203 mg (23%)
¹ H-NMR (D ₂ O) δ: 7.33 (1H, d, J = 8.7 Hz), 7.02 (1H, d, J = 2.4 Hz), 6.89 (1H, d , J = 8.7 Hz), 5.80 (1H, d, J = 4.8 Hz), 5.47 (1H, d, J = 4.8 Hz), 5.03 (1H, d, J = 14.3 Hz), 4.26 (1H, d, J = 14.3 Hz), 4.07 (1H, q, J = 7.1 Hz), 3.97-3.90 (1H, m ), 3.84-3.77 (1H, m), 3.70-3.48 (6H, m), 2.27-2.18 (4H, br m), 1.57 (3H, d, J = 7.0 Hz), 1.52 (3H, s), 1.50 (3H, s).
[M + H] = 794.36

収量：４１０ｍｇ（４５％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．４７ （１Ｈ， ｄ， Ｊ ＝ ８．４ Ｈｚ）， ７．００ （１Ｈ， ｂｒ ｓ）， ６．８１ （１Ｈ， ｂｒ ｓ）， ５．８６−５．８３ （１Ｈ， ｂｒ ｍ）， ５．４６ （１Ｈ， ｂｒ ｓ）， ４．８６−４．８３ （１Ｈ， ｂｒ ｍ）， ４．３８−４．３１ （１Ｈ， ｍ）， ４．２４ （１Ｈ， ｂｒ ｓ）， ４．１０−３．５２ （８Ｈ， ｍ）， ２．４１−２．２７ （４Ｈ， ｂｒ ｍ）， １．６０−１．５６ （３Ｈ， ｍ）， １．５２ （３Ｈ， ｂｒ ｓ）， １．４５ （３Ｈ， ｂｒ ｓ）．
［Ｍ＋Ｈ］ ＝ ８０６．３５ Example 75: Synthesis of Compound I-75

Yield: 410 mg (45%)
¹ H-NMR (D ₂ O) δ: 7.47 (1H, d, J = 8.4 Hz), 7.00 (1H, br s), 6.81 (1H, br s), 5.86 -5.83 (1H, brm), 5.46 (1H, brs), 4.86-4.83 (1H, brm), 4.38-4.31 (1H, m), 4. 24 (1H, br s), 4.10-3.52 (8H, m), 2.41-2.27 (4H, br m), 1.60-1.56 (3H, m), 52 (3H, br s), 1.45 (3H, br s).
[M + H] = 806.35

収量：４２４ｍｇ（４８％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．４７ （１Ｈ， ｄ， Ｊ ＝ ８．７ Ｈｚ）， ７．０２ （１Ｈ， ｓ）， ６．８４ （１Ｈ， ｄ， Ｊ ＝ ８．７ Ｈｚ）， ５．８２−５．８１ （１Ｈ， ｂｒ ｍ）， ５．４６−５．４５ （１Ｈ， ｂｒ ｍ）， ５．１７−５．０８ （１Ｈ， ｍ）， ４．３３−４．２３ （２Ｈ， ｍ）， ４．０７−３．５６ （９Ｈ， ｍ）， ２．４８−２．０６ （４Ｈ， ｍ）， １．６０−１．５５ （３Ｈ， ｍ）， １．５３ （３Ｈ， ｓ）， １．５１ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ８０６．３５ Example 76 Synthesis of Compound I-76

Yield: 424 mg (48%)
¹ H-NMR (D ₂ O) δ: 7.47 (1H, d, J = 8.7 Hz), 7.02 (1H, s), 6.84 (1H, d, J = 8.7 Hz) ), 5.82-5.81 (1H, br m), 5.46-5.45 (1H, br m), 5.17-5.08 (1H, m), 4.33-4.23 (2H, m), 4.07-3.56 (9H, m), 2.48-2.06 (4H, m), 1.60-1.55 (3H, m), 1.53 (3H , S), 1.51 (3H, s).
[M + H] = 806.35

収量：１０２ｍｇ（１２％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．１９ （２Ｈ， ｓ）， ７．０２ （１Ｈ， ｓ）， ５．８３ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．４７ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ４．１４−４．０６ （３Ｈ， ｍ）， ３．９９ （１Ｈ， ｂｒ ｓ）， ３．１２ （３Ｈ， ｓ）， ２．９８−２．１４ （１０Ｈ， ｍ）， １．５９ （３Ｈ， ｄ， Ｊ ＝ ７．２ Ｈｚ）， １．５３ （３Ｈ， ｓ）， １．５１ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ７８４．３９ Example 77: Synthesis of Compound I-77

Yield: 102 mg (12%)
¹ H-NMR (D ₂ O) δ: 7.19 (2H, s), 7.02 (1H, s), 5.83 (1H, d, J = 4.8 Hz), 5.47 (1H , D, J = 4.8 Hz), 4.14-4.06 (3H, m), 3.99 (1H, br s), 3.12 (3H, s), 2.98-2.14. (10H, m), 1.59 (3H, d, J = 7.2 Hz), 1.53 (3H, s), 1.51 (3H, s).
[M + H] = 784.39

化合物Ｘ−５（５４３ｍｇ、１．０ｍｍｏｌ）および化合物Ｘ−２ｂ（１．３ｇ、１．０ｍｍｏｌ）を用い、実施例３９と同様にして目的化合物Ｉ−７８を合成した。
収量：２３１ｍｇ（２５％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．２２ （２Ｈ， ｓ）， ７．０３ （１Ｈ， ｓ）， ５．７８ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．４１ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ４．９６ （１Ｈ， ｄｄ， Ｊ ＝ ９．１， ４．２ Ｈｚ）， ４．６７ （１Ｈ， ｔ， Ｊ ＝ １２．９ Ｈｚ）， ４．０６−３．９８ （２Ｈ， ｍ）， ３．５４−３．３３ （８Ｈ， ｍ）， ２．７２−２．６９ （２Ｈ， ｍ）， １．９３ （６Ｈ， ｔ， Ｊ ＝ ７．７ Ｈｚ）， １．５４ （３Ｈ， ｄ， Ｊ ＝ ７．２ Ｈｚ）．
［Ｍ＋Ｈ］ ＝ ８１４．２７ Example 78: Synthesis of Compound I-78

Using Compound X-5 (543 mg, 1.0 mmol) and Compound X-2b (1.3 g, 1.0 mmol) in the same manner as Example 39, the target compound I-78 was synthesized.
Yield: 231 mg (25%)
¹ H-NMR (D ₂ O) δ: 7.22 (2H, s), 7.03 (1H, s), 5.78 (1H, d, J = 4.8 Hz), 5.41 (1H , D, J = 4.8 Hz), 4.96 (1H, dd, J = 9.1, 4.2 Hz), 4.67 (1H, t, J = 12.9 Hz), 4.06 -3.98 (2H, m), 3.54-3.33 (8H, m), 2.72-2.69 (2H, m), 1.93 (6H, t, J = 7.7 Hz ), 1.54 (3H, d, J = 7.2 Hz).
[M + H] = 814.27

  The compounds shown below were obtained from compound X-2b and the corresponding amines as in Example 78.

収量：７５ｍｇ（８％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．２７ （２Ｈ， ｓ）， ７．０８ （１Ｈ， ｓ）， ５．７５ （１Ｈ， ｄ， Ｊ ＝ ４．６ Ｈｚ）， ５．４６ （１Ｈ， ｄ， Ｊ ＝ ４．６ Ｈｚ）， ５．１２ （１Ｈ， ｄ， Ｊ ＝ １４．２ Ｈｚ）， ４．９６ （１Ｈ， ｄｄ， Ｊ ＝ ９．６， ３．８ Ｈｚ）， ４．３１ （１Ｈ， ｄ， Ｊ ＝ １４．２ Ｈｚ）， ４．１３−４．０２ （３Ｈ， ｍ）， ３．６９−３．５１ （６Ｈ， ｍ）， ２．７７−２．６５ （２Ｈ， ｍ）， ２．２２−２．０７ （４Ｈ， ｍ）， １．５８ （３Ｈ， ｄ， Ｊ ＝ ７．０ Ｈｚ）．
［Ｍ＋Ｈ］ ＝ ７８８．２４ Example 79 Synthesis of Compound I-79

Yield: 75 mg (8%)
¹ H-NMR (D ₂ O) δ: 7.27 (2H, s), 7.08 (1H, s), 5.75 (1H, d, J = 4.6 Hz), 5.46 (1H , D, J = 4.6 Hz), 5.12 (1H, d, J = 14.2 Hz), 4.96 (1H, dd, J = 9.6, 3.8 Hz), 4.31 (1H, d, J = 14.2 Hz), 4.13-4.02 (3H, m), 3.69-3.51 (6H, m), 2.77-2.65 (2H, m ), 2.22-2.07 (4H, m), 1.58 (3H, d, J = 7.0 Hz).
[M + H] = 788.24

収量：５９ｍｇ（５％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．２４ （２Ｈ， ｓ）， ７．０７ （１Ｈ， ｓ）， ５．７７ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．４５ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ４．９７ （２Ｈ， ｄｄ， Ｊ ＝ ９．２， ３．９ Ｈｚ）， ４．１０−３．９９ （４Ｈ， ｍ）， ３．１３ （３Ｈ， ｓ）， ３．０３−２．４６ （９Ｈ， ｍ）， ２．２８−２．１２ （２Ｈ， ｍ）， １．５８ （３Ｈ， ｄ， Ｊ ＝ ７．２ Ｈｚ）．
［Ｍ＋Ｈ］ ＝ ８１４．２０ Example 80: Synthesis of Compound I-80

Yield: 59 mg (5%)
¹ H-NMR (D ₂ O) δ: 7.24 (2H, s), 7.07 (1H, s), 5.77 (1H, d, J = 4.8 Hz), 5.45 (1H , D, J = 4.8 Hz), 4.97 (2H, dd, J = 9.2, 3.9 Hz), 4.10-3.99 (4H, m), 3.13 (3H, s), 3.03-2.46 (9H, m), 2.28-2.12 (2H, m), 1.58 (3H, d, J = 7.2 Hz).
[M + H] = 814.20

収量：４２７ｍｇ（４９％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．４４−７．４１ （１Ｈ， ｍ）， ７．３３ （１Ｈ， ｓ）， ７．０１ （１Ｈ， ｓ）， ５．８４ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．４５ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ４．６５ （１Ｈ， ｄ， Ｊ ＝ １４．３ Ｈｚ）， ４．０７ （２Ｈ， ｔ， Ｊ ＝ ６．９ Ｈｚ）， ３．５９−３．４２ （６Ｈ， ｍ）， ３．３７ （２Ｈ， ｓ）， １．９５ （６Ｈ， ｔ， Ｊ ＝ ７．６ Ｈｚ）， １．５６ （３Ｈ， ｄ， Ｊ ＝ ７．０ Ｈｚ）， １．５２ （３Ｈ， ｓ）， １．５１ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ８０４．３ Example 81: Synthesis of Compound I-81

Yield: 427 mg (49%)
¹ H-NMR (D ₂ O) δ: 7.44-7.41 (1H, m), 7.33 (1H, s), 7.01 (1H, s), 5.84 (1H, d, J = 4.8 Hz), 5.45 (1H, d, J = 4.8 Hz), 4.65 (1H, d, J = 14.3 Hz), 4.07 (2H, t, J = 6.9 Hz), 3.59-3.42 (6H, m), 3.37 (2H, s), 1.95 (6H, t, J = 7.6 Hz), 1.56 (3H, d, J = 7.0 Hz), 1.52 (3H, s), 1.51 (3H, s).
[M + H] = 804.3

収量：３２５ｍｇ（５１％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．３３−７．２９ （１Ｈ， ｍ）， ７．２２ （１Ｈ， ｂｒ ｓ）， ７．００ （１Ｈ， ｂｒ ｓ）， ５．８５ （１Ｈ， ｔ， Ｊ ＝ ５．５ Ｈｚ）， ５．４５ （１Ｈ， ｔ， Ｊ ＝ ４．６ Ｈｚ）， ４．３８−４．２７ （１Ｈ， ｍ）， ４．１９−４．０７ （２Ｈ， ｍ）， ３．８８−３．４９ （７Ｈ， ｍ）， ２．４３−２．２７ （４Ｈ， ｍ）， １．６１−１．５６ （３Ｈ， ｍ）， １．５２ （３Ｈ， ｄ， Ｊ ＝ ２．５ Ｈｚ）， １．５０ （３Ｈ， ｄ， Ｊ ＝ １．９ Ｈｚ）．
［Ｍ＋Ｈ］ ＝ ７９０．２６ Example 82 Synthesis of Compound I-82

Yield: 325 mg (51%)
¹ H-NMR (D ₂ O) δ: 7.33-7.29 (1H, m), 7.22 (1H, br s), 7.00 (1H, br s), 5.85 (1H, t, J = 5.5 Hz), 5.45 (1H, t, J = 4.6 Hz), 4.38-4.27 (1H, m), 4.19-4.07 (2H, m ), 3.88-3.49 (7H, m), 2.43-2.27 (4H, m), 1.61-1.56 (3H, m), 1.52 (3H, d, J = 2.5 Hz), 1.50 (3H, d, J = 1.9 Hz).
[M + H] = 790.26

収量：３３３ｍｇ（４０％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．４４−７．４１ （１Ｈ， ｍ）， ７．３４ （１Ｈ， ｓ）， ７．０２ （１Ｈ， ｓ）， ５．８２ （１Ｈ， ｄ， Ｊ ＝ ４．９ Ｈｚ）， ５．４６ （１Ｈ， ｄ， Ｊ ＝ ４．９ Ｈｚ）， ４．２９ （１Ｈ， ｔ， Ｊ ＝ ７．４ Ｈｚ）， ４．１２−４．０４ （３Ｈ， ｍ）， ３．９５ （１Ｈ， ｂｒ ｓ）， ３．１１ （３Ｈ， ｓ）， ２．８７−２．７２ （２Ｈ， ｍ）， ２．５５−２．３２ （４Ｈ， ｍ）， ２．１７ （２Ｈ， ｄ， Ｊ ＝ １６．８ Ｈｚ）， １．５８ （３Ｈ， ｄ， Ｊ ＝ ７．０ Ｈｚ）， １．５３ （３Ｈ， ｓ）， １．５１ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ８０４．３ Example 83: Synthesis of Compound I-83

Yield: 333 mg (40%)
¹ H-NMR (D ₂ O) δ: 7.44-7.41 (1H, m), 7.34 (1H, s), 7.02 (1H, s), 5.82 (1H, d, J = 4.9 Hz), 5.46 (1H, d, J = 4.9 Hz), 4.29 (1H, t, J = 7.4 Hz), 4.12-4.04 (3H, m), 3.95 (1H, br s), 3.11 (3H, s), 2.87-2.72 (2H, m), 2.55-2.32 (4H, m), 2. 17 (2H, d, J = 16.8 Hz), 1.58 (3H, d, J = 7.0 Hz), 1.53 (3H, s), 1.51 (3H, s).
[M + H] = 804.3

収量：３０７ｍｇ（３８％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．５１−７．４８ （１Ｈ， ｍ）， ７．４０ （１Ｈ， ｓ）， ７．０２ （１Ｈ， ｓ）， ５．８０ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．４７ （１Ｈ， ｄ， Ｊ ＝ ４．８ Ｈｚ）， ５．０４ （１Ｈ， ｄ， Ｊ ＝ １４．３ Ｈｚ）， ４．２７ （１Ｈ， ｄ， Ｊ ＝ １４．３ Ｈｚ）， ４．０９ （１Ｈ， ｄｄ， Ｊ ＝ １３．９， ６．８ Ｈｚ）， ３．９７−３．３８ （８Ｈ， ｍ）， ２．２３ （４Ｈ， ｄｄ， Ｊ ＝ １２．４， ７．５ Ｈｚ）， １．５８ （３Ｈ， ｄ， Ｊ ＝ ７．０ Ｈｚ）， １．５２ （３Ｈ， ｓ）， １．５０ （３Ｈ， ｓ）．
［Ｍ＋Ｈ］ ＝ ７７８．２７ Example 84: Synthesis of Compound I-84

Yield: 307 mg (38%)
¹ H-NMR (D ₂ O) δ: 7.51-7.48 (1H, m), 7.40 (1H, s), 7.02 (1H, s), 5.80 (1H, d, J = 4.8 Hz), 5.47 (1H, d, J = 4.8 Hz), 5.04 (1H, d, J = 14.3 Hz), 4.27 (1H, d, J = 14.3 Hz), 4.09 (1H, dd, J = 13.9, 6.8 Hz), 3.97-3.38 (8H, m), 2.23 (4H, dd, J = 12 .4, 7.5 Hz), 1.58 (3H, d, J = 7.0 Hz), 1.52 (3H, s), 1.50 (3H, s).
[M + H] = 778.27

収量：３９５ｍｇ（４９％）
^１Ｈ−ＮＭＲ （Ｄ_２Ｏ） δ：７．３７−７．３３ （１Ｈ， ｍ）， ７．２５ （１Ｈ， ｓ）， ７．０２−７．００ （１Ｈ， ｂｒ ｍ）， ５．８３−５．８１ （１Ｈ， ｂｒ ｍ）， ５．４５ （１Ｈ， ｄ， Ｊ ＝ ４．９ Ｈｚ）， ５．１３ （１Ｈ， ｄｄ， Ｊ ＝ ２２．５， １４．３ Ｈｚ）， ４．３９−４．２６ （２Ｈ， ｍ）， ４．０９−３．５２ （９Ｈ， ｍ）， ２．２６−２．０４ （４Ｈ， ｍ）， １．６０−１．５４ （３Ｈ， ｂｒ ｍ）， １．５２−１．５２ （３Ｈ， ｂｒ ｍ）， １．５０ （３Ｈ， ｂｒ ｓ）．
［Ｍ＋Ｈ］ ＝ ７９０．２６ Example 85: Synthesis of Compound I-85

Yield: 395 mg (49%)
¹ H-NMR (D ₂ O) δ: 7.37-7.33 (1H, m), 7.25 (1H, s), 7.02-7.00 (1H, br m), 5.83 −5.81 (1H, br m), 5.45 (1H, d, J = 4.9 Hz), 5.13 (1H, dd, J = 22.5, 14.3 Hz), 4.39 -4.26 (2H, m), 4.09-3.52 (9H, m), 2.26-2.04 (4H, m), 1.60-1.54 (3H, br m), 1.52-1.52 (3H, br m), 1.50 (3H, br s).
[M + H] = 790.26

Example 86: Synthesis of Compound I-86

Step (1): Compound X-1 + Compound 86a → Compound I-86
To a solution of compound 86a (564 mg, 1.00 mmol) in dimethylformamide (2 mL) at 0 ° C. was added compound X-1 (932 mg, 1.0 mmol) and the resulting solution was stirred at 0 ° C. for 5 hours. . The reaction mixture was slowly added to a 5% salt solution (30 ml) (containing 1.5 g sodium bisulfite) at 0 ° C. The precipitated solid was collected by filtration, washed with water and then suspended in water. This suspension was lyophilized to give compound 86b as an orange solid. The obtained compound 86b was directly used in the next step without purification.

The total amount of the obtained compound 86b was dissolved in dichloromethane (10 mL), and this solution was cooled to −40 ° C. To this was then added anisole (1.1 mL, 10 mmol) and a 2 mol / L aluminum chloride solution (5.00 mL, 10 mmol) in nitromethane sequentially. The resulting product was stirred at 0 ° C. for 30 minutes. The reaction mixture was dissolved in water, 2 mol / L hydrochloric acid aqueous solution, and acetonitrile. The resulting solution was then washed with diisopropyl ether. After adding HP20-SS resin to the aqueous phase, acetonitrile was distilled off under reduced pressure. The resulting mixture was purified by ODS column chromatography. After adding HP20-SS resin to the obtained target compound solution, acetonitrile was distilled off under reduced pressure. The resulting mixture was purified by HP20-SS column chromatography. A 0.2N sodium hydroxide aqueous solution was added to the obtained target compound solution until the pH reached 6.0 as a whole. Thereafter, a piece of dry ice was added thereto. The resulting solution was concentrated under reduced pressure and then lyophilized to obtain Compound I-86 as a yellow powder.
Yield: 472 mg (53%).
¹ H-NMR (D 2 O) δ: 7.00 (1H, s), 6.80 (1H, s), 5.82 (1H, d, J = 4.8 Hz), 5.49 (1H, d , J = 4.8 Hz), 4.99 (1H, d, J = 14.3 Hz), 4.56 (2H, br s), 4.41-4.39 (3H, br m), 4 .14 (1H, br s), 3.73 (1H, br s), 3.52-3.50 (3H, br m), 2.24 (4H, br s), 1.55-1.44 (12H, m).
[M + H] = 805.4

Example 87: Synthesis of Compound I-87

Step (1): Compound X-1 + Compound 87a → Compound I-87
The target compound was synthesized in the same manner as in Example 86, using Compound X-1 (932 mg, 1.0 mmol) and Compound 87a (541 mg, 1.0 mmol).
Yield: 298 mg (35%)
¹ H-NMR (D 2 O) δ: 8.24 (1H, s), 7.48 (2H, d, J = 7.3 Hz), 6.98 (1H, s), 5.82 (1H, d , J = 4.9 Hz), 5.48 (1H, d, J = 4.9 Hz), 4.89 (1H, d, J = 14.3 Hz), 4.46-4.38 (2H) , Br m), 4.23 (1H, d, J = 14.3 Hz), 4.16-4.10 (1H, br m), 3.59 (2H, br s), 3.36 (3H , Br s), 2.22 (4H, d, J = 7.2 Hz), 1.55-1.47 (9H, m), 1.44 (1H, d, J = 5.6 Hz), 1.33-1.32 (2H, br m), 1.11 (2H, br s).
[M + H] = 782.42

Example 88 Synthesis of Compound I-88

Step (1): Compound X-1 + Compound 88a → Compound I-88
The target compound was synthesized in the same manner as in Example 86, using Compound X-1 (533 mg, 0.57 mmol) and Compound 88a (329 mg, 0.57 mmol).
Yield: 136 mg (27%)
¹ H-NMR (D 2 O) δ: 8.19 (1H, s), 7.41 (1H, s), 7.00 (1H, s), 5.83 (1H, d, J = 4.9 Hz) ), 5.49 (1H, d, J = 4.9 Hz), 4.89 (1H, d, J = 14.2 Hz), 4.39 (2H, s), 4.22 (1H, d , J = 14.2 Hz), 4.13 (1H, d, J = 7.0 Hz), 3.56 (2H, s), 3.36 (3H, s), 2.21 (4H, s ), 1.55-1.51 (9H, m), 1.32 (2H, s), 1.07 (2H, s).
[M + H] = 816.21

Example 89: Synthesis of Compound I-89

Step (1): Compound X-1 + Compound 89a → Compound I-89
The target compound was synthesized in the same manner as in Example 86, using Compound X-1 (932 mg, 1 mmol) and Compound 89a (620 mg, 1 mmol).
Yield: 135 mg (14%)
¹ H-NMR (D 2 O) δ: 8.45 (1H, s), 7.00 (1H, s), 6.79 (1H, s), 5.82 (1H, d, J = 4.6 Hz) ), 5.48 (1H, d, J = 4.6 Hz), 5.03 (1H, d, J = 14.4 Hz), 4.33-4.21 (3H, m), 4.07 -3.91 (2H, m), 3.73-3.48 (6H, m), 2.24 (4H, br s), 1.57 (3H, d, J = 7.0 Hz), 1 .51-1.49 (9H, m), 1.42 (3H, t, J = 6.4 Hz).
[M + H] = 782.42

Example 90: Synthesis of Compound I-90

Step (1): Compound X-1 + Compound 90a → Compound I-90
The target compound was synthesized in the same manner as in Example 86, using Compound X-1 (932 mg, 1 mmol) and Compound 90a (632 mg, 1 mmol).
Yield: 234 mg (25%)
¹ H-NMR (D 2 O) δ: 8.36 (1H, s), 7.23 (1H, s), 6.99 (1H, s), 5.83 (1H, d, J = 4.6 Hz) ), 5.48 (1H, d, J = 4.6 Hz), 5.03 (1H, d, J = 14.2 Hz), 4.30 (1H, d, J = 14.2 Hz), 4.06 (1H, br s), 3.90-3.36 (10H, m), 2.24 (4H, br s), 1.58 (3H, d, J = 6.8 Hz), 1 .51 (3H, s), 1.49 (3H, s), 1.44 (1H, d, J = 5.6 Hz), 1.29 (2H, d, J = 6.5 Hz), 1 .03 (2H, br s).
[M + H] = 873.35

Example 91 Synthesis of Compound I-91

Step (1): Compound X-1 + Compound 91a → Compound I-91
The target compound was synthesized in the same manner as in Example 86, using Compound X-1 (932 mg, 1 mmol) and Compound 91a (557 mg, 1 mmol).
Yield: 334 mg (38%)
¹ H-NMR (D 2 O) δ: 8.36 (1H, s), 7.68-7.65 (2H, m), 6.99 (1H, s), 5.83 (1H, d, J = 4.9 Hz), 5.47 (1H, d, J = 4.9 Hz), 4.90 (1H, d, J = 15.2 Hz), 4.56-4.45 (2H, m) , 4.25 (1H, d, J = 13.9 Hz), 3.59 (1H, br s), 3.39-3.36 (3H, br m), 2.26-2.23 (4H , Br m), 1.87 (9H, s), 1.56-1.49 (9H, m).
[M + H] = 798.18.

Example 92 Synthesis of Compound I-92

Step (1): Compound 92a → Compound 92b
To a solution of 92a (4 g, 9.47 mmol) in MeOH (35 ml), O- (4-methoxybenzyl) hydroxylamine (1.45 ml, 9.47 mmol) in MeOH (5 ml) at 0 ° C. under N _2. Was added. The mixture was stirred at 0 ° C. for 1 hour. The mixture was filtered and the filtrate was washed with IPE and Et ₂ O to give compound 92b (3.87 g, 73%, E / Z = 1: 15).
Compound 92b
¹ H-NMR (CDCl 3) δ: 7.34-7.27 (5H, m), 7.05 (1H, dd, J = 8.4, 1.6 Hz), 6.94-6.84 ( 9H, m), 5.16 (2H, s), 5.05 (4H, s), 4.63 (1H, s), 3.81 (3H, s), 3.79 (3H, s), 3.77 (3H, s).

Step (2): Compound 92b → Compound 92c
To a solution of 92b (1.11 g, 2.00 mmol) in DMA (10 ml) at 0 ° C. was added HOBt (0.35 g, 2.60 mmol) and WSCD HCl (0.46 g, 2.40 mmol). The mixture was stirred at 0 ° C. for 1 hour. After adding quinuclidin-4-ylmethanamine (0.33 g, 2.40 mmol) to the reaction mixture at 0 ° C., the mixture was stirred at 0 ° C. overnight. The reaction mixture was diluted with ethyl acetate, washed with aqueous sodium hydroxide, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with hexane / ethyl acetate (containing 10% triethylamine). The objective compound-containing fraction was concentrated under reduced pressure to obtain Compound 92c (0.63 g, 46%, single isomer).
Compound 92c
¹ H-NMR (DMSO-D ₆ ) δ: 8.44-8.41 (1H, br m), 7.36-7.32 (6H, m), 7.24 (1H, d, J = 1) .8 Hz), 7.10 (1H, d, J = 8.5 Hz), 6.98 (1H, dd, J = 8.5, 1.8 Hz), 6.94-6.91 (6H , M), 5.06 (4H, s), 5.00 (2H, s), 3.75 (9H, s), 2.92 (2H, d, J = 6.3 Hz), 2.54 (6H, t, J = 7.7 Hz), 1.19 (6H, t, J = 7.5 Hz).

Step (3): Compound X-24 + Compound 92c → Compound I-92
The target compound was synthesized in the same manner as in Example 86, using Compound X-24 (886 mg, 1 mmol) and Compound 92c (680 mg, 1 mmol).
Yield: 518 mg (60%)
¹ H-NMR (D 2 O) δ: 7.15 (1H, d, J = 1.8 Hz), 7.00-6.94 (3H, m), 5.85 (1H, d, J = 4. 9 Hz), 5.45 (1H, d, J = 4.9 Hz), 4.63 (1H, d, J = 14.3 Hz), 4.08-4.05 (2H, m), 3 .54-3.38 (8H, m), 1.96-1.92 (6H, m), 1.56 (3H, d, J = 7.2 Hz), 1.53 (3H, s), 1.51 (3H, s).
[M + H] = 802.14.

Example 93: Synthesis of Compound I-93

Step (1): Compound 92a → Compound 93a
To a solution of 92a (3 g, 7.10 mmol) in MeOH (30 ml) was added O-4-methylhydroxylammonium chloride (1.54 g, 18.46 mmol) and Et ₃ N (2.75 ml) under N ₂ at 0 ° C. 19.8 mmol) was added. The mixture was stirred at 0 ° C. for 5.5 hours. The mixture was concentrated under reduced pressure. The reaction mixture was diluted with ethyl acetate, washed with aqueous hydrochloric acid, water and saturated salt solution, and dried over magnesium sulfate. After filtering off magnesium sulfate, the liquid was concentrated under reduced pressure to obtain crude compound 93a (3.21 g).

Step (2): Compound 93a → Compound 93b
To a solution of 93a (3.21 g, 7.10 mmol) in DMA (20 ml) at 0 ° C. was added HOBt (1.24 g, 9.23 mmol) and WSCD HCl (1.63 g, 8.52 mmol). The mixture was stirred at 0 ° C. for 1 hour. After adding quinuclidin-4-ylmethanamine (1.19 g, 8.52 mmol) to the reaction mixture at 0 ° C., the mixture was stirred at 0 ° C. for 1 hour. The reaction mixture was diluted with ethyl acetate, washed with aqueous sodium hydroxide, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with hexane / ethyl acetate (containing 10% triethylamine). The target compound-containing fraction was concentrated under reduced pressure to obtain Compound 93b (1.59 g, 39%, E / Z = 1: 4).
Compound 93b
¹ H-NMR (DMSO-D6) δ: 8.46-8.43 (1H, m), 7.40-7.32 (4H, m), 7.27-7.24 (1H, m), 7.13-7.11 (1H, m), 7.01 (1H, dd, J = 8.4, 1.9 Hz), 6.96-6.92 (4H, m), 5.07 ( 2H, s), 4.99 (2H, s), 3.87 (2H, s), 3.76-3.75 (6H, br m), 3.01-2.97 (2H, m), 2.61-2.68 (6H, m), 1.32-1.29 (6H, m).

Step (3): Compound X-24 + Compound 93b → Compound I-93
The target compound was synthesized in the same manner as in Example 86, using Compound X-24 (886 mg, 1 mmol) and Compound 93b (680 mg, 1 mmol).
Yield: 518 mg (60%)
¹ H-NMR (D 2 O) δ: 7.17 (1H, s), 7.01-6.95 (3H, m), 5.85 (1H, d, J = 4.8 Hz), 5.46 (1H, d, J = 4.8 Hz), 4.64 (1H, d, J = 14.2 Hz), 4.09-4.06 (2H, m), 3.98 (3H, s) 3.55-3.45 (6H, m), 3.38 (2H, br s), 1.95-1.91 (6H, m), 1.57 (3H, d, J = 7.0). Hz), 1.52 (3H, s), 1.50 (3H, s).
[M + H] = 815.22.

Examples 94 and 95: Synthesis of compounds I-94 and I-95

Step (1): Compound 94a → Compound 94b
To a solution of 94a (4 g, 8.76 mmol) in MeOH (40 ml) was added O- (4-methoxybenzyl) hydroxylamine (2.09 g, 9.63 mmol) under N ₂ at 0 ° C. The mixture was stirred at 0 ° C. for 1 hour. The mixture was concentrated under reduced pressure. The reaction mixture was diluted with ethyl acetate, washed with aqueous hydrochloric acid, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure to obtain crude compound 94b (5.02 g, 8.76 mmol, E / Z = 1: 1.5).

Step (2): Compound 94b → Compounds 94c and 94d
To a solution of 94b (1.77 g, 3 mmol) in DMA (10 ml) at 0 ° C. was added HOBt (0.52 g, 3.90 mmol) and WSCD HCl (0.69 g, 3.60 mmol). The mixture was stirred at 0 ° C. for 1 hour. After adding quinuclidin-4-ylmethanamine (0.50 g, 3.60 mmol) to the reaction mixture at 0 ° C., the mixture was stirred at 0 ° C. for 1 hour. The reaction mixture was diluted with ethyl acetate, washed with aqueous sodium hydroxide, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with hexane / ethyl acetate (containing 10% triethylamine). Fractions containing the desired compound were concentrated under reduced pressure to give compound 94c (0.88 g, 41%, E / Z = 1: 10) and compound 94d (0.61.29%, E / Z = 4.5: 1). )
Compound 94c
¹ H-NMR (DMSO-D6) δ: 8.35 (1H, t, J = 6.3 Hz), 7.45 (2H, d, J = 7.2 Hz), 7.39 (2H, d , J = 8.5 Hz), 7.30 (2H, d, J = 8.6 Hz), 7.25-7.18 (2H, m), 6.97 (4H, dd, J = 11. 7, 8.7 Hz), 6.86 (2H, d, J = 31.6 Hz), 5.16 (2H, s), 5.10 (2H, s), 4.87 (2H, s) , 3.78 (3H, s), 3.76 (3H, s), 3.75 (3H, s), 2.91 (2H, d, J = 6.3 Hz), 2.58-2. 54 (6H, m), 1.21-1.14 (6H, m).
Compound 94d
¹ H-NMR (DMSO-D6) δ: 7.98 (1H, t, J = 6.3 Hz), 7.43 (2H, d, J = 8.2 Hz), 7.31-7.24 (4H, m), 7.18 (2H, d, J = 7.4 Hz), 6.98 (2H, d, J = 8.5 Hz), 6.90 (2H, d, J = 8. 5 Hz), 6.85 (2H, d, J = 8.2 Hz), 5.13 (2H, s), 5.11 (2H, s), 4.85 (2H, s), 3.77. (3H, s), 3.74 (6H, s), 2.96 (2H, d, J = 6.3 Hz), 2.73-2.70 (6H, m), 1.30-1. 26 (6H, m).

Step (3): Compound X-24 + Compound 94c → Compound I-94
The target compound was synthesized in the same manner as in Example 86 using Compound X-24 (754 mg, 0.85 mmol) and Compound 94c (608 mg, 0.85 mmol).
Yield: 410 mg (55%)
¹ H-NMR (D 2 O) δ: 7.00 (1H, s), 6.97-6.90 (2H, m), 5.85 (1H, d, J = 4.8 Hz), 5.45 (1H, d, J = 4.8 Hz), 4.62 (1H, d, J = 14.3 Hz), 4.09-4.04 (2H, m), 3.52-3.30 ( 8H, m), 1.93-1.90 (6H, m), 1.56 (3H, d, J = 7.3 Hz), 1.52 (3H, s), 1.50 (3H, s ).
[M + H] = 835.24.

Step (4): Compound X-24 + Compound 94d → Compound I-95
The compound of interest was synthesized in the same manner as in Example 86, using Compound X-24 (886 mg, 1 mmol) and Compound 94d (714 mg, 1 mmol).
Yield: 403 mg (46%)
¹ H-NMR (D 2 O) δ: 7.00 (1H, s), 6.97-6.90 (1H, m), 6.78 (1H, d, J = 8.3 Hz), 5.85 (1H, d, J = 4.8 Hz), 5.45-5.42 (1H, m), 4.64-4.59 (2H, m), 4.07-3.97 (2H, m ), 3.52-3.30 (8H, m), 1.94-1.87 (6H, m), 1.57-1.51 (9H, m).
[M + H] = 835.21

Example 96 Synthesis of Compound I-96

Step (1): Compound 94a → Compound 96a
To a solution of 94a (6 g, 13.1 mmol) in MeOH (60 ml) was added O-4-methylhydroxylammonium chloride (1.64 g, 19.7 mmol) and Et ₃ N (2.73 ml) under N ₂ at 0 ° C. 19.7 mmol). The mixture was stirred at 0 ° C. for 1.5 hours. The mixture was concentrated under reduced pressure. The reaction mixture was diluted with ethyl acetate, washed with aqueous hydrochloric acid, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure to obtain crude compound 96a (6.38 g, E / Z = 1: 2.5).

Step (2): Compound 96a → Compound 96b
To a solution of 96a (6.38 g, 13.1 mmol) in DMA (50 ml) at 0 ° C. was added HOBt (2.3 g, 17.0 mmol) and WSCD HCl (3.02 g, 17.7 mmol). The mixture was stirred at 0 ° C. for 1 hour. After adding quinuclidin-4-ylmethanamine (2.2 g, 15.7 mmol) to the reaction mixture at 0 ° C., the mixture was stirred at 0 ° C. for 1 hour. The reaction mixture was diluted with ethyl acetate, washed with aqueous sodium hydroxide, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The residue was recrystallized with hexane / ethyl acetate / a small amount of methanol to give compound 96b (0.56 g, 7%, single isomer).
Compound 96b
¹ H-NMR (DMSO-D6) δ: 8.35 (1H, t, J = 6.3 Hz), 7.44 (2H, d, J = 8.5 Hz), 7.29 (2H, d , J = 8.5 Hz), 7.23 (1H, d, J = 8.9 Hz), 7.20 (1H, d, J = 8.9 Hz), 6.98 (2H, d, J = 8.5 Hz), 6.86 (2H, d, J = 8.5 Hz), 5.15 (2H, s), 4.87 (2H, s), 3.90 (3H, s), 3.77 (3H, s), 3.74 (3H, s), 2.94 (2H, d, J = 6.3 Hz), 2.71-2.67 (6H, m), 1.30 -1.26 (6H, m).

Step (3): Compound X-24 + Compound 96b → Compound I-96
The target compound was synthesized in the same manner as in Example 86, using Compound X-24 (743 mg, 0.84 mmol) and Compound 96b (510 mg, 0.84 mmol).
Yield: 226 mg (28%)
¹ H-NMR (D 2 O) δ: 7.01 (1H, s), 6.97 (1H, d, J = 8.4 Hz), 6.91 (1H, d, J = 8.4 Hz), 5.85 (1H, d, J = 4.8 Hz), 5.45 (1H, d, J = 4.8 Hz), 4.63 (1H, d, J = 14.7 Hz), 4. 09-4.00 (5H, m), 3.53-3.43 (6H, m), 3.33 (2H, s), 1.92-1.88 (6H, m), 1.54 ( 3H, d, J = 7.3 Hz), 1.52 (3H, s), 1.50 (3H, s).
[M + H] = 849.25

Example 97 Synthesis of Compound I-97

Step (1): Compound X-24 + Compound 97a → Compound I-97
The target compound was synthesized in the same manner as in Example 86 using Compound X-24 (7.40 g, 8.37 mmol) and Compound 97a (5.56 g, 8.37 mmol).
Yield: 1.81 g (26%)
¹ H-NMR (D 2 O) δ: 7.98 (1H, s), 6.97 (1H, s), 6.62 (1H, s), 5.82 (1H, d, J = 4.5 Hz) ), 5.50 (1H, d, J = 4.5 Hz), 4.90 (1H, d, J = 14.4 Hz), 4.36 (2H, s), 4.21-4.12. (2H, m), 3.56 (1H, br s), 3.36 (3H, br s), 2.24-2.21 (4H, br m), 1.54 (3H, d, J = 7.7 Hz), 1.51 (3H, s), 1.49 (3H, s).
[M + H] = 776.18

Example 98: Synthesis of Compound I-98

Step (1): Compound 94a + → Compound 98a
To a solution of 94a (1.37 g, 3 mmol) in MeOH (6 ml) was added tert-butyl 2- (aminooxy) acetate (0.44 g, 3 mmol) under N ₂ at 0 ° C. The mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure. The reaction mixture was diluted with ethyl acetate, washed with aqueous hydrochloric acid, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The residue was recrystallized from dichloromethane / diisopropyl ether to give compound 98a (0.90 g, 51%, single isomer).
Compound 98a
¹ H-NMR (CDCl 3) δ: 7.34 (4H, d, J = 8.4 Hz), 7.23 (1H, d, J = 8.5 Hz), 6.92 (3H, dd, J = 8.4, 5.1 Hz), 6.83 (2H, d, J = 8.5 Hz), 5.08 (2H, s), 4.95 (2H, s), 4.73 (2H) , S), 3.83 (3H, s), 3.80 (3H, s), 1.51 (9H, s).

Step (2): Compound 98a → Compound 98b
Compound 98a (0.87 g, 1.49 mmol) and triethylamine (0.29 ml, 2.09 mmol) were dissolved in dimethylacetamide (6 mL), which was then dissolved in methanesulfonyl chloride (0.15 ml, 1.94 mmol) at −20 ° C. ) Was added. The mixture was stirred at −20 ° C. for 30 minutes. To this was then added quinuclidin-4-ylmethanamine (0.23 g, 1.64 mmol) at 0 ° C. The mixture was stirred at 0 ° C. for 1 hour. The reaction mixture was diluted with ethyl acetate, washed with aqueous sodium hydroxide, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with hexane / ethyl acetate (containing 10% triethylamine). The target compound-containing fraction was concentrated under reduced pressure to give compound 98b (0.72 g, 69%).
Compound 98b
¹ H-NMR (DMSO-D6) δ: 8.20 (1H, t, J = 6.1 Hz), 7.44 (2H, d, J = 8.5 Hz), 7.29 (2H, d , J = 8.5 Hz), 7.24 (2H, d, J = 7.5 Hz), 7.17 (2H, d, J = 7.5 Hz), 6.98 (2H, d, J = 8.5 Hz), 6.86 (2H, d, J = 8.5 Hz), 5.16 (2H, s), 4.87 (2H, s), 4.69 (2H, s), 3.77 (3H, s), 3.74 (3H, s), 2.99 (2H, d, J = 6.3 Hz), 2.72-2.68 (6H, m), 1.45 (9H, s), 1.33-1.29 (6H, m).

Step (3): Compound X-24 + Compound 98b → Compound I-98
The target compound was synthesized in the same manner as in Example 86, using Compound X-24 (886 mg, 1 mmol) and Compound 98b (708 mg, 1 mmol).
Yield: 567 mg (59%)
¹ H-NMR (D 2 O) δ: 7.01-6.99 (2H, m), 6.94-6.91 (1H, m), 5.85 (1H, d, J = 4.8 Hz) 5.46 (1H, d, J = 4.8 Hz), 4.65-4.62 (3H, m), 4.11-4.05 (2H, m), 3.53-3.37 (9H, m), 1.95-1.91 (6H, m), 1.56 (3H, d, J = 7.0 Hz), 1.52 (3H, s), 1.50 (3H, s).
[M + H] = 893.23

Example 99: Synthesis of Compound I-99

Step (1): Compound 94a → Compound 99a
To a solution of tert-butyl 2- (aminooxy) -2-methylpropanoate (5.25 g, 30 mmol) in MeOH (60 ml) was added 94a (9.16 g, 30 mmol) under N ₂ at 0 ° C. . The mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure. The reaction mixture was diluted with ethyl acetate, washed with aqueous hydrochloric acid, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The residue was recrystallized from dichloromethane / diisopropyl ether to obtain crude compound 99a (16 g, 87%, E / Z = 1: 1.5).

Step (2): Compound 99a → Compound 99b
To a solution of 99a (1.6 g, 2.61 mmol) in ethyl acetate (16 ml) at 0 ° C. was added WSCD HCl (0.55 g, 2.87 mmol) and DMAP (0.03 g, 0.26 mmol) and 2- (Trimethylsilyl) ethanol (0.43 ml, 2.87 mmol) was added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with ethyl acetate, washed with aqueous hydrochloric acid, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted from hexane / ethyl acetate with chloroform / methanol. The objective compound-containing fraction was concentrated under reduced pressure to obtain Compound 99b (1.23 g, 66%, E / Z = 1: 10).
Compound 99b
¹ H-NMR (CDCl 3) δ: 7.36 (4H, dd, J = 8.5, 3.8 Hz), 7.07 (1H, d, J = 8.5 Hz), 6.93 (3H , T, J = 6.8 Hz), 6.83 (2H, d, J = 8.5 Hz), 5.06 (2H, s), 4.97 (2H, s), 4.33 (2H) , T, J = 8.2 Hz), 3.84 (3H, s), 3.80 (3H, s), 1.47 (9H, s), 1.03 (2H, t, J = 8. 2 Hz), 0.02 (9H, s).

Step (3): Compound 99b → Compound 99c
To a solution of 99b (1.42 g, 2 mmol) in THF (14 ml) at 0 ° C. was added 1M TBAF in THF (4 ml, 4 mmol). The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with ethyl acetate, washed with aqueous hydrochloric acid, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure to obtain Compound 99c (1.22 g).
Compound 99c
¹ H-NMR (CDCl 3) δ: 7.37-7.33 (4H, m), 6.97 (2H, br s), 6.93 (2H, d, J = 8.6 Hz), 6. 83 (2H, d, J = 8.6 Hz), 5.07 (2H, s), 4.99 (2H, s), 3.84 (3H, s), 3.80 (3H, s), 1.50 (6H, s), 1.47 (9H, s).

Step (4): Compound 99c → Compound 99d
Compound 99c (1.22 g, 2 mmol) and triethylamine (0.38 ml, 2.80 mmol) were dissolved in dimethylacetamide (13 mL), and then methanesulfonyl chloride (0.20 ml, 2.60 mmol) was added to this at −20 ° C. added. The mixture was stirred at −20 ° C. for 30 minutes. To this was then added quinuclidin-4-ylmethanamine (0.31 g, 2.20 mmol) at 0 ° C. The mixture was stirred at 0 ° C. for 1 hour. The reaction mixture was diluted with ethyl acetate, washed with aqueous sodium hydroxide, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether to obtain Compound 99d (1.01 g, 51%, E / Z = 1: 10).
Compound 99d
¹ H-NMR (DMSO-D6) δ: 7.73 (1H, t, J = 6.5 Hz), 7.45 (2H, d, J = 8.2 Hz), 7.29 (2H, d , J = 8.2 Hz), 7.24 (1H, d, J = 8.5 Hz), 7.06 (1H, d, J = 8.5 Hz), 6.99 (2H, d, J = 8.2 Hz), 6.85 (2H, d, J = 8.2 Hz), 5.15 (2H, s), 4.88 (2H, s), 3.78 (3H, s), 3.74 (3H, s), 2.96 (2H, d, J = 6.4 Hz), 2.71-2.68 (6H, m), 1.42 (15H, s), 1.29 -1.25 (6H, m).

Step (5): Compound X-24 + Compound 99d → Compound I-99
The target compound was synthesized in the same manner as in Example 86, using Compound X-24 (901 mg, 1.02 mmol) and Compound 99d (749 mg, 1.02 mmol).
Yield: 431 mg (45%)
¹ H-NMR (D 2 O) δ: 7.01 (1H, s), 6.95 (1H, d, J = 8.3 Hz), 6.88 (1H, d, J = 8.3 Hz), 5.85 (1H, d, J = 4.6 Hz), 5.46 (1H, d, J = 4.6 Hz), 4.63 (1H, d, J = 13.9 Hz), 4. 09-4.04 (2H, m), 3.52-3.37 (6H, m), 3.30 (2H, br s), 1.92-1.89 (6H, m), 1.56 (3H, d, J = 6.9 Hz), 1.52 (3H, s), 1.50 (3H, s), 1.44 (6H, s).
[M + H] = 921.46

Example 100: Synthesis of Compound I-100

Step (1): Compound 100a + Compound 100b → Compound 100c
To a solution of 100b (28.9 g, 53 mmol) in THF (250 ml) at 0 ° C. was added 100a (6.69 g, 53 mmol) in THF (50 ml). The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with ethyl acetate, washed with aqueous sodium hydroxide, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether to obtain Compound 100c (24.1 g, 85%).
Compound 100c
¹ H-NMR (DMSO-D6) δ: 8.40 (1H, t, J = 6.0 Hz), 7.43 (2H, d, J = 8.5 Hz), 7.33 (2H, d , J = 8.5 Hz), 7.19 (1H, d, J = 8.7 Hz), 7.13 (1H, d, J = 8.7 Hz), 6.98 (2H, d, J = 8.5 Hz), 6.89 (2H, d, J = 8.5 Hz), 5.16 (2H, s), 4.89 (2H, s), 3.78 (3H, s), 3.76 (3H, s), 3.53 (2H, d, J = 6.0 Hz), 2.85-2.78 (2H, m), 2.57-2.54 (2H, m) , 2.25 (2H, s), 1.62-1.57 (2H, m), 1.24-1.18 (2H, m).

Step (2): Compound X-24 + Compound 100c → Compound I-100
The target compound was synthesized in the same manner as in Example 86, using Compound X-24 (886 mg, 1 mmol) and Compound 100c (537 mg, 1 mmol).
Yield: 500 mg (63%)
¹ H-NMR (D 2 O) δ: 7.01 (1H, s), 6.95 (1H, d, J = 8.4 Hz), 6.89 (1H, d, J = 8.4 Hz), 5.82 (1H, d, J = 4.8 Hz), 5.45 (1H, d, J = 4.8 Hz), 4.92 (1H, d, J = 14.6 Hz), 4. 28 (1H, d, J = 14.6 Hz), 4.07-4.02 (1H, m), 3.71-3.56 (6H, m), 3.44-3.42 (1H, br m), 3.35-3.33 (1H, br m), 2.24 (2H, br s), 2.01 (2H, br s), 1.57 (3H, d, J = 7. 2 Hz), 1.52 (3H, s), 1.50 (3H, s).
[M + H] = 778.19

Example 101: Synthesis of Compound I-101

Step (1): Compound 100a + Compound 98a → Compound 101a
Using Compound 98a (1.17 g, 2 mmol), Compound 101a was synthesized in the same manner as in Step (2) of Example 98.
Yield: 1.15 g (82%)
Compound 101a
¹ H-NMR (DMSO-D6) δ: 8.41 (1H, t, J = 6.1 Hz), 7.43 (2H, d, J = 8.4 Hz), 7.29 (2H, d , J = 8.4 Hz), 7.25 (2H, d, J = 8.9 Hz), 7.17 (2H, d, J = 8.9 Hz), 6.98 (2H, d, J = 8.5 Hz), 6.86 (2H, d, J = 8.5 Hz), 5.16 (2H, s), 4.88 (2H, s), 4.66 (2H, s), 3.77 (3H, s), 3.74 (3H, s), 3.54 (2H, d, J = 6.0 Hz), 2.79-2.73 (2H, m), 2.51 -2.49 (2H, m), 2.18 (2H, s), 1.60-1.52 (2H, m), 1.44 (9H, s), 1.18-1.12 2H, m).

Step (2): Compound X-24 + Compound 101a → Compound I-101
The target compound was synthesized in the same manner as in Example 86, using Compound X-24 (1 g, 1.14 mmol) and Compound 101a (788 mg, 1.14 mmol).
Yield: 453 mg (43%)
¹ H-NMR (D 2 O) δ: 7.02-6.99 (2H, m), 6.93 (1H, d, J = 8.4 Hz), 5.83 (1H, d, J = 4. 8 Hz), 5.47 (1H, d, J = 4.8 Hz), 4.89 (1H, d, J = 14.4 Hz), 4.62 (2H, s), 4.25 (1H) , D, J = 14.4 Hz), 3.97-3.92 (1H, m), 3.77-3.50 (6H, m), 3.37 (1H, d, J = 8.4) Hz), 3.24 (1H, d, J = 8.4 Hz), 2.22 (2H, br s), 1.98 (2H, br s), 1.54-1.51 (9H, m ).
Elemental analysis: C35H37ClN8Na2O13S2 (H2O) 8.6
Theoretical: C, 38.99; H, 5.07; N, 10.39; S, 5.95; Na, 4.26; Cl, 3.29 (%)
Measurements: C, 38.88; H, 4.94; N, 10.53; S, 5.95; Na, 4.40; Cl, 3.57 (%)

Examples 102 and 103: Synthesis of compounds I-102 and I-103

Step (1): Compound 100a + Compound 94b → Compounds 102a and 102b
Compound 94b (5.76 g, 9.73 mmol) and triethylamine (1.88 ml, 13.6 mmol) were dissolved in dimethylacetamide (35 mL), which was then dissolved in methanesulfonyl chloride (0.98 ml, 12.6 mmol) at −20 ° C. ) Was added. The mixture was stirred at −20 ° C. for 30 minutes. To this was then added compound 100a (1.35 g, 10.7 mmol) in DMA (5 ml) at 0 ° C. The mixture was stirred at 0 ° C. for 1 hour. The reaction mixture was diluted with ethyl acetate, washed with aqueous sodium hydroxide, water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The precipitated solid was then collected by filtration and washed with ethyl acetate to give compound 102a (3.2 g, 47%, single isomer). The residue was subjected to silica gel column chromatography, and the target compound was eluted with ethyl acetate / methanol (containing 10% triethylamine). The objective compound-containing fraction was concentrated under reduced pressure to obtain Compound 102b (2 g, 29%, E / Z = 10: 1).
Compound 102a
¹ H-NMR (DMSO-D6) δ: 8.51 (1H, t, J = 6.1 Hz), 7.44 (2H, d, J = 8.5 Hz), 7.35 (2H, d , J = 8.5 Hz), 7.28 (2H, t, J = 8.5 Hz), 7.23 (1H, d, J = 8.8 Hz), 7.18 (1H, d, J = 8.8 Hz), 6.98 (2H, d, J = 8.5 Hz), 6.93 (2H, d, J = 8.5 Hz), 6.86 (2H, d, J = 8 .5 Hz), 5.15 (2H, s), 5.08 (2H, s), 4.87 (2H, s), 3.77 (3H, s), 3.76 (3H, s), 3.75 (3H, s), 3.45 (2H, d, J = 6.1 Hz), 2.59-2.52 (2H, m), 2.31 (2H, br s) 2.03 (2H, br s), 1.44-1.38 (2H, m), 1.01-0.95 (2H, m).
Compound 102b
¹ H-NMR (DMSO-D6) δ: 8.26 (1H, t, J = 6.3 Hz), 7.43 (2H, d, J = 8.5 Hz), 7.30 (2H, d , J = 8.5 Hz), 7.24 (2H, d, J = 7.7 Hz), 7.17 (2H, d, J = 7.7 Hz), 6.97 (2H, d, J = 8.6 Hz), 6.90 (2H, dd, J = 8.6, 1.9 Hz), 6.85 (2H, d, J = 8.5 Hz), 5.12 (2H, s ), 5.11 (2H, s), 4.86 (2H, s), 3.77 (3H, s), 3.74 (6H, s), 3.50 (2H, d, J = 6. 3 Hz), 2.76-2.72 (2H, m), 2.43-2.40 (2H, m), 1.54-1.48 (2H, m), 1.19-1. 1 (2H, m).

Step (2): Compound X-24 + Compound 102a → Compound I-102
The target compound was synthesized in the same manner as E using Compound X-24 (886 mg, 1 mmol) and Compound 102a (700 mg, 1 mmol).
Yield: 432 mg (51%)
¹ H-NMR (D 2 O) δ: 7.02 (1H, s), 6.94 (2H, dd, J = 14.4, 8.3 Hz), 5.82 (1H, d, J = 4. 9 Hz), 5.46 (1H, d, J = 4.9 Hz), 4.90 (1H, d, J = 14.6 Hz), 4.24 (1H, d, J = 14.6 Hz). ), 3.96-3.91 (1H, m), 3.75-3.51 (6H, m), 3.36 (1H, d, J = 8.4 Hz), 3.23 (1H, d, J = 8.4 Hz), 2.20 (2H, s), 1.96 (2H, s), 1.54-1.51 (9H, m).
Elemental analysis: C33H36ClN8NaO11S2 (H2O) 6.7
Theoretical values: C, 41.12; H, 5.17; N, 11.62; S, 6.65; Na, 2.38; Cl, 3.68 (%)
Measurements: C, 41.02; H, 5.10; N, 11.69; S, 6.67; Na, 2.52; Cl, 3.83 (%)

Step (3): Compound X-24 + Compound 102b → Compound I-103
The target compound was synthesized in the same manner as in Example 86 using Compound X-24 (886 mg, 1 mmol) and Compound 102b (700 mg, 1 mmol).
Yield: 365 mg (43%)
¹ H-NMR (D 2 O) δ: 7.02 (1H, s), 6.96 (1H, d, J = 12.3 Hz), 6.80 (1H, d, J = 8.4 Hz), 5.82 (1H, d, J = 4.8 Hz), 5.48 (1H, d, J = 4.8 Hz), 4.89 (1H, d, J = 14.6 Hz), 4. 24 (1H, d, J = 14.6 Hz), 3.99-3.92 (1H, m), 3.75-3.52 (6H, m), 3.34 (1H, d, J = 8.5 Hz), 3.22 (1H, d, J = 8.5 Hz), 2.18 (2H, br s), 1.95 (2H, br s), 1.54-1.51 ( 9H, m).
Elemental analysis: C33H36ClN8NaO11S2 (H2O) 6.7 (NaHCO3) 0.1
Theoretical value: C, 40.89; H, 5.13; N, 11.52; S, 6.59; Na, 2.60; Cl, 3.65 (%)
Measurements: C, 40.70; H, 5.21; N, 11.60; S, 6.58; Na, 2.60; Cl, 3.84 (%)

Examples 104 and 105: Synthesis of compounds I-104 and I-105

Step (1): Compound 100a + Compound 96a → Compound 104a
The target compound was synthesized in the same manner as in Step (1) of Example 102 using Compound 96b (1.38 g, 11 mmol).
Yield: 3 g (50%, E / Z = 1: 1.5)
Compound 104a
¹ H-NMR (DMSO-D6) δ: 8.58 (1H, t, J = 6.0 Hz), 8.33 (1H, t, J = 6.0 Hz), 7.44 (4H, d , J = 7.7 Hz), 7.30 (4H, d, J = 7.2 Hz), 7.25-7.14 (4H, m), 6.98 (4H, d, J = 8. 3 Hz), 6.86 (4H, d, J = 8.3 Hz), 5.15 (4H, s), 4.88 (4H, s), 3.91 (3H, s), 3.90 (3H, s), 3.77 (6H, s), 3.74 (6H, s), 2.78-2.73 (4H, m), 2.47-2.42 (2H, m), 2.30 (2H, s), 2.16 (4H, s), 1.56-1.51 (4H, m), 1.18-1.13 (4H, m).

Step (2): Compound X-24 + Compound 104a → Compounds I-104 and I-105
The target compound was synthesized in the same manner as in Example 86, using Compound X-24 (969 mg, 1.1 mmol) and Compound 104a (650 mg, 1.1 mmol).
Yield of I-104: 140 mg (15%)
Compound 1-104
¹ H-NMR (D 2 O) δ: 7.02 (1H, s), 6.92 (2H, dd, J = 20.5, 6.0 Hz), 5.83 (1H, d, J = 4. 8 Hz), 5.46 (1H, d, J = 4.8 Hz), 4.90 (1H, d, J = 14.3 Hz), 4.25 (1H, d, J = 14.3 Hz). ), 4.03 (3H, s), 3.96-3.91 (1H, m), 3.72-3.53 (6H, m), 3.33 (1H, d, J = 8.5) Hz), 3.21 (1H, d, J = 8.5 Hz), 2.18 (2H, s), 1.96 (2H, s), 1.54-1.51 (9H, m).
Elemental analysis: C34H38ClN8NaO11S2 (H2O) 7.1 (NaHCO3) 0.2
Theoretical values: C, 41.00; H, 5.27; N, 11.18; S, 6.40; Na, 2.75; Cl, 3.54 (%)
Measurements: C, 40.69; H, 5.23; N, 11.48; S, 6.36; Na, 2.99; Cl, 3.51 (%)
Yield of I-105: 180 mg (19%)
Compound I-105
¹ H-NMR (D 2 O) δ: 7.02 (1H, s), 6.95 (1H, d, J = 8.4 Hz), 6.80 (1H, d, J = 8.4 Hz), 5.82 (1H, d, J = 4.8 Hz), 5.48 (1H, d, J = 4.8 Hz), 4.90 (1H, d, J = 14.4 Hz), 4. 24 (1H, d, J = 14.4 Hz), 4.03-3.95 (4H, m), 3.69-3.52 (6H, m), 3.35 (1H, d, J = 8.7 Hz), 3.22 (1H, d, J = 8.7 Hz), 2.18 (2H, s), 1.95 (2H, s), 1.55-1.51 (9H, m).
Elemental analysis: C34H38ClN8NaO11S2 (H2O) 6.8
Theoretical values: C, 41.68; H, 5.31; N, 11.44; S, 6.54; Na, 2.35; Cl, 3.62 (%)
Measurements: C, 41.46; H, 5.24; N, 11.61; S, 6.80; Na, 2.49; Cl, 3.60 (%)

Example 106: Synthesis of Compound I-106

Step (1): Compound X-1 + Compound 106a → Compound I-106
The target compound was synthesized in the same manner as in Example 86, using Compound X-1 (1.32 g, 1.32 mmol) and Compound 106a (720 mg, 1.32 mmol).
Yield: 510 mg (47%)
¹ H-NMR (D 2 O) δ: 8.26 (1H, s), 7.62 (1H, s), 7.30 (1H, s), 6.99 (1H, s), 5.83 (1H , D, J = 4.9 Hz), 5.48 (1H, d, J = 4.9 Hz), 5.01 (1H, t, J = 6.6 Hz), 4.89 (1H, d , J = 14.3 Hz), 4.54-4.47 (2H, m), 4.26 (1H, d, J = 14.3 Hz), 4.16-4.10 (1H, m) , 3.59 (1H, s), 2.6-2.23 (4H, m), 1.58 (6H, t, J = 6.6 Hz), 1.53-1.49 (9H, m ).
[M + H] = 873.35

Example 107: Synthesis of Compound I-107

Step (1): Compound 107a → Compound 107b
Compound 107a (15.0 g, 99 mmol) was dissolved in dimethylacetamide (150 mL), then potassium carbonate (40.9 g, 296 mmol), p-methoxybenzyl chloride (32.2 ml, 237 mmol) and sodium iodide (14 .78 g, 99 mmol) was added sequentially. The mixture was stirred at 50 ° C. for 1.5 hours. The reaction mixture was poured into water. Next, the precipitated solid was collected by filtration and washed with water and diisopropyl ether. Thus, compound 107c was obtained (35.58 g 92%).
¹ H-NMR (CDCl ₃ ) δ: 7.60 (1H, s), 7.52 (1H, d, J = 8.4 Hz), 7.36 (4H, m), 6.93-6. 89 (5H, m), 5.15 (2H, s), 5.11 (2H, s), 3.81 (6H, s), 2.51 (3H, s).

Step (2): Compound 107b → Compound 107c
Compound 107b (35.58 g, 91 mmol) was dissolved in pyridine (360 mL), and then selenium dioxide (25.1 g, 227 mmol) was added thereto. The mixture was stirred at 80 ° C. for 1 day. The reaction mixture was filtered and evaporated. The residue was diluted with aqueous hydrochloric acid and ethyl acetate, then separated, washed with water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether to obtain Compound 107c (22.0 g, 57%).
¹ H-NMR (DMSO-D ₆ ) δ: 7.51-7.50 (2H, m), 7.39-7.35 (4H, m), 7.27 (1H, d, J = 8. 3 Hz), 6.95-6.93 (4H, m), 5.18 (2H, s), 5.10 (2H, s), 3.75 (3H, s), 3.75 (3H, s).

Step (3): Compound 107c → Compound 107d
Compound 107c (4.00 g, 9.47 mmol) was dissolved in tetrahydrofuran (40 mL) and then 1-chloro-N, N, 2-trimethyl-1-propenylamine (1.503 ml, 11.36 mmol) at 0 ° C. ) Was added. The mixture was stirred at 0 ° C. for 1 hour. To this was then added 4-aminomethylquinuclidine (1.59 g, 11.36 mmol) at 0 ° C. The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with ethyl acetate and aqueous sodium hydroxide solution, then separated, washed with water and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether to obtain Compound 107d (2.54 g, 49%).
¹ H-NMR (DMSO-D ₆ ) δ: 8.69 (1H, t, J = 6.3 Hz), 7.56-7.55 (2H, m), 7.38-7.35 (4H M), 7.25 (1H, d, J = 8.8 Hz), 6.95-6.92 (4H, m), 5.17 (2H, s), 5.07 (2H, s) 3.75-3.75 (6H, m), 3.01 (2H, d, J = 6.3 Hz), 2.76-2.73 (6H, m), 1.34-1.31 (6H, m).

Step (4): Compound X-1 + Compound 107d → Compound 107e → Compound I-107
To a solution of compound 107d (545 mg, 1.00 mmol) in dimethylformamide (2 mL) at 0 ° C. was added compound X-1 (932 mg, 1.0 mmol) and the resulting solution was stirred at 0 ° C. for 3 hours. . The reaction mixture was slowly added at 0 ° C. to 5% salt solution (30 ml) (containing 1.5 g sodium bisulfite). The precipitated solid was collected by filtration, washed with water and then suspended in water. This suspension was lyophilized to give Compound 107e as an orange solid. Compound 107e was used in the next reaction without further purification.

The total amount of the obtained compound 107e was dissolved in dichloromethane (10 mL), and this solution was cooled to −40 ° C. To this was then added anisole (1.3 mL, 12 mmol) and a 2 mol / L aluminum chloride solution (6.00 mL, 12 mmol) in nitromethane sequentially. The resulting product was stirred at 0 ° C. for 30 minutes. The reaction mixture was dissolved in water, 2 mol / L hydrochloric acid aqueous solution, and acetonitrile. The resulting solution was then washed with diisopropyl ether. After adding HP20-SS resin to this aqueous phase, acetonitrile was distilled off under reduced pressure. The resulting mixture was purified by ODS column chromatography. After adding HP20-SS resin to the obtained target compound solution, acetonitrile was distilled off under reduced pressure. The resulting mixture was purified by HP20-SS column chromatography. A 0.2N sodium hydroxide aqueous solution was added to the obtained target compound solution until the pH reached 6.0 as a whole. Thereafter, a piece of dry ice was added thereto. The resulting solution was concentrated under reduced pressure and then lyophilized to obtain Compound I-107 as a yellow powder.
Yield: 592.4 mg, (64%).
¹ H-NMR (D ₂ O) δ: 7.54-7.53 (2H, m), 7.00-6.99 (2H, m), 5.84 (1H, d, J = 4.8) Hz), 5.44 (1H, d, J = 4.8 Hz), 4.65 (1H, d, J = 14.4 Hz), 4.08-4.06 (2H, m), 3. 54-3.47 (6H, m), 3.37 (2H, s), 1.95-1.93 (6H, m), 1.56 (3H, d, J = 7.1 Hz), 1 .53 (3H, s), 1.51 (3H, s).
Elemental analysis: C34H38N7O11S2Na (H2O) 5.2
Theoretical: C, 45.30; H, 5.41; N, 10.88; S, 7.11; Na, 2.55 (%)
Measurements: C, 45.00; H, 5.43; N, 11.26; S, 6.98; Na, 2.56 (%)

Example 108: Synthesis of Compound I-108

Step (1): Compound 107c + Compound 108a → Compound 108b
Compound 108b was synthesized in the same manner as in Step 3 of Example 107 using Compound 107c (4.00 g, 9.47 mmol) and Compound 108a (2.26 g, 11.36 mmol).
Yield: 1.79 g (36%)
¹ H-NMR (DMSO-D ₆ ) δ: 7.47-7.23 (7H, m), 6.95-6.93 (4H, m), 5.17 (2H, s), 5.10 (2H, s), 4.51 (1H, s), 3.72-3.66 (7H, m), 2.98-2.73 (6H, m), 2.00-1.98 (2H , M), 1.70-1.61 (3H, m).

Step (2): Compound X-1 + Compound 108b → Compound 108c → Compound I-108
The target compound was synthesized using Compound X-1 (932 mg, 1.0 mmol) and Compound 108b (531 mg, 1.0 mmol) in the same manner as in Step (4) of Example 107.
Yield: 661.3 mg, (67%)
¹ H-NMR (D ₂ O) δ: 7.45-7.42 (2H, m), 7.03-6.99 (2H, m), 5.87-5.83 (1H, m), 5.46-5.43 (1H, m), 4.95 (1H, br s), 4.85-4.81 (1H, m), 4.38-4.27 (1H, m), 4 .16-4.07 (2H, m), 3.88-3.46 (7H, m), 2.47-2.22 (4H, m), 1.60-1.56 (3H, m) , 1.53-1.50 (6H, m).
Elemental analysis: C33H36N7O11S2Na (H2O) 5.3
Theoretical: C, 44.57; H, 5.28; N, 11.03; S, 7.21; Na, 2.59 (%)
Measurements: C, 44.53; H, 5.24; N, 11.33; S, 7.11; Na, 2.68 (%)

Example 109: Synthesis of Compound I-109

Step (1): Compound 107c + Compound 109a → Compound 109b
Compound 109b was synthesized in the same manner as in Step (3) of Example 107 using Compound 107c (1.00 g, 2.37 mmol) and Compound 109a (0.36 ml, 2.84 mmol).
Yield: 459.4 mg, (37%)
¹ H-NMR (DMSO-D ₆ ) δ: 8.74 (1H, t, J = 5.8 Hz), 7.65 (1H, dd, J = 8.5, 1.8 Hz), 7. 58 (1H, d, J = 1.8 Hz), 7.39-7.34 (4H, m), 7.21 (1H, d, J = 8.5 Hz), 6.96-6.91. (4H, m), 5.17 (2H, s), 5.08 (2H, s), 3.75 (3H, s), 3.75 (3H, s), 2.54 (2H, t, J = 6.7 Hz), 2.49-2.46 (4H, m), 1.70-1.66 (4H, m).

Step (2): Compound X-1 + Compound 109b → Compound 109c → Compound I-109
The target compound was synthesized using Compound X-1 (839 mg, 0.9 mmol) and Compound 109b (467 mg, 0.9 mmol) in the same manner as in Step (4) of Example 107.
Yield: 415.0 mg, (52%)
¹ H-NMR (D ₂ O) δ: 7.60 (1H, dd, J = 8.5, 2.0 Hz), 7.55 (1H, d, J = 2.0 Hz), 7.01 (1H, s), 6.99 (1H, d, J = 8.5 Hz), 5.80 (1H, d, J = 4.8 Hz), 5.46 (1H, d, J = 4. 8 Hz), 5.04 (1H, d, J = 14.3 Hz), 4.26 (1H, d, J = 14.3 Hz), 4.07 (1H, q, J = 7.0 Hz) ), 3.97-3.77 (2H, m), 3.73-3.67 (1H, m), 3.64-3.46 (5H, m), 2.28-2.20 (4H) M), 1.57 (3H, d, J = 7.0 Hz), 1.52 (3H, s), 1.50 (3H, s).
Elemental analysis: C32H36N7O11S2Na (H2O) 4.5
Theoretical values: C, 44.54; H, 5.26; N, 11.36; S, 7.43; Na, 2.66 (%)
Measurements: C, 44.50; H, 5.18; N, 11.51; S, 7.10; Na, 2.68 (%)

Example 110: Synthesis of Compound I-110

Step (1): Compound 110a → Compound 110b
Compound 110a (2.10 g, 5.00 mmol) was dissolved in ethanol (20 mL), and then methylhydrazine (0.28 ml, 5.25 mmol) was added thereto. The mixture was stirred at room temperature for 30 minutes and then refluxed for 1 hour. The reaction mixture was evaporated. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether to obtain Compound 110b (2.28 g, 102%).
¹ H-NMR (DMSO-D ₆ ) δ: 7.68 (1H, s), 7.41-7.39 (5H, m), 6.96-6.94 (4H, m), 5.22 (2H, s), 5.21 (2H, s), 3.75 (6H, s), 3.53 (3H, s).

Step (2): Compound 110b → Compound 110c
Compound 110b (1.20 g, 2.68 mmol) was dissolved in tetrahydrofuran (12 mL), which was then added at 0 ° C. with diisopropyl azodicarboxylate (0.728 ml, 3.75 mmol) and triphenylphosphine (983 mg, 3.75 mmol). Was added. The mixture was stirred at 0 ° C. for 10 minutes. To this was then added 2-pyrrolidinoethanol (0.438 ml, 3.75 mmol) at 0 ° C. The mixture was stirred at room temperature for 1 hour. To this was then added diisopropyl ether (24 ml). Next, the precipitated solid was collected by filtration and washed with diisopropyl ether to obtain Compound 110c (0.93 g, 64%).
¹ H-NMR (CDCl ₃ ) δ: 7.82 (1H, s), 7.41-7.34 (5H, m), 6.91-6.89 (4H, m), 5.22 (2H , S), 5.19 (2H, s), 4.42 (2H, t, J = 5.9 Hz), 3.81 (3H, s), 3.81 (3H, s), 3.70 (3H, s), 2.95 (2H, t, J = 5.9 Hz), 2.67-1.62 (4H, m), 1.85-1.78 (4H, m).

Step (3): Compound X-24 + Compound 110c → Compound 110d → Compound I-110
Using Compound X-24 (886 mg, 1.0 mmol) and Compound 110c (546 mg, 1.0 mmol), in the same manner as in Step (4) of Example 107, the target compound was synthesized.
Yield: 238.2 mg, (25%)
¹ H-NMR (D ₂ O) δ: 7.45 (1H, s), 7.14 (1H, s), 7.01 (1H, s), 5.83 (1H, d, J = 4. 6 Hz), 5.47 (1H, d, J = 4.6 Hz), 4.34 (1H, d, J = 14.6 Hz), 4.08 (1H, q, J = 6.9 Hz) ), 3.96-3.82 (3H, m), 3.74-3.47 (7H, m), 2.26 (4H, br s), 1.54 (3H, d, J = 6. 9 Hz), 1.51 (3H, s), 1.49 (3H, s).
Elemental analysis: C33H37N8O11S2Na (H2O) 5.8
Theoretical: C, 43.40; H, 5.36; N, 12.27; S, 7.02; Na, 2.52 (%)
Measurements: C, 43.21; H, 5.29; N, 12.60; S, 6.97; Na, 2.65 (%)

Example 111 Synthesis of Compound I-111

Step (1): Compound 111a + Compound 111b → Compound 111c
Compound 111a (10.0 g, 31.8 mmol) was dissolved in dimethylformamide (100 mL), and then sodium hydride (3.05 g, 76.0 mmol) was added thereto at 0 ° C. The mixture was stirred at 0 ° C. for 30 minutes. Next, compound 111b (5.95 g, 35.0 mmol) and sodium iodide (9.54 g, 63.6 mmol) were sequentially added thereto. The mixture was stirred at 60 ° C. for 2 hours. The reaction mixture was diluted with ethyl acetate and water, then separated, washed with saturated salt solution and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with ethyl acetate (3% triethylamine). The objective compound-containing fraction was concentrated under reduced pressure to obtain Compound 111c (12.70 g, 97%).
¹ H-NMR (DMSO-D ₆ ) δ: 7.39-7.24 (10H, m), 5.19-4.95 (4H, m), 3.83-3.67 (1H, m) 3.13 (1H, s), 3.07 (2H, s), 2.61-2.55 (1H, m), 2.45-2.36 (4H, m), 1.66-1 .61 (4H, m).

Step (2): Compound 111c → Compound 111d
Compound 111c (12.70 g, 30.9 mmol) was dissolved in methanol (120 mL), and then 10% Pd / C (2.54 g, containing 50% water) was added thereto. The mixture was stirred for 2 hours at room temperature under hydrogen atmosphere. The reaction mixture was filtered through celite and concentrated under reduced pressure to give compound 111d (4.90 g, 111%).
¹ H-NMR (CDCl ₃ ) δ: 3.94 (1H, t, J = 6.8 Hz), 3.78 (1H, s), 2.96 (2H, t, J = 6.8 Hz) , 2.66-2.61 (3H, m), 2.58-2.52 (4H, m), 1.81-1.77 (4H, m).

Step (3): Compound 111d + Compound 110a → Compound 111e
Compound 111d (1.50 g, 10.47 mmol) was dissolved in ethanol (50 mL), and then compound 110a (4.40 g, 10.47 mmol) was added thereto. The mixture was stirred at room temperature for 1 day and then refluxed for 2 hours. The reaction mixture was evaporated. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with ethyl acetate (3% triethylamine) / methanol. The target compound-containing fraction was concentrated under reduced pressure to obtain compound 111e (2.10 g, 37%).
¹ H-NMR (CDCl ₃ ) δ: 7.73 (1H, s), 7.73 (1H, s), 7.40-7.38 (4H, m), 6.91-6.89 (4H M), 5.21 (2H, s), 5.21 (2H, s), 4.30 (2H, t, J = 7.3 Hz), 3.81 (6H, s), 3.68. (3H, s), 2.73 (2H, t, J = 7.3 Hz), 2.59-2.54 (4H, m), 1.74-1.71 (4H, m).

Step (4): Compound X-24 + Compound 111e → Compound 111f → Compound I-111
Using Compound X-24 (886 mg, 1.0 mmol) and Compound 111e (546 mg, 1.0 mmol) in the same manner as in Step (4) of Example 107, the target compound was synthesized.
Yield: 444.5 mg (46%)
¹ H-NMR (D ₂ O) δ: 7.19 (1H, s), 7.14 (1H, s), 6.99 (1H, s), 5.81 (1H, d, J = 4. 8 Hz), 5.48 (1H, d, J = 4.8 Hz), 5.12 (1H, d, J = 14.1 Hz), 4.58 (2H, br s), 4.33 ( 1H, d, J = 14.1 Hz), 4.11 (1H, q, J = 6.9 Hz), 3.84-3.51 (9H, m), 2.26 (4H, br s) , 1.59 (3H, d, J = 6.9 Hz), 1.52 (3H, s), 1.50 (3H, s).
Elemental analysis: C33H37N8O11S2Na (H2O) 6
Theoretical: C, 43.23; H, 5.39; N, 12.22; S, 6.99; Na, 2.51 (%)
Measurement: C, 42.94; H, 5.30; N, 12.54; S, 6.85; Na, 2.64 (%)

Example 112: Synthesis of Compound I-112

Step (1): Compound 110a → Compound 112a
Compound 110a (5.00 g, 11.89 mmol) was suspended in dimethylformamide (25 mL), and then hexamethyldisilazane (24.93 ml, 119 mmol) and methanol (0.48 ml, 11.89 mmol) were sequentially added thereto. added. The mixture was stirred at room temperature for 1 day, then at 50 ° C. for 2 hours and at 80 ° C. for 2 hours. The reaction mixture was slowly added to a 1 mol / L aqueous hydrochloric acid solution (240 ml) at 0 ° C. The precipitated solid was collected by filtration and washed with water and diisopropyl ether to give compound 112a (4.89 g, 98%).
¹ H-NMR (CDCl ₃ ) δ: 7.35 (4H, d, J = 8.6 Hz), 7.33 (2H, s), 6.91 (4H, d, J = 8.6 Hz) , 5.18 (4H, s), 3.82 (6H, s).

Step (2): Compound 112a → Compound 112b
Compound 112a (1.00 g, 2.38 mmol) and paraformaldehyde (0.36 g, 11.92 mmol) were suspended in dimethylformamide (10 mL), and then pyrrolidine (0.99 ml, 11.92 mmol) was added thereto. It was. The mixture was stirred at room temperature for 2 hours. To this was then added water (20 ml). The precipitated solid was then collected by filtration and washed with water to give compound 112b (1.16 g, 97%).
¹ H-NMR (CDCl ₃ ) δ: 7.37-7.34 (6H, m), 6.90 (4H, d, J = 8.6 Hz), 5.18 (4H, s), 4. 64 (2H, s), 3.82 (6H, s), 2.71-2.66 (4H, m), 1.74-1.70 (4H, m).

Step (3): Compound X-24 + Compound 112b → Compound I-112
Using Compound X-24 (886 mg, 1.0 mmol) and Compound 112b (503 mg, 1.0 mmol), the target compound was synthesized in the same manner as in Step (4) of Example 107.
Yield: 111.0 mg, (9%)
¹ H-NMR (D ₂ O) δ: 7.29 (2H, s), 7.01 (1H, s), 5.83 (1H, d, J = 4.9 Hz), 5.48 (1H , D, J = 4.9 Hz), 4.27 (1H, d, J = 14.4 Hz), 4.11 (1H, q, J = 7.2 Hz), 3.72 (1H, br s), 3.46-3.39 (3H, m), 3.28 (1H, t, J = 7.2 Hz), 2.37-2.20 (4H, m), 2.00 (1H , T, J = 7.2 Hz), 1.56 (3H, d, J = 7.2 Hz), 1.52-1.49 (6H, m).
Elemental analysis: C31H32N7O11S2Na (H2O) 5.2 (NaHCO3) 0.2
Theoretical: C, 42.77; H, 4.90; N, 11.19; S, 7.32; Na, 3.15 (%)
Measurement: C, 42.49; H, 4.85; N, 11.97; S, 7.87; Na, 3.14 (%)

Example 113: Synthesis of Compound 1-113

Step (1): Compound 113a → Compound 113b
Compound 113a (11.65 g, 51.0 mmol) was dissolved in dichloromethane (100 mL), and then boron tribromide (25 g, 100 mmol) and boron tribromide in 1 mol / L dichloromethane (20 ml, 20 mmol) were added at 0 ° C. ) Was added dropwise. The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with ice water, extracted with ethyl acetate, washed with saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure to obtain Compound 113b (10.60 g, 104%). Compound 113b was used in the next reaction without further purification.
¹ H-NMR (DMSO-D ₆ ) δ: 10.54 (2H, br s), 7.09 (1H, s), 5.22 (2H, s).

Step (2): Compound 113b → Compound 113c
The total amount of compound 113b obtained in step (1) was dissolved in dimethylacetamide (110 mL), and then potassium carbonate (21.9 g, 159 mmol), p-methoxybenzyl chloride (17.3 ml, 127 mmol) and iodide were added thereto. Sodium (7.92 g, 52.8 mmol) was added sequentially. The mixture was stirred at 50 ° C. for 1 hour. The reaction mixture was poured into water. The precipitated solid was then collected by filtration and washed with water and diisopropyl ether to give compound 113c (20.71 g, 89%).
¹ H-NMR (CDCl ₃ ) δ: 7.39-7.36 (3H, m), 7.30 (2H, d, J = 8.6 Hz), 6.94 (2H, d, J = 8 .6 Hz), 6.83 (2H, d, J = 8.6 Hz), 5.18 (2H, s), 5.11 (2H, s), 5.09 (2H, s), 84 (3H, s), 3.80 (3H, s).

Step (3): Compound 113c → Compound 113d
To a solution of compound 113c (4.41 g, 10 mmol) in tetrahydrofuran (5 mL) and methanol (5 mL) was added 2 mol / L aqueous sodium hydroxide solution (15 ml, 30 mmol). The resulting solution was stirred at 70 ° C. for 1 hour. Water and a 2 mol / L aqueous hydrochloric acid solution (18 mL) were added to the reaction mixture at 0 ° C. The precipitated solid was then collected by filtration and washed with water to give compound 113d (5.33 g, 116%).
¹ H-NMR (CDCl ₃ ) δ: 7.61 (1H, s), 7.37-7.32 (4H, m), 6.92 (2H, d, J = 7.9 Hz), 6. 83 (2H, d, J = 7.4 Hz), 5.09 (2H, s), 5.04 (2H, s), 4.98 (2H, s), 3.83 (3H, s), 3.80 (3H, s).

Step (4): Compound 113d → Compound 113e
The total amount (5.33 g, 10 mmol) of the obtained compound 113d was suspended in acetone (50 mL), and then Jones reagent (2.67 mol / L, 7.5 mL, 20 mmol) was added thereto at 0 ° C. The mixture was stirred at room temperature for 30 minutes. After diluting the reaction mixture with water, sodium bisulfite was added at 0 ° C. After the mixture was evaporated to remove acetone, the precipitated solid was collected by filtration and washed with water and diisopropyl ether to give compound 113e (3.75 g, 82%).
¹ H-NMR (CDCl ₃ ) δ: 7.39-7.37 (3H, m), 7.31 (2H, d, J = 8.3 Hz), 6.94 (2H, d, J = 8 .4 Hz), 6.83 (2H, d, J = 8.3 Hz), 5.18 (1H, s), 5.11-5.07 (4H, m), 3.84 (3H, s) ), 3.80 (3H, s).

Step (5): Compound 113e + Compound 113f → Compound 113g
Compound 113e (777 mg, 3.40 mmol) was dissolved in dimethylacetamide (30 mL), and then sodium acetate (1.40 g, 17.0 mmol) was added thereto. The mixture was stirred at room temperature for 30 minutes. Next, compound 113f (3.11 g, 6.81 mmol) was added thereto. The mixture was stirred at room temperature for 1 hour and then at 70 ° C. for 1 hour. The reaction mixture was diluted with ethyl acetate and aqueous sodium hydroxide solution, then separated, washed with water and saturated salt solution, and dried over sodium sulfate. After sodium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with ethyl acetate (10% triethylamine) / methanol (10% triethylamine). The objective compound-containing fraction was concentrated under reduced pressure to obtain 113 g (553 mg, 12%) of a compound.
¹ H-NMR (DMSO-D ₆ ) δ: 8.37 (1H, s), 7.84 (1H, s), 7.49 (2H, d, J = 8.3 Hz), 7.29 ( 2H, d, J = 8.3 Hz), 7.01 (2H, d, J = 8.3 Hz), 6.86 (2H, d, J = 8.3 Hz), 5.33 (2H, s), 5.09 (2H, s), 3.96 (2H, s), 3.79 (3H, s), 3.74 (3H, s), 2.71 (6H, br s), 1 .39 (6H, br s).

Step (6): Compound X-24 + Compound 113g → Compound 113h → Compound I-113
The target compound was synthesized in the same manner as in Step (4) of Example 107 using Compound X-24 (886 mg, 1.0 mmol) and Compound 113g (553 mg, 960 mmol).
Yield: 547.4 mg, (58%)
¹ H-NMR (D ₂ O) δ: 8.38 (1H, s), 7.37 (1H, s), 6.99 (1H, s), 5.83 (1H, d, J = 4. 9 Hz), 5.43 (1H, d, J = 4.9 Hz), 4.61 (1H, d, J = 14.4 Hz), 4.17 (2H, s), 4.09-4 .02 (2H, m), 3.55-3.38 (6H, m), 1.99 (6H, s), 1.54 (3H, d, J = 7.2 Hz), 1.51 ( 3H, s), 1.50 (3H, s).
Elemental analysis: C34H36ClN8O10S2Na (H2O) 5 (NaHCO3) 0.4
Theoretical: C, 42.91; H, 4.86; N, 11.64; S, 6.66; Na, 3.34 (%)
Measurements: C, 42.74; H, 4.97; N, 12.01; S, 6.81; Na, 3.33 (%)

Examples 114 and 115: Synthesis of compounds I-114 and I-115

Step (1): Compound 114a + Compound 113f → Compound 114b
Compound 113f (311 mg, 1.36 mmol) and sodium acetate (559 mg, 6.82 mmol) were suspended in tetrahydrofuran (6 mL), which was then suspended in tetrahydrofuran (6 mL) at −20 ° C. in compound 114a (0.62 g, 1.36 mmol) of suspension was added. The mixture was stirred at −20 ° C. for 1 hour. To this was then added acetic acid (0.39 ml, 6.82 mmol). The mixture was stirred at reflux for 1 day. The reaction mixture was diluted with ethyl acetate and aqueous sodium hydroxide solution, then separated, washed with water and saturated salt solution, and dried over sodium sulfate. After sodium sulfate was filtered off, the liquid was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with diisopropyl ether to obtain a mixture (206 mg, 26%) of compounds 114b and 114c. This mixture was used in the next reaction without further purification.
MS (m + 1) = 592

Step (2): Compound X-24 + Compounds 114b and 114c → Compounds I-114 and I-115
The target compound was synthesized in the same manner as in Step (4) of Example 107 using Compound X-24 (354 mg, 0.4 mmol) and Compounds 114b and 114c (206 mg, 0.35 mmol).
Yield: Compound I-114 (165.6 mg, 45%), Compound I-115 (16.6 mg, 5.5%)
Compound I-114
¹ H-NMR (D ₂ O) δ: 7.10 (1H, s), 7.01 (1H, s), 5.85 (1H, d, J = 4.6 Hz), 5.45 (1H , D, J = 4.6 Hz), 4.63 (1H, d, J = 13.9 Hz), 4.12-4.05 (2H, m), 3.59-3.41 (6H, m), 2.98 (2H, s), 1.97 (6H, t, J = 7.2 Hz), 1.57 (3H, d, J = 6.9 Hz), 1.52 (3H, s), 1.51 (3H, s).
Elemental analysis: C34H36ClN8O11S2Na (H2O) 6.2 (NaHCO3) 0.5
Theoretical: C, 41.07; H, 4.89; Cl, 3.51; N, 11.11; S, 6.36; Na, 3.42 (%)
Measurements: C, 40.68; H, 4.96; Cl, 3.53; N, 11.52; S, 6.41; Na, 3.32 (%)
Compound I-115
¹ H-NMR (D ₂ O) δ: 7.33 (1H, s), 6.92 (1H, s), 5.76 (1H, d, J = 4.4 Hz), 5.36 (1H , D, J = 4.4 Hz), 4.55 (1H, d, J = 14.3 Hz), 3.99-3.91 (4H, m), 3.50-3.32 (6H, m), 1.96-1.92 (6H, m), 1.48-1.43 (9H, m).
MS (m + 1) = 833

Example 116: Synthesis of Compound I-116

Step (1): Compound 110a + Compound 116a → Compound 116b
Compound 116b was synthesized in the same manner as in Reference Example 5 using Compound 110a (1.26 g, 3.0 mmol) and Compound 116a (379 mg, 3.0 mmol).
Yield: 1.35 g (85%)
¹ H-NMR (DMSO-D ₆ ) δ: 7.49 (2H, s), 7.38 (4H, d, J = 8.7 Hz), 6.95 (4H, d, J = 8.7) Hz), 5.24 (4H, s), 3.82 (2H, s), 3.75 (6H, s), 2.74-2.68 (2H, m), 2.44-2.38 (2H, m), 2.11 (2H, s), 1.50-1.44 (2H, m), 1.14-1.08 (2H, m).

Step (2): Compound X-24 + Compound 116b → Compound 116c → Compound I-116
The target compound was synthesized using Compound X-24 (886 mg, 1.0 mmol) and Compound 116b (529 mg, 1.0 mmol) in the same manner as in Step (4) of Example 107.
Yield: 568.0 mg, (62%)
¹ H-NMR (D ₂ O) δ: 7.21 (2H, s), 7.00 (1H, s), 5.79 (1H, d, J = 4.9 Hz), 5.40 (1H , D, J = 4.9 Hz), 4.23 (1H, d, J = 14.6 Hz), 4.06 (1H, q, J = 7.2 Hz), 3.91 (2H, s ), 3.70-3.47 (4H, m), 3.43 (1H, d, J = 8.5 Hz), 3.33 (1H, d, J = 8.5 Hz), 2.23 -2.13 (2H, m), 2.00-1.92 (2H, m), 1.55 (3H, d, J = 7.2 Hz), 1.52 (3H, s), 50 (3H, s).
Elemental analysis: C33H34N7O11S2Na (H2O) 6.3
Theoretical: C, 43.78; H, 5.19; N, 10.83; S, 7.08; Na, 2.54 (%)
Measurements: C, 43.76; H, 5.19; N, 10.87; S, 7.02; Na, 2.59 (%)

Example 117: Synthesis of Compound 1-117

Step (1): Compound 117a → Compound 117b
Compound 117a (1.24 g, 3.0 mmol) and 1-hydroxybenzotriazole (446 mg, 3.3 mmol) were dissolved in dichloromethane (15 mL), and then dissolved in 1-ethyl-3- (3-dimethyl hydrochloride at 0 ° C. Aminopropyl) carbodiimide (690 mg, 3.6 mmol) was added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with dichloromethane and aqueous hydrochloric acid then separated and washed with water, saturated sodium bicarbonate solution, and saturated salt solution, and dried over magnesium sulfate. After magnesium sulfate was filtered off, the liquid was concentrated under reduced pressure to obtain Compound 117b (1.72 g, 108%).
Compound 117b was used directly in the next step without purification.
¹ H-NMR (CDCl ₃ ) δ: 8.11 (1H, d, J = 8.7 Hz), 7.68-7.62 (2H, m), 7.58-7.54 (1H, m ), 7.47-7.44 (2H, m), 7.36 (2H, d, J = 8.5 Hz), 7.31 (2H, d, J = 8.5 Hz), 6.93 (2H, d, J = 8.5 Hz), 6.85 (2H, d, J = 8.5 Hz), 5.23 (2H, s), 5.12 (2H, s), 3.83 (3H, s), 3.81 (3H, s).

Step (2): Compound 117b + Compound 116a → Compound 117c
Compound 117b (1.59 g, 3.0 mmol) was dissolved in tetrahydrofuran (10 mL), and then compound 116a (379 mg, 3.0 mmol) in tetrahydrofuran (10 mL) was added thereto at 0 ° C. The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with ethyl acetate and aqueous sodium hydroxide solution, then separated, washed with water and saturated salt solution, and dried over sodium sulfate. After sodium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with ethyl acetate (10% triethylamine) / methanol (10% triethylamine). The target compound-containing fraction was concentrated under reduced pressure to obtain Compound 117c (1.54 g, 99%).
¹ H-NMR (DMSO-D ₆ ) δ: 8.53 (1H, t, J = 5.9 Hz), 7.48 (1H, s), 7.43 (2H, d, J = 8.0) Hz), 7.33 (1H, d, J = 11.0 Hz), 7.25 (2H, d, J = 8.0 Hz), 6.98 (2H, d, J = 8.0 Hz) , 6.85 (2H, d, J = 8.0 Hz), 5.14 (2H, s), 5.01 (2H, s), 3.78 (3H, s), 3.73 (3H, s), 3.58 (2H, d, J = 5.9 Hz), 2.83-2.76 (2H, m), 2.20 (2H, s), 1.58-1.52 (2H , M), 1.21-1.15 (2H, m).

Step (3): Compound X-24 + Compound 117c → Compound 117d → Compound I-117
The target compound was synthesized in the same manner as in Step (4) of Example 107 using Compound X-24 (886 mg, 1.0 mmol) and Compound 117c (521 mg, 1.0 mmol).
Yield: 202.3 mg, (22%)
¹ H-NMR (D ₂ O) δ: 7.17 (1H, d, J = 11.0 Hz), 7.13 (1H, s), 7.00 (1H, s), 5.79 (1H , D, J = 4.0 Hz), 5.41 (1H, d, J = 4.0 Hz), 4.89 (1H, d, J = 14.7 Hz), 4.25 (1H, d , J = 14.2 Hz), 4.05 (1H, q, J = 7.2 Hz), 3.69-3.56 (6H, m), 3.40 (1H, d, J = 8. 4 Hz), 3.31 (1H, d, J = 8.4 Hz), 2.25-2.17 (2H, m), 1.99-1.93 (2H, m), 1.55 ( 3H, d, J = 7.2 Hz), 1.52 (3H, s), 1.50 (3H, s).
Elemental analysis: C32H35FN7O10S2Na (H2O) 6.7 (NaHCO3) 0.1
Theoretical: C, 42.23; H, 5.36; F, 2.08; N, 10.74; S, 7.02; Na, 2.77 (%)
Measurements: C, 42.17; H, 5.21; F, 2.02; N, 10.91; S, 7.06; Na, 2.77 (%)

Example 118: Synthesis of Compound 1-118

Step (1): Compound 118a → Compound 118b + Compound 118c → Compound 118d
Compound 118b was synthesized in the same manner as in Step (1) of Example 117 using Compound 118a.
Compound 118d was synthesized in the same manner as in Step (2) of Example 117, using Compound 118b (1.67 g, 3.1 mmol) and Compound 118c (472 mg, 3.1 mmol).
Yield: 1.36 g (79%)
¹ H-NMR (DMSO-D ₆ ) δ: 8.23 (1H, t, J = 6.2 Hz), 7.43 (2H, d, J = 8.5 Hz), 7.33 (2H, d, J = 8.5 Hz), 7.18 (1H, d, J = 8.5 Hz), 7.12 (1H, d, J = 8.5 Hz), 6.97 (2H, d, J = 8.5 Hz), 6.88 (2H, d, J = 8.5 Hz), 5.15 (2H, s), 4.88 (2H, s), 3.77 (3H, s) , 3.75 (3H, s), 2.97-2.84 (6H, m), 2.60 (2H, s), 2.03-1.90 (2H, m), 1.68-1 .53 (4H, m), 1.46-1.39 (2H, m).

Step (2): Compound X-24 + Compound 118d → Compound 118e → Compound I-118
The target compound was synthesized in the same manner as in Step (4) of Example 107 using Compound X-24 (886 mg, 1.0 mmol) and Compound 118d (565 mg, 1.0 mmol).
Yield: 579.6 mg, (61%)
¹ H-NMR (D ₂ O) δ: 6.96 (1H, d, J = 8.3 Hz), 6.94 (1H, s), 6.90 (1H, d, J = 8.3 Hz) ), 5.80 (1H, d, J = 4.8 Hz), 5.43 (1H, d, J = 4.8 Hz), 4.13 (1H, d, J = 14.1 Hz), 3.98 (1H, q, J = 7.2 Hz), 3.76-3.71 (1H, m), 3.50-3.13 (7H, m), 2.56-2.44 ( 2H, m), 2.02-1.95 (2H, m), 1.88-1.69 (4H, m), 1.55 (3H, d, J = 7.2 Hz), 1.50 (3H, s), 1.48 (3H, s).
Elemental analysis: C34H39ClN7O10S2Na (H2O) 6.4
Theoretical: C, 43.28; H, 5.53; Cl, 3.76; N, 10.39; S, 6.80; Na, 2.44 (%)
Measurements: C, 43.17; H, 5.41; Cl, 3.69; N, 10.57; S, 6.85; Na, 2.47 (%)

Example 119: Synthesis of Compound I-119

Step (1): Compound 119a → Compound 119b
Compound 119a (2.53 g, 10.0 mmol) was dissolved in methanol (12.5 mL), and then a 4 mol / L dioxane solution (12.5 ml, 50 mmol) of hydrochloric acid was added thereto at 0 ° C. After the mixture was stirred at room temperature for 4 hours, the reaction mixture was evaporated. The precipitated solid was then collected by filtration and washed with ethyl acetate / methanol (1/1) and ethyl acetate. The precipitated solid was suspended in methanol (25 mL) and then sodium hydroxide (1.20 g, 30 mmol) was added thereto. The mixture was stirred at room temperature for 30 minutes, and then a piece of dry ice was added thereto. After filtering this mixture, the filtrate was concentrated under reduced pressure to give compound 119b (2.67 g, 174%). This mixture was used in the next reaction without further purification.
MS (m + 1) = 154

Step (2): Compound 119b + Compound 118b → Compound 119c
Compound 119c was synthesized in the same manner as in Step (2) of Example 117, using Compound 118b (1.09 g, 2.0 mmol) and Compound 119b (538 mg, 2.0 mmol).
Yield: 0.47 g (42%)
MS (m + 1) = 564

Step (3): Compound X-24 + Compound 119c → Compound 119d → Compound I-119
The target compound was synthesized in the same manner as in Step (4) of Example 107 using Compound X-24 (722 mg, 0.82 mmol) and Compound 119c (460 mg, 0.82 mmol).
Yield: 13 mg, (1.7%)
¹ H-NMR (D ₂ O) δ: 7.58 (1H, s), 7.01 (1H, s), 6.75 (3H, s), 5.85 (1H, s), 5.46 (1H, d, J = 5.3 Hz), 4.14-4.10 (4H, m), 3.62-3.55 (8H, m), 2.18 (6H, br s), 1 .60-1.51 (9H, m).
MS (m + 1) = 783

Example 120: Synthesis of Compound I-130

Step (1): Compound X-24 + Compound 120a → Compound 120b → Compound I-120
A solution of compound 120a (658 mg, 1.0 mmol) in dimethylformamide (2.0 mL) in dimethylformamide (2.0 mL) was cooled with ice. Next, the reaction vessel was degassed under reduced pressure, and Compound X-24 (886 mg, 1.0 mmol) was added thereto. After stirring at 0 ° C. for 6 hours, the reaction mixture was slowly added to 5% sodium chloride and aqueous sodium bisulfite solution, which was cooled with ice. The precipitated solid was collected by filtration, washed with water and suspended in water. This suspension was lyophilized to give Compound 120b as a brown solid. The obtained compound 120b was directly used in the next step without purification.

The total amount of the obtained compound 120b was dissolved in dichloromethane (10 mL), and this solution was cooled to −40 ° C. To this was then added anisole (1.09 mL, 10 mmol) and a 2 mol / L aluminum chloride solution (5.0 mL, 10 mmol) in nitromethane sequentially. The liquid was stirred at 0 ° C. for 30 minutes. Diisopropyl ether and a small amount of water were added to the reaction solution, and the resulting product was stirred to form a precipitate. The supernatant was removed by decantation. A diluted hydrochloric acid aqueous solution and acetonitrile were added to the insoluble matter adhering to the reaction vessel. The obtained product was stirred to completely dissolve insoluble matters. Next, diisopropyl ether was added thereto, and the aqueous phase was separated and recovered. The organic phase was extracted again with water and all the aqueous phases obtained were combined. To this was added HP20-SS resin. Next, acetonitrile was distilled off therefrom under reduced pressure. The resulting mixture was purified by ODS column chromatography. A 0.2 mol / L aqueous sodium hydroxide solution was added to the target compound-containing fraction until the pH reached 6.0, and a piece of dry ice was added thereto. The resulting solution was concentrated under reduced pressure and then lyophilized to obtain Compound I-120 as a yellow powder.
Yield: 534 mg (58%)
¹ H-NMR (D ₂ O) δ: 1.06 (2H, s), 1.29 (2H, d, J = 6.65 Hz), 1.51 (3H, s), 1.53 (3H , S), 1.59 (3H, d, J = 6.78 Hz), 2.06 (2H, t, J = 13.55 Hz), 2.44-2.83 (5H, m), 3 .13 (3H, s), 3.44 (1H, s), 4.01-4.22 (5H, m), 5.47 (1H, d, J = 4.77 Hz), 5.83 ( 1H, d, J = 4.77 Hz), 7.00 (1H, s), 7.23 (1H, s), 8.34 (1H, s).
Elemental _{analysis: C 39 H 42 ClN 8 O} 11 S 2 Na · 7.0H 2 O · 0.1 NaHCO 3
Theoretical: C, 44.48; H, 5.36; Cl, 3.36; N, 10.61; S, 6.07; Na, 2.40 (%)
Measurements: C, 44.18; H, 5.34; Cl, 3.27; N, 10.91; S, 6.27; Na, 2.43 (%)
MS (m + 1) = 899.38

Example 121: Synthesis of compound I-121.

Step (1): Compound X-24 + Compound 121a → Compound 121b → Compound I-121
Using a method similar to that in Example 120, compound I-121 was obtained as a yellow powder from compound X-24 (886 mg, 1.0 mmol) and compound 121a (646 mg, 1.0 mmol).
Yield: 127 mg, (14%)
¹ H-NMR (D ₂ O) δ: 1.41 (3H, t, J = 6.90 Hz), 1.51 (3H, s), 1.53 (3H, s), 1.59 (3H , D, J = 6.90 Hz), 2.07-2.14 (2H, m), 2.45-2.87 (6H, m), 3.13 (3H, s), 4.00- 4.29 (8H, m), 5.47 (1H, d, J = 4.77 Hz), 5.83 (1H, d, J = 4.77 Hz), 6.79 (1H, s), 7.01 (1H, s), 8.44 (1H, s).
MS (m + 1) = 887.32.

Example 122: Synthesis of Compound I-122

Step (1): Compound 122a → Compound 122b → Compound 122c
A solution of compound 122a (22.84 g, 168 mmol) in toluene (114 mL) was cooled to −78 ° C., and a 1 mol / L DIBAL solution (335 mL, 335 mmol) in toluene was added dropwise thereto over 50 minutes. After stirring at −78 ° C. for 50 minutes, the reaction mixture was warmed to 0 ° C. at 0 ° C. with water (13.4 mL), 15% aqueous sodium hydroxide (13.4 mL), and water (33.5 mL). It was dripped. After stirring at room temperature for 10 minutes, methanol (114 mL) and tert-butyl hydrazinecarboxylate (26.6 g, 201 mmol) were added thereto. After stirring at room temperature overnight, the insoluble material was filtered off and concentrated. The residue was dissolved in ethyl acetate and saturated aqueous citric acid solution was added until pH 4.0. The aqueous phase was separated, 8 mol / L aqueous sodium hydroxide solution was added until the pH reached 12.0, and then extracted twice with chloroform. The combined organic layers were dried over anhydrous sodium sulfate. The inorganic material was removed by filtration and then concentrated under reduced pressure. Diisopropyl ether was added thereto to precipitate a solid. The solid was collected by filtration to give compound 122c as a white solid.
Yield: 28.7 g (68%)
¹ H-NMR (CDCl ₃ ) δ: 1.49 (9H, s), 1.60 (6H, t, J = 7.72 Hz), 2.91 (6H, t, J = 7.72 Hz) , 6.92 (1H, s), 7.56 (1H, s).

Step (2): Compound 122c → Compound 122d → Compound 122e
A solution of compound 122c (28.7 g, 113 mmol) in methanol (144 mL) was cooled with ice, sodium cyanoborohydride (14.24 g, 227 mmol) was added thereto, and then a 2 mol / L aqueous hydrochloric acid solution was added at pH 4. Added until zero. After stirring at room temperature for 1.5 hours, an 8 mol / L aqueous sodium hydroxide solution was added thereto at 0 ° C. until pH 12.0, and then concentrated, and then extracted twice with ethyl acetate. The combined organic layers were washed with saturated brine and then dried over anhydrous sodium sulfate. The inorganic material was removed by filtration and then concentrated, and then dried under reduced pressure to obtain Compound 122d as an orange oil. The obtained compound 122d was directly used in the next step without purification.

The total amount of the obtained compound 122d was dissolved in methanol (144 mL), and this solution was cooled with ice. To this was slowly added a 4 mol / L hydrochloric acid solution (141 mL, 565 mmol) in 1,4-dioxane. After stirring at room temperature overnight, the reaction mixture was concentrated under reduced pressure. A 50% methanol / ethyl acetate solution was added thereto to precipitate a solid. The solid was collected by filtration to give compound 122e as a white solid.
Yield: 24.6 g (95%)
¹ H-NMR (D ₂ O) δ: 1.90 (6H, t, J = 7.97 Hz), 2.99 (2H, s), 3.39 (6H, t, J = 7.97 Hz) ).

Step (3): Compound 122e + Compound 110a → Compound 122f
To a suspension of compound 122e (17.6 g, 77 mmol) in 1,4-dioxane (144 mL) was added sodium acetate (31.6 g, 385 mmol) and compound 110a (38.8 g, 92 mmol). After stirring at room temperature for 1 hour, acetic acid (22.02 ml, 385 mmol) was added thereto. After stirring overnight at room temperature, it was stirred at 70 ° C. for 1.5 hours. Next, a 2 mol / L aqueous sodium hydroxide solution was added thereto at 0 ° C. until the pH reached 12.0, and then extracted twice with ethyl acetate. The combined organic layers were washed with saturated brine and then dried over anhydrous sodium sulfate. The inorganic material was removed by filtration and then concentrated under reduced pressure. To this was added a 5% triethylamine and methanol solution in ethyl acetate to precipitate a solid. The solid was collected by filtration to give compound 122f as a white solid.
Yield: 30.96 g (72%)
¹ H-NMR (DMSO-D ₆ ) δ: 1.40 (6H, t, J = 7.47 Hz), 2.64 (6H, t, J = 7.47 Hz), 3.59 (2H, s), 3.75 (6H, s), 5.11 (2H, s), 5.12 (2H, s), 6.94 (4H, d, J = 8.28 Hz), 7.38 ( 4H, d, J = 8.28 Hz), 7.52 (2H, s).

Step (4): Compound X-24 + Compound 122f → Compound 122g → Compound I-122
Using a method similar to that in Example 120, compound I-122 was obtained as a white powder from compound X-24 (10.0 g, 11.3 mmol) and compound 122f (6.31 g, 11.3 mmol).
Yield: 3.68 g (40%)
¹ H-NMR (D ₂ O) δ: 1.50 (3H, s), 1.51 (3H, s), 1.53 (3H, d, J = 7.53 Hz), 2.00 (6H , T, J = 7.22 Hz), 3.38-3.55 (6H, m), 3.97-4.06 (4H, m), 4.61 (1H, d, J = 14.43). Hz), 5.42 (1H, d, J = 4.77 Hz), 5.83 (1H, d, J = 4.77 Hz), 6.97 (1H, s), 7.24 (1H, s), 7.39 (1H, s).
Elemental _{analysis: C 33 H 37 N 8 O} 11 S 2 Na 1. ₂ · 5.9H ₂ O
Theoretical values: C, 43.83; H, 5.28; N, 12.03; S, 6.88; Na, 2.96 (%)
Measurements: C, 43.74; H, 5.35; N, 12.27; S, 7.03; Na, 2.86 (%)
MS (m + 1) = 799.23

Example 123: Synthesis of Compound I-123

Step (1): Compound 122a → Compound 122b → Compound 123a
Using the same method as in Step (1) of Example 122, Compound 123a was obtained as a white powder from Compound 122a (10.0 g, 73.4 mmol) and benzyl hydrazinecarboxylate (21.96 g, 132 mmol).
Yield: 14.02 g, (66%)
¹ H-NMR (DMSO-D ₆ ) δ: 1.44 (6H, t, J = 7.58 Hz), 2.74 (6H, t, J = 7.58 Hz), 5.04 (2H, s), 7.09 (1H, s), 7.31-7.40 (6H, m).

Step (2): Compound 123a → Compound 123b
To a solution of compound 123a (11.49 g, 40 mmol) in methanol (180 mL) was added 5% palladium on carbon (3.6 g, 1.7 mmol). After stirring at room temperature for 2 hours under hydrogen (1 atm), the insoluble material was removed by filtration. This was concentrated and then dried under reduced pressure to obtain Compound 123b as a white solid.
Yield: 5.97 g (97%)
¹ H-NMR (DMSO-D ₆ ) δ: 1.40 (6H, t, J = 7.65 Hz), 2.73 (6H, t, J = 7.65 Hz), 5.88 (2H, s), 6.76 (1H, s).

Step (3): Compound 123b + Compound 110a → Compound 123c
To a suspension of compound 123b (6.97 g, 45.5 mmol) in dimethylformamide (70 mL) was added compound 110a (20.08 g, 47.8 mmol) at 0 ° C. After stirring at room temperature for 2 hours, O-benzotriazole-N, N, N ′, N′-tetramethyluronium hexafluorophosphate (20.70 g, 54.6 mmol) was added thereto at 0 ° C. After stirring at room temperature for 4 hours, acetic acid (26.0 ml, 455 mmol) and sodium cyanoborohydride (4.29 g, 68.2 mmol) were added thereto at 0 ° C. After stirring overnight at room temperature, a 2 mol / L aqueous sodium hydroxide solution was added thereto, followed by extraction with ethyl acetate twice. The combined organic layers were washed with water and saturated brine and then dried over anhydrous sodium sulfate. The inorganic material was removed by filtration and then concentrated under reduced pressure. Diisopropyl ether was added thereto to precipitate a solid. The solid was collected by filtration to give compound 123c as a yellow solid.
Yield: 14.19 g (56%)
¹ H-NMR (DMSO-D ₆ ) δ: 1.37 (6H, t, J = 7.59 Hz), 2.65 (2H, d, J = 6.02 Hz), 2.73 (6H, t, J = 7.59 Hz), 3.75 (6H, s), 5.23 (4H, s), 6.95 (4H, d, J = 8.66 Hz), 7.37 (4H, d, J = 8.66 Hz), 7.46 (2H, s).

Step (4): Compound X-24 + Compound 123c → Compound I-123
Using a method similar to that in Example 120, Compound I-123 was obtained as a white powder from Compound X-24 (11.52 g, 13 mmol) and Compound 123c (7.25 g, 13 mmol).
Yield: 3.25 g (30%)
¹ H-NMR (D ₂ O) δ: 1.51 (3H, s), 1.52 (3H, s), 1.57 (3H, d, J = 7.15 Hz), 1.97 (6H , T, J = 7.65 Hz), 2.98 (2H, s), 3.41-3.58 (6H, m), 4.05-4.12 (2H, m), 4.63 ( 1H, d, J = 14.81 Hz), 5.45 (1H, d, J = 4.89 Hz), 5.85 (1H, d, J = 4.89 Hz), 7.00 (1H, s), 7.19 (2H, s).
MS (m + 1) = 799.23

Example 124 Synthesis of Compound I-124

Step (1): Compound 124a → Compound 124b
To a solution of compound 124a (30.5 g, 72 mmol) in tetrahydrofuran (305 mL) in tetrahydrofuran (305 mL) was added manganese dioxide (62.5 g, 719 mmol). After stirring overnight at room temperature, the insoluble material was removed by filtration. A 1 mol / L hydrochloric acid aqueous solution was added thereto, and the mixture was extracted twice with ethyl acetate. The combined organic layers were washed with saturated brine and then dried over anhydrous magnesium sulfate. The inorganic material was removed by filtration and then concentrated under reduced pressure. Diisopropyl ether was added thereto to precipitate a solid. The solid was collected by filtration to give compound 124b as a brown solid.
Yield: 22.76 g (75%)
¹ H-NMR (DMSO-D ₆ ) δ: 3.75 (3H, s), 3.76 (3H, s), 5.16 (2H, s), 5.17 (2H, s), 6. 92-6.96 (4H, m), 7.35-7.40 (6H, m).

Step (2): Compound 124b + Compound 122e → Compound 124c
Compound 122e (19.44 g, 85 mmol) and sodium acetate (29.1 g, 355 mmol) were added to a solution of compound 124b (30 g, 71 mmol) in dimethylformamide (300 mL). After stirring at room temperature for 1 hour, acetic acid (20.3 ml, 355 mmol) was added thereto. After stirring overnight at room temperature, ice water and a 2 mol / L sodium hydroxide aqueous solution were added thereto at 0 ° C. until pH 10.0 was reached. The precipitated solid was then collected by filtration and dissolved in tetrahydrofuran. The resulting solution was dried over anhydrous sodium sulfate. The inorganic material was removed by filtration and then concentrated under reduced pressure. Ethyl acetate was added thereto to precipitate a solid. The solid was collected by filtration to give compound 124c as a white solid.
Yield: 32.66 g (85%)
¹ H-NMR (DMSO-D ₆ ) δ: 1.42 (6H, t, J = 7.59 Hz), 2.75 (6H, t, J = 7.59 Hz), 3.75 (6H, s), 3.94 (2H, s), 5.20 (2H, s), 5.22 (2H, s), 6.94-6.97 (4H, m), 7.39 (2H, d) , J = 8.53 Hz), 7.42 (2H, d, J = 8.53 Hz), 7.54 (1H, s), 7.71 (1H, s), 8.21 (1H, s ).

Step (3): Compound X-24 + Compound 124c → Compound I-124
Using a method similar to that in Example 120, Compound I-124 was obtained as a yellow powder from Compound X-24 (886 mg, 1.0 mmol) and Compound 124c (541 mg, 1.0 mmol).
Yield: 440 mg (55%)
¹ H-NMR (D ₂ O) δ: 1.50 (3H, s), 1.52 (3H, s), 1.54 (3H, d, J = 7.40 Hz), 1.98 (6H , S), 3.47 (6H, d, J = 34.88 Hz), 4.02-4.13 (4H, m), 4.62 (1H, d, J = 14.68 Hz), 5 .42 (1H, d, J = 4.77 Hz), 5.83 (1H, d, J = 4.77 Hz), 6.97 (1H, s), 7.08 (1H, s), 7 .41 (1H, s), 8.06 (1H, s).
Elemental _{analysis: C 34 H 37 N 8 O} 10 S 2 Na · 6.5H 2 O · 0.1NaHCO 3
Theoretical values: C, 44.02; H, 5.43; N, 12.04; S, 6.89; Na, 2.72 (%)
Measurements: C, 43.83; H, 5.45; N, 12.34; S, 6.81; Na, 2.70 (%)
MS (m + 1) = 783.34

Example 125 Synthesis of Compound I-125

Step (1): Compound 125a → Compound 125b
A solution of compound 125a (10.38 g, 45 mmol) in dichloromethane (100 mL) was cooled with ice and boron tribromide (10.3 mL, 109 mmol) was added dropwise thereto. After stirring at 0 ° C. for 1 hour, the reaction mixture was poured onto ice and concentrated. Next, the precipitated solid was collected by filtration, whereby Compound 125b was obtained as a brown solid.
Yield: 8.89 g (98%)
¹ H-NMR (DMSO-D ₆ ) δ: 5.14 (2H, s), 6.92 (1H, s).

Step (2): Compound 125b → Compound 125c
To a solution of compound 125b (9.89 g, 49 mmol) in dimethylformamide (100 mL) was added potassium carbonate (20.44 g, 148 mmol), 4-methoxybenzyl chloride (16.12 mL, 118 mmol) and sodium iodide (7.39 g). 49 mmol). After stirring at 50 ° C. for 1 hour, the reaction mixture was poured into ice water. Next, the precipitated solid was collected by filtration, whereby Compound 125c was obtained as a brown solid.
Yield: 20.18 g, (93%)
¹ H-NMR (CDCl ₃ ) δ: 3.80 (3H, s), 3.84 (3H, s), 4.99 (2H, s), 5.13 (2H, s), 5.15 ( 2H, s), 6.82 (2H, d, J = 8.66 Hz), 6.90 (1H, s), 6.94 (2H, d, J = 8.66 Hz), 7.32 ( 2H, d, J = 8.66 Hz), 7.36 (2H, d, J = 8.66 Hz).

Step (3): Compound 125c → Compound 125d
To a solution of compound 125c (17.35 g, 39 mmol) in methanol (17 mL) and tetrahydrofuran (17 mL) was added 2 mol / L aqueous sodium hydroxide (59 mL, 118 mmol) in water. After stirring at 70 ° C. for 1 hour, ice water was added thereto. Next, the precipitated solid was collected by filtration to obtain Compound 125d as a white solid.
Yield: 18.60 g (98%)
¹ H-NMR (DMSO-D ₆ ) δ: 3.75 (3H, s), 3.77 (3H, s), 4.33 (2H, s), 4.81 (2H, s), 5. 06 (2H, s), 5.85 (1H, s), 6.87 (2H, d, J = 8.66 Hz), 6.96 (2H, d, J = 8.66 Hz), 7. 05 (1H, s), 7.33 (2H, d, J = 8.66 Hz), 7.41 (2H, d, J = 8.66 Hz).

Step (4): Compound 125d → Compound 125e
To a solution of compound 125d (1.92 g, 4.0 mmol) in dichloromethane (15 mL) and methanol (4 mL) was added manganese dioxide (3.47 g, 40 mmol). After stirring at room temperature for 1 hour, it was concentrated and ethyl acetate was added. Insoluble material was removed by filtration. A 1 mol / L hydrochloric acid aqueous solution was added thereto, and the mixture was extracted twice with ethyl acetate. The combined organic layers were washed with saturated brine and then dried over anhydrous magnesium sulfate. The inorganic material was removed by filtration and then concentrated under reduced pressure. Diisopropyl ether was added thereto to precipitate a solid. The solid was collected by filtration to give compound 125e as a white solid.
Yield: 1.25 g (69%)
¹ H-NMR (CDCl ₃ ) δ: 3.80 (3H, s), 3.84 (3H, s), 4.96 (2H, dd, J = 13.87, 10.10 Hz), 5. 14 (2H, dd, J = 28.36, 11.04 Hz), 6.40 (1H, s), 6.81 (2H, d, J = 8.53 Hz), 6.95 (2H, d , J = 8.53 Hz), 7.06 (1H, s), 7.28 (2H, d, J = 8.53 Hz), 7.38 (2H, d, J = 8.53 Hz).

Step (5): Compound 125e + Compound 122e → Compound 125f
To a solution of compound 125e (949 mg, 2.08 mmol) in dimethylacetamide (9.5 mL) was added compound 122e (521 mg, 2.29 mmol) and sodium acetate (852 mg, 10.4 mmol). After stirring at room temperature for 1 hour, acetic acid (0.594 ml, 10.4 mmol) was added thereto. After stirring overnight at 70 ° C., ice water and a 2 mol / L aqueous sodium hydroxide solution were added thereto at 0 ° C. until pH 10.0 was reached. Next, the precipitated solid was collected by filtration and dissolved in tetrahydrofuran. The resulting solution was dried over anhydrous sodium sulfate. The inorganic material was removed by filtration and then concentrated under reduced pressure. Ethyl acetate was added thereto to precipitate a solid. The resulting crude product silica gel column chromatography (triethylamine / methanol / ethyl acetate) was purified to obtain compound 125f as a yellow solid.
Yield: 435 mg (36%)
¹ H-NMR (DMSO-D ₆ ) δ: 1.46 (6H, t, J = 7.53 Hz), 2.80 (6H, t, J = 7.53 Hz), 3.74 (4H, s), 3.79 (3H, s), 3.92 (2H, s), 4.97 (2H, s), 5.27 (2H, s), 6.85 (2H, d, J = 8) .66 Hz), 7.01 (2H, d, J = 8.66 Hz), 7.29 (2H, d, J = 8.66 Hz), 7.50 (2H, d, J = 8.66). Hz), 7.67 (1H, s), 8.24 (1H, s).

Step (6): Compound X-24 + Compound 125f → Compound I-125
Using a method similar to that in Example 120, Compound I-125 was obtained as a yellow powder from Compound X-24 (668 mg, 0.755 mmol) and Compound 125f (435 mg, 0.755 mmol).
Yield: 196 mg (31%)
¹ H-NMR (D ₂ O) δ: 1.50 (3H, s), 1.52 (3H, s), 1.54 (3H, d, J = 7.15 Hz), 1.99 (6H , T, J = 7.47 Hz), 3.39-3.55 (6H, m), 4.02-4.09 (4H, m), 4.61 (1H, d, J = 14.31). Hz), 5.43 (1H, d, J = 4.89 Hz), 5.83 (1H, d, J = 4.89 Hz), 6.92 (1H, s), 6.98 (1H, s), 7.94 (1H, s).
Elemental _{analysis: C 34 H 36 ClN 8 O} 10 S 2 Na 1. ₄ · 7.2H ₂ O
Theoretical values: C, 41.75; H, 5.19; Cl, 3.62; N, 11.46; S, 6.56; Na, 3.29 (%)
Measurements: C, 41.71; H, 5.15; Cl, 3.46; N, 11.73; S, 6.57; Na, 3.34 (%)
MS (m + 1) = 817.42.

Example 126: Synthesis of Compound I-126

Step (1): Compound 124b + Compound 126a → Compound 126b
Using a method similar to that in step (2) of Example 124, compound 126b was obtained as a white powder from compound 124b (20.65 g, 49 mmol) and compound 126a (14.65 g, 68 mmol).
Yield: 19.57 g (76%)
¹ H-NMR (DMSO-D ₆ ) δ: 1.4-1.19 (2H, m), 1.48-1.54 (2H, m), 2.19 (2H, s), 2.39 -2.45 (2H, m), 2.66-2.72 (2H, m), 3.75 (6H, s), 4.45 (2H, s), 5.20 (2H, s), 5.23 (2H, s), 6.94-6.97 (4H, m), 7.38-7.43 (4H, m), 7.55 (1H, s), 7.72 (1H, s), 8.24 (1H, s).

Step (2): Compound X-24 + Compound 126b → Compound I-126
Using a method similar to that in Example 120, compound I-126 was obtained as a yellow powder from compound X-24 (886 mg, 1.0 mmol) and compound 126b (528 mg, 1.0 mmol).
Yield: 457 mg (58%)
¹ H-NMR (D ₂ O) δ: 1.49 (3H, s), 1.51 (3H, s), 1.53 (3H, d, J = 7.15 Hz), 2.00 (2H , S), 2.19 (2H, s), 3.37-3.66 (6H, m), 4.04 (1H, q, J = 7.15 Hz), 4.23 (1H, d, J = 14.43 Hz), 4.48 (2H, dd, J = 18.51, 14.62 Hz), 4.87 (1H, d, J = 14.43 Hz), 5.34 (1H, d, J = 4.89 Hz), 5.74 (1H, d, J = 4.89 Hz), 6.96 (1H, s), 7.10 (1H, s), 7.43 (1H, s), 8.13 (1H, s).
Elemental _{analysis: C 33 H 35 N 8 O} 10 S 2 Na · 5.2H 2 O
Theoretical: C, 44.81; H, 5.17; N, 12.67; S, 7.25; Na, 2.60 (%)
Measurements: C, 44.77; H, 5.16; N, 12.77; S, 7.52; Na, 2.81 (%)
MS (m + 1) = 769.48

Example 127: Synthesis of compound I-127

Step (1): Compound X-1 + Compound 127a → Compound I-127
Using a method similar to that in Example 120, Compound I-127 was obtained as a yellow powder from Compound X-1 (932 mg, 1.0 mmol) and Compound 127a (528 mg, 1.0 mmol).
Yield: 161 mg, (20%)
¹ H-NMR (D ₂ O) δ: 1.46 (3H, t, J = 7.22 Hz), 1.49 (3H, s), 1.52-1.53 (6H, m), 2 2.22-2.25 (4H, m), 3.36-3.39 (3H, m), 3.59-3.61 (1H, m), 4.12 (1H, q, J = 6. 90 Hz), 4.22-4.32 (3H, m), 4.44 (2H, s), 4.90 (1H, d, J = 13.93 Hz), 5.48 (1H, d, J = 4.89 Hz), 5.83 (1H, d, J = 4.89 Hz), 6.98 (1H, s), 7.07 (1H, s), 7.53 (1H, s) , 8.20 (1H, s).
Elemental _{analysis: C 34 H 38 N 7 O} 10 S 2 Na · 8.1H 2 O
Theoretical values: C, 43.55; H, 5.83; N, 10.46; S, 6.84; Na, 2.45 (%)
Measurements: C, 43.54; H, 5.85; N, 10.72; S, 6.58; Na, 2.48 (%)
MS (m + 1) = 770.35

Example 128 Synthesis of Compound I-128

Step (1): Compound X-1 + Compound 128a → Compound I-128
Using a method similar to that in Example 120, compound I-128 was obtained as a yellow powder from compound X-1 (932 mg, 1.0 mmol) and compound 128a (530 mg, 1.0 mmol).
Yield: 331 mg, (42%)
¹ H-NMR (D ₂ O) δ: 1.48-1.54 (12H, m), 2.25 (4H, s), 3.42-3.48 (2H, m), 3.53- 3.57 (1H, m), 3.74-3.76 (1H, m), 4.13 (1H, q, J = 6.99 Hz), 4.40 (1H, d, J = 14. 43 Hz), 4.50 (2H, q, J = 7.15 Hz), 4.60 (2H, s), 5.01 (1H, d, J = 14.43 Hz), 5.48 (1H , D, J = 4.77 Hz), 5.81 (1H, d, J = 4.77 Hz), 6.99 (1H, s), 7.00 (1H, s), 7.33 (1H) , S).
MS (m + 1) = 771.35

Example 129: Synthesis of Compound I-129

Step (1): Compound X-1 + Compound 129a → Compound I-129
Using a method similar to that in Example 120, compound I-129 was obtained as a yellow powder from compound X-1 (932 mg, 1.0 mmol) and compound 129a (563 mg, 1.0 mmol).
Yield: 246 mg, (30%)
¹ H-NMR (D ₂ O) δ: 1.40 (3H, t, J = 7.03 Hz), 1.50 (3H, s), 1.52 (3H, s), 1.55 (3H , D, J = 7.03 Hz), 2.23 (4H, d, J = 10.42 Hz), 3.36 (3H, s), 3.56 (1H, s), 4.11-4 .23 (4H, m), 4.37 (2H, s), 4.89 (1H, d, J = 14.18 Hz), 5.50 (1H, d, J = 4.89 Hz), 5 .83 (1H, d, J = 4.89 Hz), 6.87 (1H, s), 6.98 (1H, s), 8.09 (1H, s).
Elemental _{analysis: C 34 H 37 ClN 7 O} 10 S 2 Na · 7.4H 2 O
Theoretical values: C, 42.56; H, 5.44; Cl, 3.69; N, 10.22; S, 6.68; Na, 2.40 (%)
Measurements: C, 42.53; H, 5.39; Cl, 3.51; N, 10.41; S, 6.69; Na, 2.56 (%)
MS (m + 1) = 804.33

Example 130: Synthesis of Compound I-130

Step (1): Compound X-24 + Compound 130a → Compound I-130
Using a method similar to that in Example 120, compound I-130 was obtained as a white powder from compound X-24 (709 mg, 0.80 mmol) and compound 130a (417 mg, 0.80 mmol).
Yield: 177 mg, (29%)
¹ H-NMR (D ₂ O) δ: 1.50 (3H, s), 1.52 (3H, s), 1.58 (3H, d, J = 7.15 Hz), 2.21-2 .25 (4H, m), 3.46-3.97 (8H, m), 4.09 (1H, q, J = 7.15 Hz), 4.26 (1H, d, J = 14.31) Hz), 5.04 (1H, d, J = 14.31 Hz), 5.47 (1H, d, J = 4.77 Hz), 5.82 (1H, d, J = 4.77 Hz) 7.01 (1H, s), 7.12 (1H, s), 7.79 (1H, s).
MS (m + 1) = 733.35

Example 131 Synthesis of Compound I-131

Step (1): Compound 131a + Compound 131b → Compound 131c
To a solution of compound 131a (4.57 g, 10.0 mmol) in methanol (45 mL) at 0 ° C. was added compound 131b (877 mg, 10.5 mmol) and triethylamine (1.46 mL, 10.5 mmol). After stirring at 0 ° C. for 1 hour, the solvent was removed. The crude product was dissolved in ethyl acetate and washed with water, aqueous hydrochloric acid and brine. The organic layer was filtered, dried over magnesium sulfate and concentrated under reduced pressure to give compound 131c as a brown oil. Compound 131c was used in the next reaction without further purification.
Yield: 4.86 g (100%)
¹ H-NMR (CDCl ₃ ) δ: 7.36 (2H, d, J = 8.3 Hz), 7.32 (2H, d, J = 8.6 Hz), 7.24 (2H, s) , 6.92 (2H, d, J = 8.6 Hz), 6.82 (2H, d, J = 8.6 Hz), 5.06 (2H, s), 5.00 (2H, s) , 4.09 (3H, s), 3.83 (3H, s), 3.80 (3H, s).

Step (2): Compound 131c + Compound 131d → Compound 131e
To a solution of compound 131c (4.86 g, 10.0 mmol) in dimethylacetamide (40 mL) was added methanesulfonyl chloride (1.01 mL, 13.0 mmol) at −20 ° C. After the mixture was stirred at −20 ° C. for 30 minutes, a solution of compound 131d (1.96 g, 14.0 mmol) in dimethylacetamide (10 mL) was added to the mixture and the reaction mixture was stirred at 0 ° C. for 30 minutes. Water and ethyl acetate were added to the reaction mixture, and then extracted with ethyl acetate. The combined organic layers were washed with water, aqueous hydrochloric acid and brine. The organic layer was filtered, dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel chromatography to give compound 131e as a brown foam.
Yield: 4.10 g (67%)
¹ H-NMR (CDCl ₃ ) δ: 7.36 (2H, d, J = 8.1 Hz), 7.31 (2H, d, J = 8.3 Hz), 7.22-7.18 ( 2H, m), 6.92 (2H, t, J = 8.6 Hz), 6.82 (2H, t, J = 8.3 Hz), 5.94 (1H, t, J = 6.6) Hz), 5.03 (2H, s), 4.99 (2H, s), 4.01 (3H, s), 3.83 (3H, s), 3.79 (3H, s), 3. 24 (2H, d, J = 6.6 Hz), 2.95 (6H, t, J = 7.5 Hz), 1.47 (6H, t, J = 7.3 Hz).

Step (3): Compound X-3 + Compound 131e → Compound 131f → Compound I-131
To a solution of compound X-3 (1.00 g, 1.26 mmol) in dimethylacetamide (2.0 mL) was added sodium iodide (377 mg, 2.56 mmol) and the mixture was stirred at room temperature for 30 minutes. After the mixture was cooled to 0 ° C., a solution of compound 131e (766 mg, 1.26 mmol) in dimethylacetamide (2.0 mL) was added dropwise thereto. The reaction mixture was stirred at 0 ° C. for 2 hours and then slowly added to 5% aqueous sodium chloride solution. The precipitated solid was collected by filtration and washed with aqueous hydrochloric acid and water. Compound 131f as a crude product was dissolved in dichloromethane (12 mL), and this solution was dried over magnesium sulfate. Insoluble material was removed by filtration to obtain Compound 131f as a dichloromethane solution. Compound 131f was used in the next reaction without further purification.

To a solution of compound 131f in dichloromethane (12 mL), anisole (1.37 mL, 12.6 mmol) and a 2 mol / L aluminum chloride solution in nitromethane (6.3 mL, 12.6 mmol) were sequentially added at −20 ° C. After stirring the reaction mixture at 0 ° C. for 30 minutes, diisopropyl ether and a small amount of water were added, and the resulting mixture was stirred to form a precipitate. The supernatant was removed by decantation. A diluted hydrochloric acid aqueous solution and acetonitrile were added to the insoluble matter adhering to the reaction vessel. The obtained product was stirred to completely dissolve insoluble matters. To this was added HP20-SS resin. Next, acetonitrile was distilled off therefrom under reduced pressure. The resulting mixture was purified by ODS column chromatography. The target compound-containing fraction was concentrated under reduced pressure and then lyophilized to obtain Compound I-131 as a yellow powder.
Yield: 250 mg (24%)
¹ H-NMR (D ₂ O) δ: 7.13 (1H, s), 7.06 (1H, s), 7.00 (1H, s), 5.84 (1H, d, J = 4. 5 Hz), 5.45 (1H, d, J = 4.8 Hz), 4.65 (1H, d, J = 14.4 Hz), 4.06 (2H, t, J = 6.7 Hz) ), 3.99 (3H, s), 3.54-3.46 (6H, br m), 3.36 (2H, s), 1.92 (6H, s), 1.56 (3H, d , J = 7.1 Hz), 1.52 (6H, d, J = 7.6 Hz).
MS (m + 1) = 849.40

Example 132: Synthesis of Compound 1-132.

Step (1): Compound 132a + Compound 131b → Compound 132b
To a solution of compound 132a (4.62 g, 10.0 mmol) in methanol (22 mL) and tetrahydrofuran (22 mL) was added compound 131b (877 mg, 10.0 mmol) at 0 ° C. After stirring at 0 ° C. for 3 hours, the solvent was removed. The crude product was dissolved in ethyl acetate and washed with water, aqueous hydrochloric acid and brine. The organic layer was filtered, dried over magnesium sulfate and concentrated under reduced pressure to give compound 132b as a brown oil. Compound 132b was used in the next reaction without further purification.
Yield: 2.77 g (59%)
¹ H-NMR (CDCl ₃ ) δ: 7.34 (2H, d, J = 8.5 Hz), 7.29 (2H, d, J = 8.7 Hz), 7.08 (1H, s) , 6.99 (1H, dd, J = 10.9, 3.2 Hz), 6.91 (3H, d, J = 8.7 Hz), 6.81 (2H, d, J = 8.7). Hz), 5.05 (2H, s), 5.04 (2H, s), 4.06 (3H, s), 3.83 (3H, s), 3.79 (3H, s).

Step (2): Compound 132b + Compound 131d → Compound 132c
Using a method similar to that in step (2) of Example 131, compound 132c was obtained as a yellow foam from compound 132b (2.77 g, 5.9 mmol) and compound 131d (1.16 g, 8.3 mmol).
Yield: 1.03 g (29%)
¹ H-NMR (CDCl ₃ ) δ: 7.33 (2H, d, J = 8.6 Hz), 7.28 (2H, d, J = 8.6 Hz), 7.10 (1H, s) 7.01 (1H, dd, J = 11.1, 1.5 Hz), 6.91 (2H, d, J = 8.3 Hz), 6.81 (2H, d, J = 8.3). Hz), 5.96 (1H, s), 5.04 (2H, s), 5.01 (2H, s), 4.01 (3H, s), 3.82 (3H, s), 79 (3H, s), 3.21 (2H, d, J = 6.3 Hz), 2.91-2.89 (6H, br m), 1.43-1.41 (6H, br m) .

Step (3): Compound X-3 + Compound 132c → Compound I-132
Using the same method as in Step (3) of Example 131, Compound I-132 was obtained from Compound X-3 (1.0 g, 1.26 mmol) and Compound 132c (745 mg, 1.26 mmol).
Yield: 314 mg (27%)
¹ H-NMR (D ₂ O) δ: 7.01 (1H, s), 6.94 (1H, d, J = 11.3 Hz), 6.91 (1H, s), 5.85 (1H , D, J = 4.8 Hz), 5.46 (1H, d, J = 4.8 Hz), 4.65 (1H, d, J = 14.4 Hz), 4.07 (2H, t , J = 7.5 Hz), 3.99 (3H, d, J = 8.0 Hz), 3.50 (6H, t, J = 18.1 Hz), 3.37 (2H, s), 1.93 (6H, t, J = 7.5 Hz), 1.57 (3H, d, J = 7.2 Hz), 1.53 (3H, s), 1.51 (3H, s).
MS (m + 1) = 833.41

Example 133: Synthesis of Compound I-133

Step (1): Compound 131a + Compound 133a → Compound 133b
Using the same method as in step (1) of Example 131, compound 133b was obtained as a brown powder from compound 131a (5.03 g, 11 mmol) and compound 133a (1.62 g, 11 mmol).
Yield: 6.45 g (quantitative)
¹ H-NMR (CDCl ₃ ) δ: 7.36-7.31 (5H, m), 7.17 (1H, d, J = 7.3 Hz), 6.92 (2H, d, J = 8 .3 Hz), 6.82 (2H, d, J = 8.3 Hz), 5.04 (2H, s), 5.00 (2H, s), 4.72 (2H, s), 83 (3H, s), 3.80 (3H, s), 1.51 (9H, s).

Step (2): Compound 133b + Compound 131d → Compound 133c
Using a method similar to that in step (2) of Example 131, compound 133c was obtained as a yellow foam from compound 133b (6.45 g, 11 mmol) and compound 131d (2.16 g, 15.4 mmol).
Yield: 5.42 g (70%)
¹ H-NMR (CDCl ₃ ) δ: 7.45-7.28 (6H, m), 7.18-7.16 (1H, m), 6.92 (2H, d, J = 8.6 Hz) ), 6.81 (2H, d, J = 8.8 Hz), 5.03 (2H, s), 4.97 (2H, s), 4.67 (2H, s), 3.83 (3H) , S), 3.79 (3H, s), 3.26 (2H, d, J = 6.3 Hz), 2.93 (6H, t, J = 7.1 Hz), 1.48-1 .43 (15H, br m).

Step (3): Compound X-3 + Compound 133c → Compound I-133
Using the same method as in Step (3) of Example 131, Compound I-133 was obtained as a yellow powder from Compound X-3 (1.0 g, 1.26 mmol) and Compound 133c (892 mg, 1.26 mmol).
Yield: 260 mg (22%)
¹ H-NMR (D ₂ O) δ: 7.15 (1H, s), 7.08 (1H, s), 7.01 (1H, s), 5.84 (1H, d, J = 4. 9 Hz), 5.46 (1H, d, J = 4.8 Hz), 4.64 (1H, d, J = 14.3 Hz), 4.57 (2H, s), 4.07 (2H) , Dd, J = 10.5, 6.3 Hz), 3.49 (6H, t, J = 19.1 Hz), 3.40 (3H, s), 1.95 (6H, t, J = 7.6 Hz), 1.57 (3H, d, J = 7.0 Hz), 1.52 (3H, s), 1.50 (3H, s).
MS (m + 1) = 894.38

Example 134: Synthesis of Compound I-134

Step (1): Compound 131a + Compound 134a → Compound 134b
Using the same method as in step (1) of Example 131, compound 134b was obtained as a brown oil from compound 131a (4.57 g, 10 mmol) and compound 134a (3.03 g, 11 mmol).
Yield: 7.1 g (99%)
¹ H-NMR (CDCl ₃ ) δ: 7.49 (1H, d, J = 1.8 Hz), 7.36-7.27 (20H, m), 6.88 (2H, d, J = 8) .6 Hz), 6.83 (2H, d, J = 8.3 Hz), 5.06 (2H, s), 4.98 (2H, s), 3.81 (3H, s), 79 (3H, s).

Step (2): Compound 134b + Compound 131d → Compound 134c
Using a method similar to that in step (2) of Example 131, compound 134c was obtained as a brown oil from compound 134b (7.1 g, 9.9 mmol) and compound 131d (1.95 g, 13.9 mmol).
Yield: 1.67 g (20%)
¹ H-NMR (CDCl ₃ ) δ: 7.41-7.26 (29H, m), 6.86 (2H, d, J = 8.3 Hz), 6.82 (2H, d, J = 8 .3 Hz), 6.31 (1H, t, J = 6.3 Hz), 5.02 (2H, d, J = 5.6 Hz), 4.95 (2H, d, J = 8.6) Hz), 3.82 (3H, s), 3.78 (3H, s), 2.98 (2H, d, J = 6.3 Hz), 2.83 (6H, t, J = 7.3) Hz), 1.15 (6H, t, J = 7.3 Hz).

Step (3): Compound X-3 + Compound 134c → Compound I-134
Using a method similar to that in step (3) of Example 131, compound I-134 was obtained as a colorless powder from compound X-3 (1.0 g, 1.26 mmol) and compound 134c (1.05 g, 1.26 mmol). Obtained.
Yield: 390 mg (28%)
¹ H-NMR (D ₂ O) δ: 7.13 (1H, d, J = 1.9 Hz), 7.01 (1H, s), 6.98 (1H, d, J = 2.0 Hz) ), 5.84 (1H, d, J = 4.9 Hz), 5.44 (1H, d, J = 4.9 Hz), 4.64 (1H, d, J = 14.4 Hz), 4.06 (2H, q, J = 7.3 Hz), 3.54-3.39 (6H, m), 3.31 (2H, s), 1.91 (6H, t, J = 7. 8 Hz), 1.56 (3H, d, J = 7.0 Hz), 1.53 (3H, s), 1.51 (3H, s).
MS (m + 1) = 835.42

Example 135: Synthesis of Compound I-135

Step (1): Compound 132a + Compound 133d → Compound 135a
To a solution of compound 132a (4.99 g, 10.8 mmol) and aqueous hydrochloric acid (5.4 mL, 10.8 mmol) in methanol (25 mL) and tetrahydrofuran (25 mL) at 0 ° C. was added compound 133d (1.77 g, 12. 0 mmol) was added. After stirring at 0 ° C. for 3 hours, the solvent was removed. The crude product was dissolved in ethyl acetate and washed with water, aqueous hydrochloric acid and brine. The organic layer was filtered, dried over magnesium sulfate and concentrated under reduced pressure to give compound 135a as a brown oil. Compound 135a was used in the next reaction without further purification.
Yield: 4.41 g (65%)
¹ H-NMR (CDCl ₃ ) δ: 7.34 (2H, d, J = 8.1 Hz), 7.29 (2H, t, J = 7.7 Hz), 7.11 (2H, t, J = 13.0 Hz), 6.92 (3H, t, J = 8.0 Hz), 6.82 (2H, d, J = 8.3 Hz), 5.05 (2H, s), 5 .03 (2H, s), 4.71 (2H, s), 3.83 (3H, s), 3.78 (3H, s), 1.51 (9H, s).

Step (2): Compound 135a + Compound 131d → Compound 135b
Using a method similar to step (2) in Example 131, compound 135b was obtained as a yellow foam from compound 135a (4.41 g, 6.5 mmol) and compound 131d (1.27 g, 9.1 mmol).
Yield: 2.73 g (62%)
¹ H-NMR (CDCl ₃ ) δ: 7.33 (2H, d, J = 8.5 Hz), 7.29 (2H, d, J = 8.8 Hz), 7.14 (1H, s) , 7.04 (1H, dd, J = 11.0, 6.5 Hz), 6.91 (2H, dd, J = 5.5, 3.1 Hz), 6.81 (2H, d, J = 8.7 Hz), 5.04 (2H, s), 5.01 (2H, s), 4.66 (2H, s), 3.83 (3H, s), 3.79 (3H, s) ), 3.29 (2H, d, J = 6.4 Hz), 3.03-2.97 (6H, m), 1.60 (6H, m), 1.48 (9H, s).

Step (3): Compound X-3 + Compound 135b → Compound I-135
Using a method similar to that in step (3) of Example 131, compound I-135 was obtained as a yellow powder from compound X-3 (1.0 g, 1.26 mmol) and compound 135b (853 mg, 1.26 mmol).
Yield: 175 mg (15%)
¹ H-NMR (D ₂ O) δ: 7.01 (1H, s), 6.98-6.96 (2H, m), 5.84 (1H, d, J = 4.8 Hz), 5 .46 (1H, d, J = 4.9 Hz), 4.64 (2H, d, J = 13.9 Hz), 4.57 (2H, s), 4.08-4.06 (2H, m), 3.52-3.47 (6H, m), 3.40 (2H, s), 1.95 (6H, t, J = 7.7 Hz), 1.57 (3H, s), 1.52 (3H, s), 1.50 (3H, d, J = 5.8 Hz).
MS (m + 1) = 877.52

Example 136: Synthesis of Compound I-136

Step (1): Compound 132a + Compound 136a → Compound 136b
Using the same method as in Step (1) of Example 132, Compound 136b was obtained as a brown oil from Compound 132a (4.99 g, 10 mmol) and Compound 136a (1.90 g, 10 mmol).
Yield: 5.11 g (89%)
¹ H-NMR (CDCl ₃ ) δ: 7.32 (2H, d, J = 8.5 Hz), 7.29 (2H, d, J = 8.5 Hz), 7.11 (0H, d, J = 188.6 Hz), 7.05 (1H, s), 6.98 (1H, dd, J = 11.1, 1.6 Hz), 6.92-6.89 (4H, m), 6.81 (2H, d, J = 8.7 Hz), 5.22 (2H, s), 5.05 (2H, s), 5.03 (2H, s), 3.83 (3H, s ), 3.81 (3H, s), 3.79 (3H, s).

Step (2): Compound 136b + Compound 131d → Compound 136c
Using a method similar to that in step (2) of Example 131, compound 136c was obtained as a yellow foam from compound 136b (5.11 g, 8.9 mmol) and compound 131d (1.75 g, 12.5 mmol).
Yield: 2.4 g (39%)
¹ H-NMR (CDCl ₃ ) δ: 7.34-7.32 (4H, m), 7.29 (2H, d, J = 8.5 Hz), 7.12 (1H, s), 7. 03 (1H, dd, J = 11.0, 1.8 Hz), 6.91 (4H, d, J = 8.7 Hz), 6.81 (2H, d, J = 8.5 Hz), 5.91 (1H, t, J = 6.4 Hz), 5.15 (2H, s), 5.04 (2H, s), 5.03 (2H, s), 3.83 (3H, s ), 3.82 (3H, s), 3.79 (3H, s), 3.14 (2H, d, J = 6.5 Hz), 2.75-2.73 (6H, br m), 1.29-1.24 (6H, m).

Step (3): Compound X-3 + Compound 136c → Compound I-136
Using the same method as in Step (3) of Example 131, Compound I-136 was obtained as a colorless powder from Compound X-3 (1.0 g, 1.26 mmol) and Compound 136c (878 mg, 1.26 mmol). .
Yield: 400 mg (40%)
¹ H-NMR (D ₂ O) δ: 7.00 (1H, s), 6.95 (1H, d, J = 11.3 Hz), 6.92 (1H, s), 5.84 (1H , D, J = 4.9 Hz), 5.45 (1H, d, J = 4.8 Hz), 4.64 (1H, d, J = 14.2 Hz), 4.06 (2H, t , J = 7.0 Hz), 3.51-3.47 (6H, br m), 3.39 (3H, s), 1.96-1.94 (6H, br m), 1.56 ( 3H, d, J = 7.0 Hz), 1.54 (3H, s), 1.50 (3H, s).
MS (m + 1) = 819.54

Example 137: Synthesis of Compound I-137

Step (1): Compound 137a + Compound 134a → Compound 137b
Using a method similar to step (1) of Example 131, compound 137b was obtained as a brown oil from compound 137a (4.39 g, 9.60 mmol) and compound 134a (2.64 g, 9.60 mmol).
Yield: 2.57 g (38%)
¹ H-NMR (CDCl ₃ ) δ: 7.51-7.43 (19H, m), 6.94-6.89 (2H, m), 6.82-6.79 (2H, m), 5 .09-4.95 (4H, m), 3.84-3.74 (6H, m).

Step (2): Compound 137b + Compound 137c → Compound 137d
Using a method similar to that in step (2) of Example 131, compound 137d was obtained as a brown oil from compound 137b (2.57 g, 3.60 mmol) and compound 137c (545 mg, 4.32 mmol).
Yield: 940 mg (32%)
¹ H-NMR (CDCl ₃ ) δ: 7.34 (7H, dt, J = 25.1, 7.5 Hz), 7.23 (13H, br s), 6.93 (2H, d, J = 8.3 Hz), 6.77 (2H, d, J = 8.3 Hz), 5.11 (2H, s), 4.98 (2H, s), 3.84 (3H, s), 3 .73 (3H, s), 3.36 (2H, d, J = 5.3 Hz), 2.99-2.79 (6H, m), 1.82-1.64 (6H, br m) .

Step (3): Compound X-3 + Compound 137d → Compound I-137
To a solution of compound X-3 (908 mg, 1.14 mmol) in dimethylacetamide (2.0 mL) was added sodium iodide (342 mg, 2.29 mmol) and the mixture was stirred at room temperature for 30 minutes. After the mixture was cooled to 0 ° C., a solution of compound 137d (800 mg, 1.14 mmol) in dimethylacetamide (2.0 mL) was added dropwise thereto. The reaction mixture was stirred at 0 ° C. for 2 hours and then slowly added to 5% aqueous sodium chloride solution. The precipitated solid was collected by filtration, washed with aqueous hydrochloric acid and water, and suspended in water. This suspension was lyophilized to give the crude product as a brown solid. The obtained crude product was directly used in the next step without purification.

To a solution of the crude product in dichloromethane (12 mL), anisole (1.25 mL, 11.4 mmol) and a 2 mol / L aluminum chloride solution (5.7 mL, 11.4 mmol) in nitromethane were sequentially added at −20 ° C. . After stirring at 0 ° C. for 30 minutes, diisopropyl ether and a small amount of water were added to the reaction mixture, and the resulting mixture was stirred to form a precipitate. The supernatant was removed by decantation. A diluted hydrochloric acid aqueous solution and acetonitrile were added to the insoluble matter adhering to the reaction vessel. The obtained product was stirred to completely dissolve insoluble matters. To this was added HP20-SS resin. The acetonitrile was then distilled off under reduced pressure. The resulting mixture was purified by ODS column chromatography. The objective compound-containing fraction was concentrated under reduced pressure and then freeze-dried to obtain Compound I-137 as a yellow powder.
Yield: 280 mg (29%)
¹ H-NMR (D ₂ O) δ: 7.05-6.97 (3H, m), 5.87-5.86 (1H, m), 5.46-5.45 (1H, m), 4.31-4.07 (5H, m), 3.81-3.51 (7H, m), 2.36-2.31 (4H, m), 1.59 (3H, d, J = 6 .9 Hz), 1.53 (3H, s), 1.51 (3H, s).

Example 138: Synthesis of Compound I-138

Step (1): Compound 138a + Compound 136a → Compound 138b
To a solution of compound 138a (5.58 g, 10.0 mmol) in methanol (45 mL) at 0 ° C. acetic acid (0.572 mL, 10.0 mmol), compound 136a (1.90 g, 10.0 mmol) and triethylamine (1 .39 mL, 10.0 mmol) was added. After stirring at 0 ° C. for 1 hour, the solvent was removed. The crude product was dissolved in ethyl acetate and washed with water, aqueous hydrochloric acid and brine. The organic layer was filtered, dried over magnesium sulfate and concentrated under reduced pressure to give compound 138b as a brown oil. Compound 138b was used in the next reaction without further purification.
Yield: 5.92 g (100%)
¹ H-NMR (CDCl ₃ ) δ: 7.36-7.31 (6H, m), 7.21 (2H, s), 6.92-6.90 (4H, m), 6.82 (2H , D, J = 8.7 Hz), 5.23 (2H, s), 5.04 (2H, s), 4.99 (2H, s), 3.83 (3H, s), 3.81 (3H, s), 3.80 (3H, s).

Step (2): Compound 138b + Compound 137c → Compound 138c
Using a method similar to that in step (2) of Example 131, compound 138c was obtained as a yellow foam from compound 138b (1.78 g, 3.0 mmol) and compound 137c (492 mg, 3.9 mmol).
Yield: 800 mg (38%)
¹ H-NMR (CDCl ₃ ) δ: 7.38-7.30 (6H, m), 7.23 (1H, d, J = 5.1 Hz), 7.16 (1H, t, J = 4 .3 Hz), 6.91-6.84 (6H, m), 5.15 (2H, s), 5.08-5.06 (2H, m), 5.02-5.00 (2H, m), 4.70 (1H, br s), 3.83-3.77 (9H, m), 3.29-2.55 (8H, m), 1.92-1.73 (3H, m ), 1.22-1.17 (2H, m).

Step (3): Compound X-3 + Compound 138c → Compound I-138
Using the same method as in Step (3) of Example 137, Compound I-138 was obtained as a white powder from Compound X-3 (908 mg, 1.14 mmol) and Compound 138c (800 mg, 1.14 mmol).
Yield: 320 mg (33%, E / Z = 29: 64 or 64:29)
¹ H-NMR (D ₂ O) δ: 7.11-7.09 (2H, m), 7.00 (1H, s), 5.85-5.84 (1H, m), 5.44 ( 1H, s), 4.87 (2H, t, J = 27.9 Hz), 4.32 (1H, t, J = 15.0 Hz), 4.13-4.05 (2H, m), 3.81-3.67 (7H, br m), 2.37 (4H, s), 1.59-1.56 (3H, m), 1.52 (3H, s), 1.50 (3H , S).
MS (m + 1) = 822.5

Example 139: Synthesis of Compound I-139

Step (1): Compound 139a + Compound 137c → Compound 139b
Using a method similar to step (2) in step (2) of Example 131, compound 139b was obtained as a yellow foam from compound 139a (2.88 g, 5.0 mmol) and compound 137c (757 mg, 6.0 mmol). .
Yield: 861 mg (25%)
¹ H-NMR (CDCl ₃ ) δ: 7.34-7.27 (8H, m), 6.90-6.88 (4H, m), 6.82 (2H, d, J = 8.6 Hz) ), 5.14 (2H, s), 5.09-5.00 (4H, m), 4.69 (1H, s), 3.82-3.80 (9H, m), 3.27- 3.18 (2H, br m), 3.08-2.82 (4H, m), 2.81-2.70 (2H, m), 2.60-2.53 (1H, m), 2 .03-1.70 (3H, m), 1.42 (1H, br s).

Step (2): Compound X-3 + Compound 139b → Compound I-139
Using the same method as in Step (3) of Example 137, Compound I-139 was obtained as a colorless powder from Compound X-3 (1.0 g, 1.26 mmol) and Compound 139b (861 mg, 1.26 mmol). .
Yield: 320 mg (31%, E / Z or Z / E = 34: 63)
¹ H-NMR (D ₂ O) δ: 7.00 (1H, s), 6.96 (2H, d, J = 11.7 Hz), 5.86-5.84 (1H, m), 5 .45-5.44 (1H, m), 4.33 (2H, t, J = 14.7 Hz), 4.13-4.07 (2H, m), 3.87-3.49 (8H M), 2.38-2.36 (4H, br m), 1.59-1.57 (3H, m), 1.52 (3H, s), 1.50 (3H, s).
MS (m + 1) = 805.82

Example 140: Synthesis of Compound I-140

Step (1): Compound X-24 + Compound 140a → Compound 140b → Compound I-140
In the same manner as in Step (4) of Example 107, Compound X-24 (886 mg, 1.0 mmol) and Compound 140a (397 mg, 1.0 mmol) (synthesized according to the synthesis of WO20111225966A1) were used to synthesize the target compound. .
Yield: 334.2 mg, (37%)
¹ H-NMR (D ₂ O) δ: 7.78 (1H, s), 7.12 (1H, s), 7.00 (1H, s), 5.84 (1H, d, J = 4. 9 Hz), 5.45 (1H, d, J = 4.9 Hz), 4.64 (1H, d, J = 14.3 Hz), 4.11-4.05 (2H, m), 3 58-3.42 (6H, m), 3.39 (2H, s), 1.94 (6H, t, J = 7.8 Hz), 1.56 (3H, d, J = 7.2) Hz), 1.52 (3H, s), 1.50 (3H, s).
Elemental analysis: C32H37N8O10S2Na (H2O) 6.1
Theoretical: C, 43.15; H, 5.57; N, 12.58; S, 7.20; Na, 2.58 (%)
Measurements: C, 43.10; H, 5.45; N, 12.82; S, 7.21; Na, 2.64 (%)

Example 141: Synthesis of Compound 1-141

Step (1): Compound 141a → Compound 141b
To a cooled (0 ° C.) solution of compound 141a (17.4 g, 30.0 mmol) in DMA (200 ml) was added 39% peracetic acid (5.69 ml, 33.0 mmol). After stirring for 1 hour at 0 ° C., the mixture was quenched with 50 mL of 10% aqueous sodium bisulfite. The resulting solid was collected by filtration and washed with water and isopropanol to give 17.4 g of compound 141b (98%).
¹ H-NMR (DMSO-D ₆ ) δ: 8.57 (d, J = 8.1 Hz, 1H), 7.50 (d, J = 7.7 Hz, 2H), 7.42-7. 21 (m, 13H), 6.97 (s, 1H), 5.91 (dd, J = 8.1, 4.5 Hz, 1H), 5.03 (d, J = 4.5 Hz, 1H) ), 4.20 (d, J = 18.1 Hz, 1H), 4.01 (d, J = 18.1 Hz, 1H), 3.69 (d, J = 14.0 Hz, 1H), 3.55 (d, J = 14.0 Hz, 1H), 3.12 (s, 3H).

Step (2): Compound 141b → Compound 141c
To a solution of compound 141b (17 g, 28.6 mmol) in DMF (170 ml) was added dimethylamine hydrochloride (2.33 g, 28.6 mmol) and 36% -38% formalin (4.26 ml, 57.2 mmol). . After stirring at 50 ° C. for 30 minutes, the obtained mixture was poured into water, and the obtained solid was collected by filtration to obtain 13.2 g of compound 141c (76%).
¹ H-NMR (DMSO-D ₆ ) δ: 8.59 (d, J = 8.3 Hz, 1H), 7.53 (d, J = 7.7 Hz, 2H), 7.42-7. 23 (m, 14H), 6.95 (s, 1H), 6.51 (s, 1H), 6.45 (s, 1H), 6.05 (dd, J = 8.3, 5.0 Hz) , 1H), 5.25 (d, J = 5.0 Hz, 1H), 3.69 (d, J = 14.1 Hz, 1H), 3.58 (d, J = 14.1 Hz, 1H) ), 3.23 (s, 3H).

Step (3): Compound 141c → Compound 141d
To a cooled (−40 ° C.) solution of sodium borohydride (937 mg, 24.8 mmol) in MeOH (300 ml), a solution of compound 141c (12.5 g, 20.6 mmol) in 250 ml THF at −40 ° C. Was dripped. The mixture was stirred at −40 ° C. for 30 minutes before TFA (0.163 ml, 2.12 mmol) was added. The mixture was then concentrated in vacuo. The resulting precipitate was collected by filtration and washed with MeOH to give 9.40 g of compound 141d (75%).
¹ H-NMR (DMSO-D ₆ ) δ: 8.61 (d, J = 8.1 Hz, 1H), 7.49 (d, J = 7.7 Hz, 2H), 7.44-7. 22 (m, 13H), 6.95 (s, 1H), 5.94 (dd, J = 3.5, 8.1 Hz, 1H), 5.18 (d, J = 3.5 Hz, 1H) ), 4.06 (q, J = 7.7 Hz, 1H), 3.68 (d, J = 14.3 Hz, 1H), 3.57 (d, J = 14.3 Hz, 1H), 3.04 (s, 3H), 1.55 (d, J = 7.7 Hz, 3H).

Step (4): Compound 141d → Compound 141e
To a cooled (−40 ° C.) solution of compound 141d (9.39 g, 15.4 mmol) in DMF (100 ml) was added phosphorus tribromide (1.75 ml, 18.5 mmol). After the reaction mixture was stirred at −40 ° C. for 15 minutes, the mixture was diluted with water. The obtained solid was collected by filtration and washed with water to obtain 9.40 g of compound 141e.
¹ H-NMR (DMSO-D ₆ ) δ: 9.22 (d, J = 8.4 Hz, 1H), 7.48 (d, J = 7.8 Hz, 2H), 7.42-7. 19 (m, 13H), 6.90 (s, 1H), 5.83 (dd, J = 8.4, 5.0 Hz, 1H), 5.41 (d, J = 5.0 Hz, 1H) ), 4.26 (q, J = 7.1 Hz, 1H), 3.60-3.50 (m, 2H), 3.07 (s, 3H), 1.48 (d, J = 7. 1 Hz, 3H).

Step (5): Compound 141e → Compound 141f
To a cooled (−20 ° C.) slurry of phosphorus pentachloride (4.01 g, 19.2 mmol) in dichloromethane (60.0 ml), pyridine (1.67 ml, 21.2 mmol), then compound 141e (5.7 g, 9 .62 mmol) was added. After the mixture was stirred at 0 ° C. for 45 min, the mixture was cooled to −40 ° C., and then MeOH (23.4 ml, 577 mmol) was added in one portion to the mixture. The mixture was warmed to room temperature and diluted with water and dichloromethane. The aqueous layer was extracted with dichloromethane. The combined organic layers were washed with water and brine, dried over MgSO ₄ and filtered. To this mixture was added 4 mmol / l HCl in EtOAc (3.61 ml) and the solution was concentrated in vacuo. The resulting compound 141f as a residue was used in the next step without further purification.

Step (6): Compound 141f + Compound 141g → Compound 141h
To a cooled (−50 ° C.) solution of compound 141f (9.62 mmol) in dichloromethane (50.0 ml), compound 141 g (4.96 g, 11.5 mmol) and phenyl dichlorophosphate (1.87 ml, 12.5 mmol) N-methylmorpholine (4.23 ml, 38.5 mmol) was then added. After 1 hour at −50 ° C., the reaction mixture was poured into water. The aqueous layer was then extracted with ethyl acetate and the combined extracts were washed with water and brine, dried (MgSO ₄ ), filtered and concentrated in vacuo. The residue was purified by silica gel chromatography to give 1.25 g of compound 141h (25%).
¹ H-NMR (CDCl ₃ ) δ: 8.29 (d, J = 9.0 Hz, 1H), 7.42-7.28 (m, 11H), 6.94 (s, 1H), 6. 06 (dd, J = 9.0, 5.1 Hz, 1H), 5.29 (d, J = 5.0 Hz, 1H), 4.15-4.02 (m, 1H), 2.62 (S, 3H), 1.63 (d, J = 10.0 Hz, 3H), 1.52 (s, 15H), 1.41 (s, 9H).

Step (7): Compound 141h → Compound 141i
To a cooled (0 ° C.) solution of compound 141h (4.93 g, 5.57 mmol) in tetrahydrofuran (50.0 ml) was added magnesium bromide diethyl ether complex (7.19 g, 27.9 mmol), pyridine-4-thiol ( 1.36 g, 12.3 mmol) and potassium carbonate (1.69 g, 12.3 mmol) were added. After stirring at 0 ° C. for 2 hours, the reaction mixture was poured into water. The aqueous layer was then extracted with ethyl acetate and the combined extracts were washed with water and brine, dried (MgSO ₄ ), filtered and concentrated in vacuo. The residue was purified by silica gel chromatography to give 1.25 g of compound 141i (25%).
¹ H-NMR (CDCl ₃ ) δ: 8.39-8.32 (m, 1H), 7.44-7.21 (m, 13H), 7.08 (d, J = 5.9 Hz, 2H ), 6.98 (s, 1H), 6.05 (dd, J = 8.8, 5.1 Hz, 1H), 5.38 (d, J = 5.1 Hz, 1H), 3.82. (Q, J = 7.2 Hz, 1H), 1.63 (d, J = 9.7 Hz, 6H), 1.53 (s, 9H), 1.42 (s, 9H).

Step (8): Compound 141i + Compound 141j → Compound 141k
To a cooled (0 ° C.) solution of compound 141i (0.90 g, 1.00 mmol) in DMF (3.00 ml) was added compound 141j (0.56 g, 1.10 mmol; see WO2013002215A1). After stirring at 0 ° C. overnight, the reaction mixture was poured into water. The aqueous layer was then extracted with ethyl acetate and the combined extracts were washed with water and brine, dried (MgSO ₄ ), filtered and concentrated in vacuo. The resulting compound 141k as a residue was used in the next step without further purification.

Step (9): Compound 141k → Compound I-141
To a cooled (−20 ° C.) solution of compound 141k in dichloromethane (15.0 ml), anisole (1.09 ml, 10.0 mmol), then a 2 mol / L aluminum chloride solution in nitromethane (5.00 mL, 10.0 mmol) Was added at once. After stirring at −20 ° C. for 30 minutes, the mixture was quenched with water (15.0 ml). The resulting precipitate was dissolved in 2 mol / L hydrochloric acid aqueous solution and acetonitrile. The aqueous phase was washed with diisopropyl ether. HP20SS resin was added to this aqueous phase, and acetonitrile contained therein was distilled off under reduced pressure. The remaining suspension was loaded onto a HP20SS precolumn connected to an ODS column and purified. To the obtained target compound solution, 0.2 mol / L sodium hydroxide aqueous solution was added until the whole became pH 6.0. Next, a piece of dry ice was added thereto. The resulting solution was concentrated under reduced pressure and then lyophilized to give 508 mg of compound I-141 (65% from compound 141i).
¹ H-NMR (D ₂ O) δ: 8.38 (d, J = 6.6 Hz, 2H), 7.87 (d, J = 6.6 Hz, 2H), 7.53 (d, J = 8.6 Hz, 1H), 6.99 (s, 1H), 6.93 (d, J = 8.6 Hz, 1H), 5.85 (d, J = 5.1 Hz, 1H), 5.65 (d, J = 5.1 Hz, 1H), 4.22 (q, J = 7.2 Hz, 1H), 1.54-1.50 (m, 9H).
Elemental analysis: C30H26ClN6NaO10S3 (H2O) 5
Theoretical values: C, 41.17; H, 4.15; N, 9.60; S, 10.99; Cl, 4.05; Na, 2.63 (%)
Measurements: C, 40.88; H, 4.16; N, 9.72; S, 11.00; Cl, 4.26; Na, 2.93 (%)

Example 142: Synthesis of Compound 1-142

Step (1): Compound 142a → Compound 142b
Compound 142b was synthesized in the same manner as in Step (1) of Example 117 using Compound 142a (12.8 g, 30.0 mmol).
Yield: 14.1 g (86%)
¹ H-NMR (CDCl ₃ ) δ: 8.11 (d, J = 8.6 Hz, 1H), 7.97 (s, 1H), 7.74 (s, 1H), 7.60-7. 53 (m, 1H), 7.49-7.43 (m, 2H), 7.39 (d, J = 8.3 Hz, 2H), 7.33 (d, J = 8.3 Hz, 2H) ), 6.94 (d, J = 8.3 Hz, 2H), 6.85 (d, J = 8.3 Hz, 2H), 5.17 (s, 2H), 5.14 (s, 2H) ), 3.84 (s, 3H), 3.81 (s, 3H).

Step (2): Compound 142b → Compound 142c
Compound 142c was synthesized in the same manner as in Step (2) of Example 117 using Compound 142b (1.63 g, 3.00 mmol).
Yield: 1,53 g (95%)
¹ H-NMR (CDCl ₃ ) δ: 7.41 (d, J = 1.6 Hz, 1H), 7.37 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.5 Hz, 2H), 6.93 (d, J = 8.4 Hz, 2H), 6.82 (d, J = 8.4 Hz, 2H), 6.09 (t, J = 5. 8 Hz, 1H), 5.10 (s, 2H), 5.03 (s, 2H), 3.83 (s, 3H), 3.80 (s, 3H), 3.78 (d, J = 6.3 Hz, 2H), 3.04-2.92 (m, 2H), 2.66-2.60 (m, 2H), 2.34 (s, 2H), 1.35-1.22. (M, 2H).

Step (3): Compound 142c + Compound X-24 → Compound I-142
The target compound was synthesized using Compound X-24 (0.886 g, 1.00 mmol) and Compound 142c (0.537 g, 1.00 mmol) in the same manner as in Step (4) of Example 107.
Yield: 0.291 g (36%)
¹ H-NMR (D ₂ O) δ: 7.38 (d, J = 1.8 Hz, 1H), 7.22 (d, J = 1.8 Hz, 1H), 6.99 (s, 1H ), 5.77 (d, J = 4.7 Hz, 1H), 5.40 (d, J = 4.7 Hz, 1H), 4.90 (d, J = 14.4 Hz, 1H), 4.24 (d, J = 14.4 Hz, 1H), 4.04 (q, J = 7.1 Hz, 1H), 3.74-3.51 (m, 6H), 3.41 (d , J = 8.5 Hz, 1H), 3.31 (d, J = 8.5 Hz, 1H), 2.29-2.15 (m, 2H), 2.02-1.92 (m, 2H), 1.55 (d, J = 7.1 Hz, 3H), 1.52-1.48 (m, 6H).
Elemental analysis: C32H35ClN7NaO10S2 (H2O) 6.4
Theoretical values: C, 41.98; H, 5.26; N, 10.71; Cl, 3.87; Na, 2.51 (%)
Measurement: C, 41.94; H, 5.16; N, 10.87; Cl, 3.72; Na, 2.61 (%)

窒素下、０℃で、ＤＭＦ（５ｍＬ）中、６，７−ビス（（４−メトキシベンジル）オキシ）−１−メチル−３−（ピロリジン−１−イルメチル）キノリン−４（１Ｈ）−オン（ＷＯ２０１３０５２５６８Ａ１号 ０．５８８ｇ、１．１４ｍｍｏｌ）に、ＤＭＦ（５ｍＬ）中、化合物Ｘ−２４（１．０６３ｇ、１．２００ｍｍｏｌ）を加えた。この混合物を同じ温度で３時間にわたって撹拌し、一晩冷凍庫に置いた。この溶液を、ＮａＨＳＯ_３（１ｇ）を含有する氷冷した５％ＮａＣｌ水溶液（１００ｍＬ）に注ぎ、１５分間撹拌した。固体を濾取し、水で洗浄し、乾燥させ、ＭｅＯＨ／ＤＣＭ（０〜２０％）で溶出する自動シリカゲルクロマトグラフィー（Ｃｏｍｂｉｆｌａｓｈ ＲＦ）により精製し、化合物１４３ａ（０．２６９ｇ、収率１５％）を褐色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： １２７３．５。 Example 143: Synthesis Step of Compound I-143 (1): Compound X-24 → Compound 143a
Compound 143a: 1-((6,7-bis ((4-methoxybenzyl) oxy) -1-methyl-4-oxo-1,4-dihydroquinolin-3-yl) methyl) -1-(((4S , 6R, 7R) -7-((Z) -2-(((1- (tert-butoxy) -2-methyl-1-oxopropan-2-yl) oxy) imino) -2- (2- ( (Tert-Butoxycarbonyl) amino) thiazol-4-yl) acetamido) -2-(((4-methoxybenzyl) oxy) carbonyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4. 2.0] Oct-2-en-3-yl) methyl) pyrrolidine-1-ium iodide

6,7-bis ((4-methoxybenzyl) oxy) -1-methyl-3- (pyrrolidin-1-ylmethyl) quinolin-4 (1H) -one in DMF (5 mL) at 0 ° C. under nitrogen Compound No. X-24 (1.063 g, 1.200 mmol) in DMF (5 mL) was added to WO2013052568A1 0.588 g, 1.14 mmol). The mixture was stirred at the same temperature for 3 hours and placed in the freezer overnight. The solution was poured into ice-cold 5% aqueous NaCl (100 mL) containing NaHSO ₃ (1 g) and stirred for 15 minutes. The solid was filtered off, washed with water, dried and purified by automated silica gel chromatography (Combiflash RF) eluting with MeOH / DCM (0-20%) to give compound 143a (0.269 g, 15% yield). Was obtained as a brown solid. LCMS: (M + H) ^<+> : 1273.5.

０℃で、ＤＣＭ（１．５ｍＬ）中、化合物１４３ａ（０．２６９ｇ、０．１４２ｍｍｏｌ）に、アニソール（０．１６ｍＬ、１．４２ｍｍｏｌ）、次いでＴＦＡ（０．５０ｍＬ、６．５ｍｍｏｌ）を加えた。この混合物を室温まで温めた後、一晩撹拌した。ジイソプロピルエーテル（３０ｍＬ）を加え、この混合物を１０分間撹拌した。生じた沈殿を濾取し、ジイソプロピルエーテルで２回洗浄した（２×５ｍＬ）。固体をＭｅＣＮ（６ｍＬ）、水（６ｍＬ）、および２Ｍ ＨＣｌ水溶液（１．５ｍＬ）の混合物に溶かし、ＨＰ２０ＳＳ樹脂（６ｇ）を加えた。この混合物を濃縮乾固し、この樹脂を、ＨＰ２０ＳＳ樹脂（１０ｇ）を含有するプレカラムにロードし、０〜２０％ＭｅＣＮ／水で溶出する自動逆相クロマトグラフィーにより精製し、（４Ｓ，６Ｒ，７Ｒ）−７−（（Ｚ）−２−（２−アミノチアゾール−４−イル）−２−（（（２−カルボキシプロパン−２−イル）オキシ）イミノ）アセトアミド）−３−（（１−（（６，７−ジヒドロキシ−１−メチル−４−オキソ−１，４−ジヒドロキノリン−３−イル）メチル）ピロリジン−１−イウム−１−イル）メチル）−４−メチル−８−オキソ−５−チア−１−アザビシクロ［４．２．０］オクト−２−エン−２−カルボキシレート（６７ｍｇ、収率６２％）を灰白色固体として得た。この生成物の一部（５６ｍｇ、０．０７４ｍｍｏｌ）を水（ＨＰＬＣ級、１０ｍＬ）に懸濁させ、０℃に冷却した。激しく撹拌しているこの懸濁液にエッペンドルフピペットを用いて、０．１Ｎ ＮａＯＨ水溶液（０．７４ｍＬ、０．０７４ｍｍｏｌ）をゆっくり加えた。添加が完了した後、ドライアイス小片を加えて過剰なＮａＯＨを急冷した。次に、この淡黄色溶液を凍結させ、凍結乾燥させ、化合物Ｉ−１４３（５７ｍｇ）を灰白色固体として得た。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７５６．２． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３２ − １．４３ （ｍ， ９ Ｈ） ２．１０ （ｄ， Ｊ＝１０．８６ Ｈｚ， ４ Ｈ） ３．２５ （ｂｒ． ｓ．， ３ Ｈ） ３．４８ （ｂｒ． ｓ．， １ Ｈ） ３．８０ （ｓ， ３ Ｈ） ４．００ （ｄ， Ｊ＝６．５７ Ｈｚ， １ Ｈ） ４．１１ （ｄ， Ｊ＝１４．４０ Ｈｚ， １ Ｈ） ４．３３ （ｓ， ２ Ｈ） ４．７８ − ４．８１ （ｍ， １ Ｈ） ５．３５ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ５．７０ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ６．８７ （ｓ， １ Ｈ） ６．９６ （ｓ， １ Ｈ） ７．４８ （ｓ， １ Ｈ） ８．０５ （ｓ， １ Ｈ）． Step (2): Compound 143a → Compound I-143
Compound I-143: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((1-((6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroquinolin-3-yl) methyl) pyrrolidin-1-ium-1-yl) methyl ) -4-Methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

To the compound 143a (0.269 g, 0.142 mmol) in DCM (1.5 mL) at 0 ° C. was added anisole (0.16 mL, 1.42 mmol) followed by TFA (0.50 mL, 6.5 mmol). . The mixture was warmed to room temperature and stirred overnight. Diisopropyl ether (30 mL) was added and the mixture was stirred for 10 minutes. The resulting precipitate was collected by filtration and washed twice with diisopropyl ether (2 × 5 mL). The solid was dissolved in a mixture of MeCN (6 mL), water (6 mL), and 2M aqueous HCl (1.5 mL) and HP20SS resin (6 g) was added. The mixture was concentrated to dryness and the resin was loaded onto a pre-column containing HP20SS resin (10 g) and purified by automated reverse phase chromatography eluting with 0-20% MeCN / water (4S, 6R, 7R). ) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino) acetamido) -3-((1- ( (6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroquinolin-3-yl) methyl) pyrrolidin-1-ium-1-yl) methyl) -4-methyl-8-oxo-5 -Thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate (67 mg, 62% yield) was obtained as an off-white solid. A portion of this product (56 mg, 0.074 mmol) was suspended in water (HPLC grade, 10 mL) and cooled to 0 ° C. To this vigorously stirred suspension, an 0.1N aqueous NaOH solution (0.74 mL, 0.074 mmol) was slowly added using an Eppendorf pipette. After the addition was complete, a piece of dry ice was added to quench excess NaOH. The pale yellow solution was then frozen and lyophilized to give compound 1-143 (57 mg) as an off-white solid.
LCMS: (M + H) ^<+> : 756.2. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.32-1.43 (m, 9 H) 2.10 (d, J = 10.86 Hz, 4 H) 3.25 (br. S., 3 H) 3.48 (br. S., 1 H) 3.80 (s, 3 H) 4.00 (d, J = 6.57 Hz, 1 H) 4.11 (d, J = 14. 40 Hz, 1 H) 4.33 (s, 2 H) 4.78-4.81 (m, 1 H) 5.35 (d, J = 4.80 Hz, 1 H) 5.70 (d, J = 4.80 Hz, 1 H) 6.87 (s, 1 H) 6.96 (s, 1 H) 7.48 (s, 1 H) 8.05 (s, 1 H).

  The compounds shown below were obtained from Compound X-24 and the corresponding amines (synthesized according to the synthesis of WO2013052568A1) in the same manner as Example 143.

ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７８８．１． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．２４ − １．４８ （ｍ， １２ Ｈ） １．９９ − ２．２３ （ｍ， ４ Ｈ） ３．２２ （ｂｒ． ｓ．， ３ Ｈ） ３．４６ （ｄ， Ｊ＝３．２８ Ｈｚ， １ Ｈ） ３．９６ − ４．１７ （ｍ， ４ Ｈ） ４．２７ （ｂｒ． ｓ．， ２ Ｈ） ４．７９ （ｄ， Ｊ＝７．３３ Ｈｚ， １ Ｈ） ５．３５ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ５．７０ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ６．７０ （ｓ， １ Ｈ） ６．８５ （ｓ， １ Ｈ） ８．０３ （ｓ， １ Ｈ）． Example 144 Synthesis of Compound I-144 Compound I-144: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2- Carboxypropan-2-yl) oxy) imino) acetamido) -3-((1-((1-ethyl-5-fluoro-6,7-dihydroxy-4-oxo-1,4-dihydroquinolin-3-yl) ) Methyl) pyrrolidin-1-ium-1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

LCMS: (M + H) ^<+> : 788.1. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.24-1.48 (m, 12 H) 1.99-2.23 (m, 4 H) 3.22 (br. S., 3 H) 3.46 (d, J = 3.28 Hz, 1 H) 3.96-4.17 (m, 4 H) 4.27 (br. S., 2 H) 4.79 (d, J = 7 .33 Hz, 1 H) 5.35 (d, J = 4.80 Hz, 1 H) 5.70 (d, J = 4.80 Hz, 1 H) 6.70 (s, 1 H) 85 (s, 1 H) 8.03 (s, 1 H).

ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７９０．０． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．２７ − １．５０ （ｍ， ９ Ｈ） ２．０８ （ｂｒ． ｓ．， ４ Ｈ） ３．２１ （ｄ， Ｊ＝６．３２ Ｈｚ， ３ Ｈ） ３．４５ （ｂｒ． ｓ．， １ Ｈ） ３．６３ （ｂｒ． ｓ．， ３Ｈ） ３．９５ − ４．１２ （ｍ， ２ Ｈ） ４．２１ （ｂｒ． ｓ．， ２ Ｈ） ４．７８ （ｄ， Ｊ＝１１．６２ Ｈｚ， １ Ｈ） ５．３６ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ５．７０ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ６．６５ （ｂｒ． ｓ．， １ Ｈ） ６．８５ （ｓ， １ Ｈ） ７．９１ （ｂｒ． ｓ．， １ Ｈ）． Example 145: Synthesis of Compound I-145 Compound I-145: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2- Carboxypropan-2-yl) oxy) imino) acetamido) -3-((1-((5-chloro-6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroquinolin-3-yl) ) Methyl) pyrrolidin-1-ium-1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

LCMS: (M + H) ^<+> : 790.0. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.27-1.50 (m, 9 H) 2.08 (br.s., 4 H) 3.21 (d, J = 6.32 Hz, 3H) 3.45 (br.s., 1H) 3.63 (br.s., 3H) 3.95-4.12 (m, 2H) 4.21 (br.s., 2H) 4.78 (d, J = 11.62 Hz, 1 H) 5.36 (d, J = 4.80 Hz, 1 H) 5.70 (d, J = 4.80 Hz, 1 H) 6 .65 (br. S., 1 H) 6.85 (s, 1 H) 7.91 (br. S., 1 H).

ＤＭＦ（１００ｍＬ）中、６，７−ジメトキシキナゾリン−４（３Ｈ）−オン（５．０ｇ、２４ｍｍｏｌ）の溶液に、５０℃で１−クロロ−２−ヨードエタン（３．４８ｍＬ、４８．５ｍｍｏｌ）を滴下し、この混合物を一晩撹拌した。水を加え、この混合物を酢酸エチルで抽出した。有機層を乾燥させ（Ｎａ_２ＳＯ_４）、濃縮し、自動シリカゲルクロマトグラフィー（ＤＣＭ中１０％ＭｅＯＨ）により精製し、化合物１４６ａ（６．５ｇ、収率９６％）を黄色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ２６９．０． Example 146: Synthesis Step of Compound I-146 (1): 6,7-Dimethoxyquinazolin-4 (3H) -one → Compound 146a
Compound 146a: 3- (2-chloroethyl) -6,7-dimethoxyquinazolin-4 (3H) -one

To a solution of 6,7-dimethoxyquinazolin-4 (3H) -one (5.0 g, 24 mmol) in DMF (100 mL) was added 1-chloro-2-iodoethane (3.48 mL, 48.5 mmol) at 50 ° C. Add dropwise and stir the mixture overnight. Water was added and the mixture was extracted with ethyl acetate. The organic layer was dried (Na ₂ SO ₄ ), concentrated and purified by automated silica gel chromatography (10% MeOH in DCM) to give compound 146a (6.5 g, 96% yield) as a yellow solid. LCMS: (M + H) ^<+> : 269.0.

ＤＣＭ（１００ｍＬ）中、化合物１４６ａの溶液に、−７０℃でＢＢｒ_３を滴下し、この混合物を室温まで温め、１時間撹拌した。この混合物に０℃でＭｅＯＨを滴下した後、溶媒を真空下で除去した。残渣をシリカゲルクロマトグラフィー（ＤＣＭ中２０％ＭｅＯＨ）により精製し、化合物１４６ｂ（５．７ｇ、収率９１％）を得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ２４１．２． Step (2): Compound 146a → Compound 146b
Compound 146b: 3- (2-chloroethyl) -6,7-dihydroxyquinazolin-4 (3H) -one

To a solution of compound 146a in DCM (100 mL) was added BBr ₃ dropwise at −70 ° C. and the mixture was warmed to room temperature and stirred for 1 hour. After MeOH was added dropwise to this mixture at 0 ° C., the solvent was removed under vacuum. The residue was purified by silica gel chromatography (20% MeOH in DCM) to give compound 146b (5.7 g, 91% yield). LCMS: (M + H) ^<+> : 241.2.

ＤＭＦ（１００ｍＬ）中、１−（クロロメチル）−４−メトキシベンゼン（１４．８ｇ、９５．０ｍｍｏｌ）の溶液に、炭酸カリウム（１６．４ｇ、１１８ｍｍｏｌ）および１−（クロロメチル）−４−メトキシベンゼン（１４．８ｇ、９５．０ｍｍｏｌ）を加え、この混合物を５０℃で一晩撹拌した。水を加え、この混合物を酢酸エチルで抽出した。有機層を乾燥させ（Ｎａ_２ＳＯ_４）、濾過し、濃縮し、残渣をシリカゲルクロマトグラフィー（Ｃｏｍｂｉｆｌａｓｈ ＲＦ）を用いて精製し、化合物１４６ｃ（７．８ｇ、収率６９％）を得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ４８０．９． Step (3): Compound 146b → Compound 146c
Compound 146c: 3- (2-chloroethyl) -6,7-bis ((4-methoxybenzyl) oxy) quinazolin-4 (3H) -one

To a solution of 1- (chloromethyl) -4-methoxybenzene (14.8 g, 95.0 mmol) in DMF (100 mL) was added potassium carbonate (16.4 g, 118 mmol) and 1- (chloromethyl) -4-methoxy. Benzene (14.8 g, 95.0 mmol) was added and the mixture was stirred at 50 ° C. overnight. Water was added and the mixture was extracted with ethyl acetate. The organic layer was dried (Na ₂ SO ₄ ), filtered and concentrated, and the residue was purified using silica gel chromatography (Combiflash RF) to give compound 146c (7.8 g, 69% yield). LCMS: (M + H) ^<+> : 480.9.

ＤＣＭ（１５０ｍＬ）中、化合物１４６ｃ（７．００ｇ、１４．６ｍｍｏｌ）の溶液に、ＤＩＰＥＡ（６．３６ｍＬ、３６．４ｍｍｏｌ）およびピロリジン（３．０１ｍＬ、３６．４ｍｍｏｌ）を加え、この混合物を８０℃に加熱した。反応混合物を５％ＮａＨＣＯ_３水溶液（４０ｍＬ）、ブライン、およびＨ_２Ｏで洗浄し、有機層を乾燥させ（Ｎａ_２ＳＯ_４）、濾過し、濃縮し、残渣を自動シリカゲルクロマトグラフィー（ＤＣＭ中２０％ＭｅＯＨ）により精製し、化合物１４６ｄ（２．９ｇ、収率３９％）を得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５１６．３． Step (4): Compound 146c → Compound 146d
Compound 146d: 6,7-bis ((4-methoxybenzyl) oxy) -3- (2- (pyrrolidin-1-yl) ethyl) quinazolin-4 (3H) -one

To a solution of compound 146c (7.00 g, 14.6 mmol) in DCM (150 mL) was added DIPEA (6.36 mL, 36.4 mmol) and pyrrolidine (3.01 mL, 36.4 mmol) and the mixture was added at 80 ° C. Heated to. The reaction mixture was washed with 5% aqueous NaHCO ₃ (40 mL), brine, and H ₂ O, the organic layer was dried (Na ₂ SO ₄ ), filtered and concentrated, and the residue was chromatographed on silica gel (20 in DCM). % MeOH) to give compound 146d (2.9 g, 39% yield). LCMS: (M + H) ^<+> : 516.3.

この化合物は、化合物１４６ｄおよび化合物Ｘ−２４を用い、実施例１４３の二段階法に従って製造した。^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３７ （ｓ， ３ Ｈ） １．３９ （ｓ， ３ Ｈ） １．４７ （ｄ， Ｊ＝７．０７ Ｈｚ， ３ Ｈ） ２．１３ （ｂｒ． ｓ．， ４ Ｈ） ３．３５ − ３．６０ （ｍ， ５ Ｈ） ３．６８ （ｄ， Ｊ＝１０．６１ Ｈｚ， １ Ｈ） ３．９９ （ｑ， Ｊ＝６．９９ Ｈｚ， １ Ｈ） ４．１９ （ｄ， Ｊ＝１４．１５ Ｈｚ， １ Ｈ） ４．２４ − ４．４１ （ｍ， ２ Ｈ） ５．００ （ｄ， Ｊ＝１４．１５ Ｈｚ， １ Ｈ） ５．３４ （ｄ， Ｊ＝５．０５ Ｈｚ， １ Ｈ） ５．６９ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ６．７２ （ｓ， １ Ｈ） ６．８６ （ｓ， １ Ｈ） ７．１１ （ｓ， １ Ｈ） ８．００ （ｓ， １ Ｈ）． Step (5): Compound X-24 + Compound 146d → Compound I-146
Compound I-146
(4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino) acetamide) -3 -((1- (2- (6,7-dihydroxy-4-oxoquinazolin-3 (4H) -yl) ethyl) pyrrolidin-1-ium-1-yl) methyl) -4-methyl-8-oxo- 5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 143 using compound 146d and compound X-24. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.37 (s, 3 H) 1.39 (s, 3 H) 1.47 (d, J = 7.07 Hz, 3 H) 2.13 ( br.s., 4 H) 3.35-3.60 (m, 5 H) 3.68 (d, J = 10.61 Hz, 1 H) 3.99 (q, J = 6.99 Hz, 1 H) 4.19 (d, J = 14.15 Hz, 1 H) 4.24-4.41 (m, 2 H) 5.00 (d, J = 14.15 Hz, 1 H) 34 (d, J = 0.05 Hz, 1 H) 5.69 (d, J = 4.80 Hz, 1 H) 6.72 (s, 1 H) 6.86 (s, 1 H) 7. 11 (s, 1 H) 8.00 (s, 1 H).

無水クロロホルム（３００ｍＬ）中、６，７−ジメトキシキナゾリン−２，４（１Ｈ，３Ｈ）−ジオン（４０．０ｇ、１８０ｍｍｏｌ）の懸濁液に、（Ｅ）−トリメチルシリルＮ−（トリメチルシリル）アセトイミダート（１５６ｍＬ、６３０ｍｍｏｌ）を加え、この混合物を透明な溶液が得られるまで（２時間）室温で撹拌した。次に、ヨードメタン（１６８ｍＬ、２７００ｍｍｏｌ）を加えた。反応混合物を４８時間還流温度に加熱した。この溶液を室温に冷却した後、飽和ＮａＨＣＯ_３水溶液（３０ｍＬ）を加え、沈殿を濾取し、化合物１４７ａ（３８ｇ、収率８９％）を白色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋：２３７．１． Example 147: Synthesis Step of Compound I-147 (1): 6,7-Dimethoxyquinazoline-2,4 (1H, 3H) -dione → Compound 147a
Compound 147a:
6,7-Dimethoxy-1-methylquinazoline-2,4 (1H, 3H) -dione

To a suspension of 6,7-dimethoxyquinazoline-2,4 (1H, 3H) -dione (40.0 g, 180 mmol) in anhydrous chloroform (300 mL), (E) -trimethylsilyl N- (trimethylsilyl) acetimidate (156 mL, 630 mmol) was added and the mixture was stirred at room temperature until a clear solution was obtained (2 h). Then iodomethane (168 mL, 2700 mmol) was added. The reaction mixture was heated to reflux for 48 hours. The solution was cooled to room temperature, saturated aqueous NaHCO ₃ (30 mL) was added, and the precipitate was collected by filtration to give compound 147a (38 g, yield 89%) as a white solid. LCMS: (M + H) ^<+> : 237.1.

ＤＭＦ（２０ｍＬ）中、化合物１４７ａ（２８．０ｇ、１１９ｍｍｏｌ）の溶液に、炭酸セシウム（７７．０ｇ、２３７ｍｍｏｌ）、次いで１−クロロ−２−ヨードエタン（２１．６ｍＬ、２３７ｍｍｏｌ）を加えた。反応混合物を５０℃で一晩撹拌した。水を加え、この混合物を室温で１５分間撹拌した。白色沈殿を濾取し、水で洗浄し、化合物１４７ｂ（２９ｇ、収率８２％）を得た。粗混合物を精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ２９９．０． Step (2): Compound 147a → Compound 147b
Compound 147b:
3- (2-Chloroethyl) -6,7-dimethoxy-1-methylquinazoline-2,4 (1H, 3H) -dione

To a solution of compound 147a (28.0 g, 119 mmol) in DMF (20 mL) was added cesium carbonate (77.0 g, 237 mmol) followed by 1-chloro-2-iodoethane (21.6 mL, 237 mmol). The reaction mixture was stirred at 50 ° C. overnight. Water was added and the mixture was stirred at room temperature for 15 minutes. The white precipitate was collected by filtration and washed with water to give compound 147b (29 g, yield 82%). The crude mixture was used in the next step without purification. LCMS: (M + H) ^<+> : 299.0.

３−（２−クロロエチル）−６，７−ジメトキシ−１−メチルキナゾリン−２，４（１Ｈ，３Ｈ）−ジオン化合物１４７ｂ（２９ｇ、９７ｍｍｏｌ）および１−クロロピロリジン−２，５−ジオン（１９．５ｇ、１４６ｍｍｏｌ）をＤＭＦ（４０ｍＬ）に懸濁させ、９５℃で０．５時間加熱した。この混合物に水および酢酸エチル（３００ｍＬ）を加えた。有機相を分離し、水相を酢酸エチルで抽出した（２×３００ｍＬ）。合わせた有機相を乾燥させ、濾過し、濃縮した。残渣をシリカゲルクロマトグラフィー（ヘキサン中０〜１５％ＥｔＯＡｃ）により精製し、化合物１４７ｃ（１０ｇ、収率３１％）を得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ３３３．０． Step (3): Compound 147b → Compound 147c
Compound 147c
5-Chloro-3- (2-chloroethyl) -6,7-dimethoxy-1-methylquinazoline-2,4 (1H, 3H) -dione

3- (2-Chloroethyl) -6,7-dimethoxy-1-methylquinazoline-2,4 (1H, 3H) -dione compound 147b (29 g, 97 mmol) and 1-chloropyrrolidine-2,5-dione (19. 5 g, 146 mmol) was suspended in DMF (40 mL) and heated at 95 ° C. for 0.5 h. To this mixture was added water and ethyl acetate (300 mL). The organic phase was separated and the aqueous phase was extracted with ethyl acetate (2 × 300 mL). The combined organic phases were dried, filtered and concentrated. The residue was purified by silica gel chromatography (0-15% EtOAc in hexanes) to provide compound 147c (10 g, 31% yield). LCMS: (M + H) ^<+> : 333.0.

ＤＣＭ（２５ｍＬ）中、化合物１４７ｃ（１０ｇ、３０．０ｍｍｏｌ）の溶液に、−７８℃でＢＢｒ_３（１４．２ｍＬ、１５０ｍｍｏｌ）を加えた。この混合物を室温まで温め、２時間撹拌した。この混合物をＭｅＯＨで希釈し、数回ストリッピングし、化合物１４７ｄ（８．８ｇ、収率９６％）を黄色固体として得た。粗生成物をそれ以上精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ３０４．９． Step (4): Compound 147c → Compound 147d
Compound 147d:
5-Chloro-3- (2-chloroethyl) -6,7-dihydroxy-1-methylquinazoline-2,4 (1H, 3H) -dione

To a solution of compound 147c (10 g, 30.0 mmol) in DCM (25 mL) at −78 ° C. was added BBr ₃ (14.2 mL, 150 mmol). The mixture was warmed to room temperature and stirred for 2 hours. The mixture was diluted with MeOH and stripped several times to give compound 147d (8.8 g, 96% yield) as a yellow solid. The crude product was used in the next step without further purification. LCMS: (M + H) ^<+> : 304.9.

ＤＭＦ（１２０ｍＬ）中、化合物１４７ｄ（４．４０ｇ、１０．１ｍｍｏｌ）の溶液に、炭酸セシウム（９．８７ｇ、３０．３ｍｍｏｌ）、次いで１−（クロロメチル）−４−メトキシベンゼン（５．５０ｍＬ、４０．４ｍｍｏｌ）を加えた。反応混合物を５０℃で５時間撹拌した。水を加え、この混合物を室温で１５分間撹拌した。黄色沈殿を濾取し、水で洗浄した。粗材料を、４０ｇカラムを使用し、ＥＡ／ヘキサン（０〜３０％）で溶出する自動シリカゲルクロマトグラフィーにより精製し、化合物１４７ｅ（２．３ｇ、収率４２％）を黄色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５４５．１． Step (5): Compound 147d → Compound 147e
Compound 147e:
5-chloro-3- (2-chloroethyl) -6,7-bis ((4-methoxybenzyl) oxy) -1-methylquinazoline-2,4 (1H, 3H) -dione

To a solution of compound 147d (4.40 g, 10.1 mmol) in DMF (120 mL) was added cesium carbonate (9.87 g, 30.3 mmol) followed by 1- (chloromethyl) -4-methoxybenzene (5.50 mL, 40.4 mmol) was added. The reaction mixture was stirred at 50 ° C. for 5 hours. Water was added and the mixture was stirred at room temperature for 15 minutes. The yellow precipitate was collected by filtration and washed with water. The crude material was purified by automated silica gel chromatography using a 40 g column and eluting with EA / hexanes (0-30%) to give compound 147e (2.3 g, 42% yield) as a yellow solid. LCMS: (M + H) ^<+> : 545.1.

アセトニトリル（１００ｍＬ）中、化合物１４７ｅ（２．３ｇ、４．２ｍｍｏｌ）、ＤＩＰＥＡ（１．３６３ｇ、１０．５４ｍｍｏｌ）、およびピロリジン（０．７５０ｇ、１０．５ｍｍｏｌ）の溶液を還流温度で６時間加熱した。水を加え、生成物をＤＣＭで抽出した。有機相をＮａＨＣＯ_３水溶液、ブラインで洗浄した後、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、濃縮した。粗材料を、２４ｇカラムを使用し、ＤＣＭ中０〜５％のＭｅＯＨで溶出する自動シリカゲルクロマトグラフィーにより精製し、化合物１４７ｆ（１ｇ、収率４１％）を黄色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５８０．３． Step (6): Compound 147e → Compound 147f
Compound 147f:
5-Chloro-6,7-bis ((4-methoxybenzyl) oxy) -1-methyl-3- (2- (pyrrolidin-1-yl) ethyl) quinazoline-2,4 (1H, 3H) -dione

A solution of compound 147e (2.3 g, 4.2 mmol), DIPEA (1.363 g, 10.54 mmol), and pyrrolidine (0.750 g, 10.5 mmol) in acetonitrile (100 mL) was heated at reflux for 6 hours. . Water was added and the product was extracted with DCM. The organic phase was washed with aqueous NaHCO ₃ solution, brine, then dried over Na ₂ SO ₄ , filtered and concentrated. The crude material was purified by automated silica gel chromatography using a 24 g column and eluting with 0-5% MeOH in DCM to give compound 147f (1 g, 41% yield) as a yellow solid. LCMS: (M + H) ^<+> : 580.3.

この化合物は、化合物１４７ｆおよび化合物Ｘ−２４を用い、実施例１４３の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８２１．０． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３８ （ｓ， ３ Ｈ） １．４０ （ｓ， ３ Ｈ） １．４８ （ｄ， Ｊ＝６．８２ Ｈｚ， ３ Ｈ） ２．１２ （ｂｒ． ｓ．， ４ Ｈ） ３．３２ （ｂｒ． ｓ．， ３ Ｈ） ３．３５ − ３．６６ （ｍ， ６ Ｈ） ３．９８ − ４．０７ （ｍ， １ Ｈ） ４．１６ − ４．３６ （ｍ， ３ Ｈ） ４．９８ （ｄ， Ｊ＝１４．１５ Ｈｚ， １ Ｈ） ５．３７ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ５．６８ （ｄ， Ｊ＝４．２９ Ｈｚ， １ Ｈ） ６．４８ （ｓ， １ Ｈ） ６．９１ （ｓ， １ Ｈ）． Step (7): Compound X-24 + Compound 147f → Compound I-147
Compound I-147:
(4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino) acetamide) -3 -((1- (2- (5-Chloro-6,7-dihydroxy-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3 (4H) -yl) ethyl) pyrrolidin-1-ium -1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 143 using compound 147f and compound X-24.
LCMS: (M + H) ^<+> : 821.0. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.38 (s, 3 H) 1.40 (s, 3 H) 1.48 (d, J = 6.82 Hz, 3 H) 2.12 ( br.s., 4H) 3.32 (br.s., 3H) 3.35-3.66 (m, 6H) 3.98-4.07 (m, 1H) 4.16- 4.36 (m, 3 H) 4.98 (d, J = 14.15 Hz, 1 H) 5.37 (d, J = 4.80 Hz, 1 H) 5.68 (d, J = 4 .29 Hz, 1 H) 6.48 (s, 1 H) 6.91 (s, 1 H).

２−アミノ−４，５−ジフルオロ安息香酸メチル（４０．０ｇ、２１４ｍｍｏｌ）およびＮＣＳ（２５．９ｇ、１９４ｍｍｏｌ）をＤＭＦ（１０ｍＬ）に懸濁させ、９５℃で３０分間加熱した。この混合物に水およびＤＣＭを加えた。有機相を分離した。水相をＤＣＭで抽出した（２×１０ｍＬ）。合わせた有機相を乾燥させ、濾過し濃縮した。得られた残渣を順相クロマトグラフィー（ヘキサン中０〜４０％のＥｔＯＡｃ）により精製し、化合物１４８ａ（１１ｇ、収率２６％）を白色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ２２１．９． Example 148: Synthesis Step of Compound I-148 (1): Methyl 2-amino-4,5-difluorobenzoate → Compound 148a
Compound 148a: methyl 2-amino-3-chloro-4,5-difluorobenzoate

Methyl 2-amino-4,5-difluorobenzoate (40.0 g, 214 mmol) and NCS (25.9 g, 194 mmol) were suspended in DMF (10 mL) and heated at 95 ° C. for 30 minutes. To this mixture was added water and DCM. The organic phase was separated. The aqueous phase was extracted with DCM (2 × 10 mL). The combined organic phases were dried, filtered and concentrated. The resulting residue was purified by normal phase chromatography (0-40% EtOAc in hexanes) to provide compound 148a (11 g, 26% yield) as a white solid. LCMS: (M + H) ^<+> : 221.9.

化合物１４８ａ（１５０ｍＬ、２３８０ｍｍｏｌ）の溶液に、最初に生じた沈殿が溶けるまで塩化水素ガスを通じた。この混合物を室温で一晩撹拌した。反応混合物に水を加え、生じた沈殿を濾取し、高真空下で乾燥させ、化合物１４８ｂ（８．０ｇ、収率６７％）を灰色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ２６４．９． Step (2): Compound 148a → Compound 148b
Compound 148b:
8-Chloro-2- (chloromethyl) -6,7-difluoroquinazolin-4 (3H) -one

Hydrogen chloride gas was passed through a solution of compound 148a (150 mL, 2380 mmol) until the initially formed precipitate was dissolved. The mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the resulting precipitate was collected by filtration and dried under high vacuum to give compound 148b (8.0 g, 67% yield) as a gray solid. LCMS: (M + H) ^<+> : 264.9.

ＤＣＭ（１２０ｍＬ）中、化合物１４８ｂ（５．００ｇ、１８．９ｍｍｏｌ）の溶液に、ＤＣＭ中、ピロリジン（３．９０ｍＬ、４７．２ｍｍｏｌ）の溶液を滴下し、この混合物を室温で２時間撹拌した。反応混合物をブラインで洗浄し（３回）、有機層をＮａ_２ＳＯ_４で乾燥させ、濾過し、濃縮し、化合物１４８ｃ（５．０ｇ、収率８８％）を白色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ３００．３． Step (3): Compound 148b → Compound 148c
Compound 148c:
8-Chloro-6,7-difluoro-2- (pyrrolidin-1-ylmethyl) quinazolin-4 (3H) -one

To a solution of compound 148b (5.00 g, 18.9 mmol) in DCM (120 mL) was added dropwise a solution of pyrrolidine (3.90 mL, 47.2 mmol) in DCM and the mixture was stirred at room temperature for 2 hours. The reaction mixture was washed with brine (3 times) and the organic layer was dried over Na ₂ SO ₄ , filtered and concentrated to give compound 148c (5.0 g, 88% yield) as a white solid. LCMS: (M + H) ^<+> : 300.3.

（４−メトキシフェニル）メタノール（４６．１ｇ、３３４ｍｍｏｌ）と化合物１４８ｃ（５．００ｇ、１６．７ｍｍｏｌ）の混合物を週末にかけて８０℃で加熱した。反応混合物に水を加え、２Ｎ ＨＣｌ水溶液を用いてｐＨを２に調整し、生成物をＤＣＭで抽出した。有機層をブラインで洗浄し、濃縮し、残渣を自動逆相クロマトグラフィー（０．１％ＴＦＡを含有するＨ_２Ｏ中７０％のＭｅＣＮ）により精製した。次に、合わせた画分を、２Ｎ ＮａＯＨを用いて中和し、生成物をＤＣＭで抽出した。有機層を乾燥させ、濾過し、濃縮した後、自動シリカゲルクロマトグラフィーにより再び精製し、化合物１４８ｄ（３５０ｍｇ、収率３．９％）を得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５３６．０． Step (4): Compound 148c → Compound 148d
Compound 148d:
8-Chloro-6,7-bis ((4-methoxybenzyl) oxy) -2- (pyrrolidin-1-ylmethyl) quinazolin-4 (3H) -one

A mixture of (4-methoxyphenyl) methanol (46.1 g, 334 mmol) and compound 148c (5.00 g, 16.7 mmol) was heated at 80 ° C. over the weekend. Water was added to the reaction mixture, the pH was adjusted to 2 with 2N aqueous HCl and the product was extracted with DCM. The organic layer was washed with brine, concentrated, and the residue was purified by automated reverse phase chromatography (70% MeCN in H ₂ O containing 0.1% TFA). The combined fractions were then neutralized with 2N NaOH and the product was extracted with DCM. The organic layer was dried, filtered, concentrated and then purified again by automated silica gel chromatography to give compound 148d (350 mg, 3.9% yield). LCMS: (M + H) ^<+> : 536.0.

この化合物は、化合物１４８ｄおよび化合物Ｘ−２４を用い、実施例１４３の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７７７．１． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３５ （ｓ， ９ Ｈ） ２．１４ （ｂｒ． ｓ．， ４ Ｈ） ３．５１ − ４．０３ （ｍ， ６ Ｈ） ４．４３ （ｑ， Ｊ＝１５．４９ Ｈｚ， ２ Ｈ） ４．９３ （ｄ， Ｊ＝１３．８９ Ｈｚ， ２ Ｈ） ５．１０ （ｄ， Ｊ＝５．０５ Ｈｚ， １ Ｈ） ５．６３ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ６．８６ （ｓ， １ Ｈ） ７．２９ （ｓ， １ Ｈ）． Step (5): Compound X-24 + Compound 148d → Compound I-148
Compound I-148:
(4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino) acetamide) -3 -((1-((8-chloro-6,7-dihydroxy-4-oxo-3,4-dihydroquinazolin-2-yl) methyl) pyrrolidin-1-ium-1-yl) methyl) -4-methyl -8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 143 using compound 148d and compound X-24.
LCMS: (M + H) ^<+> : 777.1. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.35 (s, 9 H) 2.14 (br. S., 4 H) 3.51-4.03 (m, 6 H) 4.43 ( q, J = 15.49 Hz, 2 H) 4.93 (d, J = 13.89 Hz, 2 H) 5.10 (d, J = 0.05 Hz, 1 H) 5.63 (d, J = 4.80 Hz, 1 H) 6.86 (s, 1 H) 7.29 (s, 1 H).

トルエン中、塩化２，４，５−トリフルオロベンゾイル（５０ｇ、２５７ｍｍｏｌ）の溶液を、トルエン（５００ｍＬ）中、トリエチルアミン（１０７ｍＬ、７７１ｍｍｏｌ）および３−（ジメチルアミノ）アクリル酸エチル（４４．２ｇ、３０８ｍｍｏｌ）の溶液に滴下した。この混合物を９０℃で３時間撹拌した。反応混合物を冷却した後、水で洗浄し、ＥｔＯＡｃで抽出した。有機層をＮａ_２ＳＯ_４で乾燥させ、濾過し、濃縮し、化合物１４９ａ（７５ｇ、収率９７％）を褐色油状物として得た。粗生成物をそれ以上精製せずに次の工程で使用した。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ３０２．０， Example 149: Synthesis Step of Compound I-149 (1): 2,4,5-trifluorobenzoyl chloride → Compound 149a
Compound 149a: 3- (dimethylamino) -2- (2,4,5-trifluorobenzoyl) ethyl acrylate

A solution of 2,4,5-trifluorobenzoyl chloride (50 g, 257 mmol) in toluene was added to triethylamine (107 mL, 771 mmol) and ethyl 3- (dimethylamino) acrylate (44.2 g, 308 mmol) in toluene (500 mL). ). The mixture was stirred at 90 ° C. for 3 hours. After cooling the reaction mixture, it was washed with water and extracted with EtOAc. The organic layer was dried over Na ₂ SO ₄ , filtered and concentrated to give compound 149a (75 g, 97% yield) as a brown oil. The crude product was used in the next step without further purification. LCMS: (M + H) ⁺ : 302.0,

エタノール（２００ｍＬ）およびジエチルエーテル（４００ｍＬ）中、化合物１４９ａ（７０ｇ、２３２ｍｍｏｌ）の溶液をメタンアミン（５４．７ｍＬ、４６５ｍｍｏｌ）に加えた。この混合物を室温で２時間撹拌した後、この混合物をＬＣＭＳにより分析したところ、反応が完了していたことが示された。反応混合物を減圧下で濃縮し、油性残渣をＤＭＦ（５００ｍＬ）に溶かし、炭酸カリウム（９６．０ｇ、６９７ｍｍｏｌ）を加えた。この混合物を１００℃で２時間撹拌した。反応混合物に冷水を加えた。生じた沈殿を濾取し、乾燥させ、化合物１４９ｂ（４５ｇ、収７３％率）を得た。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ２６７．９。 Step (2): Compound 149a → Compound 149b
Compound 149b: ethyl 6,7-difluoro-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate

A solution of compound 149a (70 g, 232 mmol) in ethanol (200 mL) and diethyl ether (400 mL) was added to methanamine (54.7 mL, 465 mmol). After the mixture was stirred at room temperature for 2 hours, the mixture was analyzed by LCMS and showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure, the oily residue was dissolved in DMF (500 mL) and potassium carbonate (96.0 g, 697 mmol) was added. The mixture was stirred at 100 ° C. for 2 hours. Cold water was added to the reaction mixture. The resulting precipitate was collected by filtration and dried to obtain Compound 149b (45 g, yield 73% rate). LCMS: (M + H) ^<+> : 267.9.

化合物１４９ｂ（４５．０ｇ、１６８ｍｍｏｌ）、水酸化カリウム（４７２ｇ、８４２０ｍｍｏｌ）およびメタノール（１Ｌ）の混合物を還流温度で６時間加熱した。この溶液のｐＨを２に調整し、この混合物を真空濃縮した。得られた残渣を水で摩砕し、化合物１４９ｃ（３５ｇ、収率７９％）を淡黄色固体として得た。粗生成物をそれ以上精製せずに次の工程で使用した。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ２６４．０． Step (3): Compound 149b → Compound 149c
Compound 149c: 6,7-dimethoxy-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

A mixture of compound 149b (45.0 g, 168 mmol), potassium hydroxide (472 g, 8420 mmol) and methanol (1 L) was heated at reflux for 6 hours. The pH of the solution was adjusted to 2 and the mixture was concentrated in vacuo. The resulting residue was triturated with water to give compound 149c (35 g, 79% yield) as a pale yellow solid. The crude product was used in the next step without further purification. LCMS: (M + H) ^<+> : 264.0.

硫酸（３５４ｍＬ、６６４８ｍｍｏｌ）に溶かした化合物１４９ｃ（３５ｇ、１３３ｍｍｏｌ）の粘稠な暗色溶液を０℃に冷却し、およびカリウムニトロペルオキソ酸（１６．１ｇ、１６０ｍｍｏｌ）を少量ずつ加えた。氷水浴の使用により、反応混合物の温度を１０℃未満に維持した。添加が完了した後、混合物を１０℃未満に１時間維持した後、室温まで温めた。この混合物をこの温度で２時間撹拌し、その後、これを氷水（８００ｍＬ）に注いだ。沈殿した黄色固体を濾取し、水およびエタノールで洗浄した。固体を真空乾燥させ、化合物１４８ｄ（３０ｇ、収率７３％）を淡黄色固体として得た。粗生成物をそれ以上精製せずに次の工程で使用した。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ３３７．４ Step (4): Compound 149c → Compound 149d
Compound 149d: 6,7-dimethoxy-1-methyl-5-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

A viscous dark solution of compound 149c (35 g, 133 mmol) in sulfuric acid (354 mL, 6648 mmol) was cooled to 0 ° C. and potassium nitroperoxoacid (16.1 g, 160 mmol) was added in small portions. The temperature of the reaction mixture was kept below 10 ° C. by using an ice water bath. After the addition was complete, the mixture was kept below 10 ° C. for 1 hour and then warmed to room temperature. The mixture was stirred at this temperature for 2 hours before it was poured into ice water (800 mL). The precipitated yellow solid was collected by filtration and washed with water and ethanol. The solid was vacuum dried to give compound 148d (30 g, 73% yield) as a pale yellow solid. The crude product was used in the next step without further purification. LCMS: (M + H) ⁺ : 337.4

エタノール（３００ｍＬ）と水（３００ｍＬ）の混合物に、エチル化合物１４９ｄ（３０ｇ、８９ｍｍｏｌ）の溶液を２時間９０℃にて硫化ナトリウム・９Ｈ_２Ｏ（２１４ｇ、８９２ｍｍｏｌ）で処理した。この混合物を冷却した後、これを冷水に注ぎ、この溶液をｐＨ２に調整した。得られた黄色沈殿を濾取し、水で洗浄し、乾燥させ、化合物１４８ｅ（２４ｇ、収率９７％）を黄色固体として得た。粗生成物をそれ以上精製せずに次の工程で使用した。ＬＣＭＳ ：（Ｍ＋Ｈ）^＋： ２７９．０ Step (5): Compound 149d → Compound 149e
Compound 149e: 5-amino-6,7-dimethoxy-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

A solution of ethyl compound 149d (30 g, 89 mmol) was treated with sodium sulfide.9H ₂ O (214 g, 892 mmol) at 90 ° C. for 2 hours in a mixture of ethanol (300 mL) and water (300 mL). After cooling the mixture, it was poured into cold water and the solution was adjusted to pH2. The resulting yellow precipitate was collected by filtration, washed with water and dried to give compound 148e (24 g, 97% yield) as a yellow solid. The crude product was used in the next step without further purification. LCMS: (M + H) ⁺ : 279.0

濃ＨＣｌ水溶液（１２０ｍＬ）中、化合物１４９ｅ（２４ｇ、６９ｍｍｏｌ）の淡褐色懸濁液に、０℃で水（４０ｍＬ）中、ナトリウムニトロソアミド（４．６９ｇ、６９．０ｍｍｏｌ）の溶液を滴下した。この混合物を０℃で１時間撹拌した。この橙色懸濁液にＨＣｌ水溶液（１８０ｍＬ）を加え、この混合物を９５℃で６時間加熱した。反応混合物を室温まで冷却した後、水に注ぎ、沈殿を濾取し、乾燥させ、淡黄色固体として化合物１４９ｆ（１３ｇ、収率６６％）を得た。粗生成物をそれ以上精製せずに次の工程で使用した。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ２８３．９． Step (6): Compound 149e → Compound 149f
Compound 149f: 5-chloro-6-hydroxy-7-methoxy-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

To a light brown suspension of compound 149e (24 g, 69 mmol) in concentrated aqueous HCl (120 mL) was added dropwise a solution of sodium nitrosamide (4.69 g, 69.0 mmol) in water (40 mL) at 0 ° C. The mixture was stirred at 0 ° C. for 1 hour. To this orange suspension was added aqueous HCl (180 mL) and the mixture was heated at 95 ° C. for 6 hours. The reaction mixture was cooled to room temperature, poured into water, and the precipitate was collected by filtration and dried to give compound 149f (13 g, 66% yield) as a pale yellow solid. The crude product was used in the next step without further purification. LCMS: (M + H) ⁺ : 283.9.

ＤＣＭ（３００ｍＬ）中、化合物１４９ｆ（１７．６ｍＬ、４５．８ｍｍｏｌ）の溶液に、−７８℃でＢＢｒ_３（１５．２ｍＬ、１６０ｍｍｏｌ）を加えた。この混合物を室温まで温め、一晩撹拌した。この混合物をＭｅＯＨで希釈し、数回ストリッピングし、化合物１４９ｇ（１１ｇ、収率８９％）を黄色固体として得た。粗生成物をそれ以上精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ２６９．９． Step (7): Compound 149f → Compound 149g
Compound 149g: 5-chloro-6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

To a solution of compound 149f (17.6 mL, 45.8 mmol) in DCM (300 mL) at −78 ° C. was added BBr ₃ (15.2 mL, 160 mmol). The mixture was warmed to room temperature and stirred overnight. The mixture was diluted with MeOH and stripped several times to give 149 g (11 g, 89% yield) of compound as a yellow solid. The crude product was used in the next step without further purification. LCMS: (M + H) ^<+> : 269.9.

ＤＭＦ（２５０ｍＬ）中、化合物１４９ｇ（１１ｇ、４０．８ｍｍｏｌ）の溶液に、炭酸セシウム（３９．９ｇ、１２２ｍｍｏｌ）、次いで１−（クロロメチル）−４−メトキシベンゼン（２２．２ｍＬ、１６３ｍｍｏｌ）を加えた。反応混合物を５５℃で５時間撹拌した。水を加え、この混合物を室温で１５分間撹拌した。黄色沈殿を濾取し、水で洗浄し、化合物１４９ｈ（２０ｇ、収率７８％）を黄色固体として得た。粗混合物を精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ６３０．３． Step (8): Compound 149g → Compound 149h
Compound 149h: 4-methoxybenzyl 5-chloro-6,7-bis ((4-methoxybenzyl) oxy) -1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate

To a solution of compound 149 g (11 g, 40.8 mmol) in DMF (250 mL) was added cesium carbonate (39.9 g, 122 mmol) followed by 1- (chloromethyl) -4-methoxybenzene (22.2 mL, 163 mmol). It was. The reaction mixture was stirred at 55 ° C. for 5 hours. Water was added and the mixture was stirred at room temperature for 15 minutes. The yellow precipitate was collected by filtration and washed with water to give compound 149h (20 g, yield 78%) as a yellow solid. The crude mixture was used in the next step without purification. LCMS: (M + H) ^<+> : 630.3.

メタノール（１２０ｍＬ）と水（６０ｍＬ）の混合物中、化合物１４９ｈ（２０．０ｇ、３１．７ｍｍｏｌ）の懸濁液に、ＫＯＨ（３．５６ｇ、６３．５ｍｍｏｌ）を少量ずつ加えた。得られた混合物を９０℃で３時間撹拌した。反応混合物を室温まで冷却し、濃縮した。次に、残渣を水で希釈し、溶液を、２Ｎ ＨＣｌ水溶液を用いてｐＨ１に調整した。沈殿を濾取し、乾燥させ、化合物１４９ｊ（１３．５ｇ、収率８３％）を淡黄色固体として得た。粗生成物をそれ以上精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５１０．２ Step (9): Compound 149h → Compound 149j
Compound 149j: 5-chloro-6,7-bis ((4-methoxybenzyl) oxy) -1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

To a suspension of compound 149h (20.0 g, 31.7 mmol) in a mixture of methanol (120 mL) and water (60 mL) was added KOH (3.56 g, 63.5 mmol) in small portions. The resulting mixture was stirred at 90 ° C. for 3 hours. The reaction mixture was cooled to room temperature and concentrated. The residue was then diluted with water and the solution was adjusted to pH 1 using 2N aqueous HCl. The precipitate was collected by filtration and dried to obtain Compound 149j (13.5 g, yield 83%) as a pale yellow solid. The crude product was used in the next step without further purification. LCMS: (M + H) ^<+> : 510.2

ＤＭＦ（１００ｍＬ）中、化合物１４９ｊ（２．０ｇ、２．７ｍｍｏｌ）の溶液に、ＨＡＴＵ（１．０３ｇ、２．７１ｍｍｏｌ）およびＤＩＰＥＡ（１．４２ｍＬ、８．１２ｍｍｏｌ）を加え、この混合物を０．５時間撹拌した。この混合物に２−（ピロリジン−１−イル）エタンアミン（０．３４ｍＬ、２．７ｍｍｏｌ）を加えた。反応混合物をＬＣＭＳにより分析したところ、１時間で反応が完了していたことが示された。水を加え、この混合物をＤＣＭで抽出し、ブラインで洗浄した。粗材料を、２４ｇカラムを使用し、０〜２０％ＭｅＯＨ／ＤＣＭで溶出する自動シリカゲルクロマトグラフィーにより精製した。次に、純粋な生成物を重炭酸ナトリウム水溶液で洗浄し、４ｇシリカゲルカラムを使用し、０〜２０％ＭｅＯＨ／ＤＣＭで溶出してさらに精製し、化合物１４９ｋ（１．３ｇ、収率７９％）を黄色固体として得た。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ６０６．３ Step (10): Compound 149j → Compound 149k
Compound 149k: 5-chloro-6,7-bis ((4-methoxybenzyl) oxy) -1-methyl-4-oxo-N- (2- (pyrrolidin-1-yl) ethyl) -1,4-dihydro Quinoline-3-carboxamide

To a solution of compound 149j (2.0 g, 2.7 mmol) in DMF (100 mL) was added HATU (1.03 g, 2.71 mmol) and DIPEA (1.42 mL, 8.12 mmol) and the mixture was reduced to 0. Stir for 5 hours. To this mixture was added 2- (pyrrolidin-1-yl) ethanamine (0.34 mL, 2.7 mmol). The reaction mixture was analyzed by LCMS and showed that the reaction was complete in 1 hour. Water was added and the mixture was extracted with DCM and washed with brine. The crude material was purified by automated silica gel chromatography using a 24 g column and eluting with 0-20% MeOH / DCM. The pure product was then washed with aqueous sodium bicarbonate and further purified using a 4 g silica gel column eluting with 0-20% MeOH / DCM to give compound 149k (1.3 g, 79% yield). Was obtained as a yellow solid. LCMS: (M + H) ⁺ : 606.3

この化合物は、化合物１４９ｋおよび化合物Ｘ−２４を用い、実施例１４３の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７７７．１． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３６ （ｓ， ３ Ｈ） １．４０ （ｓ， ３ Ｈ） １．４７ （ｂｒ． ｓ．， ３ Ｈ） １．９９ − ２．２２ （ｍ， ４ Ｈ） ３．２７ − ４．２８ （ｍ， １３ Ｈ） ４．９０ （ｂｒ． ｓ．， １ Ｈ） ５．３７ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ５．７６ （ｂｒ． ｓ．， １ Ｈ） ６．４７ （ｂｒ． ｓ．， １ Ｈ） ６．８５ （ｓ， １ Ｈ） ８．１０ （ｂｒ． ｓ．， １ Ｈ）． Step (11): Compound X-24 + Compound 149k → Compound I-149
Compound I-149: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((1- (2- (5-chloro-6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamido) ethyl) pyrrolidine-1-ium -1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 143 using compound 149k and compound X-24.
LCMS: (M + H) ^<+> : 777.1. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.36 (s, 3 H) 1.40 (s, 3 H) 1.47 (br. S., 3 H) 1.99-2.22 ( m, 4 H) 3.27-4.28 (m, 13 H) 4.90 (br. s., 1 H) 5.37 (d, J = 4.80 Hz, 1 H) 5.76 ( br.s., 1 H) 6.47 (br.s., 1 H) 6.85 (s, 1 H) 8.10 (br.s., 1 H).

ＤＭＦ（５００ｍＬ）中、４，５−ジヒドロキシ−２−ニトロベンズアルデヒド（７９．０ｇ、４３１ｍｍｏｌ）の溶液に、Ｋ_２ＣＯ_３（１７９ｇ、１３００ｍｍｏｌ）、次いで１−（クロロメチル）−４−メトキシベンゼン（１２９ｍＬ、９４９ｍｍｏｌ）を加えた。反応混合物を５０℃で２時間撹拌した。この混合物を氷水に注ぎ、得られた懸濁液を濾過して黄色固体を得、これを乾燥させ、それ以上精製せずに次の工程で使用した（１５２ｇ、収率８３％）。 Example 150: Synthesis step of compound I-150 (1): 4,5-dihydroxy-2-nitrobenzaldehyde → compound 150a
Compound 150a: 4,5-bis ((4-methoxybenzyl) oxy) -2-nitrobenzaldehyde

To a solution of 4,5-dihydroxy-2-nitrobenzaldehyde (79.0 g, 431 mmol) in DMF (500 mL) was added K ₂ CO ₃ (179 g, 1300 mmol) followed by 1- (chloromethyl) -4-methoxybenzene ( 129 mL, 949 mmol) was added. The reaction mixture was stirred at 50 ° C. for 2 hours. The mixture was poured into ice water and the resulting suspension was filtered to give a yellow solid that was dried and used in the next step without further purification (152 g, 83% yield).

ＭｅＯＨ（１．２Ｌ）およびＤＣＭ（３００ｍＬ）中、化合物１５０ａ（１５２ｇ、３５９ｍｍｏｌ）の懸濁液に、ＫＯＨ（１０１ｇ、１８００ｍｍｏｌ）およびＩ_２（１８２ｇ、７１８ｍｍｏｌ）を加えた。反応混合物を１．５時間撹拌した。飽和重亜硫酸ナトリウム水溶液（３００ｍＬ）を加えたところ、この混合物の赤茶色が消失した。有機相を濃縮した後、この混合物にＥｔＯＡｃ（５００ｍＬ）を加えた。有機相を分離し、水相をＥｔＯＡｃで抽出した（２×５００ｍＬ）。合わせた有機相を乾燥させ、濾過し、濃縮し、化合物１５０ｂ（１２８ｇ、収率７９％）を赤色油状物として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ４５４．１． Step (2): Compound 150a → Compound 150b
Compound 150b: methyl 4,5-bis ((4-methoxybenzyl) oxy) -2-nitrobenzoate

To a suspension of compound 150a (152 g, 359 mmol) in MeOH (1.2 L) and DCM (300 mL) was added KOH (101 g, 1800 mmol) and I ₂ (182 g, 718 mmol). The reaction mixture was stirred for 1.5 hours. When a saturated aqueous sodium bisulfite solution (300 mL) was added, the reddish brown color of this mixture disappeared. After the organic phase was concentrated, EtOAc (500 mL) was added to the mixture. The organic phase was separated and the aqueous phase was extracted with EtOAc (2 × 500 mL). The combined organic phases were dried, filtered and concentrated to give compound 150b (128 g, 79% yield) as a red oil. LCMS: (M + H) ^<+> : 454.1.

水（４００ｍＬ）およびメタノール（１２００ｍＬ）中、化合物１５０ｂ（１２８ｇ、２８２ｍｍｏｌ）、鉄（１２６ｇ、２２６０ｍｍｏｌ）および塩化アンモニウム（１５１ｇ、２８２０ｍｍｏｌ）の混合物を還流下で１時間加熱した。この混合物を濾過し、回収した固体をＤＣＭで洗浄した。濾液を真空濃縮し、有機溶媒を除去した。次に、得られた水溶液にＤＣＭ（５００ｍＬ）を加え、有機相を分離し、水相をＤＣＭで抽出した（２×３００ｍＬ）。合わせた有機抽出液を濃縮し、化合物１５０ｃ（１００ｇ、収率８４％）を灰色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ４２４．０． Step (3): Compound 150b → Compound 150c
Compound 150c: methyl 2-amino-4,5-bis ((4-methoxybenzyl) oxy) benzoate

A mixture of compound 150b (128 g, 282 mmol), iron (126 g, 2260 mmol) and ammonium chloride (151 g, 2820 mmol) in water (400 mL) and methanol (1200 mL) was heated at reflux for 1 hour. The mixture was filtered and the collected solid was washed with DCM. The filtrate was concentrated in vacuo to remove the organic solvent. Next, DCM (500 mL) was added to the resulting aqueous solution, the organic phase was separated, and the aqueous phase was extracted with DCM (2 × 300 mL). The combined organic extracts were concentrated to give compound 150c (100 g, 84% yield) as a gray solid. LCMS: (M + H) ^<+> : 424.0.

水（１００ｍＬ）およびメタノール（１００ｍＬ）中、化合物１５０ｃ（１０．０ｇ、２３．６ｍｍｏｌ）の溶液に、水酸化ナトリウム（４．７２ｇ、１１８ｍｍｏｌ）を加えた。この混合物を８０℃で１時間撹拌した。メタノールを真空下で除去し、クエン酸を加えて溶液のｐＨを約６に調整した。次に、この混合物をＤＣＭで抽出した（３×１００ｍＬ）。合わせた有機抽出液を水で洗浄し、乾燥させ（Ｎａ_２ＳＯ_４）、濾過し、濃縮し、化合物１５０ｄ（８．２ｇ、収率８５％）をやや黄色の固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ４１０．３． Step (4): Compound 150c → Compound 150d
Compound 150d: 2-amino-4,5-bis ((4-methoxybenzyl) oxy) benzoic acid

To a solution of compound 150c (10.0 g, 23.6 mmol) in water (100 mL) and methanol (100 mL) was added sodium hydroxide (4.72 g, 118 mmol). The mixture was stirred at 80 ° C. for 1 hour. Methanol was removed under vacuum and citric acid was added to adjust the pH of the solution to about 6. The mixture was then extracted with DCM (3 × 100 mL). The combined organic extracts were washed with water, dried (Na ₂ SO ₄ ), filtered and concentrated to give compound 150d (8.2 g, 85% yield) as a slightly yellow solid. LCMS: (M + H) ^<+> : 410.3.

ＤＭＦ（５０ｍＬ）中、化合物１５０ｄ（３．００ｇ、７．３３ｍｍｏｌ）の溶液に、ＨＡＴＵ（３．３４ｇ、８．７９ｍｍｏｌ）およびＤＩＰＥＡ（３．８４ｍＬ、２２．０ｍｍｏｌ）を加え、得られた混合物を室温で３０分間撹拌した。次に、キヌクリジン−４−イルメタンアミン（ＷＯ２０１１１２５９６６Ａ１号、１．１３ｇ、８．０６ｍｍｏｌ）を加え、得られた混合物を室温で１時間撹拌した。この混合物に水およびＥｔＯＡｃを加えた。有機相を分離し、水相をＥｔＯＡｃで３回抽出した。合わせた有機抽出液をブラインで洗浄し、乾燥させ（Ｎａ_２ＳＯ_４）、濾過し、真空濃縮した。残渣を自動シリカゲルクロマトグラフィー（溶媒Ａ中０〜１０％溶媒Ｂ；溶媒Ａ＝ＤＣＭ、溶媒Ｂ＝１０：９０：１ ＭｅＯＨ：ＤＣＭ：ＮＨ_４ＯＨ、４０ｇカラム）により精製し、化合物１５０ｅ（２．８８ｇ、収率７４％）を褐色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５３２．５． Step (5): Compound 150d → Compound 150e
Compound 150e: 2-amino-4,5-bis ((4-methoxybenzyl) oxy) -N- (quinuclidin-4-ylmethyl) benzamide

To a solution of compound 150d (3.00 g, 7.33 mmol) in DMF (50 mL) was added HATU (3.34 g, 8.79 mmol) and DIPEA (3.84 mL, 22.0 mmol) and the resulting mixture was Stir at room temperature for 30 minutes. Next, quinuclidin-4-ylmethanamine (WO20111225966A1, 1.13 g, 8.06 mmol) was added, and the resulting mixture was stirred at room temperature for 1 hour. To this mixture was added water and EtOAc. The organic phase was separated and the aqueous phase was extracted 3 times with EtOAc. The combined organic extracts were washed with brine, dried (Na ₂ SO ₄ ), filtered and concentrated in vacuo. The residue was purified by automated silica gel chromatography (0-10% solvent B in solvent A; solvent A = DCM, solvent B = 10: 90: 1 MeOH: DCM: NH ₄ OH, 40 g column) to give compound 150e (2. 88 g, 74% yield) was obtained as a brown solid. LCMS: (M + H) ^<+> : 532.5.

メタノール（１００ｍＬ）中、化合物１５０ｅ（２．８８ｇ、５．４２ｍｍｏｌ）およびトリメトキシメタン（２．９７ｍＬ、２７．１ｍｍｏｌ）の混合物を一晩１２０℃に加熱した。溶媒を真空下で除去し、残渣をＣｏｍｂｉｆｌａｓｈシリカゲルクロマトグラフィー（溶媒Ａ中０〜１０％溶媒Ｂ；溶媒Ａ＝ＤＣＭ、溶媒Ｂ＝１０：９０：１ ＭｅＯＨ：ＤＣＭ：ＮＨ_４ＯＨ、２４ｇカラム）により精製した。回収した褐色固体をＤＣＭに溶かし、水で洗浄した。有機層を濃縮し、残渣を自動シリカゲルクロマトグラフィー（０〜１０％ＭｅＯＨ／ＤＣＭ、４ｇカラム）によりさらに精製し、化合物１５０ｆ（０．６８ｇ、収率２３％）を白黄色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５４２．５． Step (6): Compound 150e → Compound 150f
Compound 150f: 6,7-bis ((4-methoxybenzyl) oxy) -3- (quinuclidin-4-ylmethyl) quinazolin-4 (3H) -one

A mixture of compound 150e (2.88 g, 5.42 mmol) and trimethoxymethane (2.97 mL, 27.1 mmol) in methanol (100 mL) was heated to 120 ° C. overnight. The solvent was removed under vacuum and the residue was chromatographed on Combiflash silica gel (0-10% solvent B in solvent A; solvent A = DCM, solvent B = 10: 90: 1 MeOH: DCM: NH ₄ OH, 24 g column). Purified. The collected brown solid was dissolved in DCM and washed with water. The organic layer was concentrated and the residue was further purified by automated silica gel chromatography (0-10% MeOH / DCM, 4 g column) to give compound 150f (0.68 g, 23% yield) as a white yellow solid. LCMS: (M + H) ^<+> : 542.5.

この化合物は、化合物１５０ｆおよび化合物Ｘ−２４を用い、実施例１４３の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７８３．７． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３６ （ｓ， ３ Ｈ） １．３８ （ｓ， ３ Ｈ） １．４０ （ｄ， Ｊ＝７．０７ Ｈｚ， ３ Ｈ） １．８４ （ｔ， Ｊ＝７．５８ Ｈｚ， ６ Ｈ） ３．２３ − ３．４７ （ｍ， ６ Ｈ） ３．８５ − ３．９９ （ｍ， ４ Ｈ） ４．４８ （ｄ， Ｊ＝１４．４０ Ｈｚ， １ Ｈ） ５．２９ （ｄ， Ｊ＝５．０５ Ｈｚ， １ Ｈ） ５．７０ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ６．８４ （ｄ， Ｊ＝２．０２ Ｈｚ， ２ Ｈ） ７．２５ （ｓ， １ Ｈ） ７．９１ （ｓ， １ Ｈ）． Step (7): Compound X-24 + Compound 150f → Compound I-150
Compound I-150: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((4-((6,7-dihydroxy-4-oxoquinazolin-3 (4H) -yl) methyl) quinuclidin-1-ium-1-yl) methyl) -4-methyl-8 -Oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 143 using compound 150f and compound X-24.
LCMS: (M + H) ^<+> : 783.7. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.36 (s, 3 H) 1.38 (s, 3 H) 1.40 (d, J = 7.07 Hz, 3 H) 1.84 ( t, J = 7.58 Hz, 6 H) 3.23-3.47 (m, 6 H) 3.85-3.99 (m, 4 H) 4.48 (d, J = 14.40 Hz) , 1 H) 5.29 (d, J = 0.05 Hz, 1 H) 5.70 (d, J = 4.80 Hz, 1 H) 6.84 (d, J = 2.02 Hz, 2 H) 7.25 (s, 1 H) 7.91 (s, 1 H).

ＭｅＣＮ（２０ｍＬ）中、化合物１５０ｄ（１．５７ｇ、３．８３ｍｍｏｌ）の溶液に、ＨＡＴＵ（１．６０ｇ、４．２２ｍｍｏｌ）およびＤＩＰＥＡ（１．２７ｍＬ、７．６７ｍｍｏｌ）を加えた。この混合物を０．５時間撹拌した後、２−（ピロリジン−１−イル）エタンアミン（０．５８ｍＬ、４．６ｍｍｏｌ）を加えた。この混合物を１時間撹拌した後、標準的な水性の後処理により化合物１５１ａ（１．８ｇ、収率９３％）を得た。粗生成物を精製せずにそのまま次の工程に使用した。
ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ５０６．５ Example 151: Synthesis step of compound I-151 (1): compound 150d → compound 151a
Compound 151a 2-amino-4,5-bis ((4-methoxybenzyl) oxy) -N- (2- (pyrrolidin-1-yl) ethyl) benzamide

To a solution of compound 150d (1.57 g, 3.83 mmol) in MeCN (20 mL) was added HATU (1.60 g, 4.22 mmol) and DIPEA (1.27 mL, 7.67 mmol). The mixture was stirred for 0.5 h before 2- (pyrrolidin-1-yl) ethanamine (0.58 mL, 4.6 mmol) was added. After the mixture was stirred for 1 hour, standard aqueous workup gave compound 151a (1.8 g, 93% yield). The crude product was used directly in the next step without purification.
LCMS: (M + H) ⁺ : 506.5

ＴＨＦ（３０ｍＬ）中、化合物１５１ａ（１．８ｇ、３．６ｍｍｏｌ）およびＣＤＩ（１．１５５ｇ、７．１２０ｍｍｏｌ）の混合物を還流温度で４時間加熱した。この溶液を冷却し、ＤＣＭと水とで分液した。有機層をＮａＨＣＯ_３水溶液、ブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し濃縮した。粗材料を、４０ｇカラムを使用し、０〜１０％ＭｅＯＨ／ＤＣＭ（各溶媒は０．１％ＮＥｔ_３を含有する）で溶出する自動シリカゲルクロマトグラフィー（Ｃｏｍｂｉｆｌａｓｈ ＲＦ）により精製した。目的生成物を水で洗浄し、４ｇカラムを使用し、０〜１０％ＭｅＯＨ／ＤＣＭで溶出する順相クロマトグラフィーによりさらに精製し、化合物１５１ｂ（７００ｍｇ、収率３７％）を黄色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５３２．５ Step (2): Compound 151a → Compound 151b
Compound 151b: 6,7-bis ((4-methoxybenzyl) oxy) -3- (2- (pyrrolidin-1-yl) ethyl) quinazoline-2,4 (1H, 3H) -dione

A mixture of compound 151a (1.8 g, 3.6 mmol) and CDI (1.155 g, 7.120 mmol) in THF (30 mL) was heated at reflux for 4 hours. The solution was cooled and partitioned between DCM and water. The organic layer was washed with aqueous NaHCO ₃ solution, brine, dried over Na ₂ SO ₄ , filtered and concentrated. The crude material was purified by automated silica gel chromatography (Combiflash RF) using a 40 g column and eluting with 0-10% MeOH / DCM (each solvent contains 0.1% NEt ₃ ). The desired product was washed with water and further purified by normal phase chromatography using a 4 g column and eluting with 0-10% MeOH / DCM to give compound 151b (700 mg, 37% yield) as a yellow solid. . LCMS: (M + H) ⁺ : 532.5

この化合物は、化合物１５１ｂおよび化合物Ｘ−２４を用い、実施例１４３の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７７３．０． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３８ （ｓ， ３ Ｈ） １．４０ （ｓ， ３ Ｈ） １．４７ （ｄ， Ｊ＝７．０７ Ｈｚ， ３ Ｈ） ２．１０ （ｂｒ． ｓ．， ４ Ｈ） ３．３０ − ３．６４ （ｍ， ６ Ｈ） ４．０２ （ｑ， Ｊ＝７．０７ Ｈｚ， １ Ｈ） ４．１６ − ４．３６ （ｍ， ３ Ｈ） ４．９５ （ｄ， Ｊ＝１４．１５ Ｈｚ， １ Ｈ） ５．３４ （ｄ， Ｊ＝４．５５ Ｈｚ， １ Ｈ） ５．６８ （ｄ， Ｊ＝４．５５ Ｈｚ， １ Ｈ） ６．３９ （ｓ， １ Ｈ） ６．８９ （ｓ， １ Ｈ） ７．１３ （ｓ， １ Ｈ）． Step (3): Compound X-24 + Compound 151b → Compound I-151
Compound I-151: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((1- (2- (6,7-dihydroxy-2,4-dioxo-1,2-dihydroquinazolin-3 (4H) -yl) ethyl) pyrrolidine-1-ium-1- Yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-en-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 143 using compound 151b and compound X-24.
LCMS: (M + H) ^<+> : 773.0. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.38 (s, 3 H) 1.40 (s, 3 H) 1.47 (d, J = 7.07 Hz, 3 H) 2.10 ( br.s., 4H) 3.30-3.64 (m, 6H) 4.02 (q, J = 7.07 Hz, 1 H) 4.16-4.36 (m, 3H) 4.95 (d, J = 14.15 Hz, 1 H) 5.34 (d, J = 4.55 Hz, 1 H) 5.68 (d, J = 4.55 Hz, 1 H) 6. 39 (s, 1 H) 6.89 (s, 1 H) 7.13 (s, 1 H).

  The compounds shown below were obtained from Compound X-24 and the corresponding amines (synthesized according to the synthesis of WO2013052568A1) in the same manner as Example 143.

ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８２８．０． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３２ − １．３９ （ｍ， ９ Ｈ） １．４５ （ｄ， Ｊ＝６．８２ Ｈｚ， ３ Ｈ） ２．１１ （ｂｒ． ｓ．， ４ Ｈ） ３．２９ − ３．６９ （ｍ， ６ Ｈ） ３．７５ − ３．９１ （ｍ， ２ Ｈ） ３．９８ （ｑ， Ｊ＝７．０７ Ｈｚ， １ Ｈ） ４．１８ （ｄ， Ｊ＝１４．１５ Ｈｚ， １ Ｈ） ４．４１ （ｑ， Ｊ＝６．９９ Ｈｚ， ２ Ｈ） ４．９４ （ｄ， Ｊ＝１４．１５ Ｈｚ， １ Ｈ） ５．３５ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ５．６９ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ６．８６ （ｓ， １ Ｈ） ６．９１ （ｓ， １ Ｈ） ７．２４ （ｓ， １ Ｈ）． Example 152: Synthesis of Compound I-152 Compound I-152: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2- Carboxypropan-2-yl) oxy) imino) acetamide) -3-((1- (2- (1-ethyl-6,7-dihydroxy-4-oxo-1,4-dihydrocinnoline-3-carboxamide)) Ethyl) pyrrolidin-1-ium-1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

LCMS: (M + H) ^<+> : 828.0. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.32-1.39 (m, 9 H) 1.45 (d, J = 6.82 Hz, 3 H) 2.11 (br. S., 4 H) 3.29-3.69 (m, 6 H) 3.75-3.91 (m, 2 H) 3.98 (q, J = 7.07 Hz, 1 H) 4.18 (d , J = 14.15 Hz, 1 H) 4.41 (q, J = 6.99 Hz, 2 H) 4.94 (d, J = 14.15 Hz, 1 H) 5.35 (d, J = 4.80 Hz, 1 H) 5.69 (d, J = 4.80 Hz, 1 H) 6.86 (s, 1 H) 6.91 (s, 1 H) 7.24 (s, 1 H).

ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８２６．９． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．２８ （ｔ， Ｊ＝７．０７ Ｈｚ， ３ Ｈ） １．３４ （ｓ， ３ Ｈ） １．３６ （ｓ， ３ Ｈ） １．４４ （ｄ， Ｊ＝７．０７ Ｈｚ， ３ Ｈ） ２．１１ （ｂｒ． ｓ．， ４ Ｈ） ２．９９ − ３．０３ （ｍ， １ Ｈ） ３．２９ − ３．５４ （ｍ， ５ Ｈ） ３．６０ （ｂｒ． ｓ．， １ Ｈ） ３．６８ − ３．８６ （ｍ， ２ Ｈ） ３．９７ （ｄ， Ｊ＝７．０７ Ｈｚ， １ Ｈ） ４．０５ （ｄ， Ｊ＝７．０７ Ｈｚ， ２ Ｈ） ４．１６ （ｄ， Ｊ＝１４．１５ Ｈｚ， １ Ｈ） ４．９３ （ｄ， Ｊ＝１４．１５ Ｈｚ， １ Ｈ） ５．３５ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ５．６８ （ｄ， Ｊ＝４．５５ Ｈｚ， １ Ｈ） ６．７７ （ｓ， １ Ｈ） ６．８５ （ｓ， １ Ｈ） ７．２３ （ｓ， １ Ｈ） ８．２９ （ｓ， １ Ｈ）． Example 153: Synthesis of Compound I-153 Compound I-153: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2- Carboxypropan-2-yl) oxy) imino) acetamido) -3-((1- (2- (1-ethyl-6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carboxamido)) ethyl ) Pyrrolidin-1-ium-1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

LCMS: (M + H) ^<+> : 826.9. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.28 (t, J = 7.07 Hz, 3 H) 1.34 (s, 3 H) 1.36 (s, 3 H) 1.44 ( d, J = 7.07 Hz, 3 H) 2.11 (br. s., 4 H) 2.99-3.03 (m, 1 H) 3.29-3.54 (m, 5 H) 3.60 (br. S., 1 H) 3.68-3.86 (m, 2 H) 3.97 (d, J = 7.07 Hz, 1 H) 4.05 (d, J = 7 .07 Hz, 2 H) 4.16 (d, J = 14.15 Hz, 1 H) 4.93 (d, J = 14.15 Hz, 1 H) 5.35 (d, J = 4.80 Hz, 1 H) 5.68 (d, J = 4.55 Hz, 1 H) 6.77 (s, 1 H) 6.85 (s, 1 H) 7.23 (s, 1 H) .29 (s, 1 H).

ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７９８．９． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３６ （ｓ， ３ Ｈ） １．３８ （ｓ， ３ Ｈ） １．４１ （ｄ， Ｊ＝７．０７ Ｈｚ， ３ Ｈ） １．８２ （ｔ， Ｊ＝７．５８ Ｈｚ， ６ Ｈ） ３．２０ − ３．４４ （ｍ， ６ Ｈ） ３．７８ − ３．９８ （ｍ， ４ Ｈ） ４．４６ （ｄ， Ｊ＝１４．４０ Ｈｚ， １ Ｈ） ５．２９ （ｄ， Ｊ＝５．０５ Ｈｚ， １ Ｈ） ５．７０ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ６．４２ （ｓ， １ Ｈ） ６．８５ （ｓ， １ Ｈ） ７．１５ （ｓ， １ Ｈ）． Example 154: Synthesis of Compound I-154 Compound I-154: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2- Carboxypropan-2-yl) oxy) imino) acetamido) -3-((4-((6,7-dihydroxy-2,4-dioxo-1,2-dihydroquinazolin-3 (4H) -yl) methyl) Quinuclidin-1-ium-1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

LCMS: (M + H) ^<+> : 798.9. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.36 (s, 3 H) 1.38 (s, 3 H) 1.41 (d, J = 7.07 Hz, 3 H) 1.82 ( t, J = 7.58 Hz, 6 H) 3.20-3.44 (m, 6 H) 3.78-3.98 (m, 4 H) 4.46 (d, J = 14.40 Hz , 1 H) 5.29 (d, J = 0.05 Hz, 1 H) 5.70 (d, J = 4.80 Hz, 1 H) 6.42 (s, 1 H) 6.85 (s , 1 H) 7.15 (s, 1 H).

酢酸（８０ｍＬ）中、２−クロロ−３，４−ジメトキシベンズアルデヒド（２０ｇ、１００ｍｍｏｌ）および硝酸カリウム（３０．２ｇ、２９９ｍｍｏｌ）の溶液に、０℃で撹拌しながら、トリフルオロメタンスルホン酸（２６．６ｍＬ、２９９ｍｍｏｌ）を加え、得られた混合物を室温で一晩撹拌した。次に、反応混合物を水に注ぎ、飽和炭酸水素ナトリウム水溶液で中和した。沈殿を濾取し、乾燥させ、化合物１５５ａ（１９ｇ、収率７８％）を得た。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ２４６．１． Example 155: Synthesis step (1) of compound I-155: 2-chloro-3,4-dimethoxybenzaldehyde → compound 155a
Compound 155a: 2-chloro-3,4-dimethoxy-6-nitrobenzaldehyde

To a solution of 2-chloro-3,4-dimethoxybenzaldehyde (20 g, 100 mmol) and potassium nitrate (30.2 g, 299 mmol) in acetic acid (80 mL) with stirring at 0 ° C., trifluoromethanesulfonic acid (26.6 mL, 299 mmol) was added and the resulting mixture was stirred overnight at room temperature. The reaction mixture was then poured into water and neutralized with saturated aqueous sodium bicarbonate. The precipitate was collected by filtration and dried to obtain Compound 155a (19 g, yield 78%). LCMS: (M + H) ^<+> : 246.1.

ＴＨＦ（１００ｍＬ）およびｔ−ブタノール（１００ｍＬ）中、化合物１５５ａ（１９ｇ、７７ｍｍｏｌ）の溶液に、１０℃で２−メチルブト−２−エン（３８７ｍＬ、７７４ｍｍｏｌ）を加えた。次に、この溶液に、水（５０ｍＬ）中、亜塩素酸ナトリウム（２１．０ｇ、２３２ｍｍｏｌ）およびリン酸二水素ナトリウム（２７．８ｇ、２３２ｍｍｏｌ）の溶液を滴下し、この懸濁液を室温で１時間激しく撹拌した。次に、この混合物を飽和ＮＨ_４Ｃｌ水溶液で希釈し、生成物をＤＣＭで抽出した。合わせた有機抽出液をブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、真空濃縮して黄色固体を得、これをそれ以上精製せずに次の工程で使用した（２０ｇ、９９％）。ＬＣＭＳ ： （Ｍ＋Ｈ−Ｈ_２Ｏ）^＋： ２４４．１． Step (2): Compound 155a → Compound 155b
Compound 155b: 2-chloro-3,4-dimethoxy-6-nitrobenzoic acid

To a solution of compound 155a (19 g, 77 mmol) in THF (100 mL) and t-butanol (100 mL) was added 2-methylbut-2-ene (387 mL, 774 mmol) at 10 ° C. Next, a solution of sodium chlorite (21.0 g, 232 mmol) and sodium dihydrogen phosphate (27.8 g, 232 mmol) in water (50 mL) was added dropwise to the solution and the suspension was allowed to cool at room temperature. Stir vigorously for 1 hour. The mixture was then diluted with saturated aqueous NH ₄ Cl and the product was extracted with DCM. The combined organic extracts were washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated in vacuo to give a yellow solid that was used in the next step without further purification (20 g, 99% ). ^{_{LCMS: (M + H-H}} 2 O) +: 244.1.

メタノール（１００ｍＬ）中、化合物１５５ｂ（１０ｇ、３８ｍｍｏｌ）およびＰｄ／Ｃ（１．０ｇ、３８ｍｍｏｌ）の混合物を、水素雰囲気下で一晩撹拌した。この混合物を濾過し、溶媒を蒸発させ、化合物１５５ｃ（８ｇ、収率９０％）を褐色固体として得た。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ２３２．１． Step (3): Compound 155b → Compound 155c
Compound 155c: 6-amino-2-chloro-3,4-dimethoxybenzoic acid

A mixture of compound 155b (10 g, 38 mmol) and Pd / C (1.0 g, 38 mmol) in methanol (100 mL) was stirred overnight under a hydrogen atmosphere. The mixture was filtered and the solvent was evaporated to give compound 155c (8 g, 90% yield) as a brown solid. LCMS: (M + H) ⁺ : 232.1.

１００ｍＬフラスコに化合物１５５ｃ（７．０ｇ、３０ｍｍｏｌ）、トリメトキシメタン（６４．１ｇ、６０４ｍｍｏｌ）、酢酸アンモニウム（２３．３ｇ、３０２ｍｍｏｌ）およびメタノール（２０ｍＬ）に入れた。反応混合物を１２０℃で３時間撹拌した。反応混合物を濃縮した。反応混合物に水（１００ｍＬ）を加え、得られた混合物を１５分間撹拌し、濾過し、化合物１５５ｄ（６．５ｇ、収率８９％）を褐色結晶性生成物として得た。
ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ２４１．１． Step (4): Compound 155c → Compound 155d
Compound 155d: 5-chloro-6,7-dimethoxyquinazolin-4 (3H) -one

A 100 mL flask was charged with compound 155c (7.0 g, 30 mmol), trimethoxymethane (64.1 g, 604 mmol), ammonium acetate (23.3 g, 302 mmol) and methanol (20 mL). The reaction mixture was stirred at 120 ° C. for 3 hours. The reaction mixture was concentrated. Water (100 mL) was added to the reaction mixture and the resulting mixture was stirred for 15 minutes and filtered to give compound 155d (6.5 g, 89% yield) as a brown crystalline product.
LCMS: (M + H) ^<+> : 241.1.

ＤＭＦ（５ｍＬ）中、化合物１５５ｄ（３．０ｇ、１２．５ｍｍｏｌ）の溶液に、炭酸セシウム（８．１２ｇ、２４．９ｍｍｏｌ）、次いで１−クロロ−２−ヨードエタン（２．２７ｍＬ、２４．９ｍｍｏｌ）を加えた。反応混合物を５０℃で０．５時間撹拌した。水を加え、この混合物を室温で１５分間撹拌した。白色沈殿を濾取し、水で洗浄し、化合物１５５ｅ（３ｇ、収率７９％）を得た。粗混合物を精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ３０３．２． Step (5): Compound 155d → Compound 155e
Compound 155e: 5-chloro-3- (2-chloroethyl) -6,7-dimethoxyquinazolin-4 (3H) -one

To a solution of compound 155d (3.0 g, 12.5 mmol) in DMF (5 mL) was added cesium carbonate (8.12 g, 24.9 mmol) followed by 1-chloro-2-iodoethane (2.27 mL, 24.9 mmol). Was added. The reaction mixture was stirred at 50 ° C. for 0.5 hour. Water was added and the mixture was stirred at room temperature for 15 minutes. The white precipitate was collected by filtration and washed with water to give compound 155e (3 g, yield 79%). The crude mixture was used in the next step without purification. LCMS: (M + H) ^<+> : 303.2.

ＤＣＭ（１０ｍＬ）中、化合物１５５ｅ（３．０ｇ、９．９ｍｍｏｌ）の溶液に、−７８℃でトリブロモボラン（３．４０ｍＬ、３４．６ｍｍｏｌ）を加えた。この混合物を室温まで温め、一晩撹拌した。この混合物をＭｅＯＨで希釈し、濃縮し、この手順を数回繰り返し、化合物１５５ｆ（２．５ｇ、収率９２％）を得た。粗生成物をそれ以上精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ２７５．１． Step (6): Compound 155e → Compound 155f
Compound 155f: 5-chloro-3- (2-chloroethyl) -6,7-dihydroxyquinazolin-4 (3H) -one

To a solution of compound 155e (3.0 g, 9.9 mmol) in DCM (10 mL) was added tribromoborane (3.40 mL, 34.6 mmol) at −78 ° C. The mixture was warmed to room temperature and stirred overnight. The mixture was diluted with MeOH, concentrated and the procedure was repeated several times to give compound 155f (2.5 g, 92% yield). The crude product was used in the next step without further purification. LCMS: (M + H) ^<+> : 275.1.

ＤＭＦ（３０ｍＬ）中、化合物１５５ｆ（２．５ｇ、９．１ｍｍｏｌ）の溶液に、Ｋ_２ＣＯ_３（５．０２ｇ、３６．４ｍｍｏｌ）、次いで１−（クロロメチル）−４−メトキシベンゼン（５．１２ｍＬ、３６．４ｍｍｏｌ）を加えた。反応混合物を５０℃で２時間撹拌した。水を加え、この混合物を室温で１５分間撹拌した。黄色沈殿を濾取し、水で洗浄し、化合物１５５ｇ（４ｇ、収率７３％）を黄色固体として得た。粗混合物を精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５１５．４． Step (7): Compound 155f → Compound 155g
Compound 155g: 5-chloro-3- (2-chloroethyl) -6,7-bis ((4-methoxybenzyl) oxy) quinazolin-4 (3H) -one

To a solution of compound 155f (2.5 g, 9.1 mmol) in DMF (30 mL) was added K ₂ CO ₃ (5.02 g, 36.4 mmol) followed by 1- (chloromethyl) -4-methoxybenzene (5. 12 mL, 36.4 mmol) was added. The reaction mixture was stirred at 50 ° C. for 2 hours. Water was added and the mixture was stirred at room temperature for 15 minutes. The yellow precipitate was collected by filtration and washed with water to give 155 g (4 g, 73% yield) of compound as a yellow solid. The crude mixture was used in the next step without purification. LCMS: (M + H) ^<+> : 515.4.

アセトニトリル（１００ｍＬ）中、化合物１５５ｇ（４．０ｇ、７．８ｍｍｏｌ）、ＤＩＰＥＡ（２．５７ｍＬ、１５．５ｍｍｏｌ）、およびピロリジン（１．２８ｍＬ、１５．５ｍｍｏｌ）の溶液を１２時間還流温度に加熱した。反応混合物に水を加え、これをＤＣＭで抽出した。有機層をＮａＨＣＯ_３、ブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、真空濃縮した。粗材料を、８０ｇカラムを使用し、４５分かけてＤＣＭ中０〜５％ＭｅＯＨで溶出する自動シリカゲルクロマトグラフィーにより精製し、１ｇの純粋な生成物を灰色固体として得た。夾雑画分を濃縮し、ＭｅＣＮにより洗浄し、さらに８００ｍｇの生成物を得、合計１．８ｇの生成物を得た（収率４２％）。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５５０．５． Step (8): Compound 155g → Compound 155h
Compound 155h: 5-chloro-6,7-bis ((4-methoxybenzyl) oxy) -3- (2- (pyrrolidin-1-yl) ethyl) quinazolin-4 (3H) -one

A solution of compound 155 g (4.0 g, 7.8 mmol), DIPEA (2.57 mL, 15.5 mmol), and pyrrolidine (1.28 mL, 15.5 mmol) in acetonitrile (100 mL) was heated to reflux for 12 hours. . Water was added to the reaction mixture and it was extracted with DCM. The organic layer was washed with NaHCO ₃ , brine, dried over Na ₂ SO ₄ , filtered and concentrated in vacuo. The crude material was purified by automated silica gel chromatography using an 80 g column and eluting with 0-5% MeOH in DCM over 45 minutes to give 1 g of pure product as a gray solid. Contaminant fractions were concentrated and washed with MeCN to give an additional 800 mg of product, yielding a total of 1.8 g of product (42% yield). LCMS: (M + H) ^<+> : 550.5.

この化合物は、化合物１５５ｈおよび化合物Ｘ−２４を用い、実施例１４３の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７９１．４． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３７ （ｓ， ３ Ｈ） １．３９ （ｓ， ３ Ｈ） １．４７ （ｄ， Ｊ＝７．０７ Ｈｚ， ３ Ｈ） ２．１４ （ｂｒ． ｓ．， ４ Ｈ） ３．３４ − ３．５９ （ｍ， ５ Ｈ） ３．６８ （ｂｒ． ｓ．， １ Ｈ） ３．９９ （ｑ， Ｊ＝６．６５ Ｈｚ， １ Ｈ） ４．１３ − ４．３６ （ｍ， ３ Ｈ） ５．００ （ｄ， Ｊ＝１４．１５ Ｈｚ， １ Ｈ） ５．３６ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ５．７０ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ６．５８ （ｓ， １ Ｈ） ６．８７ （ｓ， １ Ｈ） ７．９９ （ｓ， １ Ｈ）． Step (9): Compound X-24 + Compound 155h → Compound I-155
Compound I-155: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((1- (2- (5-chloro-6,7-dihydroxy-4-oxoquinazolin-3 (4H) -yl) ethyl) pyrrolidin-1-ium-1-yl) methyl) -4-Methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 143 using compound 155h and compound X-24.
LCMS: (M + H) ^<+> : 791.4. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.37 (s, 3 H) 1.39 (s, 3 H) 1.47 (d, J = 7.07 Hz, 3 H) 2.14 ( br.s., 4 H) 3.34-3.59 (m, 5 H) 3.68 (br.s., 1 H) 3.99 (q, J = 6.65 Hz, 1 H) 4 .13-4.36 (m, 3 H) 5.00 (d, J = 14.15 Hz, 1 H) 5.36 (d, J = 4.80 Hz, 1 H) 5.70 (d, J = 4.80 Hz, 1 H) 6.58 (s, 1 H) 6.87 (s, 1 H) 7.99 (s, 1 H).

ＤＭＦ（１００ｍＬ）中、６，７−ビス（（４−メトキシベンジル）オキシ）−１−メチル−４−オキソ−１，４−ジヒドロキノリン−３−カルボン酸（ＷＯ２０１３０５２５６８Ａ１号、３．０ｇ、５．５ｍｍｏｌ）の溶液に、ＨＡＴＵ（３．１３ｇ、８．２３ｍｍｏｌ）およびＤＩＰＥＡ（２．８８ｍＬ、１６．５ｍｍｏｌ）を加え、この混合物を０．５時間撹拌した。次に、キヌクリジン−４−イルメタンアミン（ＷＯ２０１１１２５９６６Ａ１号、１．２８ｍＬ、８．２３ｍｍｏｌ）を加え、この混合物を２時間撹拌した。重炭酸ナトリウムを加え、この混合物を１５分間撹拌した。黄色沈殿を濾取し、水で洗浄し、２４ｇカラムを用い、ＤＣＭ中０〜２０％ＭｅＯＨで溶出する自動シリカゲルクロマトグラフィーにより精製し、化合物１５６ａ（２ｇ、収率６１％）を黄色固体として得た。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ５９８．６． Example 156: Synthesis Step of Compound I-156 (1): 6,7-bis ((4-methoxybenzyl) oxy) -1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid → Compound 156a
Compound 156a: 6,7-bis ((4-methoxybenzyl) oxy) -1-methyl-4-oxo-N- (quinuclidin-4-ylmethyl) -1,4-dihydroquinoline-3-carboxamide

6,7-bis ((4-methoxybenzyl) oxy) -1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (WO2013052568A1, 3.0 g, DMF (100 mL). To a solution of 5 mmol) was added HATU (3.13 g, 8.23 mmol) and DIPEA (2.88 mL, 16.5 mmol) and the mixture was stirred for 0.5 h. Next, quinuclidin-4-ylmethanamine (WO20111225966A1, 1.28 mL, 8.23 mmol) was added and the mixture was stirred for 2 hours. Sodium bicarbonate was added and the mixture was stirred for 15 minutes. The yellow precipitate was filtered off, washed with water and purified by automated silica gel chromatography using a 24 g column and eluting with 0-20% MeOH in DCM to give compound 156a (2 g, 61% yield) as a yellow solid. It was. LCMS: (M + H) ^<+> : 598.6.

この化合物は、化合物１５６ａおよび化合物Ｘ−２４を用い、実施例１４３の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８３９．３． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３７ （ｓ， ３ Ｈ） １．３９ （ｓ， ３ Ｈ） １．４３ （ｄ， Ｊ＝７．０７ Ｈｚ， ３ Ｈ） １．８２ （ｂｒ． ｓ．， ６ Ｈ） ３．１７ − ３．５３ （ｍ， ８ Ｈ） ３．６４ （ｓ， ３ Ｈ） ３．８９ − ４．０２ （ｍ， ２ Ｈ） ４．５２ （ｄ， Ｊ＝１４．４０ Ｈｚ， １ Ｈ） ５．３１ （ｄ， Ｊ＝４．５５ Ｈｚ， １ Ｈ） ５．７１ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ６．６４ （ｂｒ． ｓ．， １ Ｈ） ６．８５ （ｓ， １ Ｈ） ７．１６ （ｓ， １ Ｈ） ８．２０ （ｓ， １ Ｈ）． Step (2): Compound X-24 + Compound 156a → Compound I-156
Compound I-156: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((4-((6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamido) methyl) quinuclidin-1-ium-1-yl) methyl ) -4-Methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 143 using compound 156a and compound X-24.
LCMS: (M + H) ^<+> : 839.3. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.37 (s, 3 H) 1.39 (s, 3 H) 1.43 (d, J = 7.07 Hz, 3 H) 1.82 ( br.s., 6H) 3.17-3.53 (m, 8H) 3.64 (s, 3H) 3.89-4.02 (m, 2H) 4.52 (d, J = 14.40 Hz, 1 H) 5.31 (d, J = 4.55 Hz, 1 H) 5.71 (d, J = 4.80 Hz, 1 H) 6.64 (br. S., 1 H) 6.85 (s, 1 H) 7.16 (s, 1 H) 8.20 (s, 1 H).

この化合物は、６，７−ビス（（４−メトキシベンジル）オキシ）−１−メチル−４−オキソ−Ｎ−（２−（ピロリジン−１−イル）エチル）−１，４−ジヒドロキノリン−３−カルボキサミド（ＷＯ２０１３０５２５６８Ａ１号の合成に従って合成）および化合物Ｘ−２４を用い、実施例１４３の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８１３．２． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３４ （ｓ， ３ Ｈ） １．３７ （ｓ， ３ Ｈ） １．４７ （ｄ， Ｊ＝６．８２ Ｈｚ， ３ Ｈ） ２．１１ （ｂｒ． ｓ．， ４ Ｈ） ３．４２ （ｂｒ． ｓ．， ４ Ｈ） ３．４９ （ｂｒ． ｓ．， ３ Ｈ） ３．５６ − ３．８２ （ｍ， ４ Ｈ） ４．００ （ｄ， Ｊ＝６．８２ Ｈｚ， １ Ｈ） ４．１５ （ｄ， Ｊ＝１４．１５ Ｈｚ， １ Ｈ） ４．９５ （ｄ， Ｊ＝１４．１５ Ｈｚ， １ Ｈ） ５．３７ （ｄ， Ｊ＝４．５５ Ｈｚ， １ Ｈ） ５．７３ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ６．４６ （ｂｒ． ｓ．， １ Ｈ） ６．８２ （ｓ， １ Ｈ） ６．９７ （ｓ， １ Ｈ） ７．９６ （ｓ， １ Ｈ）． Example 157: Synthesis of Compound I-157 Compound I-157: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2- Carboxypropan-2-yl) oxy) imino) acetamido) -3-((1- (2- (6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamido)) ethyl ) Pyrrolidin-1-ium-1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

This compound is composed of 6,7-bis ((4-methoxybenzyl) oxy) -1-methyl-4-oxo-N- (2- (pyrrolidin-1-yl) ethyl) -1,4-dihydroquinoline-3 Prepared according to the two-step method of Example 143 using carboxamide (synthesized according to the synthesis of WO2013052568A1) and compound X-24.
LCMS: (M + H) ^<+> : 813.2. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.34 (s, 3 H) 1.37 (s, 3 H) 1.47 (d, J = 6.82 Hz, 3 H) 2.11. br.s., 4H) 3.42 (br.s., 4H) 3.49 (br.s., 3H) 3.56-3.82 (m, 4H) 4.00 (d , J = 6.82 Hz, 1 H) 4.15 (d, J = 14.15 Hz, 1 H) 4.95 (d, J = 14.15 Hz, 1 H) 5.37 (d, J = 4.55 Hz, 1 H) 5.73 (d, J = 4.80 Hz, 1 H) 6.46 (br.s., 1 H) 6.82 (s, 1 H) 6.97 ( s, 1 H) 7.96 (s, 1 H).

ＤＭＦ（１００ｍＬ）中、化合物１５５ｄ（２．５０ｇ、１０．４ｍｍｏｌ）の溶液に、５０℃で１−クロロ−３−ヨードプロパン（１．６０ｍＬ、２０．８ｍｍｏｌ）を滴下し、この混合物を一晩撹拌した。水を加え、この混合物をＥｔＯＡｃで抽出した。有機層をＮａ_２ＳＯ_４で乾燥させ、濾過し、濃縮した。残渣を自動シリカゲルクロマトグラフィー（ＤＣＭ中１０％ＭｅＯＨ）により精製し、化合物１５８ａ（２．０ｇ、収率６１％）を黄色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ３１６．８． Example 158: Synthesis Step of Compound I-158 (1): Compound 155d → Compound 158a
Compound 158a: 5-chloro-3- (3-chloropropyl) -6,7-dimethoxyquinazolin-4 (3H) -one

To a solution of compound 155d (2.50 g, 10.4 mmol) in DMF (100 mL) is added 1-chloro-3-iodopropane (1.60 mL, 20.8 mmol) dropwise at 50 ° C. and the mixture is allowed to stand overnight. Stir. Water was added and the mixture was extracted with EtOAc. The organic layer was dried over Na ₂ SO ₄ , filtered and concentrated. The residue was purified by automated silica gel chromatography (10% MeOH in DCM) to give compound 158a (2.0 g, 61% yield) as a yellow solid. LCMS: (M + H) ^<+> : 316.8.

ＤＣＭ（１００ｍＬ）中、化合物１５８ａ（２．０ｇ、６．３ｍｍｏｌ）の溶液に、−７８℃で三臭化ホウ素（２．９８ｍＬ、３１．５ｍｍｏｌ）を滴下した。反応混合物を室温までゆっくり温め、一晩撹拌した。この混合物をＭｅＯＨで希釈し、濃縮し、このプロセスを３回繰り返し、化合物１５８ｂ（１．７ｇ、収率９３％）を得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ２８８．８． Step (2): Compound 158a → Compound 158b
Compound 158b: 5-chloro-3- (3-chloropropyl) -6,7-dihydroxyquinazolin-4 (3H) -one

Boron tribromide (2.98 mL, 31.5 mmol) was added dropwise at −78 ° C. to a solution of compound 158a (2.0 g, 6.3 mmol) in DCM (100 mL). The reaction mixture was slowly warmed to room temperature and stirred overnight. The mixture was diluted with MeOH, concentrated and the process was repeated 3 times to give compound 158b (1.7 g, 93% yield). LCMS: (M + H) ^<+> : 288.8.

ＤＭＦ（１００ｍＬ）中、化合物１５８ｂ（３．６８ｇ、２３．５ｍｍｏｌ）の溶液に、炭酸カリウム（４．０６ｇ、２９．４ｍｍｏｌ）および１−（クロロメチル）−４−メトキシベンゼン（３．６８ｇ、２３．５ｍｍｏｌ）を加え、この混合物を５０℃で一晩撹拌した。水を加え、この混合物をＥｔＯＡｃで抽出した。有機層を乾燥させ（Ｎａ_２ＳＯ_４）、濾過し、濃縮した。残渣を自動シリカゲルクロマトグラフィーにより精製し、化合物１５８ｃ（３ｇ、収率９６％）を得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５２９．１． Step (3): Compound 158b → Compound 158c
Compound 158c: 5-chloro-3- (3-chloropropyl) -6,7-bis ((4-methoxybenzyl) oxy) quinazolin-4 (3H) -one

To a solution of compound 158b (3.68 g, 23.5 mmol) in DMF (100 mL) was added potassium carbonate (4.06 g, 29.4 mmol) and 1- (chloromethyl) -4-methoxybenzene (3.68 g, 23 0.5 mmol) was added and the mixture was stirred at 50 ° C. overnight. Water was added and the mixture was extracted with EtOAc. The organic layer was dried (Na ₂ SO ₄ ), filtered and concentrated. The residue was purified by automatic silica gel chromatography to obtain compound 158c (3 g, yield 96%). LCMS: (M + H) ^<+> : 529.1.

ＭｅＣＮ（１００ｍＬ）中、化合物１５８ｃ（３．３ｇ、６．２ｍｍｏｌ）の溶液に、ＤＩＰＥＡ（２．７２ｍＬ、１５．６ｍｍｏｌ）およびピロリジン（１．２９ｍＬ、１５．６ｍｍｏｌ）を加え、この混合物を８０℃に加熱した。反応混合物をＬＣＭＳにより分析したところ、出発材料が完全に消費されていないことが示された。反応混合物にヨウ化ナトリウム（１．１２１ｇ、７．４８０ｍｍｏｌ）を加え、次にこれを同じ温度で一晩撹拌した。揮発性物質を除去し、残渣をＥｔＯＡｃに溶かし、ブライン、ＮａＨＣＯ_３水溶液、および水で洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過した後、自動シリカゲルクロマトグラフィー（ＤＣＭ中１０％ＭｅＯＨ）により精製し、化合物１５８ｄ（０．９ｇ、収率２６％）を得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５６４．５． Step (4): Compound 158c → Compound 158d
Compound 158d: 5-chloro-6,7-bis ((4-methoxybenzyl) oxy) -3- (3- (pyrrolidin-1-yl) propyl) quinazolin-4 (3H) -one

To a solution of compound 158c (3.3 g, 6.2 mmol) in MeCN (100 mL) was added DIPEA (2.72 mL, 15.6 mmol) and pyrrolidine (1.29 mL, 15.6 mmol) and the mixture was added at 80 ° C. Heated. Analysis of the reaction mixture by LCMS indicated that the starting material was not completely consumed. To the reaction mixture was added sodium iodide (1.121 g, 7.480 mmol), which was then stirred at the same temperature overnight. Volatiles were removed and the residue was dissolved in EtOAc, washed with brine, aqueous NaHCO ₃ , and water, dried over Na ₂ SO ₄ , filtered and purified by automated silica gel chromatography (10% MeOH in DCM). Compound 158d (0.9 g, yield 26%) was obtained. LCMS: (M + H) ^<+> : 564.5.

この化合物は、化合物１５８ｄおよび化合物Ｘ−２４を用い、実施例１４３の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８０４．９． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．２７ （ｄ， Ｊ＝７．０７ Ｈｚ， ３ Ｈ） １．３４ （ｓ， ３ Ｈ） １．３６ （ｓ， ３ Ｈ） ２．０６ （ｂｒ． ｓ．， ４ Ｈ） ２．１７ （ｂｒ． ｓ．， ２ Ｈ） ３．２７ （ｓ， ２Ｈ） ３．３１ − ３．５０ （ｍ， ６ Ｈ） ３．８９ − ４．１２ （ｍ， ３ Ｈ） ５．０７ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ５．５７ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ６．７８ （ｓ， １ Ｈ） ６．８１ （ｓ， １ Ｈ） ８．０４ （ｓ， １ Ｈ）． Step (5): Compound X-24 + Compound 158d → Compound I-158
Compound I-158: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((1- (3- (5-chloro-6,7-dihydroxy-4-oxoquinazolin-3 (4H) -yl) propyl) pyrrolidin-1-ium-1-yl) methyl) -4-Methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 143 using compound 158d and compound X-24.
LCMS: (M + H) ^<+> : 804.9. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.27 (d, J = 7.07 Hz, 3 H) 1.34 (s, 3 H) 1.36 (s, 3 H) 2.06 ( br.s., 4H) 2.17 (br.s., 2H) 3.27 (s, 2H) 3.31-3.50 (m, 6H) 3.89-4.12 (m , 3 H) 5.07 (d, J = 4.80 Hz, 1 H) 5.57 (d, J = 4.80 Hz, 1 H) 6.78 (s, 1 H) 6.81 (s , 1 H) 8.04 (s, 1 H).

ＤＭＦ（１００ｍＬ）中、６，７−ビス（（４−メトキシベンジル）オキシ）−４−オキソ−１，４−ジヒドロキノリン−３−カルボン酸エチル（１０．０ｇ、２０．４ｍｍｏｌ）の懸濁液に、Ｋ_２ＣＯ_３（７．０６ｇ、５１．１ｍｍｏｌ）およびヨードメタン（３．１８ｍＬ、５１．１ｍｍｏｌ）を加えた。この混合物を５０℃で２時間撹拌した。水を加え、沈殿を濾取し、化合物１５９ａ（９ｇ、収率８７％）を黄色固体として得、これをそれ以上精製せずに次の工程に使用した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５０４．１． Example 159: Synthesis Step of Compound I-159 (1): 6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-1,4-dihydroquinoline-3-carboxylate → Compound 159a
Compound 159a: ethyl 6,7-bis ((4-methoxybenzyl) oxy) -1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate

Suspension of ethyl 6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-1,4-dihydroquinoline-3-carboxylate (10.0 g, 20.4 mmol) in DMF (100 mL) To was added K ₂ CO ₃ (7.06 g, 51.1 mmol) and iodomethane (3.18 mL, 51.1 mmol). The mixture was stirred at 50 ° C. for 2 hours. Water was added and the precipitate was collected by filtration to give compound 159a (9 g, 87% yield) as a yellow solid, which was used in the next step without further purification.
LCMS: (M + H) ^<+> : 504.1.

メタノール（１０ｍＬ）と水（５ｍＬ）の混合物中、化合物１５９ａ（９．０ｇ、１７．９ｍｍｏｌ）の懸濁液に、ＫＯＨ（５．０ｇ、８９ｍｍｏｌ）を少量ずつ加えた。得られた混合物を９０℃で３時間撹拌した。反応混合物を室温まで冷却し、濃縮した。残渣を水で希釈し、この溶液のｐＨを、２Ｎ ＨＣｌ水溶液を用いて１に調整した。沈殿を濾取し、乾燥させ、化合物１５９ｂ（９ｇ、収率９２％）を淡黄色固体として得た。粗生成物をそれ以上精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ４７６．４． Step (2): Compound 159a → Compound 159b
Compound 159b: 6,7-bis ((4-methoxybenzyl) oxy) -1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

To a suspension of compound 159a (9.0 g, 17.9 mmol) in a mixture of methanol (10 mL) and water (5 mL) was added KOH (5.0 g, 89 mmol) in small portions. The resulting mixture was stirred at 90 ° C. for 3 hours. The reaction mixture was cooled to room temperature and concentrated. The residue was diluted with water and the pH of this solution was adjusted to 1 using 2N aqueous HCl. The precipitate was collected by filtration and dried to give compound 159b (9 g, yield 92%) as a pale yellow solid. The crude product was used in the next step without further purification. LCMS: (M + H) ^<+> : 476.4.

ＤＭＦ（３０ｍＬ）中、化合物１５９ｂ（３．０ｇ、５．５ｍｍｏｌ）の溶液に、ＨＡＴＵ（３．１３ｇ、８．２３ｍｍｏｌ）およびＤＩＰＥＡ（２．８８ｍＬ、１６．５ｍｍｏｌ）を加えた。この混合物を０．５時間撹拌し、１，４−ジアザビシクロ［３．２．２］ノナン（１．１６ｍＬ、８．２３ｍｍｏｌ）を加えた。反応混合物を１時間撹拌した。水を加え、生成物をＤＣＭで抽出し、重炭酸ナトリウムで洗浄した。粗材料を、２４ｇカラムを使用し、ＤＣＭ中０〜２０％ＭｅＯＨで溶出する自動シリカゲルクロマトグラフィーにより精製し、化合物１５９ｃ（１．８ｇ、収率５６％）を黄色固体として得た。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ５８４．６ Step (3): Compound 159b → Compound 159c
Compound 159c: 3- (1,4-diazabicyclo [3.2.2] nonane-4-carbonyl) -6,7-bis ((4-methoxybenzyl) oxy) -1-methylquinoline-4 (1H)- on

To a solution of compound 159b (3.0 g, 5.5 mmol) in DMF (30 mL) was added HATU (3.13 g, 8.23 mmol) and DIPEA (2.88 mL, 16.5 mmol). The mixture was stirred for 0.5 h and 1,4-diazabicyclo [3.2.2] nonane (1.16 mL, 8.23 mmol) was added. The reaction mixture was stirred for 1 hour. Water was added and the product was extracted with DCM and washed with sodium bicarbonate. The crude material was purified by automated silica gel chromatography using a 24 g column and eluting with 0-20% MeOH in DCM to give compound 159c (1.8 g, 56% yield) as a yellow solid. LCMS: (M + H) ⁺ : 584.6

この化合物は、化合物１５９ｃおよび化合物Ｘ−２４を用い、実施例１４３の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８２５．１． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３３ − １．５１ （ｍ， ９ Ｈ） ２．２７ （ｂｒ． ｓ．， ４ Ｈ） ３．３１ − ３．８７ （ｍ， １０ Ｈ） ３．９２ − ４．０７ （ｍ， ２ Ｈ） ４．１１ − ４．２８ （ｍ， ２ Ｈ） ４．７５ − ４．８０ （ｍ， １ Ｈ） ５．３２ （ｄ， Ｊ＝５．０５ Ｈｚ， １ Ｈ） ５．６８ − ５．７６ （ｍ， １ Ｈ） ６．８４ − ６．９０ （ｍ， １ Ｈ） ６．９８ （ｂｒ． ｓ．， １ Ｈ） ７．４６ − ７．５４ （ｍ， １ Ｈ） ７．９６ − ８．０６ （ｍ， １Ｈ）． Step (4): Compound X-24 + Compound 159c → Compound I-159
Compound I-159: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((4- (6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroquinoline-3-carbonyl) -1,4-diazabicyclo [3.2.2] nonane -1-ium-1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-en-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 143 using compound 159c and compound X-24.
LCMS: (M + H) ^<+> : 825.1. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.33-1.51 (m, 9 H) 2.27 (br. S., 4 H) 3.31-3.87 (m, 10 H) 3.92-4.07 (m, 2 H) 4.11-4.28 (m, 2 H) 4.75-4.80 (m, 1 H) 5.32 (d, J = 5.05 Hz, 1 H) 5.68-5.76 (m, 1 H) 6.84-6.90 (m, 1 H) 6.98 (br. S., 1 H) 7.46-7.54 (M, 1H) 7.96-8.06 (m, 1H).

ＤＭＦ（５０ｍＬ）中、化合物１４９ｊ（２．５ｇ、４．９ｍｍｏｌ）の溶液に、ＨＡＴＵ（２．８０ｇ、７．３５ｍｍｏｌ）およびＤＩＰＥＡ（３．４３ｍＬ、１９．６ｍｍｏｌ）を加え、得られた混合物を室温で３０分間撹拌した。次に、１，４−ジアザビシクロ［３．２．２］ノナン（０．８０４ｇ、６．３７ｍｍｏｌ）を加え、得られた混合物を室温で１時間撹拌した。この混合物に水およびＥｔＯＡｃを加えた。有機相を分離し、水相をＥｔＯＡｃで３回抽出した。合わせた有機抽出液をブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、真空濃縮した。残渣を自動シリカゲルクロマトグラフィー（溶媒Ａ中０〜１０％溶媒Ｂ；溶媒Ａ＝ＤＣＭ、溶媒Ｂ＝１０：９０：１ ＭｅＯＨ：ＤＣＭ：ＮＨ_４ＯＨ、２４ｇカラム）により精製した。回収した褐色固体をＤＣＭに溶かし、水で洗浄した後、有機層を濃縮した。残渣を自動シリカゲルクロマトグラフィー（ＤＣＭ中０〜１０％ＭｅＯＨ、４ｇカラム）によりさらに精製し、化合物１６０ａ（１．１７ｇ、収率３９％）を褐色固体として得た。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ６１８．５． Example 160: Synthesis Step of Compound I-160 (1): Compound 149j → Compound 160a
Compound 160a: 3- (1,4-diazabicyclo [3.2.2] nonane-4-carbonyl) -5-chloro-6,7-bis ((4-methoxybenzyl) oxy) -1-methylquinoline-4 (1H) -ON

To a solution of compound 149j (2.5 g, 4.9 mmol) in DMF (50 mL) was added HATU (2.80 g, 7.35 mmol) and DIPEA (3.43 mL, 19.6 mmol) and the resulting mixture was Stir at room temperature for 30 minutes. Next, 1,4-diazabicyclo [3.2.2] nonane (0.804 g, 6.37 mmol) was added and the resulting mixture was stirred at room temperature for 1 hour. To this mixture was added water and EtOAc. The organic phase was separated and the aqueous phase was extracted 3 times with EtOAc. The combined organic extracts were washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated in vacuo. The residue was purified by automated silica gel chromatography (0-10% solvent B in solvent A; solvent A = DCM, solvent B = 10: 90: 1 MeOH: DCM: NH ₄ OH, 24 g column). The collected brown solid was dissolved in DCM and washed with water, and then the organic layer was concentrated. The residue was further purified by automated silica gel chromatography (0-10% MeOH in DCM, 4 g column) to give compound 160a (1.17 g, 39% yield) as a brown solid. LCMS: (M + H) ^<+> : 618.5.

この化合物は、化合物１６０ａおよび化合物Ｘ−２４を用い、実施例１４３の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８５９．２． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３３ − １．５５ （ｍ， ９ Ｈ） ２．０７ − ２．３４ （ｍ， ４ Ｈ） ３．３１ − ３．９１ （ｍ， １１ Ｈ） ４．２０ （ｂｒ． ｓ．， ３ Ｈ） ４．７６ （ｄ， Ｊ＝６．３２ Ｈｚ， １ Ｈ） ５．３２ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ５．７２ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ６．８４ （ｓ， １ Ｈ） ６．８５ − ６．８８ （ｍ， １ Ｈ） ７．８６ − ７．９５ （ｍ， １ Ｈ）． Step (2): Compound X-24 + Compound 160a → Compound I-160
Compound I-160: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((4- (5-chloro-6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroquinoline-3-carbonyl) -1,4-diazabicyclo [3.2 .2] Nonan-1-ium-1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-en-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 143 using compound 160a and compound X-24.
LCMS: (M + H) ^<+> : 859.2. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.33-1.55 (m, 9 H) 2.07-2.34 (m, 4 H) 3.31-3.91 (m, 11 H) 4.20 (br. S., 3 H) 4.76 (d, J = 6.32 Hz, 1 H) 5.32 (d, J = 4.80 Hz, 1 H) 5.72 (d , J = 4.80 Hz, 1 H) 6.84 (s, 1 H) 6.85-6.88 (m, 1 H) 7.86-7.95 (m, 1 H).

ＤＭＦ（１００ｍＬ）中、Ｋ_２ＣＯ_３（２４．５ｇ、１７７ｍｍｏｌ）および化合物１５５ｄ（２１．３ｇ、８９．０ｍｍｏｌ）の混合物に、室温でヨードメタン（１１．０２ｍＬ、１７７ｍｍｏｌ）を加え、得られた混合物を５０℃で１時間撹拌した。この混合物を室温まで冷却し、氷水（７００ｍＬ）に注いだ。得られた水性混合物を１５分間撹拌し、化合物１６１ａ（１９．３ｇ、収率８６％）を黄色固体として濾過した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ２５５．２． Example 161: Synthesis step of compound I-161 (1): Compound 155d → Compound 147a
Compound 161a: 5-chloro-6,7-dimethoxy-3-methylquinazolin-4 (3H) -one

To a mixture of K ₂ CO ₃ (24.5 g, 177 mmol) and compound 155d (21.3 g, 89.0 mmol) in DMF (100 mL) at room temperature was added iodomethane (11.02 mL, 177 mmol) and the resulting mixture Was stirred at 50 ° C. for 1 hour. The mixture was cooled to room temperature and poured into ice water (700 mL). The resulting aqueous mixture was stirred for 15 minutes and compound 161a (19.3 g, 86% yield) was filtered as a yellow solid. LCMS: (M + H) ^<+> : 255.2.

ＤＣＭ（１５０ｍＬ）中、化合物１６１ａ（１８．０ｇ、７０．７ｍｍｏｌ）の溶液に、−７８℃でトリブロモボラン（２４．３０ｍＬ、２４７．０ｍｍｏｌ）を加えた。この混合物を室温まで温め、一晩撹拌した。この混合物をＭｅＯＨで希釈し、濃縮し、ＭｅＯＨで再び希釈および濃縮し、この手順を数回繰り返し、化合物１６１ｂ（１６．３ｇ、収率９９％）を得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ２２７．１． Step (2): Compound 161a → Compound 161b
Compound 161b: 5-chloro-6,7-dihydroxy-3-methylquinazolin-4 (3H) -one

To a solution of compound 161a (18.0 g, 70.7 mmol) in DCM (150 mL) was added tribromoborane (24.30 mL, 247.0 mmol) at −78 ° C. The mixture was warmed to room temperature and stirred overnight. The mixture was diluted with MeOH, concentrated, diluted and concentrated again with MeOH, and this procedure was repeated several times to give compound 161b (16.3 g, 99% yield). LCMS: (M + H) ^<+> : 227.1.

ＤＭＦ（２５０ｍＬ）中、化合物１６１ｂ（１６．３ｇ、７１．９ｍｍｏｌ）の溶液に、Ｋ_２ＣＯ_３（２９．８ｇ、２１６ｍｍｏｌ）、次いで１−（クロロメチル）−４−メトキシベンゼン（２９．４ｍＬ、２１６ｍｍｏｌ）を加えた。次に、反応混合物を５０℃で２時間撹拌した。水を加え、混合物を室温で１５分間撹拌した。黄色沈殿を濾取し、水で洗浄し、化合物１６１ｃ（４０ｇ、収率９８％）を得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ４６７．２． Step (3): Compound 161b → Compound 161c
Compound 161c: 5-chloro-6,7-bis ((4-methoxybenzyl) oxy) -3-methylquinazolin-4 (3H) -one

To a solution of compound 161b (16.3 g, 71.9 mmol) in DMF (250 mL) was added K ₂ CO ₃ (29.8 g, 216 mmol) followed by 1- (chloromethyl) -4-methoxybenzene (29.4 mL, 216 mmol) was added. The reaction mixture was then stirred at 50 ° C. for 2 hours. Water was added and the mixture was stirred at room temperature for 15 minutes. The yellow precipitate was collected by filtration and washed with water to give compound 161c (40 g, yield 98%). LCMS: (M + H) ^<+> : 467.2.

メタノール（３００ｍＬ）および水（２００ｍＬ）中、化合物１６１ｃ（３６ｇ、６３ｍｍｏｌ）の溶液に、ＫＯＨ（３５５ｇ、６３２０ｍｍｏｌ）を加えた。この混合物を還流温度で一晩加熱した。この混合物を室温まで冷却し、水（１００ｍＬ）を加えた。得られた黄色沈殿を濾取し、水（２０ｍＬ）で洗浄した。残渣をジイソプロピルエーテルおよびＤＣＭ（２：１比、９００ｍＬ）で希釈し、固体を濾取し、同じ溶媒混合物ですすぎ（２×６０ｍＬ）、化合物１６１ｄ（２３．６ｇ、収率７７％）を淡褐色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ４４４．２． Step (4): Compound 161c → Compound 161d
Compound 161d: Potassium 6-amino-2-chloro-3,4-bis ((4-methoxybenzyl) oxy) benzoate

To a solution of compound 161c (36 g, 63 mmol) in methanol (300 mL) and water (200 mL) was added KOH (355 g, 6320 mmol). The mixture was heated at reflux temperature overnight. The mixture was cooled to room temperature and water (100 mL) was added. The resulting yellow precipitate was collected by filtration and washed with water (20 mL). The residue was diluted with diisopropyl ether and DCM (2: 1 ratio, 900 mL), the solid was collected by filtration, rinsed with the same solvent mixture (2 × 60 mL), and compound 161d (23.6 g, 77% yield) was pale brown Obtained as a solid. LCMS: (M + H) ^<+> : 444.2.

ＤＭＦ（２５ｍＬ）中、化合物１６１ｄ（５．０ｇ、１０．４ｍｍｏｌ）の混合物に、トリメトキシメタン（５６．７ｍＬ、５１９ｍｍｏｌ）、ＤＩＰＥＡ（１８．１２ｍＬ、１０４．０ｍｍｏｌ）およびキヌクリジン−４−イルメタンアミン二塩酸塩（ＷＯ２０１１１２５９６６Ａ１号参照、３．２９ｇ、１５．６ｍｍｏｌ）を加えた。この混合物を１１５℃で６時間撹拌した。水を加え、この混合物をＤＣＭで抽出し、２Ｎ ＮａＯＨ水溶液で洗浄した。有機抽出液を、１６０ｇ塩基性アルミナカラムを使用し、溶媒Ｂ中３０〜８０％溶媒Ａ（溶媒Ａ＝ＥｔＯＡｃ／ＥｔＯＨ／Ｅｔ_３Ｎ、７６：２４：１比；溶媒Ｂ＝ヘキサン）で溶出する自動順相クロマトグラフィーにより精製し、化合物１６１ｅ（３．０ｇ、収率５０％）を黄色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５７６．４． Step (5): Compound 161d → Compound 161e
Compound 161e: 5-chloro-6,7-bis ((4-methoxybenzyl) oxy) -3- (quinuclidin-4-ylmethyl) quinazolin-4 (3H) -one

To a mixture of compound 161d (5.0 g, 10.4 mmol) in DMF (25 mL) was added trimethoxymethane (56.7 mL, 519 mmol), DIPEA (18.12 mL, 104.0 mmol) and quinuclidin-4-ylmethanamine. Dihydrochloride (see WO2011125966A1, 3.29 g, 15.6 mmol) was added. The mixture was stirred at 115 ° C. for 6 hours. Water was added and the mixture was extracted with DCM and washed with 2N aqueous NaOH. The organic extract is eluted with 30-80% solvent A in solvent B (solvent A = EtOAc / EtOH / Et ₃ N, 76: 24: 1 ratio; solvent B = hexane) using a 160 g basic alumina column. Purification by automated normal phase chromatography gave Compound 161e (3.0 g, 50% yield) as a yellow solid. LCMS: (M + H) ^<+> : 576.4.

この化合物は、化合物１６１ｅおよび化合物Ｘ−２４を用い、実施例１４３の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８１７．４． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３７ （ｓ， ３ Ｈ） １．３９ （ｓ， ３ Ｈ） １．４２ （ｄ， Ｊ＝７．０７ Ｈｚ， ３ Ｈ） １．８６ （ｔ， Ｊ＝７．７１ Ｈｚ， ６ Ｈ） ３．２５ − ３．４６ （ｍ， ６ Ｈ） ３．８５ − ４．００ （ｍ， ４ Ｈ） ４．４９ （ｄ， Ｊ＝１４．４０ Ｈｚ， １ Ｈ） ５．３０ （ｄ， Ｊ＝５．０５ Ｈｚ， １ Ｈ） ５．７１ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ６．８４ （ｂｒ． ｓ．， １ Ｈ） ６．８６ （ｓ， １ Ｈ） ７．９６ （ｓ， １ Ｈ）． Step (6): Compound X-24 + Compound 161e → Compound I-161
Compound I-161: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((4-((5-chloro-6,7-dihydroxy-4-oxoquinazolin-3 (4H) -yl) methyl) quinuclidin-1-ium-1-yl) methyl) -4 -Methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 143 using compound 161e and compound X-24.
LCMS: (M + H) ^<+> : 817.4. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.37 (s, 3 H) 1.39 (s, 3 H) 1.42 (d, J = 7.07 Hz, 3 H) 1.86 ( t, J = 7.71 Hz, 6 H) 3.25-3.46 (m, 6 H) 3.85-4.00 (m, 4 H) 4.49 (d, J = 14.40 Hz) , 1 H) 5.30 (d, J = 0.05 Hz, 1 H) 5.71 (d, J = 4.80 Hz, 1 H) 6.84 (br. S., 1 H) 6. 86 (s, 1 H) 7.96 (s, 1 H).

アセトニトリル（４００ｍＬ）中、６−アミノ−２−クロロ−３，４−ビス（（４−メトキシベンジル）オキシ）安息香酸カリウム（５．０ｇ、１０．４ｍｍｏｌ）の溶液に、ＨＡＴＵ（３．９４ｇ、１０．４ｍｍｏｌ）およびＤＩＰＥＡ（９．０６ｍＬ、５１．９ｍｍｏｌ）を加え、この混合物を室温で０．５時間撹拌した。次に、キヌクリジン−４−イルメタンアミン二塩酸塩（ＷＯ２０１１１２５９６６Ａ１号、２．６５ｇ、１２．５ｍｍｏｌ）を加え、この混合物を室温で１時間撹拌した。水を加え、この混合物をＤＣＭで抽出し、重炭酸ナトリウム水溶液で洗浄した。粗材料を、２４ｇカラムを使用し、溶媒Ｂ中４０〜９０％溶媒Ａ（溶媒Ａ＝ＥｔＯＡｃ／ＥｔＯＨ／Ｅｔ_３Ｎ、７６：２４：１比；溶媒Ｂ＝ヘキサン）で溶出する自動シリカカラムクロマトグラフィーにより精製し、化合物１６２ａ（２．４６ｇ、収率４２％）を黄色固体として得た。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ５６６．４． Example 162 Synthesis Step of Compound I-162 (1): 6-Amino-2-chloro-3,4-bis ((4-methoxybenzyl) oxy) benzoate → Compound 162a
Compound 162a: 6-amino-2-chloro-3,4-bis ((4-methoxybenzyl) oxy) -N- (quinuclidin-4-ylmethyl) benzamide

To a solution of potassium 6-amino-2-chloro-3,4-bis ((4-methoxybenzyl) oxy) benzoate (5.0 g, 10.4 mmol) in acetonitrile (400 mL), HATU (3.94 g, 10.4 mmol) and DIPEA (9.06 mL, 51.9 mmol) were added and the mixture was stirred at room temperature for 0.5 h. Next, quinuclidin-4-ylmethanamine dihydrochloride (WO20111225966A1, 2.65 g, 12.5 mmol) was added and the mixture was stirred at room temperature for 1 hour. Water was added and the mixture was extracted with DCM and washed with aqueous sodium bicarbonate. The crude material is chromatographed on an automated silica column using a 24 g column and eluting with 40-90% solvent A in solvent B (solvent A = EtOAc / EtOH / Et ₃ N, 76: 24: 1 ratio; solvent B = hexane). Purification by chromatography gave compound 162a (2.46 g, 42% yield) as a yellow solid. LCMS: (M + H) ^<+> : 566.4.

ＴＨＦ（２０ｍＬ）中、化合物１６２ａ（１００ｍｇ、０．１７７ｍｍｏｌ）およびＣＤＩ（８６ｍｇ、０．５３ｍｍｏｌ）の混合物を２４時間還流温度に加熱した。この溶液を室温まで冷却し、ＥｔＯＡｃと水とで分液した。有機相をＮａ_２ＳＯ_４で乾燥させ、濾過し、濃縮した。粗材料を、２４ｇカラムを使用し、ＤＣＭ中０〜２０％ＭｅＯＨ（１％ＮＨ_４ＯＨ含有）で溶出する自動シリカゲルクロマトグラフィーにより精製し、化合物１６２ｂ（１００ｍｇ、収率９６％）を得た。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ５９２．４． Step (2): Compound 162a → Compound 162b
Compound 162b: 5-chloro-6,7-bis ((4-methoxybenzyl) oxy) -3- (quinuclidin-4-ylmethyl) quinazoline-2,4 (1H, 3H) -dione

A mixture of compound 162a (100 mg, 0.177 mmol) and CDI (86 mg, 0.53 mmol) in THF (20 mL) was heated to reflux for 24 hours. The solution was cooled to room temperature and partitioned between EtOAc and water. The organic phase was dried over Na ₂ SO ₄ , filtered and concentrated. The crude material was purified by automated silica gel chromatography using a 24 g column and eluting with 0-20% MeOH in DCM (containing 1% NH ₄ OH) to give compound 162b (100 mg, 96% yield). LCMS: (M + H) ^<+> : 592.4.

０℃で、ＤＭＦ（２ｍＬ）中、化合物１６２ｂ（０．１０１ｇ、０．１７１ｍｍｏｌ）の混合物に、化合物Ｘ−２４（０．１６６ｇ、０．１８８ｍｍｏｌ）を加えた。この混合物を同じ温度で１時間撹拌した。この溶液を氷冷した５％ＮａＣｌ水溶液（２０ｍＬ）に注ぎ、得られたスラリーを約１５分間撹拌した。固体を濾取し、水ですすぎ（２回）、高真空下で乾燥させ、目的生成物を黄色固体として得た（０．２７ｇ、収率７０％）。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： １３４９．６． Step (3): Compound X-24 + Compound 162b → Compound 162c
Compound 162c: 1-(((4S, 6R, 7R) -7-((Z) -2-(((1- (tert-butoxy) -2-methyl-1-oxopropan-2-yl) oxy) Imino) -2- (2-((tert-butoxycarbonyl) amino) thiazol-4-yl) acetamido) -2-(((4-methoxybenzyl) oxy) carbonyl) -4-methyl-8-oxo-5 -Thia-1-azabicyclo [4.2.0] oct-2-en-3-yl) methyl) -4-((5-chloro-6,7-bis ((4-methoxybenzyl) oxy) -2 , 4-Dioxo-1,2-dihydroquinazolin-3 (4H) -yl) methyl) quinuclidine-1-ium iodide

To a mixture of compound 162b (0.101 g, 0.171 mmol) in DMF (2 mL) at 0 ° C. was added compound X-24 (0.166 g, 0.188 mmol). The mixture was stirred at the same temperature for 1 hour. The solution was poured into ice-cooled 5% aqueous NaCl (20 mL) and the resulting slurry was stirred for about 15 minutes. The solid was filtered off, rinsed with water (twice) and dried under high vacuum to give the desired product as a yellow solid (0.27 g, 70% yield). LCMS: (M + H) ^<+> : 1349.6.

０℃で、ＤＣＭ（１ｍＬ）中、化合物１６２ｃ（０．２３３ｇ、０．１０２ｍｍｏｌ）の溶液に、アニソール（０．１１ｍＬ、１．０３ｍｍｏｌ）、次いでＴＦＡ（０．３０ｍＬ、３．８９ｍｍｏｌ）を加えた。この混合物を室温で一晩撹拌した。次に、ジイソプロピルエーテル（１０ｍＬ）を加えた。この混合物を１０分間撹拌し、沈殿を濾取し、ジイソプロピルエーテルで２回すすいだ（２×２ｍＬ）。固体をＭｅＣＮ（２ｍＬ）、水（２ｍＬ）、および２Ｍ ＨＣｌ水溶液（０．５ｍＬ）の混合物に溶かし、ＨＰ２０ＳＳ樹脂（２ｇ）を加えた。この混合物を濃縮乾固し、この樹脂を、ＨＰ２０ＳＳ樹脂（４ｇ）を含有するプレカラムにロードした。このプレカラムをＣｏｍｂｉｆｌａｓｈ装置に取り付け、溶出画分がｐＨ４．５となるまで（約５分）水で洗浄した（流速＝７５ｍＬ／分）。次に、生成物を自動逆相クロマトグラフィー（１００ｇ Ｃ１８ Ｇｏｌｄカラム、８分間１０％ＭｅＣＮ／水、その後、１５分間１８％ＭｅＣＮ／水）により精製し、（４Ｓ，６Ｒ，７Ｒ）−７−（（Ｚ）−２−（２−アミノチアゾール−４−イル）−２−（（（２−カルボキシプロパン−２−イル）オキシ）イミノ）アセトアミド）−３−（（４−（（５−クロロ−６，７−ジヒドロキシ−２，４−ジオキソ−１，２−ジヒドロキナゾリン−３（４Ｈ）−イル）メチル）キヌクリジン−１−イウム−１−イル）メチル）−４−メチル−８−オキソ−５−チア−１−アザビシクロ［４．２．０］オクト−２−エン−２−カルボキシレート（５３ｍｇ）を灰白色固体として得た。この化合物を水（ＨＰＬＣ級、１０ｍＬ）に懸濁させ、０℃で冷却した。激しく撹拌しているこの懸濁液にエッペンドルフピペットを用いて、０．１Ｎ ＮａＯＨ水溶液を溶液のｐＨが約５．５となるまでゆっくり加え、ドライアイス小片を加えて過剰なＮａＯＨを急冷した。次に、得られた透明な溶液を凍結させ、凍結乾燥させ、化合物Ｉ−１６２（５３ｍｇ、収率５９％）を灰白色固体として得た。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８３３．１． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３６ （ｓ， ３ Ｈ） １．３８ （ｓ， ３ Ｈ） １．４１ （ｄ， Ｊ＝６．５７ Ｈｚ， ３ Ｈ） １．８３ （ｂｒ． ｓ．， ６ Ｈ） ３．１４ − ３．４８ （ｍ， ６ Ｈ） ３．９１（ｄ， Ｊ＝１５．９２ Ｈｚ， ４ Ｈ） ４．４６ （ｄ， Ｊ＝１３．８９ Ｈｚ， １ Ｈ） ５．３０ （ｂｒ． ｓ．， １ Ｈ） ５．７１ （ｄ， Ｊ＝４．５５ Ｈｚ， １ Ｈ） ６．１７ − ６．３３ （ｍ， １ Ｈ） ６．８６ （ｓ， １ Ｈ）． Step (4): Compound 162c → Compound I-162
Compound I-162: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((4-((5-chloro-6,7-dihydroxy-2,4-dioxo-1,2-dihydroquinazolin-3 (4H) -yl) methyl) quinuclidine-1-ium- 1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

To a solution of compound 162c (0.233 g, 0.102 mmol) in DCM (1 mL) at 0 ° C. was added anisole (0.11 mL, 1.03 mmol) followed by TFA (0.30 mL, 3.89 mmol). . The mixture was stirred at room temperature overnight. Next, diisopropyl ether (10 mL) was added. The mixture was stirred for 10 minutes and the precipitate was filtered off and rinsed twice with diisopropyl ether (2 × 2 mL). The solid was dissolved in a mixture of MeCN (2 mL), water (2 mL), and 2M aqueous HCl (0.5 mL) and HP20SS resin (2 g) was added. The mixture was concentrated to dryness and the resin was loaded onto a precolumn containing HP20SS resin (4 g). This pre-column was attached to a Combiflash apparatus and washed with water (flow rate = 75 mL / min) until the elution fraction became pH 4.5 (about 5 minutes). The product was then purified by automated reverse phase chromatography (100 g C18 Gold column, 10% MeCN / water for 8 minutes followed by 18% MeCN / water for 15 minutes) and (4S, 6R, 7R) -7- ( (Z) -2- (2-Aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino) acetamido) -3-((4-((5-chloro- 6,7-dihydroxy-2,4-dioxo-1,2-dihydroquinazolin-3 (4H) -yl) methyl) quinuclidin-1-ium-1-yl) methyl) -4-methyl-8-oxo-5 -Thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate (53 mg) was obtained as an off-white solid. This compound was suspended in water (HPLC grade, 10 mL) and cooled at 0 ° C. To this vigorously stirred suspension, an Eppendorf pipette was used to slowly add 0.1 N NaOH aqueous solution until the pH of the solution was about 5.5, and dry ice pieces were added to quench excess NaOH. The resulting clear solution was then frozen and lyophilized to give compound I-162 (53 mg, 59% yield) as an off-white solid.
LCMS: (M + H) ^<+> : 833.1. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.36 (s, 3 H) 1.38 (s, 3 H) 1.41 (d, J = 6.57 Hz, 3 H) 1.83 ( br.s., 6H) 3.14-3.48 (m, 6H) 3.91 (d, J = 15.92 Hz, 4H) 4.46 (d, J = 13.89 Hz, 1 H) 5.30 (br. S., 1 H) 5.71 (d, J = 4.55 Hz, 1 H) 6.17-6.33 (m, 1 H) 6.86 (s, 1 H).

アセトニトリル（３００ｍＬ）中、化合物１５０ｄ（４．０ｇ、９．８ｍｍｏｌ）の溶液に、ＨＡＴＵ（４．４６ｇ、１１．７ｍｍｏｌ）およびＤＩＰＥＡ（８．５３ｍＬ、４８．８ｍｍｏｌ）を加え、この混合物を室温で０．５時間撹拌した。次に、（１Ｒ，５Ｓ）−８−メチル−８−アザビシクロ［３．２．１］オクタン−３−アミン二塩酸塩（２．４９９ｇ、１１．７２ｍｍｏｌ）を加え、この混合物を室温で２時間撹拌した。水を加え、この混合物をＤＣＭで抽出し、重炭酸ナトリウムで洗浄した。有機抽出液を、２４ｇカラムを使用し、ＤＣＭ中０〜２０％ＭｅＯＨ（１％ＮＨ_４ＯＨを含有）で溶出する自動シリカゲルクロマトグラフィーにより精製し、化合物１６３ａ（３．４ｇ、収率６６％）を黄色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋：５３２．４． Example 163: Synthesis Step of Compound I-163 (1): Compound 150d → Compound 163a
Compound 163a: 2-amino-4,5-bis ((4-methoxybenzyl) oxy) -N- (8-methyl-8-azabicyclo [3.2.1] octane-3-yl) benzamide

To a solution of compound 150d (4.0 g, 9.8 mmol) in acetonitrile (300 mL) was added HATU (4.46 g, 11.7 mmol) and DIPEA (8.53 mL, 48.8 mmol) and the mixture was at room temperature. Stir for 0.5 hour. Next, (1R, 5S) -8-methyl-8-azabicyclo [3.2.1] octane-3-amine dihydrochloride (2.499 g, 11.72 mmol) was added and the mixture was stirred at room temperature for 2 hours. Stir. Water was added and the mixture was extracted with DCM and washed with sodium bicarbonate. The organic extract was purified by automated silica gel chromatography using a 24 g column and eluting with 0-20% MeOH in DCM (containing 1% NH ₄ OH) to give compound 163a (3.4 g, 66% yield). Was obtained as a yellow solid. LCMS: (M + H) ^<+> : 532.4.

化合物１６３ａ（１．５ｇ、２．８ｍｍｏｌ）、トリメトキシメタン（３０．９ｍＬ、２８２ｍｍｏｌ）およびメタノール（３０ｍＬ）の混合物を７日間１００℃に加熱した。水を加え、この混合物をＤＣＭで抽出し、重炭酸ナトリウム水溶液で洗浄した。有機抽出液を、２４ｇカラムを使用し、ＤＣＭ中０〜１５％ＭｅＯＨ（１％ＮＨ_４ＯＨを含有）で溶出する自動シリカゲルクロマトグラフィーにより精製し、化合物１６３ｂ（１．２ｇ、収率７９％）を黄色固体として得た。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ５４２．４ Step (2): Compound 163a → Compound 163b
Compound 163b: 6,7-bis ((4-methoxybenzyl) oxy) -3- (8-methyl-8-azabicyclo [3.2.1] octane-3-yl) quinazolin-4 (3H) -one

A mixture of compound 163a (1.5 g, 2.8 mmol), trimethoxymethane (30.9 mL, 282 mmol) and methanol (30 mL) was heated to 100 ° C. for 7 days. Water was added and the mixture was extracted with DCM and washed with aqueous sodium bicarbonate. The organic extract was purified by automated silica gel chromatography using a 24 g column and eluting with 0-15% MeOH in DCM (containing 1% NH ₄ OH) to give compound 163b (1.2 g, 79% yield). Was obtained as a yellow solid. LCMS: (M + H) ⁺ : 542.4

この化合物は、化合物１６３ｂおよび化合物Ｘ−２４を用い、実施例１６２の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７８３．４． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３８ （ｓ， ３ Ｈ） １．４０ （ｓ， ３ Ｈ） １．４６ （ｄ， Ｊ＝７．０７ Ｈｚ， ３ Ｈ） ２．１８ （ｔ， Ｊ＝１６．４２ Ｈｚ， ２ Ｈ） ２．２５ − ２．３６ （ｍ， ２ Ｈ） ２．３７ − ２．５５ （ｍ， ２ Ｈ） ２．８２ − ３．００ （ｍ， ２ Ｈ） ３．０３ （ｓ， ３ Ｈ） ３．８４ − ４．０９ （ｍ， ５ Ｈ） ４．８０ − ４．９２ （ｍ， １ Ｈ） ５．３５ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ５．７１ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ６．８２ （ｓ， １ Ｈ） ６．８８ （ｓ， １ Ｈ） ７．２７ （ｓ， １ Ｈ） ８．０９ （ｓ， １ Ｈ）． Step (3): Compound X-24 + Compound 163b → Compound I-163
Compound I-163: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-(((1R, 5S, 8s) -3- (6,7-dihydroxy-4-oxoquinazolin-3 (4H) -yl) -8-methyl-8-azabicyclo [3.2. 1] Octane-8-ium-8-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-en-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 162 using compound 163b and compound X-24.
LCMS: (M + H) ^<+> : 783.4. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.38 (s, 3 H) 1.40 (s, 3 H) 1.46 (d, J = 7.07 Hz, 3 H) 2.18 ( t, J = 16.42 Hz, 2 H) 2.25-2.36 (m, 2 H) 2.37-2.55 (m, 2 H) 2.82-3.00 (m, 2 H) ) 3.03 (s, 3 H) 3.84-4.09 (m, 5 H) 4.80-4.92 (m, 1 H) 5.35 (d, J = 4.80 Hz, 1 H) 5.71 (d, J = 4.80 Hz, 1 H) 6.82 (s, 1 H) 6.88 (s, 1 H) 7.27 (s, 1 H) 8.09 (s , 1 H).

ＤＭＦ（１０ｍＬ）中、２−アミノ−４，５−ビス（（４−メトキシベンジル）オキシ）安息香酸（１．０ｇ、２．４ｍｍｏｌ）の溶液に、トリメトキシメタン（２４．０５ｍＬ、２２０．０ｍｍｏｌ）、ＤＩＰＥＡ（１．２８０ｍＬ、７．３３ｍｍｏｌ）および１−アザビシクロ［２．２．１］ヘプタン−４−イルメタンアミン二塩酸塩（０．７３０ｇ、３．６６ｍｍｏｌ）を加えた。この混合物を１１５℃で２時間撹拌した。水を加え、この混合物をＤＣＭで抽出し、２Ｎ ＮａＯＨ水溶液で洗浄した。有機抽出液を、２４ｇカラムを使用し、ＤＣＭ中０〜１５％ＭｅＯＨ（１％ＮＨ_４ＯＨを含有）で溶出する自動シリカゲルクロマトグラフィーにより精製し、化合物１６４ａ（０．４３ｇ、収率３３％）をやや黄色の固体として得た。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ５２８．４． Example 164: Synthesis Step of Compound I-164 (1): 2-amino-4,5-bis ((4-methoxybenzyl) oxy) benzoic acid → Compound 164a
Compound 164a: 3- (1-azabicyclo [2.2.1] heptan-4-ylmethyl) -6,7-bis ((4-methoxybenzyl) oxy) quinazolin-4 (3H) -one

To a solution of 2-amino-4,5-bis ((4-methoxybenzyl) oxy) benzoic acid (1.0 g, 2.4 mmol) in DMF (10 mL) was added trimethoxymethane (24.05 mL, 220.0 mmol). ), DIPEA (1.280 mL, 7.33 mmol) and 1-azabicyclo [2.2.1] heptan-4-ylmethanamine dihydrochloride (0.730 g, 3.66 mmol). The mixture was stirred at 115 ° C. for 2 hours. Water was added and the mixture was extracted with DCM and washed with 2N aqueous NaOH. The organic extract was purified by automated silica gel chromatography using a 24 g column and eluting with 0-15% MeOH in DCM (containing 1% NH ₄ OH) to give compound 164a (0.43 g, 33% yield). Was obtained as a slightly yellow solid. LCMS: (M + H) ^<+> : 528.4.

この化合物は、化合物１６４ａおよび化合物Ｘ−２４を用い、実施例１６２の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７６９．４． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３６ （ｓ， ３ Ｈ） １．３８ （ｓ， ３ Ｈ） １．４１ （ｄ， Ｊ＝７．０７ Ｈｚ， ３ Ｈ） １．９０ （ｂｒ． ｓ．， ２ Ｈ） ２．０８ （ｂｒ． ｓ．， ２ Ｈ） ３．２１ − ３．６２ （ｍ， ６ Ｈ） ３．９２ （ｄ， Ｊ＝７．０７ Ｈｚ， １ Ｈ） ４．１２ （ｄ， Ｊ＝１４．４０ Ｈｚ， １ Ｈ） ４．２７ （ｂｒ． ｓ．， ２ Ｈ） ４．７４ − ４．７７ （ｍ， １ Ｈ） ５．２４ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ５．６５ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ６．８６ （ｓ， １ Ｈ） ６．９１ （ｓ， １ Ｈ） ７．３４ （ｓ， １ Ｈ） ８．０３ （ｓ， １ Ｈ）． Step (2): Compound X-24 + Compound 164a → Compound I-164
Compound I-164: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((4-((6,7-dihydroxy-4-oxoquinazolin-3 (4H) -yl) methyl) -1-azabicyclo [2.2.1] heptane-1-ium-1 -Yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 162 using compound 164a and compound X-24.
LCMS: (M + H) ^<+> : 769.4. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.36 (s, 3 H) 1.38 (s, 3 H) 1.41 (d, J = 7.07 Hz, 3 H) 1.90 ( br.s., 2 H) 2.08 (br.s., 2 H) 3.21-3.62 (m, 6 H) 3.92 (d, J = 7.07 Hz, 1 H) 4 .12 (d, J = 14.40 Hz, 1 H) 4.27 (br. S., 2 H) 4.74-4.77 (m, 1 H) 5.24 (d, J = 4. 80 Hz, 1 H) 5.65 (d, J = 4.80 Hz, 1 H) 6.86 (s, 1 H) 6.91 (s, 1 H) 7.34 (s, 1 H) 8 .03 (s, 1 H).

ＤＭＦ（１０ｍＬ）中、化合物１６１ｄ（１．０ｇ、２．０７ｍｍｏｌ）の混合物に、トリメトキシメタン（２０．４３ｍＬ、１８７．０ｍｍｏｌ）、ＤＩＰＥＡ（１．０９ｍＬ、６．２２ｍｍｏｌ）および１−アザビシクロ［２．２．１］ヘプタン−４−イルメタンアミン二塩酸塩（０．６２０ｇ、３．１１ｍｍｏｌ）を加えた。次に、この混合物を１１５℃で２時間撹拌した。水を加え、この混合物をＤＣＭで抽出し、２Ｎ ＮａＯＨ水溶液で洗浄した。粗生成物を、２４ｇカラムを使用し、ＤＣＭ中０〜１５％ＭｅＯＨ（１％ＮＨ_４ＯＨを含有）で溶出する自動シリカゲルクロマトグラフィーにより精製し、化合物１６５ａ（０．３６ｇ、収率３１％）をやや黄色の固体として得た。ＬＣＭＳ ： （Ｍ＋Ｈ）^＋： ５６２．４． Example 165: Synthesis Step of Compound I-165 (1): Compound 161d → Compound 165a
Compound 165a: 3- (1-azabicyclo [2.2.1] heptan-4-ylmethyl) -5-chloro-6,7-bis ((4-methoxybenzyl) oxy) quinazolin-4 (3H) -one

To a mixture of compound 161d (1.0 g, 2.07 mmol) in DMF (10 mL) was added trimethoxymethane (20.43 mL, 187.0 mmol), DIPEA (1.09 mL, 6.22 mmol) and 1-azabicyclo [2 2.1] Heptane-4-ylmethanamine dihydrochloride (0.620 g, 3.11 mmol) was added. The mixture was then stirred at 115 ° C. for 2 hours. Water was added and the mixture was extracted with DCM and washed with 2N aqueous NaOH. The crude product was purified by automated silica gel chromatography using a 24 g column and eluting with 0-15% MeOH in DCM (containing 1% NH ₄ OH) to give compound 165a (0.36 g, 31% yield). Was obtained as a slightly yellow solid. LCMS: (M + H) ^<+> : 562.4.

この化合物は、化合物１６５ａおよび化合物Ｘ−２４を用い、実施例１６２の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８０２．８． ^１Ｈ ＮＭＲ （４００ ＭＨｚ， Ｄ_２Ｏ） δｐｐｍ １．３６ （ｓ， ３ Ｈ） １．３８ （ｓ， ３ Ｈ） １．４１ （ｄ， Ｊ＝７．３３ Ｈｚ， ３ Ｈ） １．９２ （ｄ， Ｊ＝１６．１７ Ｈｚ， ２ Ｈ） ２．０８ （ｂｒ． ｓ．， ２ Ｈ） ３．２０ − ３．６２ （ｍ， ６ Ｈ） ３．９３ （ｑ， Ｊ＝６．９９ Ｈｚ， １ Ｈ） ４．１１ （ｄ， Ｊ＝１４．４０ Ｈｚ， １ Ｈ） ４．２３ （ｓ， ２ Ｈ） ４．７５ （ｓ， １ Ｈ） ５．２６ （ｄ， Ｊ＝４．８０ Ｈｚ， １ Ｈ） ５．６５ （ｄ， Ｊ＝４．５５ Ｈｚ， １ Ｈ） ６．８０ （ｓ， １ Ｈ） ６．８７ （ｓ， １ Ｈ） ８．０２ （ｓ， １ Ｈ）． Step (2): Compound X-24 + Compound 165a → Compound I-165
Compound I-165: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((4-((5-chloro-6,7-dihydroxy-4-oxoquinazolin-3 (4H) -yl) methyl) -1-azabicyclo [2.2.1] heptane-1 -Ium-1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-en-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 162 using compound 165a and compound X-24.
LCMS: (M + H) ^<+> : 802.8. ¹ H NMR (400 MHz, D ₂ O) δ ppm 1.36 (s, 3 H) 1.38 (s, 3 H) 1.41 (d, J = 7.33 Hz, 3 H) 1.92 ( d, J = 16.17 Hz, 2 H) 2.08 (br. s., 2 H) 3.20-3.62 (m, 6 H) 3.93 (q, J = 6.99 Hz, 1 H) 4.11 (d, J = 14.40 Hz, 1 H) 4.23 (s, 2 H) 4.75 (s, 1 H) 5.26 (d, J = 4.80 Hz, 1 H) 5.65 (d, J = 4.55 Hz, 1 H) 6.80 (s, 1 H) 6.87 (s, 1 H) 8.02 (s, 1 H).

ＤＭＦ（１００ｍＬ）中、４−ニトロベンゼン−１，２−ジオール（９．６ｇ、６２ｍｍｏｌ）の溶液に、Ｋ_２ＣＯ_３（２５．７ｇ、１８６ｍｍｏｌ）、次いで１−（クロロメチル）−４−メトキシベンゼン（２１．０ｍＬ、１５５ｍｍｏｌ）を加えた。反応混合物を５０℃で２時間撹拌した。水を加え、この混合物を室温で１５分間撹拌した。生じた黄色沈殿を濾取し、水で洗浄し、化合物１６６ａ（２５．８ｇ、収率９５％）を黄色固体として得た。この材料を精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ＋Ｎａ）^＋： ４１８．１． Example 166: Synthesis Step of Compound I-166 (1): 4-Nitrobenzene-1,2-diol → Compound 166a
Compound 166a: 4,4 ′-(((4-nitro-1,2-phenylene) bis (oxy)) bis (methylene)) bis (methoxybenzene)

To a solution of 4-nitrobenzene-1,2-diol (9.6 g, 62 mmol) in DMF (100 mL) was added K ₂ CO ₃ (25.7 g, 186 mmol) followed by 1- (chloromethyl) -4-methoxybenzene. (21.0 mL, 155 mmol) was added. The reaction mixture was stirred at 50 ° C. for 2 hours. Water was added and the mixture was stirred at room temperature for 15 minutes. The resulting yellow precipitate was collected by filtration and washed with water to give compound 166a (25.8 g, yield 95%) as a yellow solid. This material was used in the next step without purification. LCMS: (M + H + Na) ^<+> : 418.1.

窒素雰囲気下、化合物１６６ａ（２９．５ｇ、７４．６ｍｍｏｌ）、エタノール（１５０ｍＬ）、および水（１５０ｍＬ）の混合物を１００℃で２時間、Ｎａ_２Ｓ・９Ｈ_２Ｏ（１７９ｇ、７４６ｍｍｏｌ）で処理した。この混合物を放冷した後、冷水に注いだ。生じた黄色沈殿を濾取し、水で洗浄し、乾燥させ、化合物１６６ｂ（２６．３ｇ、収率９６％）を黄色固体として得た。この材料を精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ３６６．１． Step (2): Compound 166a → Compound 166b
Intermediate 3,4-bis ((4-methoxybenzyl) oxy) aniline

Under a nitrogen atmosphere, a mixture of compound 166a (29.5 g, 74.6 mmol), ethanol (150 mL), and water (150 mL) was treated with Na ₂ S · 9H ₂ O (179 g, 746 mmol) at 100 ° C. for 2 hours. . The mixture was allowed to cool and then poured into cold water. The resulting yellow precipitate was collected by filtration, washed with water and dried to give compound 166b (26.3 g, 96% yield) as a yellow solid. This material was used in the next step without purification. LCMS: (M + H) ^<+> : 366.1.

ｉＰｒＯＨ（１５０ｍＬ）中、化合物１６６ｂ（１９．５ｇ、５３．４ｍｍｏｌ）の溶液に、室温で５−（メトキシメチレン）−２，２−ジメチル−１，３−ジオキサン−４，６−ジオン（９．６４ｍＬ、５５．９ｍｍｏｌ）を加えた。得られた混合物を２０分間８０℃に加熱した。この間にこの混合物は粘稠なスラリーとなり、撹拌が困難となった。反応混合物を室温まで冷却し、少量のｉＰｒＯＨで希釈してスラリーの流動性を高め、その後、ブフナー漏斗で濾過し、ｉＰｒＯＨですすいだ。回収した黄色固体をそれ以上精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ＋Ｎａ）^＋： ５４２．２． Step (3): Compound 166b → Compound 166c
Compound 166c: 5-(((3,4-bis ((4-methoxybenzyl) oxy) phenyl) amino) methylene) -2,2-dimethyl-1,3-dioxane-4,6-dione

To a solution of compound 166b (19.5 g, 53.4 mmol) in iPrOH (150 mL) at room temperature was 5- (methoxymethylene) -2,2-dimethyl-1,3-dioxane-4,6-dione (9. 64 mL, 55.9 mmol) was added. The resulting mixture was heated to 80 ° C. for 20 minutes. During this time, the mixture became a thick slurry, making stirring difficult. The reaction mixture was cooled to room temperature and diluted with a small amount of iPrOH to increase the fluidity of the slurry, then filtered through a Buchner funnel and rinsed with iPrOH. The collected yellow solid was used in the next step without further purification. LCMS: (M + H + Na) ^<+> : 542.2.

ジフェニルエーテル（６０ｍＬ）を、加熱マントルを用いて加熱沸騰させた。固体化合物１６６ｃ（１４．０ｇ、２６．９ｍｍｏｌ）を少量ずつ加え、得られた溶液を５分間加熱した。この混合物を生温くなるまで冷却した後、ヘキサンを加えた。この混合物をよく撹拌した後、ブフナー漏斗で濾過した。回収した固体をヘキサンに再び懸濁させ、３０分間撹拌した後、濾過し、化合物１６６ｄ（１１ｇ、収率８２％）を得た。この材料をそれ以上精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ４１８．１． Step (4): Compound 166c → Compound 166d
Compound 166d: 6,7-bis ((4-methoxybenzyl) oxy) quinolin-4 (1H) -one

Diphenyl ether (60 mL) was heated to boiling using a heating mantle. Solid compound 166c (14.0 g, 26.9 mmol) was added in small portions and the resulting solution was heated for 5 minutes. The mixture was cooled to room temperature and hexane was added. The mixture was stirred well and then filtered through a Buchner funnel. The collected solid was suspended again in hexane, stirred for 30 minutes, and then filtered to obtain Compound 166d (11 g, yield 82%). This material was used in the next step without further purification. LCMS: (M + H) ^<+> : 418.1.

エタノール（３０ｍＬ）中、化合物１６６ｄ（５．１０ｇ、１２．２ｍｍｏｌ）のスラリーを８０℃で２０分間加熱して、出発材料の溶解を補助した（注：出発材料は高温下で完全には溶解しないが、全ての塊が崩壊する）。この混合物を油浴から取り出し、１Ｍ水酸化ナトリウム水溶液（３０．５ｍＬ、３０．５ｍｍｏｌ）およびホルムアルデヒド（３７％水溶液、２５．５ｍＬ、３４２ｍｍｏｌ）を加え、この混合物を８０℃で４時間加熱した。反応混合物を、氷を加えることにより室温まで冷却し、得られたスラリーを２０分間撹拌して塊を崩壊させた。生成物を、ブフナー漏斗を通して濾取した。固体を水、次いでヘキサンで洗浄し、真空下で一晩乾燥させ、化合物１６６ｅ（４．６９ｇ、収率８６％）を黄褐色固体として得た。この材料を精製せずに使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ４４８．２． Step (5): Compound 166d → Compound 166e
Compound 166e: 3- (hydroxymethyl) -6,7-bis ((4-methoxybenzyl) oxy) quinolin-4 (1H) -one

A slurry of compound 166d (5.10 g, 12.2 mmol) in ethanol (30 mL) was heated at 80 ° C. for 20 minutes to aid in dissolution of the starting material (Note: starting material does not dissolve completely at high temperature) But all the masses collapse). The mixture was removed from the oil bath and 1M aqueous sodium hydroxide (30.5 mL, 30.5 mmol) and formaldehyde (37% aqueous solution, 25.5 mL, 342 mmol) were added and the mixture was heated at 80 ° C. for 4 hours. The reaction mixture was cooled to room temperature by adding ice and the resulting slurry was stirred for 20 minutes to break up the mass. The product was filtered through a Buchner funnel. The solid was washed with water then hexane and dried under vacuum overnight to give compound 166e (4.69 g, 86% yield) as a tan solid. This material was used without purification. LCMS: (M + H) ^<+> : 448.2.

ＴＨＦ（７２．６ｍＬ）中、水素化ナトリウム（０．３２６ｇ、８．１４ｍｍｏｌ）の懸濁液に、化合物１６６ｅ（４．６ｇ、７．４ｍｍｏｌ）を加え、この混合物を室温で３０分間撹拌した。次に、ＳＥＭＣｌ（１．４４ｍＬ、８．１４ｍｍｏｌ）を加え、この混合物を室温で３時間撹拌した。この混合物をシリカゲルで濃縮し、得られた残渣を自動シリカゲルクロマトグラフィー（１００％ＤＣＭ、次いで１０分かけて０〜１０％ＭｅＯＨ／ＤＣＭ、４０ｇカラム）により精製し、化合物１６６ｆ（２．２ｇ、収率５１％）を暗褐色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５７８．２． Step (6): Compound 166e → Compound 166f
Compound 166f: 3- (hydroxymethyl) -6,7-bis ((4-methoxybenzyl) oxy) -1-((2- (trimethylsilyl) ethoxy) methyl) quinolin-4 (1H) -one

To a suspension of sodium hydride (0.326 g, 8.14 mmol) in THF (72.6 mL) was added compound 166e (4.6 g, 7.4 mmol) and the mixture was stirred at room temperature for 30 minutes. Then SEMCl (1.44 mL, 8.14 mmol) was added and the mixture was stirred at room temperature for 3 hours. The mixture was concentrated on silica gel and the resulting residue was purified by automated silica gel chromatography (100% DCM, then 0-10% MeOH / DCM over 10 minutes, 40 g column) to give compound 166f (2.2 g, yield). 51%) was obtained as a dark brown solid. LCMS: (M + H) ^<+> : 578.2.

ＤＣＭ（５０ｍＬ）中、化合物１６６ｆ（２．２ｇ、３．８ｍｍｏｌ）の溶液に、二酸化マンガン（４．９７ｇ、５７．１ｍｍｏｌ）を加え、この混合物を室温で一晩撹拌した。この混合物をセライトケークで濾過し、ＤＣＭですすぎ、濾液を濃縮し、化合物１６６ｇ（２．１ｇ、収率９６％）を黄色固体として得た。この材料を精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５７６．２． Step (7): Compound 166f → Compound 166g
Compound 166g: 6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-1-((2- (trimethylsilyl) ethoxy) methyl) -1,4-dihydroquinoline-3-carbaldehyde

To a solution of compound 166f (2.2 g, 3.8 mmol) in DCM (50 mL) was added manganese dioxide (4.97 g, 57.1 mmol) and the mixture was stirred at room temperature overnight. The mixture was filtered through a Celite cake, rinsed with DCM, and the filtrate was concentrated to give 166 g (2.1 g, 96% yield) of compound as a yellow solid. This material was used in the next step without purification. LCMS: (M + H) ^<+> : 576.2.

ＤＣＭ（４０ｍＬ）中、化合物１６６ｇ（２．１ｇ、３．７ｍｍｏｌ）の溶液に、ピロリジン（０．４５２ｍＬ、５．４７ｍｍｏｌ）および酢酸（１０．４μＬ、０．１８２ｍｍｏｌ）を加え、この均質な溶液を室温で３０分間撹拌した。次に、ＮａＢＨ（ＯＡｃ）_３（１．５５ｇ、７．３０ｍｍｏｌ）を加え、この混合物を１．５時間撹拌した。反応混合物をＤＣＭで希釈した後、飽和ＮａＨＣＯ_３（水溶液）、ＮａＯＨ（水溶液）、およびブラインで順次洗浄した。有機層を濃縮した後、ＭｅＯＨ（３０ｍＬ）および５Ｎ ＮａＯＨ（２ｍＬ）を加えた。得られた混合物を室温で０．５時間撹拌した。揮発性物質を除去し、残渣を自動シリカゲルクロマトグラフィーにより２回精製し、化合物１６６ｈ（１．６５ｇ、収率７２％）を淡黄色固体として得た。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ６３１．３． ^１Ｈ ＮＭＲ （ＤＭＳＯ−ｄ_６） ：７．９６ （ｓ， １Ｈ）， ７．６４ （ｓ， １Ｈ）， ７．４１ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ７．３８ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ６．９６ （ｄ， Ｊ＝６．６ Ｈｚ， ２Ｈ）， ６．９４ （ｄ， Ｊ＝６．６ Ｈｚ， ２Ｈ）， ５．６１ （ｓ， ２Ｈ）， ５．１９ （ｓ， ２Ｈ）， ５．１２ （ｓ， ２Ｈ）， ３．７６ （ｓ， ３Ｈ）， ３．７５ （ｓ， ３Ｈ）， ３．５１ （ｔ， Ｊ＝８．３ Ｈｚ， ２Ｈ）， ３．４７ （ｓ， ２Ｈ）， ２．４４−２．５０ （ｍ， ４Ｈ）， １．６２−１．７４ （ｍ， ４Ｈ）， ０．７８−０．８９ （ｍ， ２Ｈ）， −０．０８ （ｓ， ９Ｈ）． Step (8): Compound 166g → Compound 166h
Compound 166h: 6,7-bis ((4-methoxybenzyl) oxy) -3- (pyrrolidin-1-ylmethyl) -1-((2- (trimethylsilyl) ethoxy) methyl) quinolin-4 (1H) -one

To a solution of compound 166 g (2.1 g, 3.7 mmol) in DCM (40 mL) was added pyrrolidine (0.452 mL, 5.47 mmol) and acetic acid (10.4 μL, 0.182 mmol) and the homogeneous solution was added. Stir at room temperature for 30 minutes. NaBH (OAc) ₃ (1.55 g, 7.30 mmol) was then added and the mixture was stirred for 1.5 hours. The reaction mixture was diluted with DCM and then washed sequentially with saturated NaHCO ₃ (aq), NaOH (aq), and brine. After the organic layer was concentrated, MeOH (30 mL) and 5N NaOH (2 mL) were added. The resulting mixture was stirred at room temperature for 0.5 hour. Volatiles were removed and the residue was purified twice by automated silica gel chromatography to give compound 166h (1.65 g, 72% yield) as a pale yellow solid.
LCMS: (M + H) ^<+> : 631.3. ¹ H NMR (DMSO-d ₆ ): 7.96 (s, 1H), 7.64 (s, 1H), 7.41 (d, J = 8.6 Hz, 2H), 7.38 (d, J = 8.6 Hz, 2H), 6.96 (d, J = 6.6 Hz, 2H), 6.94 (d, J = 6.6 Hz, 2H), 5.61 (s, 2H) , 5.19 (s, 2H), 5.12 (s, 2H), 3.76 (s, 3H), 3.75 (s, 3H), 3.51 (t, J = 8.3 Hz, 2H), 3.47 (s, 2H), 2.44-2.50 (m, 4H), 1.62-1.74 (m, 4H), 0.78-0.89 (m, 2H) , −0.08 (s, 9H).

この化合物は、化合物１６６ｈおよび化合物Ｘ−２４を用い、実施例１６２の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７４２．１． ７４２．４． ^１Ｈ ＮＭＲ （Ｄ_２Ｏ）： ８．０５ （ｓ， １Ｈ）， ７．４１ （ｓ， １Ｈ）， ６．８９ （ｓ， １Ｈ）， ６．８６ （ｓ， １Ｈ）， ５．７０ （ｄ， Ｊ＝４．８ Ｈｚ， １Ｈ）， ５．３４ （ｄ， Ｊ＝４．８ Ｈｚ， １Ｈ）， ４．７６−４．８３ （ｍ， ２Ｈ）， ４．２７−４．４４ （ｍ， ２Ｈ）， ４．１１ （ｄ， Ｊ＝１３．９ Ｈｚ， １Ｈ）， ３．９１−４．０４ （ｍ， １Ｈ）， ３．３９−３．５５ （ｍ， １Ｈ）， ３．１６−３．３４ （ｍ， ３Ｈ）， １．９６−２．２０ （ｍ， ４Ｈ）， １．３４−１．３９ （ｍ， ９Ｈ）． Step (9): Compound X-24 + Compound 166h → Compound I-166
Compound I-166: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((1-((6,7-dihydroxy-4-oxo-1,4-dihydroquinolin-3-yl) methyl) pyrrolidin-1-ium-1-yl) methyl) -4- Methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 162 using compound 166h and compound X-24.
LCMS: (M + H) ^<+> : 742.1. 742.4. ¹ H NMR (D ₂ O): 8.05 (s, 1H), 7.41 (s, 1H), 6.89 (s, 1H), 6.86 (s, 1H), 5.70 (d , J = 4.8 Hz, 1H), 5.34 (d, J = 4.8 Hz, 1H), 4.76-4.83 (m, 2H), 4.27-4.44 (m, 2H), 4.11 (d, J = 13.9 Hz, 1H), 3.91-4.04 (m, 1H), 3.39-3.55 (m, 1H), 3.16-3 .34 (m, 3H), 1.96-2.20 (m, 4H), 1.34-1.39 (m, 9H).

硫酸（４０ｍＬ、７５０ｍｍｏｌ）中、６，７−ジメトキシキノリン−４（１Ｈ）−オン（１０ｇ、４８．７ｍｍｏｌ）の粘稠な暗色溶液を０℃に冷却し、硝酸カリウム（４．９３ｇ、４８．７ｍｍｏｌ）を、温度を１０℃未満に維持しながら少量ずつ加えた。添加が完了した後、この混合物を１０分間撹拌し、氷水（３００ｍＬ）に注いだ。沈殿した黄色固体を濾取し、水およびエタノールで洗浄した。固体を回収し、真空乾燥させ、化合物１６７ａ（１３．２ｇ、収率１０８％）を淡黄色固体として得た。この粗材料を精製せずに次の工程で使用した。ＬＣＭＳ：（Ｍ＋Ｈ）^＋： ２５０．９． Example 167: Synthesis Step of Compound I-167 (1): 6,7-Dimethoxyquinolin-4 (1H) -one → Compound 167a
Compound 167a: 6,7-dimethoxy-5-nitroquinolin-4 (1H) -one

A viscous dark solution of 6,7-dimethoxyquinolin-4 (1H) -one (10 g, 48.7 mmol) in sulfuric acid (40 mL, 750 mmol) was cooled to 0 ° C. and potassium nitrate (4.93 g, 48.7 mmol). ) Was added in small portions while maintaining the temperature below 10 ° C. After the addition was complete, the mixture was stirred for 10 minutes and poured into ice water (300 mL). The precipitated yellow solid was collected by filtration and washed with water and ethanol. The solid was collected and dried in vacuo to give compound 167a (13.2 g, 108% yield) as a pale yellow solid. This crude material was used in the next step without purification. LCMS: (M + H) ^<+> : 250.9.

ＥｔＯＨ（４０ｍＬ）およびＤＣＭ（８０ｍＬ）中、化合物１６６ａ（１３．２ｇ、５２．８ｍｍｏｌ）の溶液を真空下に置き、水素雰囲気でフラッシュし、このプロセスを６回繰り返した。次に、１０％Ｐｄ／Ｃ（５．６１ｇ、５．２８ｍｍｏｌ）を加えた。この混合物を１２時間撹拌した後、濾過し、多量のエタノールですすいだ。濾液を濃縮し、化合物１６７ｂ（１１．３ｇ、収率８８％）を黄色固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ２２０．９． Step (2): Compound 167a → Compound 167b
Compound 167b: 5-amino-6,7-dimethoxyquinolin-4 (1H) -one

A solution of compound 166a (13.2 g, 52.8 mmol) in EtOH (40 mL) and DCM (80 mL) was placed under vacuum and flushed with a hydrogen atmosphere and the process was repeated 6 times. Then 10% Pd / C (5.61 g, 5.28 mmol) was added. The mixture was stirred for 12 hours, then filtered and rinsed with copious amounts of ethanol. The filtrate was concentrated to give compound 167b (11.3 g, 88% yield) as a yellow solid. LCMS: (M + H) ^<+> : 220.9.

０℃で、濃ＨＣｌ水溶液（５０ｍＬ、１６５０ｍｍｏｌ）中、化合物１６７ｂ（１２．２ｇ、５５．４ｍｍｏｌ）の撹拌混合物に、水（１７ｍＬ）中、亜硝酸ナトリウム（４．０１ｇ、５８．２ｍｍｏｌ）の溶液を滴下した。この混合物を０℃で１０分間撹拌し、この時点で、ＬＣＭＳは、１個のメトキシ基が脱メチル化されたジアゾ中間体の形成を示した。この橙色懸濁液に、濃ＨＣｌ水溶液（５０ｍＬ）を加え、得られた混合物を９５℃で１時間加熱した。反応混合物を室温まで冷却し、濾過し、乾燥させ、化合物１６７ｃ（１０．２ｇ、収率７６％）を淡黄色固体として得た。粗生成物を精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ２２５．９． Step (3): Compound 167b → Compound 167c
Compound 167c: 5-chloro-6-hydroxy-7-methoxyquinolin-4 (1H) -one

To a stirred mixture of compound 167b (12.2 g, 55.4 mmol) in concentrated aqueous HCl (50 mL, 1650 mmol) at 0 ° C., a solution of sodium nitrite (4.01 g, 58.2 mmol) in water (17 mL). Was dripped. The mixture was stirred at 0 ° C. for 10 minutes, at which point LCMS showed the formation of a diazo intermediate in which one methoxy group was demethylated. To this orange suspension was added concentrated aqueous HCl (50 mL) and the resulting mixture was heated at 95 ° C. for 1 h. The reaction mixture was cooled to room temperature, filtered and dried to give compound 167c (10.2 g, 76% yield) as a pale yellow solid. The crude product was used in the next step without purification. LCMS: (M + H) ^<+> : 225.9.

ＤＣＭ（１００ｍＬ）中、化合物１６７ｃ（９．０ｇ、４０ｍｍｏｌ）の溶液に、−７８℃でトリブロモボラン（５．６６ｍＬ、５９．８ｍｍｏｌ）を加えた。この混合物を室温で２時間撹拌した。この混合物をＭｅＯＨ（５０ｍＬ）で希釈し、濃縮し、このプロセスを５回繰り返し、化合物１６７ｄ（１２．５ｇ、収率１４８％）を褐色固体として得た。この材料を精製せずに次の工程に送った。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ２１１．９． Step (4): Compound 167c → Compound 167d
Compound 167d: 5-chloro-6,7-dihydroxyquinolin-4 (1H) -one

To a solution of compound 167c (9.0 g, 40 mmol) in DCM (100 mL) was added tribromoborane (5.66 mL, 59.8 mmol) at −78 ° C. The mixture was stirred at room temperature for 2 hours. The mixture was diluted with MeOH (50 mL), concentrated and the process was repeated 5 times to give compound 167d (12.5 g, 148% yield) as a brown solid. This material was sent to the next step without purification. LCMS: (M + H) ^<+> : 211.9.

ＤＭＦ（１００ｍＬ）中、化合物１６７ｆ（１０．５ｇ、２９．８ｍｍｏｌ）の溶液に、Ｋ_２ＣＯ_３（８．２３ｇ、５９．５ｍｍｏｌ）、次いで１−（クロロメチル）−４−メトキシベンゼン（８．０７ｍＬ、５９．５ｍｍｏｌ）を加えた。反応混合物を５０℃で２時間撹拌した。水（２００ｍＬ）およびＤＣＭ（１５０ｍＬ）を加え、この混合物を室温で１５分間撹拌した。水相をＤＣＭで抽出した（２回）。合わせた有機相を乾燥させ、濾過し、濃縮して残渣を得、これを自動順相クロマトグラフィー（ＤＣＭ中０〜１０％ＭｅＯＨ）により精製し、化合物１６７ｅ（５．３ｇ、収率３９％）を深紅の固体として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ４５２．１． Step (5): Compound 167d → Compound 167e
Compound 167e 5-chloro-6,7-bis ((4-methoxybenzyl) oxy) quinolin-4 (1H) -one

To a solution of compound 167f (10.5 g, 29.8 mmol) in DMF (100 mL) was added K ₂ CO ₃ (8.23 g, 59.5 mmol) followed by 1- (chloromethyl) -4-methoxybenzene (8. 07 mL, 59.5 mmol) was added. The reaction mixture was stirred at 50 ° C. for 2 hours. Water (200 mL) and DCM (150 mL) were added and the mixture was stirred at room temperature for 15 minutes. The aqueous phase was extracted with DCM (twice). The combined organic phases were dried, filtered and concentrated to give a residue which was purified by automated normal phase chromatography (0-10% MeOH in DCM) to give compound 167e (5.3 g, 39% yield). Was obtained as a crimson solid. LCMS: (M + H) ^<+> : 452.1.

エタノール（２００ｍＬ）中、化合物１６７ｅ（２５ｇ、５５ｍｍｏｌ）のスラリーを８０℃に加熱して、出発材料の溶解を補助した（注：出発材料は高温下で完全には溶解しないが、全ての塊が崩壊する）。この混合物を油浴から取り出し、１Ｍ水酸化ナトリウム（水溶液）（２７７ｍＬ、２７７ｍｍｏｌ）およびホルムアルデヒド（３７％水溶液、８２ｍＬ、１１００ｍｍｏｌ）を加え、この混合物を８０℃で３時間加熱した。反応混合物を室温まで冷却し、得られたスラリーをブフナー漏斗で濾過した。固体を水、次いでヘキサンで洗浄し、化合物１６７ｆ（２０．４ｇ、収率７７％）を黄褐色固体として得た。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ４８２．０． ^１Ｈ ＮＭＲ （ＤＭＳＯ−ｄ_６）： １１．５５ （ｄ， Ｊ＝５．８ Ｈｚ， １Ｈ）， ７．７０ （ｄ， Ｊ＝５．８ Ｈｚ， １Ｈ）， ７．４８ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ７．３０ （ｄ， Ｊ＝８．８ Ｈｚ， ２Ｈ）， ７．０９ （ｓ， １Ｈ）， ７．０１ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ６．８５ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ５．１７ （ｓ， ２Ｈ）， ４．８６ （ｓ， ２Ｈ）， ４．３２ （ｄ， Ｊ＝５．１ Ｈｚ， ２Ｈ）， ３．７９ （ｓ， ３Ｈ）， ３．７４ （ｓ， ３Ｈ）． Step (6): Compound 167e → Compound 167f
Compound 167f: 5-chloro-3- (hydroxymethyl) -6,7-bis ((4-methoxybenzyl) oxy) quinolin-4 (1H) -one

A slurry of compound 167e (25 g, 55 mmol) in ethanol (200 mL) was heated to 80 ° C. to aid in dissolution of the starting material (Note: The starting material does not dissolve completely at high temperature, but all lumps are Collapse). The mixture was removed from the oil bath, 1M sodium hydroxide (aq) (277 mL, 277 mmol) and formaldehyde (37% aq, 82 mL, 1100 mmol) were added and the mixture was heated at 80 ° C. for 3 h. The reaction mixture was cooled to room temperature and the resulting slurry was filtered through a Buchner funnel. The solid was washed with water and then hexane to give compound 167f (20.4 g, 77% yield) as a tan solid.
LCMS: (M + H) ^<+> : 482.0. ¹ H NMR (DMSO-d ₆ ): 11.55 (d, J = 5.8 Hz, 1H), 7.70 (d, J = 5.8 Hz, 1H), 7.48 (d, J = 8.6 Hz, 2H), 7.30 (d, J = 8.8 Hz, 2H), 7.09 (s, 1H), 7.01 (d, J = 8.6 Hz, 2H), 6 .85 (d, J = 8.6 Hz, 2H), 5.17 (s, 2H), 4.86 (s, 2H), 4.32 (d, J = 5.1 Hz, 2H), 3 .79 (s, 3H), 3.74 (s, 3H).

ＤＭＦ（８００ｍＬ）中、化合物１６７ｆ（２８ｇ、５１．１ｍｍｏｌ）の懸濁液に、水素化ナトリウム（２．０５ｇ、５１．１ｍｍｏｌ）を加え、この混合物を室温で３０分間撹拌した。次に、（２−（クロロメトキシ）エチル）トリメチルシラン（９．０５ｍＬ、５１．１ｍｍｏｌ）を加え、この混合物を室温で１時間撹拌した。反応混合物をＬＣ−ＭＳにより分析したところ、一部の出発材料がなお存在していることが示された。反応混合物に水を加え、沈殿を濾取した。この沈殿でシリカゲルおよびＤＣＭを加え、得られた混合物を濃縮し、自動シリカゲルクロマトグラフィー（１００％ＤＣＭ、次いで０〜１０％ＭｅＯＨ／ＤＣＭ）により精製し、化合物１６７ｇ（１１ｇ、収率１９％）を褐色油状物として得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ６１２．２． Step (7): Compound 167f → Compound 167g
Compound 167g: 5-chloro-3- (hydroxymethyl) -6,7-bis ((4-methoxybenzyl) oxy) -1-((2- (trimethylsilyl) ethoxy) methyl) quinolin-4 (1H) -one

To a suspension of compound 167f (28 g, 51.1 mmol) in DMF (800 mL) was added sodium hydride (2.05 g, 51.1 mmol) and the mixture was stirred at room temperature for 30 minutes. Next, (2- (chloromethoxy) ethyl) trimethylsilane (9.05 mL, 51.1 mmol) was added and the mixture was stirred at room temperature for 1 hour. Analysis of the reaction mixture by LC-MS indicated that some starting material was still present. Water was added to the reaction mixture, and the precipitate was collected by filtration. Silica gel and DCM were added to the precipitate and the resulting mixture was concentrated and purified by automated silica gel chromatography (100% DCM, then 0-10% MeOH / DCM) to give 167 g (11 g, 19% yield) of compound. Obtained as a brown oil. LCMS: (M + H) ^<+> : 612.2.

ＤＣＭ（９０ｍＬ）中、５−クロロ−３−（ヒドロキシメチル）−６，７−ビス（（４−メトキシベンジル）オキシ）−１−（（２−（トリメチルシリル）エトキシ）メチル）キノリン−４（１Ｈ）−オン（５．４８ｇ、６．６２ｍｍｏｌ）の溶液に、酸化マンガン（ＩＶ）（８．６４ｇ、９９．０ｍｍｏｌ）を加え、この混合物を室温で一晩撹拌した。この混合物をセライトケークで濾過し、ＤＣＭですすぎ、濾液を真空濃縮し、化合物１６７ｈ（４．２ｇ、収率８０％）を得た。この材料をそれ以上精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ６１０．２． Step (8): Compound 167 g → Compound 167 h
Compound 167h: 5-chloro-6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-1-((2- (trimethylsilyl) ethoxy) methyl) -1,4-dihydroquinoline-3-carba Rudehide

5-Chloro-3- (hydroxymethyl) -6,7-bis ((4-methoxybenzyl) oxy) -1-((2- (trimethylsilyl) ethoxy) methyl) quinoline-4 (1H in DCM (90 mL) To a solution of) -one (5.48 g, 6.62 mmol) was added manganese (IV) oxide (8.64 g, 99.0 mmol) and the mixture was stirred at room temperature overnight. The mixture was filtered through celite cake, rinsed with DCM, and the filtrate was concentrated in vacuo to give compound 167h (4.2 g, 80% yield). This material was used in the next step without further purification. LCMS: (M + H) ^<+> : 610.2.

ＴＨＦ（１４０ｍＬ）およびｔ−ブタノール（１４０ｍＬ）中、化合物１６７ｈ（３．６４ｇ、４．５９ｍｍｏｌ）の溶液に、１０℃で２−メチルブト−２−エン（２２．９７ｍＬ、４５．９０ｍｍｏｌ）を加えた。次に、最初の溶液に、水（４５ｍＬ）中、亜塩素酸ナトリウム（１．２４６ｇ、１３．７８ｍｍｏｌ）およびリン酸二水素ナトリウム（１．６５３ｇ、１３．７８ｍｍｏｌ）の溶液を滴下し、この混合物を室温で一晩撹拌した。次に、この混合物を飽和ＮＨ_４Ｃｌ（水溶液）で希釈し、ＤＣＭで抽出した。合わせた有機抽出液をブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、真空濃縮し、化合物１６７ｉ（２，５６ｇ、収率８９％）を白色固体として得、これをそれ以上精製せずに次の工程で使用した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ６２６．１． ^１Ｈ ＮＭＲ （ＤＭＳＯ−ｄ_６）： ９．０８ （ｓ， １Ｈ）， ７．５７ （ｓ， １Ｈ）， ７．４９ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ７．３０ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ７．０１ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ６．８６ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ５．９１ （ｓ， ２Ｈ）， ５．３３ （ｓ， ２Ｈ）， ４．９５ （ｓ， ２Ｈ）， ３．７９ （ｓ， ３Ｈ）， ３．７５ （ｓ， ３Ｈ）， ３．６２ （ｔ， Ｊ＝８．０ Ｈｚ， ２Ｈ）， ０．８８ （ｔ， Ｊ＝８．０ Ｈｚ， ２Ｈ）， −０．０５ （ｓ， ９Ｈ）． Step (9): Compound 167h → Compound 167i
Compound 167i: 5-chloro-6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-1-((2- (trimethylsilyl) ethoxy) methyl) -1,4-dihydroquinoline-3-carvone acid

To a solution of compound 167h (3.64 g, 4.59 mmol) in THF (140 mL) and t-butanol (140 mL) was added 2-methylbut-2-ene (22.97 mL, 45.90 mmol) at 10 ° C. . Next, a solution of sodium chlorite (1.246 g, 13.78 mmol) and sodium dihydrogen phosphate (1.653 g, 13.78 mmol) in water (45 mL) was added dropwise to the first solution and the mixture Was stirred overnight at room temperature. The mixture was then diluted with saturated NH ₄ Cl (aq) and extracted with DCM. The combined organic extracts were washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated in vacuo to give compound 167i (2,56 g, 89% yield) as a white solid that was further purified. Used in the next step.
LCMS: (M + H) ^<+> : 626.1. ¹ H NMR (DMSO-d ₆ ): 9.08 (s, 1H), 7.57 (s, 1H), 7.49 (d, J = 8.6 Hz, 2H), 7.30 (d, J = 8.6 Hz, 2H), 7.01 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 5.91 (s, 2H) , 5.33 (s, 2H), 4.95 (s, 2H), 3.79 (s, 3H), 3.75 (s, 3H), 3.62 (t, J = 8.0 Hz, 2H), 0.88 (t, J = 8.0 Hz, 2H), −0.05 (s, 9H).

ＤＭＦ（５０ｍＬ）中、化合物１６７ｉ（２．２０ｇ、３．５１ｍｍｏｌ）の溶液に、ＨＡＴＵ（１．６０ｇ、４．２２ｍｍｏｌ）およびＤＩＰＥＡ（１．８４ｍＬ、１０．５ｍｍｏｌ）を加え、得られた混合物を室温で３０分間撹拌した。次に、２−（ピロリジン−１−イル）エタンアミン（０．４７ｍＬ、３．７ｍｍｏｌ）を加え、得られた混合物を室温で１時間撹拌した。この混合物に水およびＥｔＯＡｃを加え、水相をＥｔＯＡｃで３回抽出した。合わせた有機抽出液をブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、真空濃縮した。得られた残渣を自動順相クロマトグラフィー（２４ｇカラム、溶媒Ａ中０〜１０％溶媒Ｂ；溶媒Ａ＝ＤＣＭ、溶媒Ｂ＝１０：９０：１ ＭｅＯＨ：ＤＣＭ：ＮＨ_４ＯＨ）により精製した。回収した固体をＤＣＭに溶かし、水で洗浄した後、有機層を真空濃縮した。残渣を小（４ｇ）シリカゲルカラム（ＤＣＭ中０〜１０％ＭｅＯＨ）に通し、化合物１６７ｊ（１．３１ｇ、収率５２％）を褐色固体として得た。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７２２．３． ^１Ｈ ＮＭＲ （ＤＭＳＯ−ｄ_６）： ９．８８ （ｔ， Ｊ＝５．６ Ｈｚ， １Ｈ）， ８．８４ （ｓ， １Ｈ）， ７．４８ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ７．４５ （ｓ， １Ｈ）， ７．３０ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ７．０１ （ｄ， Ｊ＝８．８ Ｈｚ， ２Ｈ）， ６．８５ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ５．８１ （ｓ， １Ｈ）， ５．２８ （ｓ， ２Ｈ）， ４．９１ （ｓ， ２Ｈ）， ３．７９ （ｓ， ３Ｈ）， ３．７５ （ｓ， ３Ｈ）， ３．５９ （ｔ， Ｊ＝７．８ Ｈｚ， ２Ｈ）， ３．４４ （ｑ， Ｊ＝６．３ Ｈｚ， ２Ｈ）， ２．５８ （ｔ， Ｊ＝６．４ Ｈｚ， ２Ｈ）， ２．４４−２．５０ （ｍ， ４Ｈ）， １．６４−１．７４ （ｍ， ４Ｈ）， ０．８７ （ｔ， Ｊ＝７．８ Ｈｚ， ２Ｈ）， −０．０６ （ｓ， ９Ｈ）． Step (10): Compound 167i → Compound 167j
Compound 167j: 5-chloro-6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-N- (2- (pyrrolidin-1-yl) ethyl) -1-((2- (trimethylsilyl) Ethoxy) methyl) -1,4-dihydroquinoline-3-carboxamide

To a solution of compound 167i (2.20 g, 3.51 mmol) in DMF (50 mL) was added HATU (1.60 g, 4.22 mmol) and DIPEA (1.84 mL, 10.5 mmol) and the resulting mixture was Stir at room temperature for 30 minutes. Next, 2- (pyrrolidin-1-yl) ethanamine (0.47 mL, 3.7 mmol) was added and the resulting mixture was stirred at room temperature for 1 hour. Water and EtOAc were added to the mixture and the aqueous phase was extracted 3 times with EtOAc. The combined organic extracts were washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated in vacuo. The resulting residue was purified by automated normal phase chromatography (24 g column, 0-10% solvent B in solvent A; solvent A = DCM, solvent B = 10: 90: 1 MeOH: DCM: NH ₄ OH). The collected solid was dissolved in DCM and washed with water, and then the organic layer was concentrated in vacuo. The residue was passed through a small (4 g) silica gel column (0-10% MeOH in DCM) to give compound 167j (1.31 g, 52% yield) as a brown solid.
LCMS: (M + H) ^<+> : 722.3. ¹ H NMR (DMSO-d ₆ ): 9.88 (t, J = 5.6 Hz, 1H), 8.84 (s, 1H), 7.48 (d, J = 8.6 Hz, 2H) , 7.45 (s, 1H), 7.30 (d, J = 8.6 Hz, 2H), 7.01 (d, J = 8.8 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 5.81 (s, 1H), 5.28 (s, 2H), 4.91 (s, 2H), 3.79 (s, 3H), 3.75 (s, 3H), 3.59 (t, J = 7.8 Hz, 2H), 3.44 (q, J = 6.3 Hz, 2H), 2.58 (t, J = 6.4 Hz, 2H) , 2.44-2.50 (m, 4H), 1.64-1.74 (m, 4H), 0.87 (t, J = 7.8 Hz, 2H), −0.06 (s, 9H)

この化合物は、化合物１６７ｊおよび化合物Ｘ−２４を用い、実施例１６２の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８３３．２． ^１Ｈ ＮＭＲ （Ｄ_２Ｏ）： ８．２６ （ｂｒ． ｓ．， １Ｈ）， ６．８７ （ｓ， １Ｈ）， ６．４７−６．５７ （ｍ， １Ｈ）， ５．７０ （ｄ， Ｊ＝４．５ Ｈｚ， １Ｈ）， ５．３５ （ｄ， Ｊ＝４．５ Ｈｚ， １Ｈ）， ４．９０ （ｄ， Ｊ＝１４．９ Ｈｚ， １Ｈ）， ４．１７ （ｄ， Ｊ＝１４．１ Ｈｚ， １Ｈ）， ３．９６ （ｄ， Ｊ＝５．３ Ｈｚ， １Ｈ）， ３．６９−３．９０ （ｍ， ２Ｈ）， ３．５６−３．６７ （ｍ， １Ｈ）， ３．２６−３．５５ （ｍ， ６Ｈ）， ２．１０ （ｂｒ． ｓ．， ４Ｈ）， １．４５ （ｄ， Ｊ＝６．６ Ｈｚ， ３Ｈ）， １．３８ （ｓ， ３Ｈ）， １．３６ （ｓ， ３Ｈ）． Step (11): Compound X-24 + Compound 167j → Compound I-167
Compound I-167: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((1- (2- (5-chloro-6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carboxamido) ethyl) pyrrolidin-1-ium-1-yl ) Methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 162 using compound 167j and compound X-24.
LCMS: (M + H) ^<+> : 833.2. ¹ H NMR (D ₂ O): 8.26 (br. S., 1H), 6.87 (s, 1H), 6.47-6.57 (m, 1H), 5.70 (d, J = 4.5 Hz, 1H), 5.35 (d, J = 4.5 Hz, 1H), 4.90 (d, J = 14.9 Hz, 1H), 4.17 (d, J = 14 .1 Hz, 1H), 3.96 (d, J = 5.3 Hz, 1H), 3.69-3.90 (m, 2H), 3.56-3.67 (m, 1H), 3 26-3.55 (m, 6H), 2.10 (br. S., 4H), 1.45 (d, J = 6.6 Hz, 3H), 1.38 (s, 3H), 1 .36 (s, 3H).

ＤＣＭ（７００ｍＬ）中、５−クロロ−１−エチル−６，７−ビス（（４−メトキシベンジル）オキシ）−４−オキソ−１，４−ジヒドロキノリン−３−カルボン酸（ＷＯ２０１３０５２５６８参照、６．１１ｇ、１１．７ｍｍｏｌ）およびキヌクリジン−４−イルメタンアミン（１．７９９ｇ、１２．８３ｍｍｏｌ）の溶液に、室温でＤＩＰＥＡ（３．０５ｍＬ、１７．５ｍｍｏｌ）およびＰｙＢＯＰ（７．２８ｇ、１４．０ｍｍｏｌ）を加え、反応混合物を一晩撹拌した。この混合物を濃縮し、残渣を自動シリカゲルクロマトグラフィー（１２０ｇカラム、ＤＣＭ中０〜１０％ＭｅＯＨ）により精製し、単離された生成物を飽和ＮａＨＣＯ_３水溶液、ブライン、および水で順次洗浄した。得られた材料を小（２４ｇ）シリカゲルカラム（ＤＣＭ中０〜１０％ＭｅＯＨ）から溶出させ、生成物（２．２８ｇ、収率３０％）を白色固体として得た。この材料は次工程で反応性が高くなく、^１Ｈ ＮＭＲにより、おそらくは対イオンとして何らかの形態のシリカゲルを伴った塩形態で存在すると決定された。この材料をＭｅＯＨに懸濁させ、１当量の５Ｎ ＮａＯＨ（水溶液）を加えた。この混合物を１５分間撹拌した後、濾過し、ＭｅＯＨですすぎ、化合物１６８ａ（１．８２ｇ）を得た。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ６４６．１． ^１Ｈ ＮＭＲ （ＤＭＳＯ−ｄ_６）： １０．０４ （ｔ， Ｊ＝６．１ Ｈｚ， １Ｈ）， ８．７４ （ｓ， １Ｈ）， ７．５１ （ｄ， Ｊ＝８．８ Ｈｚ， ２Ｈ）， ７．３１ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ７．２９ （ｂｒ． ｓ．， １Ｈ）， ７．０２ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ６．８６ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ５．３６ （ｓ， ２Ｈ）， ４．９１ （ｓ， ２Ｈ）， ４．５０ （ｑ， Ｊ＝６．８ Ｈｚ， ２Ｈ）， ３．７９ （ｓ， ３Ｈ）， ３．７５ （ｓ， ３Ｈ）， ３．１１ （ｄ， Ｊ＝５．８ Ｈｚ， ２Ｈ）， ２．６９−２．７９ （ｍ， ６Ｈ）， １．２８−１．３７ （ｍ， ９Ｈ）． Example 168: Synthesis Step of Compound I-168 (1): 5-Chloro-1-ethyl-6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-1,4-dihydroquinoline-3 -Carboxylic acid-> compound 168a
Compound 168a: 5-chloro-1-ethyl-6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-N- (quinuclidin-4-ylmethyl) -1,4-dihydroquinoline-3-carboxamide

5. 5-Chloro-1-ethyl-6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-1,4-dihydroquinoline-3-carboxylic acid in DCM (700 mL) (see WO201305568, 6. 11 g, 11.7 mmol) and quinuclidin-4-ylmethanamine (1.799 g, 12.83 mmol) in DIPEA (3.05 mL, 17.5 mmol) and PyBOP (7.28 g, 14.0 mmol) at room temperature. And the reaction mixture was stirred overnight. The mixture was concentrated, the residue was purified by automated silica gel chromatography (120 g column, 0-10% MeOH in DCM) and the isolated product was washed sequentially with saturated aqueous NaHCO ₃ solution, brine, and water. The resulting material was eluted from a small (24 g) silica gel column (0-10% MeOH in DCM) to give the product (2.28 g, 30% yield) as a white solid. This material was not highly reactive in the next step and was determined by ¹ H NMR to be present in salt form, possibly with some form of silica gel as the counter ion. This material was suspended in MeOH and 1 equivalent of 5N NaOH (aq) was added. The mixture was stirred for 15 minutes then filtered and rinsed with MeOH to give compound 168a (1.82 g).
LCMS: (M + H) ^<+> : 646.1. ¹ H NMR (DMSO-d ₆ ): 10.04 (t, J = 6.1 Hz, 1H), 8.74 (s, 1H), 7.51 (d, J = 8.8 Hz, 2H) , 7.31 (d, J = 8.6 Hz, 2H), 7.29 (br. S., 1H), 7.02 (d, J = 8.6 Hz, 2H), 6.86 (d , J = 8.6 Hz, 2H), 5.36 (s, 2H), 4.91 (s, 2H), 4.50 (q, J = 6.8 Hz, 2H), 3.79 (s) 3H), 3.75 (s, 3H), 3.11 (d, J = 5.8 Hz, 2H), 2.69-2.79 (m, 6H), 1.28-1.37 ( m, 9H).

この化合物は、化合物１６８ａおよび化合物Ｘ−２４を用い、実施例１６２の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８８７．４． ^１Ｈ ＮＭＲ （Ｄ_２Ｏ）： ８．３１ （ｓ， １Ｈ）， ６．８５ （ｓ， １Ｈ）， ６．７０ （ｂｒ． ｓ．， １Ｈ）， ５．７０ （ｄ， Ｊ＝４．５ Ｈｚ， １Ｈ）， ５．３０ （ｄ， Ｊ＝４．８ Ｈｚ， １Ｈ）， ４．５２ （ｄ， Ｊ＝１４．１ Ｈｚ， １Ｈ）， ３．９９−４．１６ （ｍ， ２Ｈ）， ３．８６−３．９８ （ｍ， ２Ｈ）， ３．２４−３．５０ （ｍ， ８Ｈ）， １．８３ （ｂｒ． ｓ．， ６Ｈ）， １．４２ （ｄ， Ｊ＝６．８ Ｈｚ， ３Ｈ）， １．３８ （ｓ， ３Ｈ）， １．３６ （ｓ， ３Ｈ）， １．２２−１．３０ （ｍ， ３Ｈ）． Step (2): Compound X-24 + Compound 168a → Compound I-168
Compound I-168:
(4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino) acetamide) -3 -((4-((5-chloro-1-ethyl-6,7-dihydroxy-4-oxo-1,4-dihydroquinolin-3-carboxamido) methyl) quinuclidin-1-ium-1-yl) methyl) -4-Methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 162 using compound 168a and compound X-24.
LCMS: (M + H) ^<+> : 887.4. ¹ H NMR (D ₂ O): 8.31 (s, 1H), 6.85 (s, 1H), 6.70 (br.s., 1H), 5.70 (d, J = 4.5 Hz, 1H), 5.30 (d, J = 4.8 Hz, 1H), 4.52 (d, J = 14.1 Hz, 1H), 3.99-4.16 (m, 2H), 3.86-3.98 (m, 2H), 3.24-3.50 (m, 8H), 1.83 (br.s., 6H), 1.42 (d, J = 6.8 Hz) , 3H), 1.38 (s, 3H), 1.36 (s, 3H), 1.22-1.30 (m, 3H).

ＤＭＦ（２５ｍＬ）中、化合物１６７ｉ（９８０ｍｇ、１．５６ｍｍｏｌ）の溶液に、ＨＡＴＵ（７１４ｍｇ、１．８８ｍｍｏｌ）およびＤＩＰＥＡ（１．０９ｍＬ、６．２６ｍｍｏｌ）を加え、得られた混合物を室温で３０分間撹拌した。次に、キヌクリジン−４−イルメタンアミン二塩酸塩（ＷＯ２０１１１２５９６６Ａ１号、３６７ｍｇ、１．７２ｍｍｏｌ）を加え、得られた混合物を室温で１時間撹拌した。この混合物に水およびＥｔＯＡｃを加え、水相をＥｔＯＡｃで３回抽出した。合わせた有機抽出液をブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、真空濃縮した。残渣を自動順相クロマトグラフィー（２４ｇカラム、溶媒Ａ中４５〜９０％溶媒Ｂ；溶媒Ａ＝ヘキサン、溶媒Ｂ＝３：１ ＥｔＯＡｃ／ＥｔＯＨ（２％ＮＨ_４ＯＨ含有））により精製し、目的生成物を褐色固体として得た。この材料の^１Ｈ ＮＭＲは、この生成物が塩形態として存在することを示唆した。固体をＭｅＯＨに懸濁させ、２００μＬの６Ｎ ＮａＯＨ水溶液を加え、この時、この混合物は均質となった。この溶液を５分間撹拌した後、これを、ＭｅＯＨで溶出するＳＣＸカラムに通した。次に、この生成物を、１％ＮＨ_４ＯＨを含有するＭｅＯＨで溶出することにより回収した。回収した材料を濃縮した後、ＭｅＯＨへの再溶解と濃縮をさらに２回行い、全てのＮＨ_４ＯＨが確実に除去されるようにした。このプロセスにより、化合物１６９ａ（０．８９６ｇ、収率７６％）を褐色固体として得た。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７４８．７． ^１Ｈ ＮＭＲ （ＤＭＳＯ−ｄ_６） ： ９．９４ （ｔ， Ｊ＝６．１ Ｈｚ， １Ｈ）， ８．８６ （ｓ， １Ｈ）， ７．４８ （ｄ， Ｊ＝８．８ Ｈｚ， ２Ｈ）， ７．４６ （ｓ， １Ｈ）， ７．３０ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ７．０１ （ｄ， Ｊ＝８．８ Ｈｚ， ２Ｈ）， ６．８５ （ｄ， Ｊ＝８．８ Ｈｚ， ２Ｈ）， ５．８２ （ｓ， ２Ｈ）， ５．２８ （ｓ， ２Ｈ）， ４．９１ （ｓ， ２Ｈ）， ３．７９ （ｓ， ３Ｈ）， ３．７５ （ｓ， ３Ｈ）， ３．５９ （ｔ， Ｊ＝８．０ Ｈｚ， ２Ｈ）， ３．１３ （ｄ， Ｊ＝６．１ Ｈｚ， ２Ｈ）， ２．７２−２．８２ （ｍ， ６Ｈ）， １．３０−１．４０ （ｍ， ６Ｈ）， ０．８７ （ｔ， Ｊ＝７．８ Ｈｚ， ２Ｈ）， −０．０６ （ｓ， ９Ｈ）． Example 169: Synthesis Step of Compound I-169 (1): Compound 167i → Compound 169a
Compound 169a:
5-chloro-6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-N- (quinuclidin-4-ylmethyl) -1-((2- (trimethylsilyl) ethoxy) methyl) -1,4 -Dihydroquinoline-3-carboxamide

To a solution of compound 167i (980 mg, 1.56 mmol) in DMF (25 mL) was added HATU (714 mg, 1.88 mmol) and DIPEA (1.09 mL, 6.26 mmol) and the resulting mixture was at room temperature for 30 min. Stir. Next, quinuclidin-4-ylmethanamine dihydrochloride (WO20111225966A1, 367 mg, 1.72 mmol) was added and the resulting mixture was stirred at room temperature for 1 hour. Water and EtOAc were added to the mixture and the aqueous phase was extracted 3 times with EtOAc. The combined organic extracts were washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated in vacuo. The residue was purified by automated normal phase chromatography (24 g column, 45-90% solvent B in solvent A; solvent A = hexane, solvent B = 3: 1 EtOAc / EtOH (containing 2% NH ₄ OH)) to yield the desired product The product was obtained as a brown solid. ¹ H NMR of this material suggested that the product existed as a salt form. The solid was suspended in MeOH and 200 μL of 6N aqueous NaOH was added, at which time the mixture became homogeneous. The solution was stirred for 5 minutes before it was passed through an SCX column eluting with MeOH. The product was then recovered by eluting with MeOH containing 1% NH ₄ OH. After the collected material was concentrated, it was redissolved in MeOH and concentrated twice more to ensure removal of all NH ₄ OH. This process gave compound 169a (0.896 g, 76% yield) as a brown solid.
LCMS: (M + H) ^<+> : 748.7. ¹ H NMR (DMSO-d ₆ ): 9.94 (t, J = 6.1 Hz, 1H), 8.86 (s, 1H), 7.48 (d, J = 8.8 Hz, 2H) , 7.46 (s, 1H), 7.30 (d, J = 8.6 Hz, 2H), 7.01 (d, J = 8.8 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 5.82 (s, 2H), 5.28 (s, 2H), 4.91 (s, 2H), 3.79 (s, 3H), 3.75 (s, 3H), 3.59 (t, J = 8.0 Hz, 2H), 3.13 (d, J = 6.1 Hz, 2H), 2.72-2.82 (m, 6H), 30-1.40 (m, 6H), 0.87 (t, J = 7.8 Hz, 2H), -0.06 (s, 9H).

この化合物は、化合物１６９ａおよび化合物Ｘ−２４を用い、実施例１６２の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８５９．５． ^１Ｈ ＮＭＲ （Ｄ_２Ｏ） □： ８．１０ （ｓ， １Ｈ）， ６．８５ （ｓ， １Ｈ）， ６．４１ （ｓ， １Ｈ）， ５．７１ （ｄ， Ｊ＝４．８ Ｈｚ， １Ｈ）， ５．３２ （ｄ， Ｊ＝４．８ Ｈｚ， １Ｈ）， ４．５２ （ｄ， Ｊ＝１４．１ Ｈｚ， １Ｈ）， ３．８２−４．０３ （ｍ， ２Ｈ）， ３．２９−３．５３ （ｍ， ６Ｈ）， ３．２３ （ｂｒ． ｓ．， ２Ｈ）， １．７６−１．８９ （ｍ， ６Ｈ）， １．４３ （ｄ， Ｊ＝６．８ Ｈｚ， ３Ｈ）， １．３９ （ｓ， ３Ｈ）， １．３７ （ｓ， ３Ｈ）． Step (2): Compound X-24 + Compound 169a → Compound I-169
Compound I-169:
(4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino) acetamide) -3 -((4-((5-chloro-6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carboxamido) methyl) quinuclidin-1-ium-1-yl) methyl) -4-methyl -8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 162 using compound 169a and compound X-24.
LCMS: (M + H) ^<+> : 859.5. ¹ H NMR (D ₂ O) □: 8.10 (s, 1H), 6.85 (s, 1H), 6.41 (s, 1H), 5.71 (d, J = 4.8 Hz, 1H), 5.32 (d, J = 4.8 Hz, 1H), 4.52 (d, J = 14.1 Hz, 1H), 3.82-4.03 (m, 2H), 3. 29-3.53 (m, 6H), 3.23 (br. S., 2H), 1.76-1.89 (m, 6H), 1.43 (d, J = 6.8 Hz, 3H ), 1.39 (s, 3H), 1.37 (s, 3H).

  The compounds shown below were obtained from compound X-24 and the corresponding amines (synthesized as in Examples 163 to 169).

ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８９９．５． ^１Ｈ ＮＭＲ （Ｄ_２Ｏ） ： ８．２９ （ｓ， １Ｈ）， ７．１４ （ｓ， １Ｈ）， ６．８５ （ｓ， １Ｈ）， ５．６６−５．７３ （ｍ， １Ｈ）， ５．７０ （ｄ， Ｊ＝４．８ Ｈｚ， １Ｈ）， ５．３０ （ｄ， Ｊ＝４．８ Ｈｚ， １Ｈ）， ４．５１ （ｄ， Ｊ＝１４．４ Ｈｚ， １Ｈ）， ３．８８−４．００ （ｍ， ２Ｈ）， ３．３０−３．５０ （ｍ， ７Ｈ）， ３．２３ （ｂｒ． ｓ．， ２Ｈ）， １．８２ （ｂｒ． ｓ．， ６Ｈ）， １．４２ （ｄ， Ｊ＝６．８ Ｈｚ， ３Ｈ）， １．３８ （ｓ， ３Ｈ）， １．３６ （ｓ， ３Ｈ）， １．１６ （ｄ， Ｊ＝６．３ Ｈｚ， ２Ｈ）， ０．９２ （ｂｒ． ｓ．， ２Ｈ）． Example 170 Synthesis of Compound I-170 Compound I-170: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2- Carboxypropan-2-yl) oxy) imino) acetamido) -3-((4-((5-chloro-1-cyclopropyl-6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-) Carboxamido) methyl) quinuclidin-1-ium-1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

LCMS: (M + H) ^<+> : 899.5. ¹ H NMR (D ₂ O): 8.29 (s, 1H), 7.14 (s, 1H), 6.85 (s, 1H), 5.66-5.73 (m, 1H), 5 .70 (d, J = 4.8 Hz, 1H), 5.30 (d, J = 4.8 Hz, 1H), 4.51 (d, J = 14.4 Hz, 1H), 3.88 -4.00 (m, 2H), 3.30-3.50 (m, 7H), 3.23 (br.s., 2H), 1.82 (br.s., 6H), 1.42 (D, J = 6.8 Hz, 3H), 1.38 (s, 3H), 1.36 (s, 3H), 1.16 (d, J = 6.3 Hz, 2H), 0.92 (Br.s., 2H).

ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８５９．２． ^１Ｈ ＮＭＲ （Ｄ_２Ｏ） ： ８．１９ （ｂｒ． ｓ．， １Ｈ）， ６．８８ （ｓ， １Ｈ）， ６．５４ （ｂｒ． ｓ．， １Ｈ）， ５．７０ （ｄ， Ｊ＝４．８ Ｈｚ， １Ｈ）， ５．３４ （ｄ， Ｊ＝４．５ Ｈｚ， １Ｈ）， ４．０７−４．２６ （ｍ， １Ｈ）， ３．９１−４．０４ （ｍ， ３Ｈ）， ３．８６ （ｂｒ． ｓ．， １Ｈ）， ２．９８ （ｂｒ． ｓ．， ３Ｈ）， ２．４１−２．８１ （ｍ， ５Ｈ）， ２．２２−２．４０ （ｍ， ３Ｈ）， １．９０−２．０５ （ｍ， ２Ｈ）， １．４５ （ｄ， Ｊ＝６．３ Ｈｚ， ３Ｈ）， １．４０ （ｓ， ３Ｈ）， １．３８ （ｓ， ３Ｈ）． Example 171: Synthesis of Compound I-171 Compound I-171: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2- Carboxypropan-2-yl) oxy) imino) acetamido) -3-(((1R, 5S, 8s) -3- (5-chloro-6,7-dihydroxy-4-oxo-1,4-dihydroquinoline- 3-Carboxamide) -8-methyl-8-azabicyclo [3.2.1] octane-8-ium-8-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4. 2.0] Oct-2-ene-2-carboxylate sodium salt

LCMS: (M + H) ^<+> : 859.2. ¹ H NMR (D ₂ O): 8.19 (br.s., 1H), 6.88 (s, 1H), 6.54 (br.s., 1H), 5.70 (d, J = 4.8 Hz, 1H), 5.34 (d, J = 4.5 Hz, 1H), 4.07-4.26 (m, 1H), 3.91-4.04 (m, 3H), 3.86 (br.s., 1H), 2.98 (br.s., 3H), 2.41-2.81 (m, 5H), 2.22-2.40 (m, 3H), 1.90-2.05 (m, 2H), 1.45 (d, J = 6.3 Hz, 3H), 1.40 (s, 3H), 1.38 (s, 3H).

ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８７３．５． ^１Ｈ ＮＭＲ （Ｄ_２Ｏ） □： ８．１１ （ｂｒ． ｓ．， １Ｈ）， ６．８６ （ｓ， １Ｈ）， ６．４５ （ｂｒ． ｓ．， １Ｈ）， ５．７１ （ｄ， Ｊ＝４．０ Ｈｚ， １Ｈ）， ５．３３ （ｍ， １Ｈ）， ４．５３ （ｄ， Ｊ＝１４．１ Ｈｚ， １Ｈ）， ３．９４ （ｍ， ２Ｈ）， ３．５４ （ｍ， ３Ｈ）， ３．３２−３．５０ （ｍ， ７Ｈ）， ３．２３ （ｍ， ２Ｈ）， １．８３ （ｍ， ６Ｈ）， １．４３ （ｄ， Ｊ＝６．３ Ｈｚ， ３Ｈ）， １．３９ （ｓ， ３Ｈ）， １．３８ （ｓ， ３Ｈ）． Example 172: Synthesis of Compound I-172 Compound I-172: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2- Carboxypropan-2-yl) oxy) imino) acetamido) -3-((4-((5-chloro-6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide) ) Methyl) quinuclidin-1-ium-1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-en-2-carboxylate sodium salt

LCMS: (M + H) ^<+> : 873.5. ¹ H NMR (D ₂ O) □: 8.11 (br. S., 1H), 6.86 (s, 1H), 6.45 (br. S., 1H), 5.71 (d, J = 4.0 Hz, 1H), 5.33 (m, 1H), 4.53 (d, J = 14.1 Hz, 1H), 3.94 (m, 2H), 3.54 (m, 3H) ), 3.32-3.50 (m, 7H), 3.23 (m, 2H), 1.83 (m, 6H), 1.43 (d, J = 6.3 Hz, 3H), 1 .39 (s, 3H), 1.38 (s, 3H).

ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８７３．５． ^１Ｈ ＮＭＲ （Ｄ_２Ｏ） ： ８．２８ （ｓ， １Ｈ）， ６．８９ （ｓ， １Ｈ）， ６．６４ （ｂｒ． ｓ．， １Ｈ）， ５．６７−５．７４ （ｍ， １Ｈ）， ５．７１ （ｄ， Ｊ＝４．５ Ｈｚ， １Ｈ）， ５．３５ （ｄ， Ｊ＝４．５ Ｈｚ， １Ｈ）， ４．６４−４．６７ （ｍ， １Ｈ）， ４．１３−４．２０ （ｍ， １Ｈ）， ３．９４−４．０５ （ｍ， ３Ｈ）， ３．８３−３．９１ （ｍ， １Ｈ）， ３．６８ （ｓ， ３Ｈ）， ３．０１ （ｓ， ３Ｈ）， ２．５８−２．８０ （ｍ， ３Ｈ）， ２．４４−２．５７ （ｍ， ２Ｈ）， ２．３０−２．４１ （ｍ， ２Ｈ）， １．９３−２．０６ （ｍ， ３Ｈ）， １．４６ （ｄ， Ｊ＝６．８ Ｈｚ， ３Ｈ）， １．４０ （ｓ， ３Ｈ）， １．３８ （ｓ， ３Ｈ）． Example 173: Synthesis of Compound I-173 Compound I-171: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2- Carboxypropan-2-yl) oxy) imino) acetamido) -3-(((1R, 5S, 8s) -3- (5-chloro-6,7-dihydroxy-1-methyl-4-oxo-1,4 -Dihydroquinoline-3-carboxamide) -8-methyl-8-azabicyclo [3.2.1] octane-8-ium-8-yl) methyl) -4-methyl-8-oxo-5-thia-1- Azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

LCMS: (M + H) ^<+> : 873.5. ¹ H NMR (D ₂ O): 8.28 (s, 1H), 6.89 (s, 1H), 6.64 (br.s., 1H), 5.67-5.74 (m, 1H) ), 5.71 (d, J = 4.5 Hz, 1H), 5.35 (d, J = 4.5 Hz, 1H), 4.64-4.67 (m, 1H), 4.13 -4.20 (m, 1H), 3.94-4.05 (m, 3H), 3.83-3.91 (m, 1H), 3.68 (s, 3H), 3.01 (s 3H), 2.58-2.80 (m, 3H), 2.44-2.57 (m, 2H), 2.30-2.41 (m, 2H), 1.93-2.06 (M, 3H), 1.46 (d, J = 6.8 Hz, 3H), 1.40 (s, 3H), 1.38 (s, 3H).

ｉＰｒＯＨ（８００ｍＬ）中、化合物１６６ｂ（１００ｇ、２７４ｍｍｏｌ）の溶液に、室温で２−（エトキシメチレン）マロン酸ジエチル（６０．３ｍＬ、３０１ｍｍｏｌ）を加えた。得られた溶液を４０分間８０℃に加熱した。この間に、この懸濁液をより粘稠となり、撹拌が困難であった。この混合物を室温まで冷却し、少量のｉＰｒＯＨで希釈してスラリーの流動性を高め、ブフナー漏斗で濾過し、ｉＰｒＯＨですすぎ、化合物１７４ａ（１４０ｇ、収率９６％）を得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５３６．４． Example 174: Synthesis Step of Compound I-174 (1): Compound 166b → Compound 174a
Compound 174a: 2-(((3,4-bis ((4-methoxybenzyl) oxy) phenyl) amino) methylene) diethyl malonate

To a solution of compound 166b (100 g, 274 mmol) in iPrOH (800 mL) was added diethyl 2- (ethoxymethylene) malonate (60.3 mL, 301 mmol) at room temperature. The resulting solution was heated to 80 ° C. for 40 minutes. During this time, the suspension became more viscous and difficult to stir. The mixture was cooled to room temperature, diluted with a small amount of iPrOH to increase the fluidity of the slurry, filtered through a Buchner funnel and rinsed with iPrOH to give compound 174a (140 g, 96% yield). LCMS: (M + H) ^<+> : 536.4.

ジフェニルエーテル（１６７ｍＬ）を、加熱マントルを用いて加熱沸騰させた。化合物１７４ａ（１５．６ｇ、２９．０ｍｍｏｌ）を少量ずつ加え、得られた溶液を１０分間加熱した。得られた暗色溶液を室温まで冷却し、ヘキサンで希釈した。この全体の手順をさらに８回行い（合計１４０ｇの出発材料を処理した）、各バッチからのヘキサン混合物を合わせ、濾過し、粗生成物を灰色固体として得た。この固体をヘキサンで再び希釈し、得られたスラリーを３０分間撹拌し、濾過した。回収した固体をＭｅＯＨで希釈し、３０分間８０℃に加熱した後、濾過し、化合物１７４ｂ（７５ｇ、収率５９％）を得た。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ４９０．３． Step (2): Compound 174a → Compound 174b
Compound 174b: ethyl 6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-1,4-dihydroquinoline-3-carboxylate

Diphenyl ether (167 mL) was heated to boiling using a heating mantle. Compound 174a (15.6 g, 29.0 mmol) was added in small portions and the resulting solution was heated for 10 minutes. The resulting dark solution was cooled to room temperature and diluted with hexane. This entire procedure was performed 8 more times (a total of 140 g of starting material was processed) and the hexane mixtures from each batch were combined and filtered to give the crude product as a gray solid. The solid was diluted again with hexane and the resulting slurry was stirred for 30 minutes and filtered. The collected solid was diluted with MeOH, heated to 80 ° C. for 30 minutes, and then filtered to obtain Compound 174b (75 g, yield 59%). LCMS: (M + H) ^<+> : 490.3.

ＴＨＦ（３００ｍＬ）中、化合物１７４ｂ（２０．０ｇ、４０．９ｍｍｏｌ）の懸濁液に、Ｋ_２ＣＯ_３（８．４７ｇ、６１．３ｍｍｏｌ）およびＳＥＭＣｌ（７．９７ｍｌ、４４．９ｍｍｏｌ）を加えた。この混合物を室温で３時間撹拌した。この混合物に水を加え、ＴＨＦを蒸発させた。残った混合物をＤＣＭで抽出した（３×２００ｍＬ）。合わせた有機相を乾燥させ、濾過し、濃縮し、化合物１７４ｃ（２３ｇ、収率９１％）を赤色油状物として得た。この材料を精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ６２０．５． Step (3): Compound 174b → Compound 174c
Compound 174c: ethyl 6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-1-((2- (trimethylsilyl) ethoxy) methyl) -1,4-dihydroquinoline-3-carboxylate

To a suspension of compound 174b (20.0 g, 40.9 mmol) in THF (300 mL) was added K ₂ CO ₃ (8.47 g, 61.3 mmol) and SEMCl (7.97 ml, 44.9 mmol). . The mixture was stirred at room temperature for 3 hours. Water was added to the mixture and the THF was evaporated. The remaining mixture was extracted with DCM (3 × 200 mL). The combined organic phases were dried, filtered and concentrated to give compound 174c (23 g, 91% yield) as a red oil. This material was used in the next step without purification. LCMS: (M + H) ^<+> : 620.5.

水（２００ｍＬ）およびＭｅＯＨ（２００ｍＬ）中、化合物１７４ｃ（２３ｇ、３７ｍｍｏｌ）の溶液に、ＮａＯＨ（７．４２ｇ、１８６ｍｍｏｌ）を加えた。この混合物を８０℃で１時間撹拌した。メタノールを蒸発させ、この溶液にＨＣｌ水溶液を加えてｐＨを６に調整した。沈殿した固体を濾取し、化合物１７４ｄ（１９．８ｇ、収率９０％）を灰色固体として得た。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ５９２．２． ^１Ｈ ＮＭＲ （ＤＭＳＯ−ｄ_６） ： ８．６３ （ｓ， １Ｈ）， ７．７５ （ｓ， １Ｈ）， ７．４１ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ７．３７ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ７．３４ （ｓ， １Ｈ）， ６．９２−６．９７ （ｍ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ６．９２−６．９７ （ｍ， Ｊ＝９．０ Ｈｚ， ２Ｈ）， ５．６６ （ｓ， ２Ｈ）， ５．１９ （ｓ， ２Ｈ）， ５．０９ （ｓ， ２Ｈ）， ３．７６ （ｓ， ３Ｈ）， ３．７５ （ｓ， ３Ｈ）， ３．５４ （ｔ， Ｊ＝７．８ Ｈｚ， ２Ｈ）， ０．８４ （ｔ， Ｊ＝７．８ Ｈｚ， ２Ｈ）， −０．０７ （ｓ， ９Ｈ）． Step (4): Compound 174c → Compound 174d
Compound 174d: 6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-1-((2- (trimethylsilyl) ethoxy) methyl) -1,4-dihydroquinoline-3-carboxylic acid

To a solution of compound 174c (23 g, 37 mmol) in water (200 mL) and MeOH (200 mL) was added NaOH (7.42 g, 186 mmol). The mixture was stirred at 80 ° C. for 1 hour. Methanol was evaporated and aqueous HCl was added to the solution to adjust the pH to 6. The precipitated solid was collected by filtration to obtain Compound 174d (19.8 g, yield 90%) as a gray solid.
LCMS: (M + H) ^<+> : 592.2. ¹ H NMR (DMSO-d ₆ ): 8.63 (s, 1H), 7.75 (s, 1H), 7.41 (d, J = 8.6 Hz, 2H), 7.37 (d, J = 8.6 Hz, 2H), 7.34 (s, 1H), 6.92-6.97 (m, J = 8.6 Hz, 2H), 6.92-6.97 (m, J = 9.0 Hz, 2H), 5.66 (s, 2H), 5.19 (s, 2H), 5.09 (s, 2H), 3.76 (s, 3H), 3.75 (s 3H), 3.54 (t, J = 7.8 Hz, 2H), 0.84 (t, J = 7.8 Hz, 2H), −0.07 (s, 9H).

ＤＭＦ（２５０ｍＬ）中、化合物１７４ｄ（２４．０ｇ、４０．６ｍｍｏｌ）の溶液に、ＨＡＴＵ（１８．５ｇ、４８．７ｍｍｏｌ）およびＤＩＰＥＡ（２８．３ｍＬ、１６２ｍｍｏｌ）を加え、得られた混合物を室温で３０分間撹拌した。次に、１，４−ジアザビシクロ［３．２．２］ノナン（５．６３ｇ、４４．６ｍｍｏｌ）を加え、この混合物を室温で１時間撹拌した。水およびＥｔＯＡｃを加え、水相をＥｔＯＡｃで３回抽出した。合わせた有機抽出液をブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、真空濃縮した。残渣を順相クロマトグラフィー（２４ｇカラム、溶媒Ａ中０〜１０％溶媒Ｂ；溶媒Ａ＝ＤＣＭ、溶媒Ｂ＝１０：９０：１ ＭｅＯＨ：ＤＣＭ：ＮＨ_４ＯＨ）により精製した。単離された固体をＤＣＭに溶かし、水で洗浄した後、有機層を濃縮した。残渣を小シリカゲルカラム（４ｇ、０〜１０％ＭｅＯＨ／ＤＣＭ）から溶出させ、化合物１７４ｅ（１６．４ｇ、収率５８％）を褐色固体として得た。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７００．６． ^１Ｈ ＮＭＲ （ＤＭＳＯ−ｄ_６） ： ８．２２ （ｓ， １Ｈ）， ７．６７ （ｓ， １Ｈ）， ７．４１ （ｄ， Ｊ＝８．８ Ｈｚ， ２Ｈ）， ７．３９ （ｄ， Ｊ＝９．１ Ｈｚ， ２Ｈ）， ７．３５ （ｓ， １Ｈ）， ６．９５ （ｄ， Ｊ＝８．８ Ｈｚ， ２Ｈ）， ６．９５ （ｄ， Ｊ＝８．８ Ｈｚ， ２Ｈ）， ５．６３ （ｓ， ２Ｈ）， ５．２１ （ｓ， ２Ｈ）， ５．１４ （ｓ， ２Ｈ）， ４．５３ （ｂｒ． ｓ．， １Ｈ）， ３．７６ （ｓ， ６Ｈ）， ３．４６−３．５９ （ｔ， Ｊ＝８．１ Ｈｚ， ２Ｈ）， ３．３６−３．４２ （ｍ， １Ｈ）， ２．７８−３．０４ （ｍ， ６Ｈ）， １．４３−２．０２ （ｍ， ４Ｈ）， ０．８８−１．３４ （ｍ， ３Ｈ）， ０．８４ （ｔ， Ｊ＝８．０ Ｈｚ， ２Ｈ）， −０．０７ （ｓ， ９Ｈ）．
注：この中間体は、^１Ｈ ＮＭＲにより認められるように、アミド回転異性体の混合物として存在する。主要な回転体のシフトだけを報告する。 Step (5): Compound 174d → Compound 174e
Compound 174e: 3- (1,4-diazabicyclo [3.2.2] nonane-4-carbonyl) -6,7-bis ((4-methoxybenzyl) oxy) -1-((2- (trimethylsilyl) ethoxy ) Methyl) quinolin-4 (1H) -one

To a solution of compound 174d (24.0 g, 40.6 mmol) in DMF (250 mL) was added HATU (18.5 g, 48.7 mmol) and DIPEA (28.3 mL, 162 mmol) and the resulting mixture was at room temperature. Stir for 30 minutes. Then 1,4-diazabicyclo [3.2.2] nonane (5.63 g, 44.6 mmol) was added and the mixture was stirred at room temperature for 1 hour. Water and EtOAc were added and the aqueous phase was extracted 3 times with EtOAc. The combined organic extracts were washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated in vacuo. The residue was purified by normal phase chromatography (24 g column, 0-10% solvent B in solvent A; solvent A = DCM, solvent B = 10: 90: 1 MeOH: DCM: NH ₄ OH). The isolated solid was dissolved in DCM and washed with water, then the organic layer was concentrated. The residue was eluted from a small silica gel column (4 g, 0-10% MeOH / DCM) to give compound 174e (16.4 g, 58% yield) as a brown solid.
LCMS: (M + H) ^<+> : 700.6. ¹ H NMR (DMSO-d ₆ ): 8.22 (s, 1H), 7.67 (s, 1H), 7.41 (d, J = 8.8 Hz, 2H), 7.39 (d, J = 9.1 Hz, 2H), 7.35 (s, 1H), 6.95 (d, J = 8.8 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H) , 5.63 (s, 2H), 5.21 (s, 2H), 5.14 (s, 2H), 4.53 (br. S., 1H), 3.76 (s, 6H), 3 .46-3.59 (t, J = 8.1 Hz, 2H), 3.36-3.42 (m, 1H), 2.78-3.04 (m, 6H), 1.43-2 .02 (m, 4H), 0.88-1.34 (m, 3H), 0.84 (t, J = 8.0 Hz, 2H), -0.07 (s, 9H).
Note: This intermediate exists as a mixture of amide rotamers, as observed by ¹ H NMR. Only major rotor shifts are reported.

この化合物は、化合物１７４ｅおよび化合物Ｘ−２４を用い、実施例１６２の二段階法に従って製造した。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８１１．３． ^１Ｈ ＮＭＲ （Ｄ_２Ｏ） ： ８．００ （ｓ， １Ｈ）， ７．４２ （ｓ， １Ｈ）， ６．９１ （ｓ， １Ｈ）， ６．８５ （ｓ， １Ｈ）， ５．７１ （ｄ， Ｊ＝４．８ Ｈｚ， １Ｈ）， ５．３２ （ｄ， Ｊ＝５．１ Ｈｚ， １Ｈ）， ４．７７ （ｂｒ． ｓ．， １Ｈ）， ４．１７ （ｄ， Ｊ＝１４．１ Ｈｚ， １Ｈ）， ３．８７−４．０８ （ｍ， ２Ｈ）， ３．２６−３．８５ （ｍ， ８Ｈ）， ２．２６ （ｍ， ３Ｈ）， １．４５ （ｄ， Ｊ＝７．３ Ｈｚ， ３Ｈ）， １．３９ （ｓ， ３Ｈ）， １．３７ （ｓ， ３Ｈ）．
注：この類似体は、^１Ｈ ＮＭＲにより認められるように、アミド回転異性体の混合物として存在する。主要な回転体のシフトだけを報告する。主要な回転体のシフトだけを報告する。 Step (4): Compound X-24 + Compound 174e → Compound I-174
Compound I-174: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((4- (6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carbonyl) -1,4-diazabicyclo [3.2.2] nonane-1-ium -1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

This compound was prepared according to the two-step method of Example 162 using compound 174e and compound X-24.
LCMS: (M + H) ^<+> : 811.3. ¹ H NMR (D ₂ O): 8.00 (s, 1H), 7.42 (s, 1H), 6.91 (s, 1H), 6.85 (s, 1H), 5.71 (d , J = 4.8 Hz, 1H), 5.32 (d, J = 5.1 Hz, 1H), 4.77 (br.s., 1H), 4.17 (d, J = 14.1). Hz, 1H), 3.87-4.08 (m, 2H), 3.26-3.85 (m, 8H), 2.26 (m, 3H), 1.45 (d, J = 7. 3 Hz, 3H), 1.39 (s, 3H), 1.37 (s, 3H).
Note: This analog exists as a mixture of amide rotamers as seen by ¹ H NMR. Only major rotor shifts are reported. Only major rotor shifts are reported.

  The compounds shown below were obtained from compound X-24 and the corresponding amines (synthesized according to the synthesis of WO2013052568A1) in the same manner as in the above examples.

ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８２５．６． ^１Ｈ ＮＭＲ （Ｄ_２Ｏ） ： ８．３９ （ｓ， １Ｈ）， ７．３４ （ｓ， １Ｈ）， ６．８６ （ｓ， １Ｈ）， ６．６８ （ｂｒ． ｓ．， １Ｈ）， ５．７１ （ｄ， Ｊ＝４．８ Ｈｚ， １Ｈ）， ５．３１ （ｄ， Ｊ＝４．５ Ｈｚ， １Ｈ）， ４．５０ （ｄ， Ｊ＝１４．４ Ｈｚ， １Ｈ）， ３．８５−４．０２ （ｍ， ２Ｈ）， ３．３８−３．５４ （ｍ， ３Ｈ）， ３．２２−３．３７ （ｍ， ５Ｈ）， １．８２ （ｂｒ． ｓ．， ６Ｈ）， １．４２ （ｄ， Ｊ＝６．６ Ｈｚ， ３Ｈ）， １．３９ （ｓ， ３Ｈ）， １．３７ （ｓ， ３Ｈ）． Example 175: Synthesis of Compound I-175 Compound I-175: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2- Carboxypropan-2-yl) oxy) imino) acetamido) -3-((4-((6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carboxamido) methyl) quinuclidine-1-ium -1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

LCMS: (M + H) ^<+> : 825.6. ¹ H NMR (D ₂ O): 8.39 (s, 1H), 7.34 (s, 1H), 6.86 (s, 1H), 6.68 (br.s., 1H), 5. 71 (d, J = 4.8 Hz, 1H), 5.31 (d, J = 4.5 Hz, 1H), 4.50 (d, J = 14.4 Hz, 1H), 3.85− 4.02 (m, 2H), 3.38-3.54 (m, 3H), 3.22-3.37 (m, 5H), 1.82 (br. S., 6H), 1.42 (D, J = 6.6 Hz, 3H), 1.39 (s, 3H), 1.37 (s, 3H).

ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７９９．６． ^１Ｈ ＮＭＲ （Ｄ_２Ｏ） ： ８．１９ （ｓ， １Ｈ）， ７．１４ （ｓ， １Ｈ）， ６．８４ （ｓ， １Ｈ）， ６．６３ （ｓ， １Ｈ）， ５．７０ （ｄ， Ｊ＝４．５ Ｈｚ， １Ｈ）， ５．３５ （ｄ， Ｊ＝４．８ Ｈｚ， １Ｈ）， ４．９１ （ｄ， Ｊ＝１４．１ Ｈｚ， １Ｈ）， ４．１６ （ｄ， Ｊ＝１４．４ Ｈｚ， １Ｈ）， ３．９２−４．０１ （ｍ， １Ｈ）， ３．６６−３．８８ （ｍ， ２Ｈ）， ３．５６−３．６５ （ｍ， １Ｈ）， ３．３１−３．５２ （ｍ， ５Ｈ）， １．９８−２．１９ （ｍ， ４Ｈ）， １．４５ （ｄ， Ｊ＝７．１ Ｈｚ， ３Ｈ）， １．３７ （ｓ， ３Ｈ）， １．３５ （ｓ， ３Ｈ）． Example 176: Synthesis of Compound I-176 Compound I-176: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2- Carboxypropan-2-yl) oxy) imino) acetamido) -3-((1- (2- (6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carboxamido) ethyl) pyrrolidine-1 -Ium-1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-en-2-carboxylate sodium salt

LCMS: (M + H) ^<+> : 799.6. ¹ H NMR (D ₂ O): 8.19 (s, 1H), 7.14 (s, 1H), 6.84 (s, 1H), 6.63 (s, 1H), 5.70 (d , J = 4.5 Hz, 1H), 5.35 (d, J = 4.8 Hz, 1H), 4.91 (d, J = 14.1 Hz, 1H), 4.16 (d, J = 14.4 Hz, 1H), 3.92-4.01 (m, 1H), 3.66-3.88 (m, 2H), 3.56-3.65 (m, 1H), 3. 31-3.52 (m, 5H), 1.98-2.19 (m, 4H), 1.45 (d, J = 7.1 Hz, 3H), 1.37 (s, 3H), 1 .35 (s, 3H).

ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８４５．３． ^１Ｈ ＮＭＲ （Ｄ_２Ｏ）： ７．８７ （ｂｒ． ｓ．， １Ｈ）， ６．８４ （ｓ， １Ｈ）， ６．７０ （ｂｒ． ｓ．， １Ｈ）， ５．７１ （ｄ， Ｊ＝４．８ Ｈｚ， １Ｈ）， ５．３１ （ｄ， Ｊ＝４．８ Ｈｚ， １Ｈ）， ４．７４−４．８１ （ｍ， １Ｈ）， ４．１４−４．２８ （ｍ， ２Ｈ）， ３．９２−４．０８ （ｍ， １Ｈ）， ３．２８−３．９１ （ｍ， ８Ｈ）， ２．０３−２．３４ （ｍ， ４Ｈ）， １．４４ （ｄ， Ｊ＝７．１ Ｈｚ， ３Ｈ）， １．３８ （ｓ， ３Ｈ）， １．３６ （ｓ， ３Ｈ）． 注：この類似体は、^１Ｈ ＮＭＲにより認められるように、アミド回転異性体の混合物として存在する。主要な回転体のシフトだけを報告する。主要な回転体のシフトだけを報告する。 Example 177: Synthesis of Compound I-177 Compound I-177: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2- Carboxypropan-2-yl) oxy) imino) acetamido) -3-((4- (5-chloro-6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carbonyl) -1,4 -Diazabicyclo [3.2.2] nonane-1-ium-1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene- 2-carboxylate sodium salt

LCMS: (M + H) ^<+> : 845.3. ¹ H NMR (D ₂ O): 7.87 (br.s., 1H), 6.84 (s, 1H), 6.70 (br.s., 1H), 5.71 (d, J = 4.8 Hz, 1H), 5.31 (d, J = 4.8 Hz, 1H), 4.74-4.81 (m, 1H), 4.14-4.28 (m, 2H), 3.92-4.08 (m, 1H), 3.28-3.91 (m, 8H), 2.03-2.34 (m, 4H), 1.44 (d, J = 7.1) Hz, 3H), 1.38 (s, 3H), 1.36 (s, 3H). Note: This analog exists as a mixture of amide rotamers as seen by ¹ H NMR. Only major rotor shifts are reported. Only major rotor shifts are reported.

ＤＭＦ（８０ｍＬ）中、化合物１６７ｉ（２．５６ｇ、３．２７ｍｍｏｌ）の溶液に、ＨＡＴＵ（１．４９ｇ、３．９２ｍｍｏｌ）およびＤＩＰＥＡ（２．２９ｍＬ、１３．１ｍｍｏｌ）を加えた後、得られた混合物を室温で３０分間撹拌した。次に、１−アザビシクロ［２．２．１］ヘプタン−４−イルメタンアミン二塩酸塩（ＷＯ２０１１１２５９６６Ａ１号、０．７１６ｇ、３．６０ｍｍｏｌ）を加え、得られた混合物を室温で１時間撹拌した。この混合物に水およびＥｔＯＡｃを加え、水相をＥｔＯＡｃで３回抽出した。合わせた有機抽出液をブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、真空濃縮した。残渣を、Ｃｏｍｂｉｆｌａｓｈ装置でＢｉｏｔａｇｅ ＫＰ−ＮＨカラム（ヘキサン中、４５〜９０％ ３：１ ＥｔＯＡｃ／ＥｔＯＨ）を用いて精製し、化合物１７８ａ（５６０ｍｇ、収率２３％）を淡黄色固体として得た。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ７３４．４． ^１Ｈ ＮＭＲ （ＤＭＳＯ−ｄ_６）： １０．０１ （ｔ， Ｊ＝５．８ Ｈｚ， １Ｈ）， ８．８７ （ｓ， １Ｈ）， ７．４８ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ７．４６ （ｓ， １Ｈ）， ７．３０ （ｄ， Ｊ＝８．３ Ｈｚ， ２Ｈ）， ７．０１ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ６．８５ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ５．８２ （ｓ， ２Ｈ）， ５．２８ （ｓ， ２Ｈ）， ４．９１ （ｓ， ２Ｈ）， ３．７９ （ｓ， ３Ｈ）， ３．７４ （ｓ， ３Ｈ）， ３．６７ （ｄ， Ｊ＝５．８ Ｈｚ， ２Ｈ）， ３．５５−３．６２ （ｍ， ４Ｈ）， ２．７０−２．８４ （ｍ， ２Ｈ）， ２．１６ （ｓ， ２Ｈ）， １．７３−１．８１ （ｍ， ２Ｈ）， １．４６−１．５８ （ｍ， ２Ｈ）， １．１３−１．２８ （ｍ， ２Ｈ）， ０．８７ （ｔ， Ｊ＝８．０ Ｈｚ， ２Ｈ）， −０．０６ （ｓ， ９Ｈ）． Example 178: Synthesis Step of Compound I-178 (1): Compound 167i → Compound 178a
Compound 178a: N- (1-azabicyclo [2.2.1] heptan-4-ylmethyl) -5-chloro-6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-1-(( 2- (Trimethylsilyl) ethoxy) methyl) -1,4-dihydroquinoline-3-carboxamide

Obtained after adding HATU (1.49 g, 3.92 mmol) and DIPEA (2.29 mL, 13.1 mmol) to a solution of compound 167i (2.56 g, 3.27 mmol) in DMF (80 mL) The mixture was stirred at room temperature for 30 minutes. Next, 1-azabicyclo [2.2.1] heptan-4-ylmethanamine dihydrochloride (WO20111259966A1, 0.716 g, 3.60 mmol) was added and the resulting mixture was stirred at room temperature for 1 hour. Water and EtOAc were added to the mixture and the aqueous phase was extracted 3 times with EtOAc. The combined organic extracts were washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated in vacuo. The residue was purified on a Combiflash apparatus using a Biotage KP-NH column (45-90% 3: 1 EtOAc / EtOH in hexanes) to give compound 178a (560 mg, 23% yield) as a pale yellow solid.
LCMS: (M + H) ^<+> : 734.4. ¹ H NMR (DMSO-d ₆ ): 10.01 (t, J = 5.8 Hz, 1H), 8.87 (s, 1H), 7.48 (d, J = 8.6 Hz, 2H) , 7.46 (s, 1H), 7.30 (d, J = 8.3 Hz, 2H), 7.01 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 5.82 (s, 2H), 5.28 (s, 2H), 4.91 (s, 2H), 3.79 (s, 3H), 3.74 (s, 3H), 3.67 (d, J = 5.8 Hz, 2H), 3.55-3.62 (m, 4H), 2.70-2.84 (m, 2H), 2.16 (s , 2H), 1.73-1.81 (m, 2H), 1.46-1.58 (m, 2H), 1.13-1.28 (m, 2H), 0.87 (t, J = .0 Hz, 2H), -0.06 (s, 9H).

０℃で、ＤＭＦ（３．６０ｍＬ）中、化合物１７８ａ（０．８４０ｇ、１．０７５ｍｍｏｌ）の溶液に、ＤＭＦ（３．６０ｍＬ）中、化合物Ｘ−２４（１．００ｇ、１．１３ｍｍｏｌ）の溶液を加え、この混合物を０℃で３０分間撹拌した。ＮａＣｌの氷冷溶液（５％水溶液、３０ｍＬ）を加え、得られたスラリーを０℃で１５分間撹拌し、濾過し、真空乾燥させ、化合物１７８ｂ（１．６４ｇ、収率７２％）を得た。この材料を精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： １４９２．５． Step (2): Compound X-24 + Compound 178a → Compound 178b
Compound 178b: 1-(((4S, 6R, 7R) -7-((Z) -2-(((1- (tert-butoxy) -2-methyl-1-oxopropan-2-yl) oxy) Imino) -2- (2-((tert-butoxycarbonyl) amino) thiazol-4-yl) acetamido) -2-(((4-methoxybenzyl) oxy) carbonyl) -4-methyl-8-oxo-5 -Thia-1-azabicyclo [4.2.0] oct-2-en-3-yl) methyl) -4-((5-chloro-6,7-bis ((4-methoxybenzyl) oxy) -4 -Oxo-1-((2- (trimethylsilyl) ethoxy) methyl) -1,4-dihydroquinoline-3-carboxamido) methyl) -1-azabicyclo [2.2.1] heptane-1-ium

To a solution of compound 178a (0.840 g, 1.075 mmol) in DMF (3.60 mL) at 0 ° C., a solution of compound X-24 (1.00 g, 1.13 mmol) in DMF (3.60 mL). And the mixture was stirred at 0 ° C. for 30 minutes. An ice-cold solution of NaCl (5% aqueous solution, 30 mL) was added and the resulting slurry was stirred at 0 ° C. for 15 minutes, filtered and dried in vacuo to give compound 178b (1.64 g, 72% yield). . This material was used in the next step without purification. LCMS: (M + H) ^<+> : 1492.5.

−４０℃で、ＤＣＭ（１５ｍＬ）中、化合物１７８ｂ（１．６４ｇ、０．７６９ｍｍｏｌ）の溶液に、アニソール（０．８４０ｍＬ、７．６９ｍｍｏｌ）およびニトロメタン中１ＭのＡｌＣｌ_３（７．６９ｍＬ、７．６９ｍｍｏｌ）を加えた。得られた塊状混合物を０℃で３０分間撹拌し、ＭｅＣＮ、水、および１Ｎ ＨＣｌ水溶液の溶液（１：１：０．２５比、３０ｍＬ）、次いで３０ｍＬのｉＰｒ_２Ｏを加えた。有機層を０．５Ｍ ＨＣｌ水溶液中２０％ＭｅＣＮの溶液で抽出した（２×３０ｍＬ）。合わせた水層にＨＰ２０ＳＳ樹脂（８ｇ）を加え、この混合物を全てのＭｅＣＮが除去される濃縮した。このサンプルを、さらなるＨＰ２０ＳＳ樹脂（１５ｇ）をプレロードしたローディングカートリッジで濾過した。このカートリッジをＣｏｍｂｉｆｌａｓｈに取り付け、１００％水を、それらの画分がｐＨ＞４となるまで、カートリッジから溶出させた。逆相Ｃｏｍｂｉｆｌａｓｈカラムを取り付け（１００ｇ Ｃ１８カラム）、１０分間０〜２０％ＭｅＣＮ／水、次いで１５分にわたって３０％ＭｅＣＮ／水を用いて生成物を溶出させた。純粋な画分を回収し、化合物１７８ｃ（３７０ｍｇ、収率５５％）を得た。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８４５．３． ^１Ｈ ＮＭＲ （ＤＭＳＯ−ｄ_６）： １０．３８−１０．５４ （ｍ， １Ｈ）， ９．８６ （ｂｒ． ｓ．， １Ｈ）， ８．４３ （ｓ， １Ｈ）， ７．３１ （ｂｒ． ｓ．， ２Ｈ）， ６．９２ （ｂｒ． ｓ．， １Ｈ）， ６．７２ （ｓ， １Ｈ）， ５．７１−５．８４ （ｍ， １Ｈ）， ５．２６ （ｄ， Ｊ＝５．１ Ｈｚ， １Ｈ）， ４．９３ （ｍ， １Ｈ）， ３．９２−４．００ （ｍ， １Ｈ）， ３．８１−３．９２ （ｍ， １Ｈ）， ３．４８−３．６３ （ｍ， ６Ｈ）， ３．２２−３．２８ （ｍ， ２Ｈ）， １．９４−２．１０ （ｍ， ２Ｈ）， １．７１ （ｂｒ． ｓ．， ２Ｈ）， １．４７ （ｓ， ３Ｈ）， １．４４ （ｓ， ３Ｈ）， １．１１−１．３３ （ｍ， ３Ｈ）． Step (3): Compound 178b → Compound 178c
Compound 178c: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino) acetamide ) -3-((4-((5-chloro-6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carboxamido) methyl) -1-azabicyclo [2.2.1] heptane- 1-ium-1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-en-2-carboxylate

To a solution of compound 178b (1.64 g, 0.769 mmol) in DCM (15 mL) at −40 ° C., anisole (0.840 mL, 7.69 mmol) and 1M AlCl ₃ (7.69 mL, 7.69 mmol) in nitromethane. 69 mmol) was added. The resulting bulk mixture was stirred at 0 ° C. for 30 minutes and a solution of MeCN, water, and 1N aqueous HCl (1: 1: 0.25 ratio, 30 mL) was added followed by 30 mL of iPr ₂ O. The organic layer was extracted with a solution of 20% MeCN in 0.5M aqueous HCl (2 × 30 mL). To the combined aqueous layer was added HP20SS resin (8 g) and the mixture was concentrated to remove all MeCN. The sample was filtered through a loading cartridge preloaded with additional HP20SS resin (15 g). The cartridge was attached to a Combiflash and 100% water was eluted from the cartridge until their fractions were pH> 4. A reverse phase Combiflash column was attached (100 g C18 column) and the product was eluted with 0-20% MeCN / water for 10 minutes and then 30% MeCN / water for 15 minutes. The pure fractions were collected to give compound 178c (370 mg, yield 55%).
LCMS: (M + H) ^<+> : 845.3. ¹ H NMR (DMSO-d ₆ ): 10.38-10.54 (m, 1H), 9.86 (br.s., 1H), 8.43 (s, 1H), 7.31 (br. s., 2H), 6.92 (br. s., 1H), 6.72 (s, 1H), 5.71-5.84 (m, 1H), 5.26 (d, J = 5. 1 Hz, 1H), 4.93 (m, 1H), 3.92-4.00 (m, 1H), 3.81-3.92 (m, 1H), 3.48-3.63 (m 6H), 3.22-3.28 (m, 2H), 1.94-2.10 (m, 2H), 1.71 (br.s., 2H), 1.47 (s, 3H) , 1.44 (s, 3H), 1.11-1.33 (m, 3H).

水（１１ｍＬ）およびアセトニトリル（５．５２ｍＬ）中、化合物１７８ｃ（１４０ｍｇ、０．１６４ｍｍｏｌ）の激しく撹拌している溶液を、氷浴を用いて０℃に冷却し、ｐＨが５．５となるまで０．１Ｍ ＮａＯＨ水溶液を滴下した。ドライアイスの小片を加えて過剰な水酸化ナトリウムを急冷した後、アセトニトリルを真空下で除去した。残った溶液を凍結乾燥により濃縮し、化合物Ｉ−１７８（１３９ｍｇ、収率９７％）を得た。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８４５．３． ^１Ｈ ＮＭＲ （Ｄ_２Ｏ）： ８．１２ （ｓ， １Ｈ）， ６．８０ （ｓ， １Ｈ）， ６．４０ （ｓ， １Ｈ）， ５．６３ （ｄ， Ｊ＝４．８ Ｈｚ， １Ｈ）， ５．２４ （ｄ， Ｊ＝４．５ Ｈｚ， １Ｈ）， ４．７５−４．８０ （ｍ， １Ｈ）， ４．１５ （ｄ， Ｊ＝１４．７ Ｈｚ， １Ｈ）， ３．９８ （ｍ， １Ｈ）， ３．６０ （ｍ， ６Ｈ）， ３．３３ （ｄ， Ｊ＝７．６ Ｈｚ， １Ｈ）， ３．２１ （ｄ， Ｊ＝７．８ Ｈｚ， １Ｈ）， ２．１１ （ｍ， ２Ｈ）， １．８７ （ｍ， ２Ｈ）， １．４２ （ｄ， Ｊ＝６．８ Ｈｚ， ３Ｈ）， １．３６ （ｓ， ３Ｈ）， １．３４ （ｓ， ３Ｈ）． Step (4): Compound 178c → Compound I-178
Compound I-178: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((4-((5-chloro-6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carboxamido) methyl) -1-azabicyclo [2.2.1] Heptane-1-ium-1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate sodium salt

A vigorously stirred solution of compound 178c (140 mg, 0.164 mmol) in water (11 mL) and acetonitrile (5.52 mL) is cooled to 0 ° C. using an ice bath until the pH is 5.5. 0.1M NaOH aqueous solution was added dropwise. After adding a small piece of dry ice to quench excess sodium hydroxide, the acetonitrile was removed in vacuo. The remaining solution was concentrated by lyophilization to obtain Compound I-178 (139 mg, yield 97%).
LCMS: (M + H) ^<+> : 845.3. ¹ H NMR (D ₂ O): 8.12 (s, 1H), 6.80 (s, 1H), 6.40 (s, 1H), 5.63 (d, J = 4.8 Hz, 1H ), 5.24 (d, J = 4.5 Hz, 1H), 4.75-4.80 (m, 1H), 4.15 (d, J = 14.7 Hz, 1H), 3.98. (M, 1H), 3.60 (m, 6H), 3.33 (d, J = 7.6 Hz, 1H), 3.21 (d, J = 7.8 Hz, 1H), 2.11. (M, 2H), 1.87 (m, 2H), 1.42 (d, J = 6.8 Hz, 3H), 1.36 (s, 3H), 1.34 (s, 3H).

ＤＭＦ（２５ｍＬ）中、化合物１５１ｄ（１．００ｇ、１．６９ｍｍｏｌ）の溶液に、ＨＡＴＵ（０．７７１ｇ、２．０３ｍｍｏｌ）およびＤＩＰＥＡ（１．１８ｍＬ、６．７６ｍｍｏｌ）を加え、得られた混合物を室温で３０分間撹拌した。次に、１−アザビシクロ［２．２．１］ヘプタン−４−イルメタンアミン（ＷＯ２０１１１２５９６６Ａ１号、０．３３７ｇ、１．６９０ｍｍｏｌ）を加え、得られた混合物を室温で１時間撹拌した。この混合物に水およびＥｔＯＡｃを加え、水相をＥｔＯＡｃで３回抽出した。合わせた有機抽出液をブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、真空濃縮した。残渣を自動クロマトグラフィー（１００％ヘキサン、次いでヘキサン中、０〜４５％ ３：１ ＥｔＯＡｃ／ＥｔＯＨ、５５ｇ Ｂｉｏｔａｇｅ（登録商標）ＫＰ−ＮＨカラム）により精製し、化合物１７９ａ（５６０ｍｇ、収率４７％）を褐色固体として得た。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋：７００．４． ^１Ｈ ＮＭＲ （ＤＭＳＯ−ｄ_６）： １０．２１ （ｔ， Ｊ＝５．３ Ｈｚ， １Ｈ）， ８．８６ （ｓ， １Ｈ）， ７．７８ （ｓ， １Ｈ）， ７．４４ （ｓ， １Ｈ）， ７．４２ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ７．３８ （ｄ， Ｊ＝８．６ Ｈｚ， ２Ｈ）， ６．９５ （ｄ， Ｊ＝８．１ Ｈｚ， ２Ｈ）， ６．９６ （ｄ， Ｊ＝７．８ Ｈｚ， ２Ｈ）， ５．８１ （ｓ， ２Ｈ）， ５．２３ （ｓ， ２Ｈ）， ５．１８ （ｓ， ２Ｈ）， ３．７６ （ｓ， ３Ｈ）， ３．７５ （ｓ， ３Ｈ）， ３．６７ （ｄ， Ｊ＝５．３ Ｈｚ， ２Ｈ）， ３．５５ （ｔ， Ｊ＝７．８ Ｈｚ， ２Ｈ）， ２．６９−２．８７ （ｍ， ２Ｈ）， ２．４３−２．５０ （ｍ， ２Ｈ）， ２．１８ （ｓ， ２Ｈ）， １．４６−１．６２ （ｍ， ２Ｈ）， １．２１−１．２８ （ｍ， ２Ｈ）， ０．８３ （ｔ， Ｊ＝７．８ Ｈｚ， ２Ｈ）， −０．０８ （ｓ， ９Ｈ）． Example 179: Synthesis Step of Compound I-179 (1): Compound 151d → Compound 179a
Compound 179a: N- (1-azabicyclo [2.2.1] heptan-4-ylmethyl) -6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-1-((2- (trimethylsilyl ) Ethoxy) methyl) -1,4-dihydroquinoline-3-carboxamide

To a solution of compound 151d (1.00 g, 1.69 mmol) in DMF (25 mL) was added HATU (0.771 g, 2.03 mmol) and DIPEA (1.18 mL, 6.76 mmol) and the resulting mixture was Stir at room temperature for 30 minutes. Next, 1-azabicyclo [2.2.1] heptan-4-ylmethanamine (WO2011125966A1, 0.337 g, 1.690 mmol) was added and the resulting mixture was stirred at room temperature for 1 hour. Water and EtOAc were added to the mixture and the aqueous phase was extracted 3 times with EtOAc. The combined organic extracts were washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated in vacuo. The residue was purified by automated chromatography (100% hexane, then 0-45% 3: 1 EtOAc / EtOH in hexane, 55 g Biotage® KP-NH column) and compound 179a (560 mg, 47% yield) Was obtained as a brown solid.
LCMS: (M + H) ^<+> : 700.4. ¹ H NMR (DMSO-d ₆ ): 10.21 (t, J = 5.3 Hz, 1H), 8.86 (s, 1H), 7.78 (s, 1H), 7.44 (s, 1H), 7.42 (d, J = 8.6 Hz, 2H), 7.38 (d, J = 8.6 Hz, 2H), 6.95 (d, J = 8.1 Hz, 2H) , 6.96 (d, J = 7.8 Hz, 2H), 5.81 (s, 2H), 5.23 (s, 2H), 5.18 (s, 2H), 3.76 (s, 3H), 3.75 (s, 3H), 3.67 (d, J = 5.3 Hz, 2H), 3.55 (t, J = 7.8 Hz, 2H), 2.69-2. 87 (m, 2H), 2.43-2.50 (m, 2H), 2.18 (s, 2H), 1.46-1.62 (m, 2H), 1.21-1.28 ( m 2H), 0.83 (t, J = 7.8 Hz, 2H), -0.08 (s, 9H).

０℃で、ＤＭＦ（２．６１ｍＬ）中、化合物１７９ａ（５６０ｍｇ、０．７８４ｍｍｏｌ）の溶液に、ＤＭＦ（２．６１ｍＬ）中、化合物Ｘ−２４（７２９ｍｇ、０．８２３ｍｍｏｌ）の溶液を加え、この混合物を０℃で３０分間撹拌した。ＮａＣｌの冷溶液（５％水溶液、３０ｍＬ）を加え、得られたスラリーを０℃で１５分間撹拌し、濾過し、真空下で乾燥させ、化合物１７９ｂ（１．１５ｇ、収率９２％）を得た。この材料を精製せずに次の工程で使用した。ＬＣＭＳ： （Ｍ＋Ｈ）^＋： １４５７．５． Step (2): Compound X-24 + Compound 179a → Compound 179b
Compound 179b: 4-((6,7-bis ((4-methoxybenzyl) oxy) -4-oxo-1-((2- (trimethylsilyl) ethoxy) methyl) -1,4-dihydroquinoline-3-carboxamide ) Methyl) -1-(((4S, 6R, 7R) -7-((Z) -2-(((1- (tert-butoxy) -2-methyl-1-oxopropan-2-yl) oxy ) Imino) -2- (2-((tert-butoxycarbonyl) amino) thiazol-4-yl) acetamido) -2-(((4-methoxybenzyl) oxy) carbonyl) -4-methyl-8-oxo- 5-thia-1-azabicyclo [4.2.0] oct-2-en-3-yl) methyl) -1-azabicyclo [2.2.1] heptane-1-ium

To a solution of compound 179a (560 mg, 0.784 mmol) in DMF (2.61 mL) at 0 ° C. was added a solution of compound X-24 (729 mg, 0.823 mmol) in DMF (2.61 mL). The mixture was stirred at 0 ° C. for 30 minutes. A cold solution of NaCl (5% aqueous solution, 30 mL) was added and the resulting slurry was stirred at 0 ° C. for 15 minutes, filtered and dried under vacuum to give compound 179b (1.15 g, 92% yield). It was. This material was used in the next step without purification. LCMS: (M + H) ^<+> : 1457.5.

−４０℃で、ＤＣＭ（１５ｍＬ）中、化合物１７９ｂ（１．１３ｇ、０．６４６ｍｍｏｌ）の溶液に、アニソール（０．８４ｍＬ、７．７ｍｍｏｌ）およびニトロメタン中１ＭのＡｌＣｌ_３（６．４６ｍＬ、６．４６ｍｍｏｌ）を加えた。得られた塊状混合物を０℃で３０分間撹拌した。ＭｅＣＮ、水、および１Ｎ ＨＣｌ水溶液の混合物（１：１：０．２５比、３０ｍＬ）、次いで３０ｍＬのｉＰｒ_２Ｏを加えた。有機層を０．５Ｍ ＨＣｌ水溶液中２０％のＭｅＣＮ溶液で抽出した（２×３０ｍＬ）。合わせた水層にＨＰ２０ＳＳ樹脂（１０ｇ）を加え、この混合物を濃縮してアセトニトリルを除去した。残ったスラリーを、ＨＰ２０ＳＳ樹脂（２０ｇ）をプレロードしたローディングカートリッジで濾過した。このカートリッジをＣｏｍｂｉｆｌａｓｈ装置に取り付け、それらの画分がｐＨ＞４となるまで１００％水でフラッシュした。Ｙａｍａｚｅｎ Ｕｌｔｒａｐａｃｋ ＯＤＳ−Ｓ−５０Ｃガラスカラムを取り付け、生成物を５分間１００％Ｈ_２Ｏ、３０分にわたって０〜１８％ＭｅＣＮ／Ｈ_２Ｏ、および１０分間１８％ＭｅＣＮ／Ｈ_２Ｏで溶出させた。最も純粋な画分を回収し、化合物１７９ｃ（２００ｍｇ、収率３８％）を得た。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８１１．４． ^１Ｈ ＮＭＲ （ＤＭＳＯ−ｄ_６）： １２．８２ （ｂｒ． ｓ．， １Ｈ）， １０．５３ （ｔ， Ｊ＝５．３ Ｈｚ， １Ｈ）， １０．３７ （ｂｒ． ｓ．， １Ｈ）， １０．０６ （ｂｒ． ｓ．， １Ｈ）， ９．４４ （ｂｒ． ｓ．， １Ｈ）， ８．４７ （ｂｒ． ｓ．， １Ｈ）， ７．５２ （ｓ， １Ｈ）， ７．３３ （ｂｒ． ｓ．， ２Ｈ）， ７．００ （ｓ， １Ｈ）， ６．７０ （ｓ， １Ｈ）， ５．７５ （ｄｄ， Ｊ＝７．３， ５．３ Ｈｚ， １Ｈ）， ５．２６ （ｄ， Ｊ＝５．１ Ｈｚ， １Ｈ）， ４．９９−５．１８ （ｍ， １Ｈ）， ３．９１−４．０９ （ｍ， ２Ｈ）， ３．４３−３．６２ （ｍ， ８Ｈ）， １．９２−２．１３ （ｍ， ２Ｈ）， １．６４−１．７８ （ｍ， ２Ｈ）， １．４６ （ｓ， ３Ｈ）， １．４４ （ｓ， ３Ｈ）， １．１９−１．３８ （ｍ， ３Ｈ）． Step (3): Compound 179b → Compound 179c
Compound 179c: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino) acetamide ) -3-((4-((6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carboxamido) methyl) -1-azabicyclo [2.2.1] heptane-1-ium- 1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-en-2-carboxylate

At −40 ° C., a solution of compound 179b (1.13 g, 0.646 mmol) in DCM (15 mL) was added to anisole (0.84 mL, 7.7 mmol) and 1M AlCl _{3 in} nitromethane (6.46 mL, 6. 46 mmol) was added. The resulting bulk mixture was stirred at 0 ° C. for 30 minutes. A mixture of MeCN, water, and 1N aqueous HCl (1: 1: 0.25 ratio, 30 mL) was added followed by 30 mL of iPr ₂ O. The organic layer was extracted with a 20% MeCN solution in 0.5M aqueous HCl (2 × 30 mL). HP20SS resin (10 g) was added to the combined aqueous layers and the mixture was concentrated to remove acetonitrile. The remaining slurry was filtered through a loading cartridge preloaded with HP20SS resin (20 g). The cartridges were attached to a Combiflash apparatus and flushed with 100% water until their fractions were pH> 4. A Yamazen Ultrapack ODS-S-50C glass column was attached and the product was eluted with 100% H ₂ O for 5 minutes, 0-18% MeCN / H ₂ O for 30 minutes, and 18% MeCN / H ₂ O for 10 minutes. . The purest fraction was collected to give compound 179c (200 mg, 38% yield).
LCMS: (M + H) ^<+> : 811.4. ¹ H NMR (DMSO-d ₆ ): 12.82 (br.s., 1H), 10.53 (t, J = 5.3 Hz, 1H), 10.37 (br.s., 1H), 10.06 (br.s., 1H), 9.44 (br.s., 1H), 8.47 (br.s., 1H), 7.52 (s, 1H), 7.33 (br , S., 2H), 7.00 (s, 1H), 6.70 (s, 1H), 5.75 (dd, J = 7.3, 5.3 Hz, 1H), 5.26 (d , J = 5.1 Hz, 1H), 4.99-5.18 (m, 1H), 3.91-4.09 (m, 2H), 3.43-3.62 (m, 8H), 1.92-2.13 (m, 2H), 1.64-1.78 (m, 2H), 1.46 (s, 3H), 1.44 (s, 3H), 19-1.38 (m, 3H).

水（１１ｍＬ）およびアセトニトリル（５．５０ｍＬ）中、化合物１７９ｃ（２００ｍｇ、０．２４５ｍｍｏｌ）を、氷浴を用いて０℃に冷却し、０．２Ｍ ＮａＯＨ水溶液をｐＨが５．５となるまで滴下した。ドライアイスの小片を加えて過剰な水酸化ナトリウムを急冷した後、真空下でアセトニトリルを除去した。残った溶液を凍結乾燥により濃縮し、化合物Ｉ−１７９（２０３ｍｇ、収率９９％）を得た。
ＬＣＭＳ： （Ｍ＋Ｈ）^＋： ８１１．２． ^１Ｈ ＮＭＲ （Ｄ_２Ｏ）： ８．３０ （ｓ， １Ｈ）， ７．１８ （ｓ， １Ｈ）， ６．８０ （ｓ， １Ｈ）， ６．６４ （ｓ， １Ｈ）， ５．６１ （ｄ， Ｊ＝４．８ Ｈｚ， １Ｈ）， ５．２０ （ｄ， Ｊ＝４．８ Ｈｚ， １Ｈ）， ４．７３−４．７８ （ｍ， １Ｈ）， ４．１４ （ｄ， Ｊ＝１４．４ Ｈｚ， １Ｈ）， ３．９７ （ｑ， Ｊ＝７．３ Ｈｚ， １Ｈ）， ３．６４ （ｄ， Ｊ＝６．８ Ｈｚ， ２Ｈ）， ３．４２−３．６０ （ｍ， ４Ｈ）， ３．３１ （ｄ， Ｊ＝８．３ Ｈｚ， １Ｈ）， ３．２３ （ｄ， Ｊ＝８．６ Ｈｚ， １Ｈ）， ２．０１−２．２０ （ｍ， ２Ｈ）， １．７９−１．９３ （ｍ， ２Ｈ）， １．４１ （ｄ， Ｊ＝７．１ Ｈｚ， ３Ｈ）， １．３５ （ｓ， ３Ｈ）， １．３３ （ｓ， ３Ｈ）． Step (4): Compound 179c → Compound I-179
Compound I-179: (4S, 6R, 7R) -7-((Z) -2- (2-aminothiazol-4-yl) -2-(((2-carboxypropan-2-yl) oxy) imino ) Acetamido) -3-((4-((6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carboxamido) methyl) -1-azabicyclo [2.2.1] heptane-1- Ium-1-yl) methyl) -4-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-en-2-carboxylate sodium salt

Compound 179c (200 mg, 0.245 mmol) in water (11 mL) and acetonitrile (5.50 mL) was cooled to 0 ° C. using an ice bath and 0.2 M aqueous NaOH solution was added dropwise until the pH was 5.5. did. After adding a small piece of dry ice to quench excess sodium hydroxide, the acetonitrile was removed under vacuum. The remaining solution was concentrated by lyophilization to obtain Compound I-179 (203 mg, yield 99%).
LCMS: (M + H) ^<+> : 811.2. ¹ H NMR (D ₂ O): 8.30 (s, 1H), 7.18 (s, 1H), 6.80 (s, 1H), 6.64 (s, 1H), 5.61 (d , J = 4.8 Hz, 1H), 5.20 (d, J = 4.8 Hz, 1H), 4.73-4.78 (m, 1H), 4.14 (d, J = 14. 4 Hz, 1H), 3.97 (q, J = 7.3 Hz, 1H), 3.64 (d, J = 6.8 Hz, 2H), 3.42-3.60 (m, 4H) 3.31 (d, J = 8.3 Hz, 1H), 3.23 (d, J = 8.6 Hz, 1H), 2.01-2.20 (m, 2H), 1.79- 1.93 (m, 2H), 1.41 (d, J = 7.1 Hz, 3H), 1.35 (s, 3H), 1.33 (s, 3H).

工程（１）：化合物１８０ａ→化合物１８０ｂ
化合物１８０ａ（１．４５ｇ、７．９ｍｍｏｌ）をテトラヒドロフラン（１５ｍＬ）に溶かし、次にこれに０℃で水素化リチウムアルミニウム（０．３ｇ、７．９ｍｍｏｌ）を加えた。この混合物を０℃で１時間撹拌した。次に、反応混合物に０℃で硫酸ナトリウム十水和物を加えた。この混合物を室温で１時間撹拌した。次に、反応混合物にヒドラジンカルボン酸ｔｅｒｔ−ブチル（２．１ｇ、１５．７ｍｍｏｌ）を加えた。室温で一晩撹拌した後、不溶物を濾去し、その後、酢酸エチルに溶かし、飽和クエン酸水溶液を加えた。水相を分離し、クロロホルムで抽出した。合わせた有機層を無水硫酸マグネシウムで乾燥させた。硫酸マグネシウムを濾去した後、液体を減圧下に置き、化合物１８０ｂ（２．２８ｇ、１１３％）を得た。得られた化合物１８０ｂを精製せずにそのまま次の工程で使用した。
^１Ｈ−ＮＭＲ （ＤＭＳＯ−Ｄ_６） δ：１０．５２ （１Ｈ， ｓ）， ７．５５ （１Ｈ， ｓ）， ２．８５−２．７７ （２Ｈ， ｍ）， ２．２９ （２Ｈ， ｓ）， １．７８−１．７０ （２Ｈ， ｍ）， １．４２ （９Ｈ， ｓ）， １．３８ （２Ｈ， ｓ）， １．２６−１．１６ （２Ｈ， ｍ）． Example 180: Synthesis of Compound I-180

Step (1): Compound 180a → Compound 180b
Compound 180a (1.45 g, 7.9 mmol) was dissolved in tetrahydrofuran (15 mL), and then lithium aluminum hydride (0.3 g, 7.9 mmol) was added thereto at 0 ° C. The mixture was stirred at 0 ° C. for 1 hour. Next, sodium sulfate decahydrate was added to the reaction mixture at 0 ° C. The mixture was stirred at room temperature for 1 hour. Next, tert-butyl hydrazinecarboxylate (2.1 g, 15.7 mmol) was added to the reaction mixture. After stirring at room temperature overnight, the insoluble material was removed by filtration, then dissolved in ethyl acetate, and saturated aqueous citric acid solution was added. The aqueous phase was separated and extracted with chloroform. The combined organic layer was dried over anhydrous magnesium sulfate. After magnesium sulfate was filtered off, the liquid was placed under reduced pressure to give compound 180b (2.28 g, 113%). The obtained compound 180b was directly used in the next step without purification.
¹ H-NMR (DMSO-D ₆ ) δ: 10.52 (1H, s), 7.55 (1H, s), 2.85-2.77 (2H, m), 2.29 (2H, s ), 1.78-1.70 (2H, m), 1.42 (9H, s), 1.38 (2H, s), 1.26-1.16 (2H, m).

Step (2): Compound 180b → Compound 180c
The total amount (2.28 g) of the obtained compound 180b was dissolved in methanol (25 mL), and then sodium cyanoborohydride (1.2 g, 19.1 mmol) was added thereto at 0 ° C. The mixture was stirred at 0 ° C. for 10 minutes, and then a 2 mol / L hydrochloric acid aqueous solution was added until the pH reached 4.0. After stirring at room temperature for 2 hours, the mixture was concentrated, 8 mol / L aqueous sodium hydroxide solution was added thereto, and the mixture was extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate. After sodium sulfate was filtered off, the liquid was placed under reduced pressure to give compound 180c (2.99 g, 130%). The obtained compound 180c was directly used in the next step without purification.
¹ H-NMR (DMSO-D ₆ ) δ: 8.22 (1H, s), 4.30 (1H, s), 2.98 (2H, d, J = 4.0 Hz), 2.75- 2.69 (2H, m), 2.47-2.41 (2H, m), 2.14 (2H, s), 1.53-1.38 (13H, m).

Step (3): Compound 180c → Compound 180d
The total amount (2.99 g) of the obtained compound 180c was dissolved in methanol (24 mL), and then a 4 mol / L hydrochloric acid solution (23.8 mL, 95 mmol) in 1,4-dioxane was added thereto at 0 ° C. After stirring at room temperature overnight, the reaction mixture was concentrated under reduced pressure. Next, the precipitated solid was collected by filtration and washed with 50% methanol / ethyl acetate solution to obtain Compound 180d (2.31 g, 113%).
¹ H-NMR (DMSO-D ₆ ) δ: 10.78 (1H, s), 7.45-7.20 (4H, m), 3.28-3.22 (2H, m), 3.18 (2H, s), 3.07 (2H, s), 1.97-1.91 (2H, m), 1.72-1.66 (2H, m).

Step (4): Compound 180d + Compound 180e → Compound 180f
To a suspension of the total amount of compound 180d (2.31 g) in 1,4-dioxane (45 mL) was added sodium acetate (3.91 g, 47.7 mmol) and compound 180e (4.81 g, 11.4 mmol). ) Was added. After stirring at room temperature for 1 hour, it was stirred at 70 ° C. for 2 hours. The reaction mixture was diluted with a mixture of ethyl acetate / tetrahydrofuran and aqueous sodium hydroxide, then separated, washed with water and saturated salt solution, and dried over sodium sulfate. After sodium sulfate was filtered off, the liquid was concentrated under reduced pressure. The liquid containing the compound was subjected to silica gel column chromatography, and the target compound was eluted with ethyl acetate (10% triethylamine) / methanol (10% triethylamine). The objective compound-containing fraction was concentrated under reduced pressure to obtain Compound 180f (1.79 g, 35%).
¹ H-NMR (DMSO-D ₆ ) δ: 7.60 (1H, s), 7.49 (1H, s), 7.40-7.36 (4H, m), 6.96-6.93 (4H, m), 5.16 (2H, s), 5.15 (2H, s), 4.18 (2H, s), 3.75 (3H, s), 3.75 (3H, s) , 2.74-2.68 (2H, m), 2.47-2.41 (2H, m), 2.30 (2H, s), 1.57-1.51 (2H, m), 1 20-1.14 (2H, m).

Step (4): Compound X-24 + Compound 180f → Compound 180h → Compound I-180
The target compound was synthesized in the same manner as in Example 120 using Compound X-24 (886 mg, 1.0 mmol) and Compound 180f (544 mg, 1.0 mmol).
Yield: 225 mg (28%)
¹ H-NMR (D ₂ O) δ: 7.47 (1H, s), 7.27 (1H, s), 6.98 (1H, s), 5.76 (1H, d, J = 4. 3 Hz), 5.37 (1H, d, J = 4.3 Hz), 4.88 (1H, d, J = 14.4 Hz), 4.34 (2H, s), 4.24 (1H , D, J = 14.4 Hz), 4.06 (1H, q, J = 7.0 Hz), 3.64-3.43 (6H, m), 2.23-2.15 (2H, m), 2.04-1.97 (2H, m), 1.54 (3H, d, J = 7.0 Hz), 1.51 (3H, s), 1.49 (3H, s).
LCMS (m + 1) = 785

  The compounds shown in the table below can be obtained by procedures similar to those exemplified above.

Test example 1
The in vitro antibacterial activity of the compound (I) of the present invention was evaluated.
(Method)
The minimum inhibitory concentration (MIC: μg / mL) was measured according to the CLSI (Clinical and Laboratory Standards Institute) method, the amount of inoculum was 5 × 10 ⁵ cfu / mL, and a positive medium containing human apo-transferrin was used as a test medium. The test was performed using a micro liquid dilution method using an ion-adjusted Iso-Sensitite broth. The list of bacteria used is as follows.

(result)
The test results are shown in the table below. Inhibitory activity values are expressed in micrograms / mL (μg / ml).

Test example 2
The in vivo antibacterial activity of the compound (I) of the present invention was evaluated.
(Method)
In vivo activity was evaluated in a mouse systemic infection model. Five-week-old male Jcl: ICR mice (CLEA Japan, Inc.) were used for testing and aeruginosa SR27001 (MDRP) was used as a test strain.
Infection was performed by intraperitoneal injection of 5.0 × 10 4 CFU / mouse bacteria mixed with 5.0% mucin. Test compounds were administered by intraperitoneal injection 1 hour and 5 hours after infection.
ED50 was calculated by the logit method using the survival rate on day 7 after infection.

(result)
The test results are shown in the table below.

  As indicated above, the compound (I) of the present invention has a broad antibacterial spectrum, in particular a strong antibacterial spectrum against gram-negative bacteria, and / or efficacy against multidrug-resistant bacteria, and further produces β-lactamase High stability against gram-negative bacteria.

Formulation Example 1
A powder of the compound of the invention is formulated to prepare an injection.

  The compound of the present invention has a broad antibacterial spectrum against gram-negative and gram-positive bacteria and is effective as an antibacterial agent having high stability against β-lactamase-producing gram-negative bacteria. Furthermore, the compounds of the present invention have good properties and high water solubility and are therefore particularly effective as injections.

Claims (8)

The following formula:

In the compound monomers other represented pharmaceutical composition containing acceptable salts their pharmaceutically. The following formula:

In the compound monomers other represented pharmaceutical composition containing acceptable salts their pharmaceutically. The pharmaceutical composition according to claim 1 or 2 , for use in antibacterial therapy. The pharmaceutical composition according to claim 3 , for use in therapy for infections caused by gram-negative bacteria. The pharmaceutical composition according to claim 4 , for use in therapy for infections caused by β-lactamase-producing gram-negative bacteria. E. coli, Klebsiella, Serratia, Enterobacter, Citrobacter, Morganella, Providencia, Proteus, etc. Gram-negative bacteria selected from negative bacteria,
Gram-negative bacteria Pseudomonas aeruginosa, Pseudomonas other than P. aeruginosa, Stenotrophomonas, Stenotrophomonas, Burkhol Non-glucose-fermenting Gram-negative bacteria selected from Burkholderia or Acinetobacter Class B type metallo-β-lactamase-producing Gram-negative multidrug resistant bacteria, or spectrum extended β- The pharmaceutical composition according to claim 1 or 2 , for use in therapy for infection by a lactamase (ESBL) -producing bacterium. 7. Medicament according to claim 6 , for use in therapy against infections caused by Gram-positive bacteria selected from methicillin-resistant Staphylococcus aureus (MRSA) or penicillin-resistant Streptococcus pneumoniae (PRSP). Composition. Respiratory tract infection, urinary tract infection, respiratory infection, sepsis, nephritis, cholecystitis, oral infection, endocarditis, pneumonia, osteomyelitis, otitis media, enteritis, empyema, wound infection or opportunistic The pharmaceutical composition according to claim 6 , which is used for the treatment of a bacterial infection which is an infection.